Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Lipid-associated sialic acid

Lipid-associated sialic acid

Lipid-associated sialic acid refers to the covalent attachment of sialic acid residues to lipid molecules, such as glycolipids and gangliosides.
This modification can play a crucial role in cellular signaling, cell-cell interactions, and immune responses.
Researchers studying lipid-associated sialic acid may investigate its involvement in various biological processes and its potential as a biomarker or therapeutic target for conditions like cancer, neurological disorders, and metabolic diseases.
Understanding the complex interplay between lipids and sialic acid can provide valuable insights into health and disease states.

Most cited protocols related to «Lipid-associated sialic acid»

1
Lipid Extraction and Analysis Protocol
Cited 2 times
Samples obtained from the different experimental conditions were dialyzed, lyophilized and lipids were extracted with chloroform/methanol 2:1 (v/v) (Riboni et al. 1992 (link)). Total lipid extracts were subjected to a two-phase partitioning resulting in the separation of an aqueous phase containing gangliosides and an organic phase containing all other lipids. The ganglioside content of brain lysates was determined in the aqueous phases as lipid-bound sialic acid by the resorcinol method (Svennerholm 1957 (link)). The phospholipid content of the brain lysates was determined in the organic phases as phosphate after perchloric acid digestion by the method of Bartlett (Bartlett 1959 (link)).
Lipids were separated by mono–dimensional HPTLC carried out with the following solvent systems: hexane/ethyl-acetate 3:2 (v/v) for the analysis of cholesterol, chloroform/methanol/acetic acid/water 30:20:2:1 (v/v/v/v) for phospholipids, chloroform/methanol/0.2% aqueous CaCl2 for gangliosides. Identification of lipids after separation was assessed by co-migration with lipid standards. Cholesterol was visualized by spraying the TLC with anysaldeyhde and quantified by densitometry and comparison with 0.1–2 μg of a standard compound. Phospholipids were detected by spraying the TLC with a molybdate reagent (Vaskovsky and Kostetsky 1968 (link)). Gangliosides in the lysates were visualized with p-dimethylaminobenzaldeyhde. Gangliosides in gradient fractions were analyzed by incubating the TLC with Clostridium perfringens neuraminidase followed by incubation with HRP–conjugated cholera toxin B (Davidsson et al. 1991 (link)). The relative amounts of lipids were determined by densitometry using the Molecular Analyst program (Bio-Rad Laboratories, Hercules, CA, USA).
Radioactive lipids were detected and quantified by radioactivity imaging performed with a Beta-Imager 2000 instrument (Biospace, Paris, France) using an acquisition time of about 48 h. The radioactivity associated with individual lipids was determined with the specific β-Vision software provided by Biospace. The radioactivity associated with cells, lipids, lipid extracts, and aqueous or organic phases was determined by liquid scintillation counting.
Scandroglio F., Venkata J.K., Loberto N., Prioni S., Schuchman E.H., Chigorno V., Prinetti A, & Sonnino S. (2008). LIPID CONTENT OF BRAIN, OF BRAIN MEMBRANE LIPID DOMAINS, AND OF NEURONS FROM ACID SPHINGOMYELINASE DEFICIENT MICE (ASMKO). Journal of neurochemistry, 107(2), 329-338.
Publication 2008
Acetic Acid Brain Cells Chloroform Choleragenoid Cholesterol Clostridium perfringens Densitometry Digestion ethyl acetate Gangliosides Hexanes Lipids Methanol molybdate N-Acetylneuraminic Acid Neuraminidase Perchloric Acid Phosphates Phospholipids Radioactivity resorcinol Solvents Vision
2
HDL Lipidome, Proteome, and Cholesterol Efflux Capacity
Cited 1 time
The statistical analysis plan
was posted before analysis (https://ilins.ucdavis.edu/). With our sample size of 40 per
group, we can detect an effect size of 0.64 SD in the mean difference
between groups, assuming an alpha of 0.05 and 80% power. Data were
analyzed on an intention-to-treat basis whereby children were included
regardless of adherence to the intervention. Data analysis was performed
in R (3.6.1). The distributions of outcome variables and key baseline
variables were inspected for normality using the Shapiro–Wilks
test. A Shapiro–Wilks statistic larger than 0.95 was considered
normally distributed. Outcome variables were transformed as necessary
with a natural log transformation, and if this still did not normalize
the distribution, normalized ranks or categories were created. Maternal
background characteristics were summarized as mean ± SD according
to their intervention group assignment at enrollment (IFA or SQ-LNS).
The household assets index, housing index, and household food insecurity
access score were calculated as proxy indicators for women’s
socioeconomic status as reported previously.5 (link) The children’s growth status was expressed as weight for
age z-score (WAZ), length for age z-score (LAZ), weight for length
z-score (WLZ), and head circumference z-score (HCZ), calculated according
to the World Health Organization standard.49 (link)Unadjusted and adjusted linear models were used to test the
impact of the intervention group (SQ-LNS vs IFA) on the HDL lipidome,
proteome, and CEC. The adjusted model included the mother’s
baseline characteristics, including height, BMI, age, years of formal
education, household food insecurity access score, asset index, housing
index, malaria status, maternal AGP and CRP, and child’s sex.
A covariate was included in the adjusted model if it was correlated
with the outcome variable using Pearson’s correlation test
(p < 0.1). We hypothesized that SQ-LNS provided
to both mothers and their children would increase child CEC; we conducted
a one-tailed test for significance because it is very unlikely that
SQ-LNS could cause a decrease in this outcome, given that SQ-LNS contain
ALA, which has been shown to increase CEC in vitro.22 (link) Two-tailed tests were performed for the lipidomics primary
outcomes, HDL EOD18, ACL, and surface/core lipid ratio,
and for the proteomics primary outcomes, HDL APOA1, SAA1, SAA2, and
APOL1 level. We hypothesized that because the SQ-LNS supplement provided
essential fatty acids, the average desaturation and chain length of
the fatty acids within HDL particles and the ratio of surface lipids
(i.e., phospholipids) to core lipids (i.e., cholesterol esters) would
be altered among children in the SQ-LNS group. We also hypothesized
that the content of the main apolipoprotein associated with HDL and
APOA1, as well as the content of proteins linked to immune activation
and inflammation (i.e., SAA1, SAA2, and APOL1), would be altered in
the SQ-LNS group.
An exploratory analysis was performed to examine
whether the intervention
group was related to the secondary outcomes, HDL lipidome species
or glycopeptides, using linear models with two-tailed tests. In the
exploratory analysis, a Benjamini–Hochberg test was performed
to correct for multiple testing. Enrichment analysis was performed
using the phyper function in R’s stats package to test whether
the glycopeptides of each protein were enriched in either intervention
groups. Enrichment is characterized as the total amount of glycopeptides
of a particular protein across all glycosylation sites as a measure
of the degree of glycosylation of that protein. The glycan signal
nomenclature follows the conventions of the Consortium for Functional
Glycomics. The glycopeptides are labeled as Protein_Position_GlycanComposition_ChargeState.
Glycan compositions are written as four-digit numbers indicating the
number of hexose (mannose or galactose), N-acetylhexosamine
(N-acetylgalactosamine), fucose, N-acetylneuraminic acid, or sialic acid (Neu5Ac), respectively. For
example, A1AT_70_5402 represents the glycopeptide of A1AT consisting
of 5 hexose, 4 N-acetylhexosamine, 0 fucose, and
2 Neu5Ac.
An additional exploratory analysis was performed to
examine the
association between HDL glycosylation and CEC to identify which compositional
changes to the HDL particles were associated with improvement in cholesterol
efflux. We have previously found that glycoprofiles of HDL-associated
proteins were highly correlated with CEC.21 (link) For the association between CEC and HDL glycosylation, a Spearman’s
test was used to reduce the effect of outliers.
We also explored
the associations between HDL variables (lipidome,
proteome, and CEC) and growth outcomes, including growth status at
18 months (WAZ, LAZ, WLZ, and HCZ) and change in WAZ, LAZ, WLZ, and
HCZ from 12 to 18 months, using both unadjusted and adjusted models.
The potential covariates in the adjusted models included maternal
age, height, BMI, malaria status, hemoglobin, asset, and housing index,
household food insecurity access score, and years of formal education,
as well as child morbidity (number of episodes of respiratory infections,
fever, loose stool, and poor appetite from 6 to 18 months). Covariates
were included in the adjusted model if they were correlated with the
growth outcome using Pearson’s correlation test (p < 0.1).
Hong B.V., Zhu C., Wong M., Sacchi R., Rhodes C.H., Kang J.W., Arnold C.D., Adu-Afarwuah S., Lartey A., Oaks B.M., Lebrilla C.B., Dewey K.G, & Zivkovic A.M. (2021). Lipid-Based Nutrient Supplementation Increases High-Density Lipoprotein (HDL) Cholesterol Efflux Capacity and Is Associated with Changes in the HDL Glycoproteome in Children. ACS Omega, 6(47), 32022-32031.
Publication 2021
3
Hepatic Antioxidant and Oxidative Stress Markers
The activities of serum aspartate (AST) and alanine transaminases (ALT) were analyzed by the method of Reitman and Frankel [21 ] while alkaline phosphatase (ALP) and γ-glutamyltransferase (γ-GT) were estimated by methods of Bergmeyer [22 ] and Szasz [23 (link)] respectively. The total sialic acid (TSA) [24 (link)] and lipid associated sialic acid (LASA) [25 (link)] levels in the serum and liver tissue were also measured. In the liver tissue, malondialdehyde (MDA) [26 (link)], nitrite [27 (link)] and antioxidants such as superoxide dismutase (SOD) [28 (link)], catalase (CAT) [29 (link)], glutathione peroxidase (GPx) [30 (link)], glutathione reductase (GR) [31 (link)], glutathione-S-transferase (GST) [32 (link)], total thiol (T-SH) [33 (link)], reduced glutathione (GSH) [34 ], levels were determined. Protein thiols (PrPr-SHs) content was calculated from the difference between the values of T-SH and GSH and expressed as µmoles of PrPr-SH/mg protein.
Monga J., Pandit S., Chauhan R.S., Chauhan C.S., Chauhan S.S, & Sharma M. (2013). Growth Inhibition and Apoptosis Induction by (+)-Cyanidan-3-ol in Hepatocellular Carcinoma. PLoS ONE, 8(7), e68710.
Publication 2013
Alanine Transaminase Alkaline Phosphatase Antioxidants Aspartate Catalase Glutathione Reductase Glutathione S-Transferase lipid-associated sialic acid Liver Malondialdehyde N-Acetylneuraminic Acid Nitrites Peroxidase, Glutathione Proteins Reduced Glutathione Serum Sulfhydryl Compounds Superoxide Dismutase Tissues
4
Quantitative Lipidomic Profiling by NMR
Lipid profiling was based on the Liposcale test, which quantifies the main classes of lipoproteins [very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), intermediate-density lipoprotein (IDL) and high-density lipoprotein (HDL)] for cholesterol and triglycerides56 (link),57 (link). The signals from choline compounds and glycoproteins were resolved by spectral deconvolution into four and three Lorentzian analytical functions, respectively. The three glycoprotein functions were classified from highest to lowest chemical shift in (1) Sialic acid, (2) Glc/GalNAc, and (3) Lipid-associated, according to previous published methodology36 (link). For each of these functions, the total area (proportional to concentration) was determined. The method has been previously validated for plasma samples of adult and cord blood, over a wide concentration range of lipoproteins, thus providing quantitative measurements for triglycerides and cholesterol estimations14 (link).
Youssef L., Simões R.V., Miranda J., García-Martín M.L., Paules C., Crovetto F., Amigó N., Cañellas N., Gratacos E, & Crispi F. (2021). Paired maternal and fetal metabolomics reveal a differential fingerprint in preeclampsia versus fetal growth restriction. Scientific Reports, 11, 14422.
Publication 2021
Adult Cholesterol Choline Glycoproteins High Density Lipoproteins Lipids Lipoprotein (a) Lipoproteins Lipoproteins, IDL Low-Density Lipoproteins N-Acetylneuraminic Acid Plasma Triglycerides Umbilical Cord Blood Very Low Density Lipoprotein
5
Integrative Genetics Uncover Lipid Regulators
Data analysis was largely performed using R79 in RStudio80 . Data formatting was performed utilizing R/dplyr_0.8.381 , R/tidyr_1.0.082 and R/reshape2_1.4.383 and visualizations were created using R/ggplot2_3.2.184 , R/RColorBrewer_1.1–285 , and for exploratory analysis, R/plotly_4.9.086 . Heatmaps were generated using R/pheatmap_1.0.1287 and manhattan plots were generated based on code accessible via the R graph gallery.88 All boxplots were generated by ggplot2:geom_boxplot with the first and third quartiles (25th and 75th percentile) for lower and upper hinges, 1.5x interquartile range for the length of the whiskers, center line at median (50% quantile), and all raw data points, including outliers shown. Statistical t-test calculations were performed with MetaboAnalyst 4.0.89 A 95% Bayesian confidence interval (CI) for each QTL was calculated using the function find_peaks() in R/qtl2.27 Human Mouse homologues were obtained from the MGI homology database (available here: http://www.informatics.jax.org/downloads/reports/HOM_MouseHumanSequence.rpt).
Allele effects for each QTL were generated using the scan1blup() function of R/qtl2.27 (link) SNP associations were performed using the scan1snps() function in R/qtl2_0.2027 (link) accessing variants from the database cc_variants.sqlite (available here: https://ndownloader.figshare.com/files/18533342) and genes from mouse_genes_mgi.sqlite (available here: https://ndownloader.figshare.com/files/17609252) via R/RSQLite_2.1.2.90 To nominate candidate gene drivers at lipid-associated QTL, we integrated the lipid data collected in the present study, with hepatic gene expression data previously obtained from a separate cohort of DO mice.34 (link) We reasoned a locus that demonstrated a hepatic cis-eQTL and a lipid-associated QTL with a similar allele effect patterns is likely to be driving the two phenotypes. We focused on cis-eQTL, as these are expression traits responding to local genetic variation. We computed the Pearson’s correlation between the allele effect patterns for all cis-eQTL at a locus to which one or more lipids co-mapped. We performed the same calculation for hepatic cis-pQTL identified in the previous study.34 (link) For example, at the Chr 10 locus, we identified >25 QTL of unknown lipids in plasma and liver, all of which showed a strong NOD-driven allele effect pattern. About half of these QTL showed NOD as the high allele and half showed NOD as the low allele. We first computed the average allele effect pattern for the NOD-high lipids and the NOD-low lipids. We then identified 55 cis-eQTL and 16 cis-pQTL that were within ±2 Mbp of the lipid QTL at ~127 Mbp on Chr 10, and calculated the correlation between their allele effect patterns and the NOD-high and NOD-low lipid QTL. One gene showed a very strong correlation; B4galnt1. The overall correlation between the allele effects of the lipid QTL and the cis-eQTL or cis-pQTL was very low (e.g., 0), suggesting that the vast majority expression traits are responding to genetic variants different than the lipid traits. However, the correlation between the lipid traits and either the expression or protein level for B4galnt1 was >|0.97|. As B4galnt1 is a known gangliosidase, we then asked if the MS fragmentation pattern for the unknown lipids is consistent with gangliosides. It is worth noting that GM3 ganglioside standard (Cayman Chemicals, Ann Arbor, MI, Item No. 15587) contained N-acetyl-neuraminidate (NANA) - the only sialic acid made by humans. All gangliosides observed in the DO samples contain N-glycolyl-neuraminidate (NGNA), a major sialic acid in mice.91 (link),92 (link) This powerful approach enabled us to combine the lipid data from one DO study with the gene expression and proteomic data of another DO study to nominate one candidate gene.
Linke V., Overmyer K.A., Miller I.J., Brademan D.R., Hutchins P.D., Trujillo E.A., Reddy T.R., Russell J.D., Cushing E.M., Schueler K.L., Stapleton D.S., Rabaglia M.E., Keller M.P., Gatti D.M., Keele G.R., Pham D., Broman K.W., Churchill G.A., Attie A.D, & Coon J.J. (2020). A large-scale genome-lipid association map guides lipid identification. Nature metabolism, 2(10), 1149-1162.
Publication 2020

Most recents protocols related to «Lipid-associated sialic acid»

1
Angiopoietin-like Protein 4 in Nephrotic Syndrome
Not available on PMC !

EXAMPLE 4

  • 1. Falk R, Jennette C, Nachman P H. Primary glomerular disease. In The Kidney, Brenner B M, editor, 6th edition, 1263-1349 (2000).
  • 2. Gutman, A. & Shafrir, E. Adipose tissue in experimental nephrotic syndrome. Am. J. Physiol. 205, 702-706 (1963).
  • 3. Vaziri, N. D. Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int. 63, 1964-1976 (2003).
  • 4. Shearer, G. C. & Kaysen G A. Endothelial bound lipoprotein lipase (LpL) depletion in hypoalbuminemia results from decreased endothelial binding, not decreased secretion. Kidney Int. 70, 647-653 (2006).
  • 5. Reaven, Kolterman, O. G. & Reaven, G. M. Ultrastructural and physiological evidence for corticosteroid-induced alterations in hepatic production of very low density lipoprotein particles. J. Lipid Res. 15, 74-83 (1974).
  • 6. Tsukamoto, Y., Kokubo, T., Horii, A., Moriya, R. & Kobayashi, Y. Lipoprotein derangement during steroid treatment in minimal-change nephrotic syndrome. Nephron 73, 606-612 (1996).
  • 7. Liu, G., Clement, L., Kanwar, Y. S., Avila-Casado, C. & Chugh, S. S. ZHX proteins regulate podocyte gene expression during the development of nephrotic syndrome. J. Biol. Chem. 281, 39681-39692 (2006).
  • 8. Yoon, J. C. et al. Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol. Cell. Biol. 20, 5343-5349 (2000).
  • 9. Kersten, S. et al. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J. Biol. Chem. 275, 28488-28493 (2000).
  • 10. Kim, I. et al. Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis. Biochem. J. 346, 603-610 (2000).
  • 11. Yoshida, K., Shimizugawa, T., Ono, M. & Furukawa, H. Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase. J. Lipid Res. 43, 1770-1772 (2002).
  • 12. Ge, H., et al. Oligomerization and regulated proteolytic processing of angiopoietin-like protein 4. J. Biol. Chem. 279, 2038-2045 (2004).
  • 13. Ge, H., Yanq, G., Yu, X., Pourbahrami, T. & Li, C. Oligomerization state-dependent hyperlipidemic effect of angiopoietin-like protein 4. J. Lipid Res. 45, 2071-2079 (2004).
  • 14. Romeo, S., et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat. Genet. 39, 513-516 (2007),
  • 15. Romeo, S. et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J. Clin. Invest. 119:70-79 (2009).
  • 16. Eremina, V., et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358, 1129-1136 (2008).
  • 17. Davis, B., et al. Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia, J. Am. Soc. Nephrol. 18, 2320-2329 (2007).
  • 18. Avila-Casado, C., et al. Proteinuria in rats induced by serum from patients with collapsing glomerulopathy. Kidney Int. 66, 133-143 (2004).
  • 19. Mandard, S., et al. The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J. Biol. Chem. 281: 934-944 (2006).
  • 20. Clement, L., et al. Early changes in gene expression that influence the course of primary glomerular disease. Kidney Int. 72, 337-347 (2007).
  • 21. Cazes, A, et al. Extracellular matrix-bound angiopoietin-like 4 inhibits endothelial cell adhesion, migration, and sprouting and alters actin cytoskeleton. Circ. Res. 99, 1207-1215 (2006).
  • 22. Malicdan, M. C., Noguchi, S., Hayashi, Y. K., Nonaka, I. & Nishino, I. Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-h IBM mouse model. Nat. Med. 15, 690-695 (2009).
  • 23. Galeano, B. et al. Mutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine. J. Clin. Invest. 117, 1585-1594 (2007).
  • 24. Ruge, T. et al, Lipoprotein lipase in the kidney: activity varies widely among animal species. Am. J. Physiol. Renal Physiol. 287, F1131-F1139 (2004).
  • 25. Koliwad, S. K. et al. Angiopoietin-like 4 (ANGPTL4/FIAF) is a direct glucocorticoid receptor target and participates in glucocorticoid-regulated triglyceride metabolism. J. Biol. Chem. 284, 25593-25601 (2009).
  • 26. Liu, G. at al. Neph1 and nephrin interaction in the slit diaphragm is an important determinant of glomerular permeability. J. Clin. Invest. 112, 209-221 (2003).
  • 27. Dijkman, H. B. P. M., Mentzel, S., de Jong, A. S. & Assmann, K. J. M. RNA in situ hybridization using digoxigenin-labeled cRNA probes. Biochemica 2, 23-27 (1995).
  • 28. Isogai, S., Mogami, K., Shiina, N. & Yoshino, G. Initial ultrastructural changes in pore size and anionic sites of the glomerular basement membrane in streptozotocin-induced diabetic rats and their prevention by insulin treatment. Nephron. 83, 53-58 (1999).
  • 29. Bakker, W. W. et al. Altered activity of plasma hemopexin in patients with minimal change disease in relapse. Pediatr. Nephrol. 20, 1410-1415 (2005).
  • 30. Graves, R. A., Tontonoz, P., Platt, K. A., Ross, S. R. & Spiegelman, B. M. Identification of a fat cell enhancer: analysis of requirements for adipose tissue-specific gene expression. J. Cell Biochem. 49, 219-224 (1992).
  • 31. Yoshida, K., Ono, M., Koishi, R. & Furukawa, H. Characterization of the 5′ regulatory region of the mouse angiopoietin-like protein 4. Vet. Res. Commun. 28, 299-305 (2004).
  • 32. Zeng, L. et al. HMG CoA reductase inhibition modulates VEGF-induced endothelial cell hyperpermeability by preventing RhoA activation and myosin regulatory light chain phosphorylation. FASEB J. 19, 1845-1847 (2005).
  • 33. Romeo, S. et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglyceride and increase HDL. Nature Genetics, 39, 513-517 (2007).
  • 34. Yin, Wu et al. Genetic variation in Angptl4 provides insight into protein processing and function, J. Biol. Chem., 284, 13213-13222 (2009).

  • 1. Nachman, P. H, Jennette, J. C. & Falk, R. Primary glomerular disease. in The Kidney, 8th edn. (ed. Brenner, B. M.) 987-1066 (Elsevier, Philadelphia, 2008).
  • 2. Marsh, J. B. & Drabkin, D. L. Experimental reconstruction of metabolic pattern of lipid nephrosis: key role of hepatic protein synthesis in hyperlipemia. Metabolism 9, 946-955 (1960).
  • 3. Vaziri N. D. Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int. 63, 1964-1976 (2003).
  • 4. Weinstock, P. H. et al. Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. J. Clin. Invest. 96, 2555-2568 (1995).
  • 5. Shearer, G. C. & Kaysen, G. A. Endothelial bound lipoprotein lipase (LpL) depletion in hypoalbuminemia results from decreased endothelial binding, not decreased secretion. Kidney Int, 70, 647-653 (2006)
  • 6. Clement, L. C. et al., Podocyte—secreted Angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med. 17, 117-122 (2011).
  • 7. Chugh, S. S., Clement, L. C. & Macé, C. New insights into human minimal change disease: Lessons from animal models. Am, J. Kid. Dis. 59, 284-292 (2012).
  • 8. Yoshida, K., Shimizugawa, T., Ono, M. & Furukawa, H. Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase. J. Lipid Res. 43, 1770-1772 (2002).
  • 9. Sukonina, V., Lookene, A., Olivecrona, T. & Olivecrona, G. Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc. Natl. Acad. Sci. USA 103, 17450-17455 (2006).
  • 10. Romeo, S. et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat. Genet. 39, 513-516 (2007).
  • 11. Yin, W. et al. Genetic variation in ANGPTL4 provides insights into protein processing and function. J. Biol. Chem, 284, 13213-13222 (2009).
  • 12. Clement L. et al. Early changes in gene expression that influence the course of primary glomerular disease. Kidney Int, 72, 337-347 (2007).
  • 13. Liu, G., Clement, L., Kanwar, Y. S., Avila-Casado, C. & Chugh, S. S. ZHX proteins regulate podocyte gene expression during the development of nephrotic syndrome. J. Biol. Chem, 281, 39681-39692 (2006).
  • 14. Nakamura, T. et al. Sclerotic lesions in the glomeruli of Buffalo/Mna rats. Nephron 43, 50-55 (1986).
  • 15. Le Berre, L. et al. Extrarenal effects on the pathogenesis and relapse of idiopathic nephrotic syndrome in Buffalo/Mna rats. J. Clin. Invest. 109, 491-498 (2002).
  • 16. Neuger, L. et al. Effects of heparin on the uptake of lipoprotein lipase in rat liver. BMC Physiol. 4, 13 (2004).
  • 17. Zhu, P. et al. Angiopoietin-like 4 protein elevates the prosurvival intracellular O2(−):H2O2 ratio and confers anoikis resistance to tumors. Cancer Cell 19, 401-415 (2011).
  • 18. Mandard, S. et al. The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J. Biol. Chem. 281, 934-944 (2006).
  • 19. Zilleruelo, G., Hsia, S. L., Freundlich, M., Gorman, H. M. & Strauss, J. Persistence of serum lipid abnormalities in children with idiopathic nephrotic syndrome. J. Pediatr. 104, 61-64 (1984).
  • 20. Yu, X. et al. Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart. Proc. Natl. Acad. Sci. U.S.A. 102, 1767-1772 (2005).
  • 21. Koliwad, S. K. et al. Angiopoietin-like 4 (ANGPTL4, fasting-induced adipose factor) is a direct glucocorticoid receptor target and participates in glucocorticoid-regulated triglyceride metabolism. J. Biol. Chem. 284, 25593-25601 (2009).
  • 22. Eremina, V. et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358, 1129-1136 (2008).
  • 23. Maynard, S. E., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin. Invest. 111, 649-658 (2003).
  • 24. Venkatesha, S. et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 12, 642-649 (2006).
  • 25. Wei, C. et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat. Med. 17, 952-960 (2011).
  • 26. Wei, C. et al. Circulating suPAR in Two Cohorts of Primary FSGS. J. Am. Soc. Nephrol. 23, 2051-2059 (2012).
  • 27. Avila-Casado, C. et al. Proteinuria in rats induced by serum from patients with collapsing glomerulopathy. Kidney Int, 66, 133-143 (2004).
  • 28. Chugh, S. S., & Clement, L. C. Telomerase at the center of collapsing glomerulopathy. Nat. Med. 18, 26-27 (2012).
  • 29. Chugh, S. et al. Aminopeptidase A: A nephritogenic target antigen of nephrotoxic serum. Kidney Int. 59, 601-613 (2001).
  • 30. Imamura, S. et al. A novel method for measuring human lipoprotein lipase and hepatic lipase activities in postheparin plasma. J. Lipid Res. 49, 1431-1437 (2008).
  • 31. Liu, G., et al. Neph1 and nephrin interaction in the slit diaphragm is an important determinant of glomerular permeability. J. Clin. Invest. 112, 209-221 (2003).
  • 32. Chang, S. F., Reich, B., Brunzell, J. D. & Will, H. Detailed characterization of the binding site of the lipoprotein lipase-specific monoclonal antibody 5D2. J. Lipid Res. 39, 2350-2359 (1998).

TABLE 4
LEGEND TO THE SEQUENCE LISTING
SEQ ID NO: 1Variant 1 of human Angptl4 polypeptide
SEQ ID NO: 2cDNA sequence of variant 1 of human Angptl4
SEQ ID NO: 3Variant 2 of human Angptl4 polypeptide
SEQ ID NO: 4cDNA sequence of variant 2 of human Angptl4
SEQ ID NO: 5Rat Angptl4 polypeptide
SEQ ID NO: 6cDNA sequence of rat Angptl4 polypeptide
SEQ ID NO: 7Mouse Angptl4 polypeptide
SEQ ID NO: 8cDNA sequence of mouse Angptl4 polypeptide
SEQ ID NO: 9Variant 1 of human Angptl4 polypeptide with substitutions
SEQ ID NO: 10Variant 2 of human Angptl4 polypeptide with substitutions
SEQ ID NOS: 11-22PCR primers and probes (see text)
SEQ ID NO: 23N-terminal multispecies consensus sequence with substitutions
SEQ ID NO: 24Central multispecies consensus sequence with substitutions
SEQ ID NO: 25C-terminal multispecies consensus sequence with substitutions
SEQ ID NO: 26N-terminal human consensus sequence with substitutions
SEQ ID NO: 27C-terminal human consensus sequence with substitutions
SEQ ID NO: 28Mutant variant of human Angptl4 polypeptide DKMNVLAHGLLQLGQGL
SEQ ID NOS: 29-90Sequences from Table 2
SEQ ID NO: 91Reverse primer for amplification of aP2-Angptl4 construct
SEQ ID NO: 92Probe for identification of aP2-Angptl4 construct
SEQ ID NO: 93cDNA encoding peptide of SEQ ID NO: 80
SEQ ID NO: 94cDNA encoding the peptide of SEQ ID NO: 87

US11866468B2. Methods for treatment of nephrotic syndrome and related conditions (2024-01-09). None [US]. Inventors: Sumant S Chugh [US].
Patent 2024
2
Evaluating Tuberculosis Antibody Profiles
Some previous studies in children have demonstrated improved specificities achieved by combining both protein and glycolipid antigens within serological assays [26 (link)–29 (link)]. Furthermore, several studies have illuminated the potential for heightened sensitivity through the combined analysis of multiple antigen targets, effectively overcoming the interindividual heterogeneity of the human humoral immune response to M. tuberculosis [26 (link)–33 (link)].
We will analyse antibodies concentrations and properties against single protein antigens, single glycolipid antigens [12 (link), 34 (link)–40 (link)], as well as multiple antigens in combination (Table 2). The types of antigens include cell wall fractions, whole cell lysates, and total lipids of M. tuberculosis. The selection of protein antigens is based on results from large protein microarray studies in adults [41 (link)–46 (link)], one large multiplex bead-based study in children [31 (link)], and published and unpublished data from an adult study performed in the U.K (MIMIC study; personal communication M. Tebruegge) [47 ]. In order to enhance specificity, the overlap of the antigen targets for M. tuberculosis with Bacillus Calmette-Guérin (BCG) and other non-tuberculous mycobacteria will be reduced.

Key protein, glycolipid, and multiple antigens

TypeNameRv number/Full name
ProteinFbpC (Ag85C)Rv0129c
PstS3Rv0928
PstS1Rv0934
PapA4Rv1528
GarARv1827
Apa (Mpt32)Rv1860
FbpB (Ag85B)Rv1886c
Mpt63Rv1926c
Mpt64Rv1980c
HspX (Acr)Rv2031c
AcgRv2032
Rv2034Rv2034
Hrp1Rv2626c
EsxO-EsxPRv2346-Rv2347
EspARv3616c
FbpD (Mpt51)Rv3803c
FbpA (Ag85A)Rv3804c
EsxB (CFP-10)Rv3874
EsxA (ESAT-6)Rv3875
EsxA-EsxB (ESAT6-CFP10)Rv3875-Rv3874
EspD-EspCRv3614-Rv3615
EspBRV3881c
Ag85 complexRv3804c-Rv1886c-Rv0129c
GlycolipidLAMLipoarabinomannan
PDIMPhthiocerol dimycocerosates
TDMTrehalose dimycolates
TMMTrehalose monomycolates
PGLPhenolic glycolipid
Multiple antigens (H37Rv)Cell wall fractionscontains proteins and non-protein compounds such as mAGP of M. tuberculosis
Cell membrane fractionscontains the cytoplasmic membrane and components of the outer lipid layer.
Whole cell lysatescontains proteins, lipids and carbohydrates present within the M. tuberculosis bacterial cell
Total hypoxic lipidscontaining hypoxic culture M. tuberculosis
Total normoxic lipidscontaining normoxic culture M. tuberculosis

Abbreviations: Acg - alpha-crystallin homolog -coregulated gene; Acr - alpha-crystallin homolog; Ag85 complex - antigen 85 complex; Apa - alanine and proline rich secreted protein; CFP-10 - culture filtrate protein-10; ESAT-6 - early secreted antigenic target-6; EspA - ESX-1 secretion-associated protein A; EsxA/B/C/D/O/P - early secretory antigenic target homolog A/B/C/D/O/P; FbpA/B/C/D - fibronectin binding protein A/B/C/D; GarA - Glycogen accumulation regulator A; Hrp1 - hypoxic response protein 1; HspX - heat shock protein-X; Mpt32/51/63/64 - Proteins purified from Mycobacterium tuberculosis 32/51/63/64; PapA4 - polyketide synthase (PKS) associated protein; PstS1/3 - periplasmic phosphate-binding lipoprotein S1/3

Together with targeted M. tuberculosis antigens, this study will evaluate the following distinct properties of the antibodies: isotypes and their subclasses, FcR binding profiles, and antibody glycosylation patterns (refer to Fig. 1). The rational for this is to obtain further information about the immune response to the antigen. TB disease results from a combination of the mycobacteria infecting and the resulting pathologic immune response. Therefore, antibody concentrations may only reflect on exposure, timepoint, and burden of mycobacteria, whereas additional properties such as FcR may reflect on the fact if the immune response producing tissue damage and pathology or not. This is shown in studies in children with TB disease that have demonstrated the potential enhancement of serological assay sensitivity through the integration of diverse antibody isotypes [48 (link)–50 (link)]. Recent advancements in adult research have indicated that an evaluation of certain antibody properties, such as FcRs binding profiles and glycosylation patterns, could potentially enable the differentiation between TB disease and infection [12 (link), 13 (link)].

Overview of the antibody properties

Interaction between the surface of M. tuberculosis, binding of the antibody and the recognition of the antibody by an immune cell. Sections A, B, and C detail the different antibody properties: A) antibody isotypes and IgG subclasses B) glycosylation patterns of antibodies, including a core glycan and potential additional sugar residues (1–4) C) activating and inhibiting FcRs with varying affinities for antibody binding

Abbreviations: Mtb -Mycobacterium tuberculosis; FcR -fragmented crystallizable region (Fc) receptor; IgM - immunoglobulin M; IgD - immunoglobulin D, IgG1 − 4 - immunoglobulin G1 − 4; IgA - immunoglobulin A, N - N-acetylglucosamine; M - mannose; G - galactose; S - sialic acid; F - fucose

As a quality control and potential normalisation variable, we will measure the total antibody concentration of each isotype and the total antibody concentration binding to distinct FcRs.
Neudecker D., Fritisch N., Sutter T., Lu L., Lu P., Tebruegge M., Santiago-Garcia B, & Ritz N. (2024). Evaluation of serological assays for the diagnosis of childhood tuberculosis disease: a study protocol. BMC Infectious Diseases, 24, 481.
Publication 2024
3
Therapeutic Cell-Based Approaches for Hemophilia and aHUS
Not available on PMC !

Example 79

1. Hemophilia

A patient suffering from hemophilia A is diagnosed. A composition of exogenous FVIII expressing enucleated hematopoietic cells is prepared as described herein. 10{circumflex over ( )}9 of the cells are administered intravenously to the patient. The clotting rate is assessed with a standard in vitro clotting time assay known in the art. Circulating antibodies against FVIII are detected in serum as described herein. The levels of circulating antibodies are assessed to track the effectiveness of immune tolerance induction. If the clotting cascade activity is insufficient to ensure healthy coagulation, recombinant or isolated FVIII are administered concurrently intravenously in order to reduce the symptoms of hemophilia A.

2. Atypical Hemolytic Uremic Syndrome

A patient suffering from atypical hemolytic uremic syndrome (aHUS) is diagnosed. A composition of exogenous CFH expressing enucleated hematopoietic cells is prepared as described herein. 10{circumflex over ( )}9 of the cells are administered intravenously to the patient. The symptomatic hemolysis rate is assessed with a standard urinary hemolysis assay known in the art. Circulating antibodies against CFH are detected in serum as described herein. The levels of circulating antibodies are assessed to track the effectiveness of immune tolerance induction. The patient is administered the treatment until the symptoms of the disease are seen to ameliorate using the assays described herein.

3. Multiple Sclerosis

An individual with multiple sclerosis (MS) receives a single infusion of 1×10{circumflex over ( )}9 antigen expressing enucleated hematopoietic cells expressing the antigenic polypeptide myelin basic protein (MBP), produced and formulated as described herein. At the day of study drug administration, the patient is monitored in a phase 1 inpatient unit for 24 hours. Measurement of the primary outcome is performed at month 3 and additional safety follow-up is performed until month 6 with consecutive clinical, MRI, and general physical examinations as well as clinical and laboratory analyses to assess adverse events and monitor MS disease activity. The procedure is repeated until tolerance is induced such that the symptoms of MS are ameliorated in the individual. See, for example, Andreas Lutterotti et al. Sci Transl Med 5, 188ra75 (2013).

Frequency of different cell subsets is analyzed in whole blood (EDTA tubes) by flow cytometry with the following antibody panels: for immune cell subsets (granulocytes, eosinophils, monocytes, and B, T, NK, and NK T cells)—anti-CD45 (PE-Cy7, eBioscience), anti-CD16, (APC-Cy7, BioLegend), anti-CD19 [fluorescein isothiocyanate (FITC), BD], anti-CD14 (V450, BD), anti-CD3 [peridinin chlorophyll protein (PerCP), BD], and anti-CD56 [phycoerythrin (PE), eBioscience]; for T cell subsets including CD4+, FoxP3+ Tregs, regulatory CD8+CD57+ILT2+, and proinflammatory CD8+CD161high T cells-anti-CD3 (PE-Cy7, eBioscience), anti-CD4 (APC, eBioscience), anti-CD8 [Pacific Blue (PB), Dako-Biozol], anti-FoxP3 (PE, Miltenyi), anti-CD25 (APC, eBioscience), anti-CD57 (FITC, BD), anti-ILT2 (PE, Beckman), and anti-CD161 (APC, Miltenyi). The corresponding isotype controls are included in all stainings. Cells are analyzed with an LSR-II flow cytometer (BD) and FACSDiva Software (BD).

Peripheral blood mononuclear cells (PBMCs) are isolated by Ficoll density gradient centrifugation (PAA), and functional phenotype of T cells is evaluated by intracellular cytokine staining as follows: 5×10{circumflex over ( )}5 freshly isolated PBMCs are incubated overnight in 200 ml of X-VIVO 15 (Lonza) in a sterile FACS tube. The next day, cells are stimulated with phorbol 12-myristate 13-acetate (50 ng/ml, Sigma) and ionomycin (1 mg/ml, Sigma) in the presence of brefeldin A (10 mg/ml, eBioscience) for 5 hours. After washing with phosphate-buffered saline, cells are stained with LiveDead kit (AmCyan, Invitrogen), fixed, permeabilized, and stained with different antibodies: anti-IL-17 (Alexa Fluor 647; eBioscience), anti-IL-4 (PE-Cy7, BioLegend), anti-IFN-g (FITC, BioLegend), anti-IL-10 (PE; BioLegend), anti-CD3 (PE, DakoCytomation), anti-CD4 (PB, DakoCytomation), and anti-CD8 (PB, BioLegend) or with the corresponding isotype controls.

The antigen-specific T cell responses toward the myelin peptide used in the study are measured in freshly isolated PBMCs before the tolerization procedure and after 3 months. Antigen-specific T cell responses are analyzed by proliferation assays with thymidine incorporation. Briefly, isolated PBMCs are seeded in 96-well plates at 1.5×10{circumflex over ( )}5 PBMCs per well in X-VIVO 15 medium (Lonza) with 1 mM of peptide. Forty-eight wells are seeded per antigen, and six wells only with medium as negative control in each plate. TTx (5 mg/ml) (Novartis Behring) is used as positive control. On day 7, plates are incubated for 15 hours with 1 mCi of [3H] thymidine (Hartmann Analytic). [3H] thymidine-pulsed plates are analyzed with a scintillation b counter (Wallac 1450, PerkinElmer). The scintillation counts (CPM) of each well are measured. Wells showing CPM higher than the mean+3 SDs of the unstimulated wells are considered as positive.

Many modifications and other embodiments of the inventions set forth herein will come to mind to one skilled in the art to which these inventions pertain having the benefit of the teachings presented in the foregoing descriptions and the associated drawings. Therefore, it is to be understood that the inventions are not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended claims. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.

All publications and patent applications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Tables A-J

TABLE A
Circulating cells
Embryonic stem cells (ESC)Induced pluripotent stem cells
(iPSC)
Cord blood stem cell (CD-SC)Mesenchymal stem cell
CD34+ cellsPolychromatic normoblasts
Hematopoietic stem cells (HSC)Orthochromatic normoblasts
Spleen colony forming unit (CFU-S)Proerythroblast
Common myeloid progenitor (CMP)Polychromatophilic erythrocyte
cells capable of forming a granulocyte,
erythrocyte, monocyte, or
megakaryocyte (CFU-GEMM)
Blastocyte colony-forming cellsNormoblast
Burst-forming unit erythroid (BFU-E)Platelets
Megakaryocyte-erythroid progenitorLeukocytes
(MEP) cell
Colony-forming unit erythroid (CFU-E)Lymphoid cells
ReticulocytesT cells
ErythrocytesB cells

TABLE A1
Erythroid cells
Embryonic stem cells (ESC)Induced pluripotent stem cells
(iPSC)
Cord blood stem cell (CD-SC)Polychromatic normoblasts
CD34+ cellsOrthochromatic normoblasts
Hematopoietic stem cells (HSC)Proerythroblast
Spleen colony forming unit (CFU-S)Polychromatophilic erythrocyte
Common myeloid progenitor (CMP)Normoblast
cells capable of forming a granulocyte,
erythrocyte, monocyte, or
megakaryocyte (CFU-GEMM)
Blastocyte colony-forming cells
Burst-forming unit erythroid (BFU-E)
Megakaryocyte-erythroid progenitor
(MEP) cell
Erythroid forming colony unit (CFU-E)
Reticulocytes
Erythrocytes

TABLE B
Circulating cell associated proteins
CD1
CD2
CD3
CD4
CD5
CD6
CD7
CD8
CD9
CD10
CD11a
CD11b
CD11c
CD12w
CD13
CD14
CD15
CD16
CD17
CD18
CD19
CD20
CD21
CD22
CD23
CD24
CD25
CD26
CD27
CD28
CD29
CD30
CD31
CD32
CD33
CD34
CD35
CD36
CD37
CD38
CD39
CD40
CD41
CD42
CD43
CD44
CD45
CD46
CD47
CD48
CD49a
CD49b
CD49c
CD49d
CD49e
CD49f
CD53
CD54
CD55
CD56
CD57
CD58
CD59
CD61
CD62E
CD62L
CD62P
CD63
CD68
CD69
CD71
CD72
CD73
CD74
CD80
CD81
CD82
CD83
CD86
CD87
CD88
CD89
CD90
CD91
CD95
CD96
CD100
CD103
CD105
CD106
CD107
CD107a
CD107b
CD109
CD117
CD120
CD122
CD127
CD132
CD133
CD134
CD135
CD138
CD141
CD142
CD143
CD144
CD147
CD151
CD152
CD154
CD156
CD158
CD163
CD165
CD166
CD168
CD184
CD186
CD195
CD197
CD199
CD209
CD202a
CD220
CD221
CD235a
CD271
CD279
CD303
CD304
CD309
CD326
TLR 1
TLR 2
TLR 4
TLR 5
TLR 6

TABLE C
Erythrocyte associated proteins
2′,3′-cyclic-Creatine kinaseHypothetical proteinRAP1A or RAP1B
nucleotide 3′-XP_100510
phosphodiesterase
AcetylcholinesteraseDC 38Hypothetical proteinRAP2B
XP_100619
Actin alpha andDuodenal cytochrome bHypothetical proteinRh blood D group
beta chainXP_100665antigen polypeptide
AdenosineEnhancer proteinHypothetical proteinRhesus D category VI
deaminaseXP_100925type III protein
Adducin alphaErythroblastHypothetical proteinSimilar to adhesive
subunitmembrane-associatedXP_103707plaque matrix protein
proteinprecursor
Aldolase AFar upstream elementHypothetical proteinSimilar to ankyrin 1
binding proteinXP_106269
Ankyrin 1 isoform 2Flotillin 1Ig heavy chain V-V regionSimilar to flotillin 2
Ankyrin 1 isoform 4Flotillin 2 47KellSimilar to glycophorin A
Ankyrin 1 spliceGlucose transporterKIAA0340Similar to Lutheran
form 2glycoproteinblood group
Aquaporin 1GlutathioneKIAA1741 proteinSimilar to RAS-related
transferaseprotein RAB-15
Arginase type 1Glyceraldehyde-3-Lyn B proteinSimilar to RAS-related
phosphateprotein RAL-A
dehydrogenase
Arginase type 1Glycophorin AMembrane protein p55Similar to tropomyosin
erythroid variant
ATP-binding cassetteGlycophorin APhosphatidylinositol-4-Similar to tropomyosin
half-transporterprecursorphosphate 5 kinase type III4 18
ATP-binding cassetteGlycophorin C isoform 1PhosphoribosylSolute carrier family 2
subfamily C member 6pyrophosphate synthetase(facilitated glucose
transporter) member 1
bA421H8.2 (novelHemoglobin alphaPoly (A)-specificSolute carrier family
protein)ribonuclease29 (nucleoside
transporter) member 1
B-CAM proteinHemoglobin betaPresenilin-associatedSpectrin alpha chain
protein
Block ofHemoglobin deltaProtein band 3Spectrin beta chain
proliferation 1
C-1-tetrahydrofolateHemoglobin epsilonProtein band 4.1Translation initiation
synthasefactor 2C
Calcium transportingHemoglobin gammaProtein band 4.1Tropomodulin
ATPase 4(elliptocytosis 1, RH-linked)
CD55HGTD-PProtein band 4.2Tropomyosin 3
CD58Hypothetical proteinProtein band 4.9 (dematin)Tropomyosin isoform
XP_061743 or
XP_089854
CD59 antigenHypothetical proteinProtein band 7.2b,Tropomyosinalpha
XP_091430stomatinchain (smooth muscle)
26
Cell surfaceHypothetical proteinRAB 35Unknown protein
glycoprotein CD44XP_091724
Channel-like integralHypothetical proteinRabphilin-3 A-integratingVesicle-associated
membrane proteinXP_092517proteinmembrane protein 2
(synaptobrevin 2)
ComplementHypothetical proteinRal A binding proteinZona pellucida binding
receptor 1XP_095819protein
Adipocyte plasmaStomatinMyosin-9Histone H1.1
membrane-
associated protein
AmmoniumStomatin-like protein 2Protein 4.1Histone H2A type 1-
transporter Rh type AB/E
Aquaporin 1Thioredoxin-relatedSpectrin alpha chain,Histone H3.1
transmembraneerythrocyte
protein 4
Aquaporin 7TMCC2Spectrin beta chain,Histone H4
erythrocyte
ATP-binding cassetteTransferrin receptorTalin-1Lamin A/C
sub-family Bprotein 1
member 6,
mitochondrial
Band 3 anionTransmembrane andTalin-2Lamina-associated
transport proteincoiled-coil domainpolypeptide 2, isoform
family 2alpha
BasiginUrea transporter 1Tropomodulin-1Lamina-associated
polypeptide 2,
isoforms beta/gamma
CD44Zinc transporter 1Tropomyosin 1 (Alpha)Lamin-B receptor
isoform 4
CD4755 kDa erythrocyteTropomyosin 3Lamin-B1
membrane protein
EquilibrativeActin, alpha cardiacTropomyosin alpha-3 chainLamin-B2
nucleosidemuscle
transporter 1
ErythroidActin, cytoplasmicTubulin alpha-1 chainMatrin-3
membrane-
associated protein
Flotillin-1Actin-related protein 2Tubulin beta chainMultiple inositol
polyphosphate
phosphatase 1
Flotillin-2Actin-related proteinTubulin, alpha 1 (TestisN-acylneuraminate
2/3 complex subunitspecific)cytidylyltransferase
1B
Glucose transporter,Actin-related proteinTubulin, alpha 8Neutral alpha-
type 12/3 complex subunit 2glucosidase AB
Glycophorin-AActin-related protein 3Tubulin, beta 6Nuclear pore complex
protein Nup93
Glycophorin-BAlpha-actinin-4VinculinNuclear pore
membrane
glycoprotein 210
Glycophorin-CAlpha-adducin78 kDa glucose-regulatedNucleolin
protein
Immunoglobulin-likeAnkyrin-1Antigen KI-67Nucleoporin NUP188
domain-containinghomolog
receptor 1
Integrin alpha-XAnkyrin-3ATP-dependent RNANucleoprotein TPR
helicase DDX39A
Integrin beta-1Beta-actin-like protein 2CalnexinPrelamin-A/C
Kell blood groupBeta-adducinCalreticulinProtein disulfide-
glycoproteinisomerase
Large neutral aminoCapping protein (ActinDNA topoisomerase 1Protein disulfide-
acids transporterfilament) muscle Z-isomerase A4
small subunit 3line, beta
MembraneCortactinDNA-dependent proteinProtein disulfide-
transport protein XKkinase catalytic subunitisomerase A6
Membrane-DematinDolichyl-Protein ERGIC-53
associateddiphosphooligosaccharide-
progesteroneprotein glycosyltransferase
receptor component 248 kDa subunit
MonocarboxylateDynactin 2 (P50),Dolichyl-Ribophorin II
transporter 1isoform CRA _bdiphosphooligosaccharide-
protein glycosyltransferase
subunit 1
MultidrugErythrocyteEndoplasmic reticulumTransitional
resistance-membrane proteinresident protein 29endoplasmic reticulum
associated protein 4band 4.2ATPase
Neutral cholesterolFilamin-AEndoplasmic reticulumUDP-
ester hydrolase 1resident protein 44glucose:glycoprotein
glucosyltransferase 1
Plasma membraneGamma-adducinEndoplasminCD59
calcium-transporting
ATPase 1
Plasma membraneGelsolinER-Golgi SNARE of 24 kDa
calcium-transporting
ATPase 3
Plasma membraneKinesin-1 heavy chainFACT complex subunit
calcium-transportingSPT16
ATPase 4
Probable E3Microtubule-Glucosidase 2 subunit beta
ubiquitin-proteinassociated protein
ligase C12orf51RP/EB family member 1
Rh blood group,Myosin light chain 4Heme oxygenase 1
CcEe antigens
SLC43A3Myosin lightHemogen
polypeptide 6
Sodium/calciumMyosin, heavy chainHeterochromatin protein
exchanger SCL8A311, smooth muscle1-binding protein 3
Sodium/potassium-Myosin-10High mobility group
transporting ATPaseprotein B1
subunit alpha-1
Sodium/potassium-Myosin-14High mobility group
transporting ATPaseprotein B2
subunit beta-3

TABLE C1
Erythrocyte transmembrane proteins
Aquaporin 1
Cell surface glycoprotein CD44
Channel-like integral membrane protein
Complement receptor 1
Erythroblast membrane-associated protein
Glucose transporter glycoprotein
Glycophorin A
Glycophorin A precursor
Glycophorin C isoform 1
Kell
Membrane protein p55
Protein band 3
Rh blood D group antigen polypeptide
Rhesus D category VI type III protein
Similar to glycophorin A
Similar to Lutheran blood group
Solute carrier family 2 (facilitated glucose transporter) member 1
Solute carrier family 29 (nucleoside transporter) member 1

TABLE C2
Erythrocyte GPI-linked proteins
Acetylcholinesterase
CD55
CD58
CD59 antigen

TABLE C3
Erythrocyte intracellular proteins
2′,3′-cyclic-nucleotide 3′-phosphodiesterase
Actin alpha and beta chains
Adenosine deaminase
Adducin alpha subunit
Aldolase A
Ankyrin 1 isoform 2
Ankyrin 1 isoform 4
Ankyrin 1 splice form 2
Arginase type 1
Arginase type 1 erythroid variant
ATP-binding cassette half-transporter
ATP-binding cassette subfamily C member 6
bA421H8.2 (novel protein)
B-CAM protein
Block of proliferation 1
C-1-tetrahydrofolate synthase
Calcium transporting ATPase 4
Creatine kinase
DC 38
Duodenal cytochrome b
Enhancer protein
Far upstream element binding protein
Flotillin 1
Flotillin 2 47
Glutathione transferase
Glyceraldehyde-3-phosphate dehydrogenase
Hemoglobin alpha
Hemoglobin beta
Hemoglobin delta
Hemoglobin epsilon
Hemoglobin gamma
HGTD-P
Hypothetical protein XP_061743 or XP_089854
Hypothetical protein XP_091430
Hypothetical protein XP_091724
Hypothetical protein XP_092517
Hypothetical protein XP_095819
Hypothetical protein XP_100510
Hypothetical protein XP_100619
Hypothetical protein XP_100665
Hypothetical protein XP_100925
Hypothetical protein XP_103707
Hypothetical protein XP_106269
Ig heavy chain V-V region
KIAA0340
KIAA1741 protein
Lyn B protein
Phosphatidylinositol-4-phosphate 5 kinase type III
Phosphoribosyl pyrophosphate synthetase
Poly (A)-specific ribonuclease
Presenilin-associated protein
Protein band 4.1
Protein band 4.1 (elliptocytosis 1, RH-linked)
Protein band 4.2
Protein band 4.9 (dematin)
Protein band 7.2b, stomatin
RAB 35
Rabphilin-3 A-integrating protein
Ral A binding protein
RAP1A or RAP1B
RAP2B
Similar to adhesive plaque matrix protein precursor
Similar to ankyrin 1
Similar to flotillin 2
Similar to RAS-related protein RAB-15
Similar to RAS-related protein RAL-A
Similar to tropomyosin
Similar to tropomyosin 4
Spectrin alpha chain
Spectrin beta chain
Translation initiation factor 2C
Tropomodulin
Tropomyosin 3
Tropomyosin isoform
Tropomyosinalpha chain (smooth muscle) 26
Unknown protein
Vesicle-associated membrane protein 2 (synaptobrevin 2)
Zona pellucida binding protein

TABLE D
Conjugation methods
Zero-length x-linker
EDC
EDC plus sulfo NHS
CMC
DCC
DIC
Woodward's reagent K
N,N′-carbonyldiimidazole
Schiff base + reductive amination
Homobifunctional NHS esters
DSP
DTSSP
DSS
BS{circumflex over ( )}3
DST
Sulfo-DST
BSOCOES
Sulfo-BSOCOES
EGS
Sulfo-EGS
DSG
DSC
Homobifunctional Imidoesters
DMA
DMP
DMS
DTBP
Sulfhydryl reactive x-linkers
DPDPB
BMH
Difluorobenzene derivatives
DFDNB
DFDNPS
Photoreactive x-linker
BASED
Homobifunctional aldehydes
Formaldehyde
Glutaraldehyde
bis-epoxide
1,4-butanediol diglycidyl ether
Homobifunctional hydrazides
adipic acid dihydrazide
carbohydrazide
Bis-diazonium derivative
o-tolidine diazotized
Bis-diazotized benzidine
Amine-sulfhydryl x-linker
SPDP, LC-SPDP, sulfo-LC-SPDP
SMPT and sulfo-LC-SMPT
SMCC and sulfo-SMCC
MBS and sulfo-MBS
SIAB and sulfo-SIAB
SMPB and sulfo-SMPB
GMBS and sulfo-GMBS
SIAX and SIAXX
SIAC and SIACX
NPIA
Carbonyl-sulfydryl x-linker
MPBH
M2C2H
PDPH
amine-photoreactive x-linker
NHS-ASA, Sulfo-NHS-ASA
Sulfo-NHS-LC-ASA
SASD
HSAB and sulfo-HSAB
SANPAH and sulfo-SANPAH
ANB-NOS
SAND
SADP and sulfo-SADP
Sulfo-SAPB
SAED
Sulfo-SAMCA
p-Nitrophenyl diazopyruvate
PNP-DTP
sulfhydryl-photoreactive x-linker
ASIB
APDP
Benzophenone-4-iodoacetamide
Benzophenone-4-maleimide
Carbonyl-photoreactive x-linker
ABH
Carboxylate-photoreactive x-linker
ASBA
arginine-photoreactive x-linker
APG
Bioorthogonal reactions
Diels-alder reagent pairs
Hydrazine-aldehyde reagent pairs
Boronic acid salicylhydroxamate
Click chemistry
Staudinger ligation

TABLE D1
Enzymatic conjugation methods
Enzymatic reactions
SpyCatcher/SpyTag
Spy0128 derivatives
Transpeptidases
Isopeptidases
Sortase
DD-transpeptidase
Peptidyl transferase
G-glutamyl transpeptidase
D-glutamyl transpeptidase
Farnesyltransferase
Prenyltranferase
Dimethylallyltrans-transferase
Geranylgeranyl pyrophosphate synthase
Dehydrodolichol diphosphate synthase

TABLE E
Chemistry of reactive groups
Amine reactions
Isothyocyantes
Isocyanates
Acyl azides
NHS esters
Sulfonyl chlorides
Aldehydes and glyoxals
Epoxides and oxiranes
Carbonates
Arylating agents
Imidoesters
Carbodiimides
Anhydrides
Fuorphenyl esters
Hydroxymethyl phosphine derivatives
Guanidination of amines
Thiol reactions
Haloacetyl and alkl halide derivatives
Maleimides
Aziridines
Acryloyl derivatives
Arylating agents
Thil-disulfide exchange reagents
Vinylsulfone derivatives
Metal-thiol dative bonds
Carboxylate rections
Diazoalkanes and diazoacetyl compounds
Carbonyldiimidazole
Carbodiimides
Hydroxyl reactions
Epoxides and oxiranes
Carbonyldiimidazole
N,N′0disuccinimidyl carbonate
N-hydroxysuccinimidyl chloroformate
Oxidation with periodate
Enzymatic oxidation
Alkyl halogens
Isocyanates
Aldehyde and Ketone reactions
Hydrazine derivatives
Schiff base formation
Reductive amination
Mannich condensation
Active hydrogen reactions
Diazonium derivatives
Mannich condensation
Iodination reactions
Cycloaddition reactions
Diels-Alder reaction
Complex formation with boronic acid derivatives
Click chemistry: Cu-promoted Azide-
Alkyne [3 + 2] cycloaddition

TABLE F
Autoimmune diseases and antigens
DiseaseKnown antigen
Acute rheumatic fevercross reactive antibodies to cardiac muscle
alopecia areataTrychohyalin, keratin 16
ANCA-associated vasculitisNeutrophil cytoplasmic antigen, proteinase 3, myeloperodixase,
bacterial permiability increasing factor
autoimmune gastritisH, K adenosine triphosphatase
autoimmune hemolyticRh blood group antigens, I antigen
anemia
autoimmune hepatitisnuclear protein, liver-kidney microsome type 1, liver cytosol type 1
autoimmune myocarditiscardiac myosin
Autoimmune thyroiditisThyroid peroxidase, thyroglobulin, thyroid-stimulating hormone
receptor
Autoimmune uveitisRetinal arrestin (S-antigen)
dermatomyositisMi2 ATPase
diabetes (type 1)Pancreatic beta cell antigen
goodpasture's syndromeNoncollagenous domain of basement membrane collagen type IV
Graves' diseaseThyroid stimulating hormone receptor
Guillain-Barré syndromeNeurofascin-186, gliomedin, nodal adhesion molecueles
HypoglycemiaInsulin receptor
idiopathicPlatelet integrin GpIIb, GpIIIa
thrombocytopenic purpura
Insulin resistant diabetesInsulin receptor
Membranous nephritisPhospholipase A2
mixed essentialrheumatoid factor IgG complexes
cryoglobulinemia
multiple sclerosisMyelin basic protein, proteolipid protein, myelin oligodendrocyte
glycoprotein
myasthenia gravisAcetylcholine receptor
Myasthenia gravis - MUSCMuscarinic receptor
pemphigus/pemphigoidEpidermal cadherin
pernicious anemiaintrinsic factor (Gastric)
polymyositisnuclear and nucleolar antigen
primary biliary cirrhosisneutrophil nuclear antigen, mitochondrial multienzyme complex
psoriasisPSO p27
rheumatoid arthritisrheumatoid factor IgG complexes, synovial joint antigen, citrullinated
protein, carbamylated protein
scleroderma/systemicScl-86, nucleolar scleroderma antigen
sclerosis
Sjögren's syndromeSS-B, Lupus La protein
systemic lupusDNA, histones, ribosomes, snRNP, scRNP
erythematosus
vitiligoVIT-90, VIT-75, VIT-40
Wegener's granulomatosisneutrophil nuclear antigen
AntiphospholipidBeta-2 glycoprotein 1
syndrome (APS) &
catastrophic APS
Chemotherapy inducedNeuronal antigens
peripheral neuropathy
ThromboticADAMTS13
thrombocytopenic purpura
Atypical hemolytic uremicComplement factor H
syndrome

TABLE G
Inflammatory diseases and antigens
DiseaseAntigen
Crohn's diseaseFlagellin, microbial antigens
Ulcerative colitisNeutrophil cytoplasmic antigen, microbial
antigens
Celiac diseaseGluten
Inflammatory bowel diseaseMicrobial antigens

TABLE H
Allergic disease triggers
AllergyAntigen
Animalfel d 1, can f6
dander
Black2S albumin, vicilin-like (7S) protein
walnut
Brazil2S albumin, legumin-like (11S) seed storage protein
nut
Cashew7S vicilin-like protein, legumin-like 11S seed storage protein
nut
ChestnutChitinase 1b, lipid transfer protein Cas s8
DustDer p2
mites
EggOvomucoid, ovalbumin, ovotransferrin, lysozyme, alpha-livetin
English2S albumin, 7S vicilin-like protein, lipid transfer protein, legumin-like 11S seed storage
walnutprotein
FishParvalbumins
HazelnutBet v1 homologue, profilin, lipid transfer protein, 11s globulin-like protein, 7S vicilin-like
protein
InsectMelittin, phospholipase A2, hyaluronidase, acid phosphatase, protease, antigen 5, Api
venomm1-4, Bom p1, p4, Dol m1, 2, 5; Vesp c1, c5; Pol a1, a2, a5; Ves v1, v2, v5; Sol I 1-4
LatexHev b 1, 2, 3, 5, 6.01, 6.02, 8, 9, 11
MilkAlpha s1 casein, beta-lactoglobulin
Moldenzymes, toxins, cell wall components
PeanutAra h1, Ara h2, Ara h3, Ara h6
PollenAconitate hydratase, fructose bisphosphate aldolase, ATP synthase, luminal binding
protein, calmodulin, calreticulin, chaperonin, enolase, lipid transfer protein 1, lipid
transfer protein 2, profilins
Pollen,Phl p 1, 2, 4, 5, 6, 11, 12, 13
grass
Shellfisharginine kinase, tropomyosin, myosin light chain, sarcoplasmic calcium binding protein,
triose phosphate isomerase, aldolase, titin
SoyGly m1 soybean hydrophobic protein, gly m4, gly m5, gly m6, Gly m 2s albumin, lipid
transfer proteins, alpha-globulin,
TreeLipid transfer proteins, profilins, Bet v1-related family, legumins, vicilins, 2S albumins
nuts
Wheatgluten, prolamins, 2S albumins, lipid transer proteins, a-amylase/protease inhibitors,
puroindoline, alpha-globulin, alpha-gliadin, beta-gliadin, gamma-gliadin, fast-omega-
gliadin, slow-omega-gliadin

TABLE I
Therapeutic proteins to treat diseases
Brand NameCompanyIndication
AmeviveAstellas PharmaModerate to severe chronic plaque
psoriasis
BayGamBayerHepatitis A, measles, varicella, rubella,
immunoglobulin deficiency
CinnoVexCinnaGenMultiple Sclerosis
SynagisMedlummneRespiratory syncytial virus (RSV) infections
LucentisRoche GenentechWet age-related macular degeneration
(AMD)
ActemraHoffman-La RocheRheumatoid Arthritis
AvastinRoche GenentechVarious cancers
BenefixPfizerHeamophelia B/Christmas disease
(coagulation factor IX defficiency)
BenlystaHGS, GlaxoSmithKlineSystemic lupus erythematosus (SLE)
BexxarGlaxoSmithKline, CorixaCD20+. follicular, NHL
CampathGenzymeB-cell chronic lymphocytic leukemia (B-CLL
CeredaseGenzymeType I Gaucher disease
CerezymeGenzymeType 1 Gaucher's disease
ErbituxLillyMetastatic colorectal cancer
Helixate FSCSL BehringHaemophilia A
HerceptinRoche GenentechBreast cancer
Kogenate FSBayer HealthcareHaemophilia A
LumizymeGenzymePompe disease (glycogen storage disease
type II)
NovoSevenNovo NordiskHemophilia A or B patients with inhibitors
to Factor VIII or Factor IX and in patients
with acquired hemophilia
PrivigenCSL BehringIVIG therapy
RecombinateBaxter, WyethHaemophilia A
RefactoPfizerHaemophilia A
RemicadeJannssen Biotech (J&J)Rheumatoid Arthritis, Crohn's Disease,
Ankylosing Spondylitis, Plaque Psoriasis,
Ulcerative Colitis
ReoProLillyPTCA (Angioplasty) adjunct
Rituxan/MabTheraRoche Genentech/BiogenBlood cancers and rheumatoid arthritis
Idec
SimulectNovartisOrgan rejection prophylaxis
SolirisAlexion PharmaceuticalsParoxysmal nocturnal hemoglobinuria
(PNH), atypical hemolytic uremic syndrome
(aHUS)
TysabriBiogen Idec, Elan Pharma.Multiple Sclerosis, Crohn's Disease
VectibixAmgenTreatment of epidermal growth factor
receptor (EGFR)-expressing, metastatic
colorectal carcinoma (mCRC)
XynthaWyethHaemophilia A (factor VIII defficiency)
ZenapaxRoche/PDLProphylaxis of acute organ rejection in
patients receiving renal transplants
ArcalystRegeneron PharmaceuticalsCryopyrin-Associated Periodic Syndromes
(CAPS), including FCAS and MWS
BetaseronBayer HealthcareMultiple Sclerosis, myocardial disease
CetrotideMerck SeronoInfertility
CimziaUCBRheumatoid Arthritis, Crohn's Disease
CopaxoneTeva PharmaceuticalsMultiple Sclerosis, Crohn's disease,
glaucoma, motor neurone disease,
Huntingtons chorea, neurodegenerative
disease
EnbrelAmgen, WyethRheumatoid Arthritis, psoriasis
EpogenAmgenAnemia
HumiraAbbottRheumatoid Arthritis, Crohn's Disease
KineretAmgen, BiovitrumActive Rheumatoid Arthritis
LantusSanofi-AventisDiabetes
PegasysRoche GenentechChronic hepatitis C, chronic hepatitis B
ProliaAmgen, GSKOsteoporosis, therapy-induced bone loss
(breast or ovarian cancer), bone
metastatase, giant cell tumor of bone,
multiple myeloma
———
RebifMerck Serono, PfizerMultiple Sclerosis (relapsing)
SimponiJohnson & JohnsonRheumatoid Arthritis, Crohn's Disease,
Ulcerative Cilitis, Ankylosing Spondylitis,
Psoriatic Arthritis
StelaraCentocor, Janssen-CilagModerate to severe plaque psoriasis who
are candidates for phototherapy or
systemic therapy.
VivaglobinCSL BehringPrimary Immune Defficiency (PID)
XgevaAmgenBone Metastasis from Solid Tumors
XolairRoche Genentech, NovartisModerate to severe persistent allergic
asthma
AvonexBiogen IdecMultiple Sclerosis (relapsing)
AranespAmgenAnemia
OrenciaBristol-Myers-SquibbRheumatoid arthritis, juvenile ideopathic
arthritis
ProcritJannssen Biotech (J&J)Anemia
ErwinazeJazzAcute lymphoblastic luekemia

TABLE J
Therapeutic protein classes to treat diseases
AAV capsid protein
alglucosidase alpha
Anti C5
Anti gp Iib/IIIa
Anti IGE
Anti IL-12, Anti IL-23
Anti RANK ligand
Anti-alpha 4 integrin
Anti-APRIL
Anti-BAFF
Anti-CD20
Anti-CD52
Anti-EGFR
Anti-Her2
Anti-IL2 receptor
Anti-IL6 receptor
Anti-PD1
Anti-RSV protein F
Anti-TNFa
Anti-VEGF
Asparaginase
CTLA4
Erythropoietin
Factor IX
Factor VII
Factor VIII
Glatiramer acetate
glucocerebrosidase
GnRH antagonist
IgG
IL1R antagonist
IL1R or IL1 antagonist
Insulin
Interferon alpha
interferon beta
Lentivirus capsid protein
LFA3-Fc
Retrovirus capsid protein
TACI-Ig
TNF-receptor
Tables 1-8

TABLE 1
Erythroid Polypeptides and Non-Exogenous antigen Polypeptides
ABO blood groupsStomatinPetersDAF Cromer
Aquaporin 3TropomyosinRasmussenGerbich (GYPC)
AubergersGlucose transporterReidCD47
Band 3AdducinREITGlycophorin A, B, C
BasiginRabphilinSARABand 3 (AE3)
C41C1 tetrahydrofolateRhesus blood D groupGYPB Ss
synthase
CD44Vel groupAldolaseC4A, C4B Chido, Rodgers
C4 component of
complement
Cis ABLan antigenTropomodulinHLA Bg HLA class I
Diego (Di)At antigenArginaseRHAG Rh-associated
Ammonium transport
Colton antigenJr antigenCreatine kinaseglycoprotein
Complement ComponentAnWj antigenB-Cam proteinColton (Co) Water
4channel protein
alpha(1,3)Sd antigenRap1AACHE Cartwright (Yt)
fucosyltransferaseAcetylcholinesterase
CR1BattyBennett-GoodspeedGlutathione transferase
DAFBilkesP antigen systemGlycophorin C
DiegoWright (Wr)Rh blood groupAquaporin
DuffyBoxXg antigen systemErythroblast associated
membrane protein
Hh/Bombay antigenChristiansenXK proteinCD44
ii antigenalpha(1,2)Yt/Cartwright antigenSynaptobrevin 2
fucosyltransferasesystem
Indian blood groupHJKCD58Ribonuclease
KellHOFMRhABO glycosyl transferases
KiddJFVAnWj Adhesion receptorCD59
Lewis antigenJONEsSciannaCD44
Lutheran antigenJensenRadinMER2
MNS antigen systemKatagiriDuodenal cytochrome BDOK Dombrock ADP-
ribosyltransferase
Cost groupLivesayDARC (Duffy)SEMA7A JMH Putative
adhesion receptor
Er groupMilneCR1 Knops-McCoyUMOD Sda Tamm-
Horsfall protein
(uromodulin)
DematinOldeideFP FamilyAnion exchanger
channel protein (band 3,
AE1)
Indian (In)Annexin FamilyTweety FamilyCTL Family
Kidd (Jk) UreaBcl-2 FamilyUT FamilyDAACS Family
transporter
FUT3 Lewis (Le)Bestrophin FamilyVIC FamilyDASS family
Adenosine deaminaseBNip3 FamilyAAAP FamilyDMT family
OK Oka Neurothelin,CD20 Familytransferrin receptorENT Family
putative adhesion
molecule
LW Adhesion receptorCLIC Familyc-KITGPH Family
FUT2 Secretor (Se)Connexin FamilyInsulin receptors 1 & 2GUP Family
FUT1 Hh alphaCRAC-C FamilyEstrogen receptorLCT Family
LU Lutheran (Lu)Ctr FamilyDexamethasone receptorMC family
Adhesion receptor
P1 GlycosyltransferaseE-CIC FamilyJAK2 kinaseMET Family
XK Kx PutativeENaC FamilyABC familyMFS Family
neurotransmitter
transporter
XG Xg formerly calledGIC FamilyArsAB familyMOP Family
PBDX
MIC2ICC FamilyF-ATPase FamilyMTC Family
HemoglobinInnexin FamilyIISP FamilyNCS2 Family
AnkyrinIRK-C FamilyMPT FamilyNramp Family
SpectrinLIC FamilyP-ATPase FamilyNSS Family
KEL Kell (K, k, Kp, Js)MIP FamilyAE familyOAT Family
Metalloproteinase
TorkildsenMIT familyAPC FamilyOST Family
Rab 35NSCC2 FamilyArsB FamilyOxa1 Family
Ral A binding proteinPCC FamilyBASS FamilyPiT Family
Zona pellucida bindingPlamolipin FamilyCaCA FamilyPNaS Family
protein
Lyn B proteinPLB FamilyCCC FamilyPOT Family
KIaa1741 proteinPLM FamilyCDF FamilyRFC Family
DC38Presenilin FamilyCIC FamilyRND Family*
Calciums transportingRIR-CaC FamilyCNT FamilySSS Family
ATPase
ACC FamilyTRIC FamilyCPA1 FamilySTRA6 Family
Amt FamilyTRP-CC FamilyCPA2 FamilySulP Family
ZIP FamilyHCC FamilyNIPA FamilyN-MDE Family
ATP-E FamilyLPI FamilyPPI FamilyEpo receptor
dsRNA-T FamilyMagT1 FamilyPPI2 FamilyMgtE Family

TABLE 2
Erythroid Promoters
PromoterGene
beta globin promoterbeta globin
3′ beta-globin enhancerbeta globin
beta globin locus control regionbeta globin
GATA-1 promoterGATA-1
GYPA promoterGlycophorin A
HK1 promoterHexokinase

TABLE 3
Sequences of Complement Receptor 1
4A. CR1 isoform S precursor, Homo sapiens NCBI Reference Sequence No.
NP_000642.3
   1mgassprspe pvgppapglp fccggsllav vvllalpvaw gqcnapewlp farptnltde
  61fefpigtyln yecrpgysgr pfsiiclkns vwtgakdrcr rkscrnppdp vngmvhvikg
 121iqfgsqikys ctkgyrligs ssatciisgd tviwdnetpi cdripcglpp titngdfist
 181nrenfhygsv vtyrcnpgsg grkvfelvge psiyctsndd qvgiwsgpap qciipnkctp
 241pnvengilvs dnrslfslne vvefrcqpgf vmkgprrvkc qalnkwepel pscsrvcqpp
 301pdvlhaertq rdkdnfspgq evfyscepgy dlrgaasmrc tpqgdwspaa ptcevkscdd
 361fmgqllngrv lfpvnlqlga kvdfvcdegf qlkgssasyc vlagmeslwn ssvpvceqif
 421cpsppvipng rhtgkplevf pfgktvnytc dphpdrgtsf dligestirc tsdpqgngvw
 481sspaprcgil ghcqapdhfl faklktqtna sdfpigtslk yecrpeyygr pfsitcldnl
 541vwsspkdvck rkscktppdp vngmvhvitd iqvgsrinys cttghrligh ssaecilsgn
 601aahwstkppi cqripcglpp tiangdfist nrenfhygsv vtyrcnpgsg grkvfelvge
 661psiyctsndd qvgiwsgpap qciipnkctp pnvengilvs dnrslfslne vvefrcqpgf
 721vmkgprrvkc qalnkwepel pscsrvcqpp pdvlhaertq rdkdnfspgq evfyscepgy
 781dlrgaasmrc tpqgdwspaa ptcevkscdd fmgqllngrv lfpvnlqlga kvdfvcdegf
 841qlkgssasyc vlagmeslwn ssvpvceqif cpsppvipng rhtgkplevf pfgktvnytc
 901dphpdrgtsf dligestirc tsdpqgngvw sspaprcgil ghcqapdhfl faklktqtna
 961sdfpigtslk yecrpeyygr pfsitcldnl vwsspkdvck rkscktppdp vngmvhvitd
1021iqvgsrinys cttghrligh ssaecilsgn aahwstkppi cgripcglpp tiangdfist
1081nrenfhygsv vtyrcnpgsg grkvfelvge psiyctsndd qvgiwsgpap qciipnkctp
1141pnvengilvs dnrslfslne vvefrcqpgf vmkgprrvkc qalnkwepel pscsrvcqpp
1201pdvlhaertq rdkdnfspgq evfyscepgy dlrgaasmrc tpqgdwspaa ptcevkscdd
1261fmgqllngrv lfpvnlqlga kvdfvcdegf qlkgssasyc vlagmeslwn ssvpvceqif
1321cpsppvipng rhtgkplevf pfgkavnytc dphpdrgtsf dligestirc tsdpqgngvw
1381sspaprcgil ghcqapdhfl faklktqtna sdfpigtslk yecrpeyygr pfsitcldnl
1441vwsspkdvck rkscktppdp vngmvhvitd iqvgsrinys cttghrligh ssaecilsgn
1501tahwstkppi cqripcglpp tiangdfist nrenfhygsv vtyrcnlgsr grkvfelvge
1561psiyctsndd qvgiwsgpap qciipnkctp pnvengilvs dnrslfslne vvefrcqpgf
1621vmkgprrvkc qalnkwepel pscsrvcqpp peilhgehtp shqdnfspgq evfyscepgy
1681dlrgaaslhc tpqgdwspea prcavkscdd flgqlphgrv lfplnlqlga kvsfvcdegf
1741rlkgssvshc vlvgmrslwn nsvpvcehif cpnppailng rhtgtpsgdi pygkeisytc
1801dphpdrgmtf nligestirc tsdphgngvw sspaprcels vraghcktpe qfpfasptip
1861indfefpvgt slnyecrpgy fgkmfsiscl enlvwssved ncrrkscgpp pepfngmvhi
1921ntdtqfgstv nyscnegfrl igspsttclv sgnnvtwdkk apiceiisce ppptisngdf
1981ysnnrtsfhn gtvvtyqcht gpdgeqlfel vgersiycts kddqvgvwss ppprcistnk
2041ctapevenai rvpgnrsfft lteiirfrcq pgfvmvgsht vqcqtngrwg pklphcsrvc
2101qpppeilhge htlshqdnfs pgqevfysce psydlrgaas lhctpqgdws peaprctvks
2161cddflgqlph grvllplnlq lgakvsfvcd egfrlkgrsa shcvlagmka lwnssvpvce
2221qifcpnppai lngrhtgtpf gdipygkeis yacdthpdrg mtfnligess irctsdpqgn
2281gvwsspaprc elsvpaacph ppkiqnghyi gghvslylpg mtisyicdpg yllvgkgfif
2341ctdqgiwsql dhyckevncs fplfmngisk elemkkvyhy gdyvtlkced gytlegspws
2401qcqaddrwdp plakctsrth dalivgtlsg tiffilliif lswiilkhrk gnnahenpke
2461vaihlhsqgg ssvhprtlqt neensrvlp (Seq. ID No. 1)
4B. CR1 isoform F precursor, Homo sapiens NCBI Reference Sequence No.
NP_000564.2
   1mgassprspe pvgppapglp fccggsllav vvllalpvaw gqcnapewlp farptnltde
  61fefpigtyln yecrpgysgr pfsiiclkns vwtgakdrcr rkscrnppdp vngmvhvikg
 121iqfgsqikys ctkgyrligs ssatciisgd tviwdnetpi cdripcglpp titngdfist
 181nrenfhygsv vtyrcnpgsg grkvfelvge psiyctsndd qvgiwsgpap qciipnkctp
 241pnvengilvs dnrslfslne vvefrcqpgf vmkgprrvkc qalnkwepel pscsrvcqpp
 301pdvlhaertq rdkdnfspgq evfyscepgy dlrgaasmrc tpqgdwspaa ptcevkscdd
 361fmgqllngrv lfpvnlqlga kvdfvcdegf qlkgssasyc vlagmeslwn ssvpvceqif
 421cpsppvipng rhtgkplevf pfgktvnytc dphpdrgtsf dligestirc tsdpqgngvw
 481sspaprcgil ghcqapdhfl faklktqtna sdfpigtslk yecrpeyygr pfsitcldnl
 541vwsspkdvck rkscktppdp vngmvhvitd iqvgsrinys cttghrligh ssaecilsgn
 601aahwstkppi cqripcglpp tiangdfist nrenfhygsv vtyrcnpgsg grkvfelvge
 661psiyctsndd qvgiwsgpap qciipnkctp pnvengilvs dnrslfslne vvefrcqpgf
 721vmkgprrvkc qalnkwepel pscsrvcqpp pdvlhaertq rdkdnfspgq evfyscepgy
 781dlrgaasmrc tpqgdwspaa ptcevkscdd fmgqllngrv lfpvnlqlga kvdfvcdegf
 841qlkgssasyc vlagmeslwn ssvpvceqif cpsppvipng rhtgkplevf pfgkavnytc
 901dphpdrgtsf dligestirc tsdpqgngvw sspaprcgil ghcqapdhfl faklktqtna
 961sdfpigtslk yecrpeyygr pfsitcldnl vwsspkdvck rkscktppdp vngmvhvitd
1021iqvgsrinys cttghrligh ssaecilsgn tahwstkppi cqripcglpp tiangdfist
1081nrenfhygsv vtyrcnlgsr grkvfelvge psiyctsndd qvgiwsgpap qciipnkctp
1141pnvengilvs dnrslfslne vvefrcqpgf vmkgprrvkc qalnkwepel pscsrvcqpp
1201peilhgehtp shqdnfspgq evfyscepgy dlrgaaslhc tpqgdwspea prcavkscdd
1261flgqlphgrv lfplnlqlga kvsfvcdegf rlkgssvshc vlvgmrslwn nsvpvcehif
1321cpnppailng rhtgtpsgdi pygkeisytc dphpdrgmtf nligestirc tsdphgngvw
1381sspaprcels vraghcktpe qfpfasptip indfefpvgt slnyecrpgy fgkmfsiscl
1441enlvwssved ncrrkscgpp pepfngmvhi ntdtqfgstv nyscnegfrl igspsttclv
1501sgnnvtwdkk apiceiisce ppptisngdf ysnnrtsfhn gtvvtyqcht gpdgeqlfel
1561vgersiycts kddqvgvwss ppprcistnk ctapevenai rvpgnrsfft lteiirfrcq
1621pgfvmvgsht vqcqtngrwg pklphcsrvc qpppeilhge htlshqdnfs pgqevfysce
1681psydlrgaas lhctpqgdws peaprctvks cddflgqlph grvllplnlq lgakvsfvcd
1741egfrlkgrsa shcvlagmka lwnssvpvce qifcpnppai lngrhtgtpf gdipygkeis
1801yacdthpdrg mtfnligess irctsdpqgn gvwsspaprc elsvpaacph ppkiqnghyi
1861gghvslylpg mtisyicdpg yllvgkgfif ctdqgiwsql dhyckevncs fplfmngisk
1921elemkkvyhy gdyvtlkced gytlegspws qcqaddrwdp plakctsrth dalivgtlsg
1981tiffilliif lswiilkhrk gnnahenpke vaihlhsqgg ssvhprtlqt neensrvlp
(Seq. ID No. 2)
4C. Predicted CRI isoform X1, Homo sapiens, NCBI Reference Sequence No.
XP_005273121.1
   1mclgrmgass prspepvgpp apglpfccgg sllavvvlla lpvawgqcna pewlpfarpt
  61nltdefefpi gtylnyecrp gysgrpfsii clknsvwtga kdrcrrkscr nppdpvngmv
 121hvikgiqfgs qikysctkgy rligsssatc iisgdtviwd netpicdrip cglpptitng
 181dfistnrenf hygsvvtyrc npgsggrkvf elvgepsiyc tsnddqvgiw sgpapqciip
 241nkctppnven gilvsdnrsl fslnevvefr cqpgfvmkgp rrvkcqalnk wepelpscsr
 301vcqpppdvlh aertqrdkdn fspgqevfys cepgydlrga asmrctpqgd wspaaptcev
 361kscddfmgql lngrvlfpvn lqlgakvdfv cdegfqlkgs sasycvlagm eslwnssvpv
 421ceqifcpspp vipngrhtgk plevfpfgkt vnytcdphpd rgtsfdlige stirctsdpq
 481gngvwsspap rcgilghcqa pdhflfaklk tqtnasdfpi gtslkyecrp eyygrpfsit
 541cldnlvwssp kdvckrksck tppdpvngmv hvitdiqvgs rinyscttgh rlighssaec
 601ilsgnaahws tkppicqrip cglpptiang dfistnrenf hygsvvtyrc npgsggrkvf
 661elvgepsiyc tsnddqvgiw sgpapqciip nkctppnven gilvsdnrsl fslnevvefr
 721cqpgfvmkgp rrvkcqalnk wepelpscsr vcqpppdvlh aertqrdkdn fspgqevfys
 781cepgydlrga asmrctpqgd wspaaptcev kscddfmgql lngrvlfpvn lqlgakvdfv
 841cdegfqlkgs sasycvlagm eslwnssvpv ceqifcpspp vipngrhtgk plevfpfgkt
 901vnytcdphpd rgtsfdlige stirctsdpq gngvwsspap rcgilghcqa pdhflfaklk
 961tqtnasdfpi gtslkyecrp eyygrpfsit cldnlvwssp kdvckrksck tppdpvngmv
1021hvitdiqvgs rinyscttgh rlighssaec ilsgnaahws tkppicqlcq pppdvlhaer
1081tqrdkdnfsp gqevfyscep gydlrgaasm rctpqgdwsp aaptcevksc ddfmgqllng
1141rvlfpvnlql gakvdfvcde gfqlkgssas ycvlagmesl wnssvpvceq ifcpsppvip
1201ngrhtgkple vfpfgkavny tcdphpdrgt sfd1igesti rctsdpqgng vwsspaprcg
1261ilghcqapdh flfaklktqt nasdfpigts lkyecrpeyy grpfsitcld nlvwsspkdv
1321ckrkscktpp dpvngmvhvi tdiqvgsrin yscttghrli ghssaecils gntahwstkp
1381picqripcgl pptiangdfi stnrenfhyg svvtyrcnlg srgrkvfelv gepsiyctsn
1441ddqvgiwsgp apqciipnkc tppnvengil vsdnrslfsl nevvefrcqp gfvmkgprrv
1501kcqalnkwep elpscsrvcq pppeilhgeh tpshqdnfsp gqevfyscep gydlrgaasl
1561hctpqgdwsp eaprcavksc ddflgqlphg rvlfplnlql gakvsfvcde gfrlkgssvs
1621hcvlvgmrsl wnnsvpvceh ifcpnppail ngrhtgtpsg dipygkeisy tcdphpdrgm
1681tfnligesti rctsdphgng vwsspaprce lsvraghckt peqfpfaspt ipindfefpv
1741gtslnyecrp gyfgkmfsis clenlvwssv edncrrkscg pppepfngmv hintdtqfgs
1801tvnyscnegf rligspsttc lvsgnnvtwd kkapiceiis ceppptisng dfysnnrtsf
1861hngtvvtyqc htgpdgeqlf elvgersiyc tskddqvgvw ssppprcist nkctapeven
1921airvpgnrsf ftlteiirfr cqpgfvmvgs htvqcqtngr wgpklphcsr vcqpppeilh
1981gehtlshqdn fspgqevfys cepsydlrga aslhctpqgd wspeaprctv kscddflgql
2041phgrvllpln lqlgakvsfv cdegfrlkgr sashcvlagm kalwnssvpv ceqifcpnpp
2101ailngrhtgt pfgdipygke isyacdthpd rgmtfnlige ssirctsdpq gngvwsspap
2161rcelsvpaac phppkiqngh yigghvslyl pgmtisyicd pgyllvgkgf ifctdqgiws
2221qldhyckevn csfplfmngi skelemkkvy hygdyvtlkc edgytlegsp wsqcqaddrw
2281dpplakctsr thdalivgtl sgtiffilli iflswiilkh rkgnnahenp kevaihlhsq
2341ggssvhprtl qtneensrvl p (Seq. ID No. 3)

TABLE 4
Targets
General Classes of Targets
MicrobesPolypeptidesDNAAmino Acids
FungiToxinsRNAPrions
BacteriaLipidsParasitesCytokines
VirusCellsCellular debrisComplement-
associated molecules
Complement-Related Targets
Immune complexesC3dgC4aC6
Factor BC3dkC4bC7
Factor DC3eC2C8
ProperdinBbC4bpC9
C3membrane attackMannose-Binding Lectin (MBL)
complex
C3aC1qMBL-Associated Serine Protease 1 (MASP1)
C3bC1rMBL-Associated Serine Protease 2 (MASP2)
iC3bC1sC5
C3cC4C5a
Infectious Disease-Related Targets
LipopolysaccharidesCell invasion proteinIntermedilysinSecreted effector
protein sptP
Zona occludens toxinCholera enterotoxinInvasion protein sipASeeligeriolysin
Actin polymerization proteinCysteine proteaseIota toxin componentSerine protease
RickAIa
Actin polymerization proteinCytolethal distendingIvanolysinShiga toxin
RickAtoxin
Adenosine monophosphate-CytolysinLepBSphingomyelinase
protein transferase vopS
adenylate cyclaseCytotoxic necrotizingLethal factorStaphylokinase
factor
Adenylate cyclase ExoYCytotoxinLeukotoxinStreptokinase
ADP-ribosyltransferaseDermonecrotic toxinListeriolysinStreptolysin
enzymatic component
AerolysinDeubiquitinaseMicrobial collagenaseStreptopain
Alpha-toxinDiphtheria toxinOuter membraneSuilysin
protein IcsA
autotransporter
AlveolysinEnterohemolysinPanton-ValentineSuperantigen
Leucocidin F
AlveolysinEnterotoxinPerfringolysinT3SS secreted effector
EspF
Anthrolysin OEpidermal cellPertussis toxinTetanus toxin
differentiation
inhibitor
Arp2/3 complex-activatingExoenzymePhospholipaseTir
protein rickA
Binary ADP-ribosyltransferaseExotoxinPlasminogen activatorTolC
CDT toxin
Botulinum neurotoxinG-nucleotidePneumolysinToxic shock syndrome
exchange factortoxin
C2 toxin, component IIGuanine nucleotideProtective antigenZink-carboxypeptidase
exchange factor sopE
CagAHeat stableProtein kinaseZink-carboxypeptidase
enterotoxin
Calmodulin-sensitive adenylateIgA-specific serinePyolysinZn-dependent
cyclaseendopeptidasepeptidase
autotransporter
Cell cycle inhibiting factorInositol phosphateRTX toxin
phosphatase sopB
Other Molecular Targets
G-CSFIL3IL10MIP1a
GM-CSFIL4IL12MIP1b
M-CSFIL5IFNaTGFb
IL1aIL6IFNbTNFa
IL1bIL7IFNgTNFb
IL2IL8Self-antibodiesNon-self antibodies
PRPPRPcPRPscPRPres
Lipid & Cell Targets
Circulating tumor cellsvery low density lipidtriglyceridesFatty acids
(VLDL)
Metastaseshigh densitychylomicronsCholesterol
lipoprotein
Eukaryotic cellslow densityapolipoproteins
lipoprotein

TABLE 5
Diseases and Conditions
Cancers
AcuteColorectal cancerMacroglobulinemia,Pleuropulmonary
lymphoblasticWaldenströmBlastoma, Childhood
leukaemia (ALL)
Acute myeloidCraniopharyngioma, ChildhoodMale Breast CancerPregnancy and Breast
leukaemia (AML)Cancer
AdrenocorticalCutaneous T-Cell LymphomaMalignant FibrousPrimary Central
CarcinomaHistiocytoma of Bone andNervous System (CNS)
OsteosarcomaLymphoma
AIDS-Related KaposiDuctal Carcinoma In Situ (DCIS)MelanomaProstate Cancer
Sarcoma
AIDS-RelatedEmbryonal Tumors,Merkel Cell CarcinomaRare cancers
lymphomaChildhood
Anal CancerEndometrial CancerMesotheliomaRectal Cancer
Appendix CancerEpendymoma, ChildhoodMetastatic SquamousRenal cell carcinoma
Neck Cancer with Occult
Primary
Astrocytomas,Epithelial cancerMidline Tract CarcinomaRenal Pelvis and
ChildhoodInvolving NUT GeneUreter, Transitional
Cell Cancer
AtypicalEsophageal CancerMolar pregnancyRetinoblastoma
Teratoid/Rhabdoid
Tumor, Childhood
Basal CellEsthesioneuroblastoma,Mouth and oropharyngealRhabdomyosarcoma
CarcinomaChildhoodcancer
Bile duct cancerEwing sarcomaMultiple EndocrineSalivary Gland Cancer
Neoplasia Syndromes,
Childhood
Bladder cancerExtragonadal Germ Cell TumorMultipleSarcoma
Myeloma/Plasma Cell
Neoplasm
Bone cancerExtrahepatic Bile Duct CancerMycosis FungoidesSecondary cancers
Bowel cancerEye CancerMyelodysplasticSézary Syndrome
Syndromes
Brain Stem Glioma,Gallbladder CancerMyelodysplastic/Skin Cancer
ChildhoodMyeloproliferative
Neoplasms
Brain tumoursGastric cancerMyeloproliferativeSkin cancer (non
Disorders, Chronicmelanoma)
Breast cancerGastrointestinal Carcinoid TumorNasal Cavity andSmall Cell Lung Cancer
Paranasal Sinus Cancer
Bronchial Tumors,Germ Cell TumorNasopharyngeal cancerSmall Intestine Cancer
Childhood
Burkitt LymphomaGestational trophoblasticNeuroblastomaSoft Tissue Sarcoma
tumours (GTT)
Cancer of unknownGliomaNon-Hodgkin LymphomaSquamous Cell
primaryCarcinoma
Cancer spread toHairy cell leukaemiaNon-Small Cell LungSquamous Neck
boneCancerCancer with Occult
Primary, Metastatic
Cancer spread toHead and neck cancerOesophageal cancerStomach (Gastric)
brainCancer
Cancer spread toHeart Cancer, ChildhoodOral CancerStomach cancer
liver
Cancer spread toHepatocellular (Liver) CancerOral Cavity CancerT-Cell Lymphoma,
lungCutaneous - see
Mycosis Fungoides
and Sézary Syndrome
Carcinoid TumorHistiocytosis, Langerhans CellOropharyngeal CancerTesticular cancer
Carcinoma ofHodgkin LymphomaOsteosarcoma (BoneThroat Cancer
Unknown PrimaryCancer)
Cardiac (Heart)Hypopharyngeal CancerOsteosarcoma andThymoma and Thymic
Tumors, ChildhoodMalignant FibrousCarcinoma
Histiocytoma
Central NervousIntraocular MelanomaOvarian CancerThyroid Cancer
System Atypical
Teratoid/Rhabdoid
Tumor,
Childhood
Central NervousIslet Cell Tumors, PancreaticPancreatic CancerTransitional Cell
System EmbryonalNeuroendocrine TumorsCancer of the Renal
Tumors, ChildhoodPelvis and Ureter
Central NervousKidney cancerPancreaticUnknown primary
System, ChildhoodNeuroendocrine Tumorscancer
(Islet Cell Tumors)
Cervical cancerLangerhans Cell HistiocytosisPapillomatosis, ChildhoodUreter and Renal
Pelvis, Transitional
Cell Cancer
Chordoma,Laryngeal CancerParagangliomaUrethral Cancer
Childhood
ChoriocarcinomaLeukemiaParathyroid CancerUterine Cancer,
Endometrial
ChronicLip and Oral Cavity CancerPenile CancerUterine Sarcoma
Lymphocytic
Leukemia (CLL)
Chronic myeloidLiver cancerPharyngeal CancerVaginal cancer
leukaemia (CML)
ChronicLobular Carcinoma In Situ (LCIS)PheochromocytomaVulvar Cancer
Myeloproliferative
Disorders
Colon cancerLow Malignant Potential TumorPituitary TumorWaldenström
Macroglobulinemia
LymphomaLung CancerPlasma CellWilms Tumor
Neoplasm/Multiple
Myeloma
Complement and Immune Complex-Related Diseases
Age-relatedANCA-associated vasculitisGlomerulonephritis -MYH9-related disease
macular(Includes Pauci-immune)sparse hair - telangiectasis
degeneration
Atypical hemolyticAnti-glomerular basementGoodpasture's sndromeNail-patella syndrome
uremic syndromemembrane disease
(Goodpasture's)
AutoimmuneArthus ReactionGranulomatosis withNail-patella-like renal
hemolytic anemiapolyangiitis (ANCA anddisease
Wegeners)
C1 inhibitorAsthmaGuillain-Barre syndromeNephritis
deficiency
C1q deficiencyAtypical hemolytic uremicHemolytic angioedemaNon-amyloid
syndrome(HAE)monoclonal
immunoglobulin
deposition disease
C1r deficiencyAutoimmune inner ear diseaseHenoch-SchonleinPauci-immune
(AIED) Sensorineural hearing losspurpuraglomerulonephritis
C1s deficiencyAutoimmune uveitisHIVICKPediatric systemic
lupus erythematosus
C2 deficiencyAutosomal dominantHypersensitivty vasculitisPierson syndrome
intermediate Charcot-Marie-
Tooth disease type E
C3 deficiencyBehçet diseaseHypocomplementemicPolyarteritis
urticarial vasculitis
C4 deficiencyBerger (IgA) NephropathyIdiopathic membranouspolyarteritis nodosa
glomerulonephritis
C5 deficiencyBuergers diseaseIdiopathic nephroticPolymyalgia
syndromerheumatica
C6 deficiencyCentral nervous system vasculitisIgA nephropathy (Berger'sPolymyositis
disease)
C7 deficiencyChoroiditisIgAPolymyositis/
nephropathy/vasculitisdermatomyositis
(Henoch-Schonlein
purpura)
C8 deficiencyChronic demyelinatingImmunePoststaphilococcal
polyneuropathy (CIDP)thrombocytopeniaglomerulonephritis
C9 deficiencyChurg-strauss syndromeImmunobullous diseasesPoststeptococcal
glomerulonephritis
CD55 deficiencyCogan's syndromeImmunotactoid orPrimary
fibrillary glomerulopathymembranoproliferative
glomerulonephritis
CD59 deficiencyCollagen type III glomerulopathyInfection-relatedRapidly progressive
glomerulonephritisglomerulonephritis
(Crescentic)
Complement FactorCongenital and infantileInflammatory myopathiesRapidly progressive
I deficiencynephrotic syndromeglomerulonephritis
(RPGN)
Complement factor-Congenital membranousJuvenile dermatomyositisRasmussen syndrome
H related 1(CFHR1)nephropathy due to maternal
deficiencyanti-neutral endopeptidase
alloimmunization
Complement factor-Cryoglobulinaemia/ColdJuvenile polymyositisReactive arthritis
H related 3(CFHR3)agglutinin diease
deficiency
CR3/CR4Cryoglobulinemic vasculitisKawasaki diseaseRelapsing
defieciencypolychondritis
(leukocyte adhesion
deficiency 1)
Factor B deficiencyCutaneous vasculitisLipoproteinRenal amyloidosis
glomerulopathy
Factor D deficiencyDemyelinating myopathiesLupus nephritisReynolds syndrome
(paraprotein associated)
Factor H deficiencyDenys-Drash syndromeLupus nephropathyRheumatoid arthritis
Factor I deficiencyDermatomyositisMay Hegglin anomalySarcoidosis (Nesnier
Boeck Schuamann
Disease)
Ficolin 3 deficiencyDermatomyositisMembranoglomerularSchimke immuno-
nephritisosseous dysplasia
MASP2 deficiencyDiabetic nephropathyMembranoproliferativeScleroderma
glomerulonephritis
MBL deficiencyDrug-induced immune complexMembranoproliferativeSebastian syndrome
vasculitisglomerulonephritis Type I
(MPGN Type I)
Non-alcoholicEosinophilic granulomatosis withMembranoproliferativeSecondary
steatohepatitispolyangiitis (Churgg-Strauss)glomerulonephritis Type IIamyloidosis
(Dense Deposit Disease,
MPGN Type II)
ParoxysmalEpstein SyndromeMembranoproliferativeSevere or recurring
nocturnalglomerulonephritis TypeC diff colitis
hemoglobinuriaIII (MPGN Type III)
Properdin deficiencyEssential mixed cryoglobulinemiaMembranouseSjogren's syndrome
glomerulonephritis
Action myoclonus -Familial Mediterranean feverMenieres diseaseStaphylococcal or
renal failurestreptococcal sepsis
syndrome
Acute respiratoryFamilial renal amyloidosisMicroscopic polyangiitisStiff person syndrome
disease syndrome
(ARDS)/Severe
acute respiratory
syndrome (SARS)
Acute serumFamilial steroid-resistantMinimal change diseaseSystemic lupus
sicknessnephrotic syndrome witherythematosus
sensorineural deafness
Adult-onset StillFarmer's lungMixed connective tissueSystemic sclerosis
diseasedisease
Age-relatedFechtner SyndromeMostly large vesselTakayasu arteritis
macularvasculitis
degeneration
AL amyloidosisFibronectin glomerulopathymostly medium vesselToxic epidermal
vasculitisnecrolysis (Stevens
Johnson syndrome)
Alport's syndromeFibrosing alveolitisMostly small vesselTransplantation/
vsculitisreperfusion (solid
organ)
Alzheimer's diseaseFocal segmental glomerularMuckle-Wells syndromeVasculitis
Amyloidosis (AL,Focal segmentalMyasthenia gravisWegener's
AA, MIDD, Other)glomerulosclerosisgranulomatosis
Giant cell arteritisFrasier syndromeGalloway-Mowat syndrome
Type 1 diabetesMyasthenia gravisGraves' diseasePernicious anemia
Crohn's diseasealopecia areatathrombocytopenicPrimary biliary
purpuracirrhosis
Ulcerative colitisautoimmune hepatitisGuillain-Barre syndromePsoriasis
Inflammatoryautoimmune deramtomyositisAutoimmune myocarditisRheumatoid arthritis
bowel syndrome
Multiple sclerosisJuvenile idiopathic arthritisAutoimmune pemphigusVitiligo
Enzyme Deficiencies & Vascular Diseases
2,4-dienoyl-CoAFabry disease (1:80,000 toIsobutyryl-CoAPeripheral
reductase1:117,000)dehydrogenaseneuropathy
deficiency
2-Methyl-3-hydroxyFamilial hypercholesterolemiaIsovaleric acidemiaPeroxisomal disorders
butyric aciduria(1:500)(1:50,000; e.g.,
Zellweger syndrome,
neonatal
adrenoleukodystrophy,
Refsum's disease)
2-methylbutyryl-Familial myocardial infarct/strokeLactase deficiencyPhenylketonuria
CoA dehydrogenase(common)
3-hydroxy-3-Fatty acid oxidation disordersLesch-Nyhan syndromePrimary hyperoxaluria
methylglutaryl(1:10,000)
(HMG) aciduria
3-methylglutaconicGalactokinase deficiencyLipoprotein lipasePropionic acidemia
aciduriadeficiency (rare)
3-oxothiolaseGalactose epimeraselong-chain l-3-hdroxyacyl-Recurrent emesis
deficiencyCoA dehydrogenase
(1:100,000)
4-hydroxybutyricGalactosemiaLysinuric proteinShort-chain acyl-CoA
aciduriaintolerance (rare)dehydrogenase
5,10-methylenetetra-Galactosemia (1:40,000)Lysinuric proteinSucrase-isomaltase
hydrofolate reductaseintolerance (rare)deficiency (rare)
deficiency
(common)
5-OxoprolinuriaGaucher's diseaseMalonic acidemiaSymptoms of
(pyroglutamicpancreatitis
aciduria)
AbetalipoproteinemiaGlutaric acidemia type IMaple syrup urine diseaseTransferase deficient
(rare)galactosemia
(Galactosemia type 1)
Acute IntermittentGlutaric acidemia Type IIMedium chain acyl-CoATrifunctional protein
Porphyriadehydrogenasedeficiency
AlkaptonuriaGlutathione SynthetaseMedium/short chain L-3-Tyrosinemia type 1
Deficiency w/5-oxoprolinuriahydroxy acyl-CoA
dehydrogenase
ArgininemiaGlutathione SynthetaseMedum-chain ketoacyl-Tyrosinemia type 2
Deficiency w/o 5-oxoprolinuriacoA thiolase
argininosuccinateGlycogenolysis disordersMetachromaticTyrosinemia type 3
aciduria(1:20,000)leukodystrophy
(1:100,000)
BenignGlycogenosis, type I (1:70,000)MetachromaticUpward gaze paralysis
hyperphenylalaninemialeukodystrophy
(1:100,000)
beta ketothiolaseHemolytic anemia due toMethylmalonic acidemiaVery long chain acyl-
deficiencyadenylate kinase deficiency(Cbl C)CoA dehydrogenase
Biopterin cofactorHemolytic anemia due toMethylmalonic acidemiaWilson Disease
biosynthesis defectsdeficiency in Glucose 6(Cbl D)
phosphate dehydrogenase
Biopterin cofactorHemolytic anemia due toMethylmalonic acidemiaAicardi-Goutieres
regenerationdiphosphoglycerate mutase(vitamin b12 non-Syndrome (may be an
defectsdeficiencyresponsive)allelic form of CLE)
biotin-unresponsiveHemolytic anemia due toMethylmalonic acidemiaCutaneous lupus
3-methylcrotonyl-erythrocyte adenosinew/0 homocystinuriaerythematosus
CoA carboxylasedeaminase overproduction
deficiency
CarbamoylHemolytic anemia due toMethylmalonic aciduriaDermatitis
phosphateglucophosphate isomeraseand homocystinuriaherpetiformis
synthetasedeficiency
CarnitineHemolytic anemia due toMitochondrial disordershemophilia A
acylcarnitineglutathione reductase deficiency(1:30,000)
translocase
CarnitineHemolytic anemia due toMitochondrial disordershemophilia B
palmitoyltransferase Iglyceraldehyde-3-phosphate(1:30,000; e.g.,
dehydrogenase deficiencycytochrome-c oxidase
deficiency; MELAS
syndrome; Pearson's
syndrome [all rare])
CarnitineHemolytic anemia due toMitochondrial disordersIdiopathic steroid
palmitoyltransferase IIpyrimidine 5′ nucleotidase(1:30,000; e.g., Leighsensitive nephrotic
deficiencydisease, Kearns-Sayresyndrome (same as
syndrome [rare])focal segmental
glomerulaosclerosis)
Carnitine uptakeHemolytic anemia due to red cellMitochondrial disordersImmune
defectpyruvate kinase deficiency(1:30,000; e.g., lipoamidethrombocytopenic
dehydrogenase deficiencypurpura
[rare])
citrullinemia type IHHH syndrome (rare)Mitochondrial disordersMyasthenia gravis
(1:30,000; e.g., Pearson's
syndrome [rare])
Citrullinemia type IIhomocysteinuriaMultiple carboxylaseOligoarticular juvenile
(holocarboxylasearthritis
synthetase)
CongenitalHomocystinuria (1:200,000)Multiple carboxylaseScleroderma
disorders ofdeficiency (e.g.,
glycosylation (rare)holocarboxylase
synthetase [rare]) and
biotinidase deficiencies
(1:60,000)
D-2-hydroxyglutarichyperammonemia/ornithinemia/Muscle cramps/spasticitySolar urticaria (maybe
aciduriacitrullinemia (ornithineprotophyria
transporter defect)erythema)
D-2-hydroxyglutaricaciduriaHyperlipoproteinemia, types IMyoadenylate deaminaseThrombotic
(rare)and IV (rare)deficiency (1:100,000)thrombocytopenic
purpura
EnteropeptidaseHypermethioninemia due toNiemann-Pick disease,Tubulointerstitial
deficiency (rare)glycine N-methyltransferasetype C (rare)nephritis with Uveitis/
deficiencyATIN
EthylmalonicHypermethioninemiaNonketoticVon willebrand
encephalopathyencephalopathy due tohyperglycinemiadisease
adenosine kinase deficiency
Hyperprolinemia
Infectious Diseases & agents
AcinetobacterDengue haemorrhagic feverInfection-inducedSepsis
immune complex
vasculitis
Arcobacter butzleriDisseminated infection withKlebsiellaSerratia
infection - bloodmycobacterium avium complex -
infectionblood infection
ArcobacterE. coliLeprosy/Hansen's diseaseStaphylococcus
cryaerophilusAureus
infection - blood
infection
ArcobacterEnterobacterMalariaStenotrophomonas
infection - bloodmaltophilia - blood
infectioninfection
BacteremiaEnterococcusMeningococcusStreptococcal Group A
invasive disease -
blood infection
BacterialGlanders - blood infectionMethicillin ResistantStreptococcus
endocarditisStaphylococcus Aureuspneumoniae
CampylobacterGonorrheaPseudomonasStreptococcus
fetus infection -pyogenes
blood infection
CampylobacterHepatitisRhodococcus equi - bloodTrypanosomiasis
jejuni infection -infection
blood infection
CandidaHuman Immunodeficiency VirusSalmonellaYellow fever
Coagulase-negative Staphylococcus

TABLE 6
Exogenous antigens
General Classes of Exogenous antigens
Ankyrin repeat proteinsFibronectinsLyases
AntibodiesComplement receptorsGPI-linked polypeptidesNanobodies
AptamersCyclic peptidesHEAT repeat proteinsNucleic Acids
ARM repeat proteinsDARPinsHydrolasesPolypeptides
CarbohydratesDNAsesKinasesSingle-chain variable fragments
(scFv)
Cell surface receptorsEnzymesLipoproteinsTetratricopeptide repeat
proteins
Complement-Related Exogenous antigens
C1 inhibitorC4 binding proteinCR3Factor I
C3 Beta chain ReceptorCD59CR4Homologous restriction factor
C3aRCR1Decay-accelerating factorMembrane cofactor protein
(DAF)(MCP)
C3eRCR2Factor HPRELP
Enzymes
triacylglycerol lipasebile-acid-CoA hydrolaseferuloyl esterasephosphatidate phosphatase
(S)-methylmalonyl-CoAbis(2-ethylhexyl)phthalateformyl-CoA hydrolasephosphatidylglycerophosphatase
hydrolaseesterase
[acyl-carrier-protein]bisphosphoglyceratefructose-bisphosphatasephosphatidylinositol deacylase
phosphodiesterasephosphatase
[phosphorylase]Carboxylic-Ester Hydrolasesfumarylacetoacetasephosphodiesterase I
phosphatase
1,4-lactonasecarboxymethylenebutenolidasefusarinine-Cphosphoglycerate phosphatase
ornithinesterase
11-cis-retinyl-palmitatecellulose-polysulfatasegalactolipasephosphoglycolate phosphatase
hydrolase
1-alkyl-2-cephalosporin-C deacetylasegluconolactonasephosphoinositide phospholipase
acetylglycerophosphocholineC
esterase
2′-hydroxybiphenyl-2-cerebroside-sulfataseglucose-1-phosphatasephospholipase A1
sulfinate desulfinase
2-pyrone-4,6-dicarboxylatecetraxate benzylesteraseglucose-6-phosphatasephospholipase A2
lactonase
3′,5′-bisphosphatechlorogenate hydrolaseglutathione thiolesterasephospholipase C
nucleotidase
3-hydroxyisobutyryl-CoAchlorophyllaseglycerol-1-phosphatasephospholipase D
hydrolase
3′-nucleotidasecholinesteraseglycerol-2-phosphatasephosphonoacetaldehyde
hydrolase
3-oxoadipate enol-lactonasecholine-sulfataseglycerophosphocholinephosphonoacetate hydrolase
phosphodiesterase
3-phytasecholoyl-CoA hydrolaseGlycosidases, i.e. enzymesphosphonopyruvate hydrolase
that hydrolyse O- and S-
glycosyl compounds
4-hydroxybenzoyl-CoAchondro-4-sulfataseglycosulfatasephosphoprotein phosphatase
thioesterase
4-methyloxaloacetatechondro-6-sulfataseGlycosylasesPhosphoric-diester hydrolases
esterase
4-phytasecitrate-lyase deacetylasehistidinol-phosphatasePhosphoric-monoester
hydrolases
4-pyridoxolactonasecocaine esterasehormone-sensitive lipasePhosphoric-triester hydrolases
5′-nucleotidasecutinaseHydrolysing N-glycosylphosphoserine phosphatase
compounds
6-acetylglucose deacetylasecyclamate sulfohydrolaseHydrolysing S-glycosylpoly(3-hydroxybutyrate)
compoundsdepolymerase
6-phosphogluconolactonaseCysteine endopeptidaseshydroxyacylglutathionepoly(3-hydroxyoctanoate)
hydrolasedepolymerase
a-amino-acid esteraseCysteine-typehydroxybutyrate-dimerpolyneuridine-aldehyde esterase
carboxypeptidaseshydrolase
a-Amino-acyl-peptideD-arabinonolactonasehydroxymethylglutaryl-CoAprotein-glutamate
hydrolaseshydrolasemethylesterase
acetoacetyl-CoA hydrolasedeoxylimonate A-ring-iduronate-2-sulfatasequorum-quenching N-acyl-
lactonasehomoserine lactonase
acetoxybutynylbithiophenedGTPaseinositol-phosphateretinyl-palmitate esterase
deacetylasephosphatase
acetylajmaline esterasedihydrocoumarin hydrolasejuvenile-hormone esteraseSerine dehyrdatase or serine
hydroxymethyl transferase
acetylalkylglycerolDipeptidaseskynureninaseSerine endopeptidases
acetylhydrolase
acetylcholinesteraseDipeptide hydrolasesL-arabinonolactonaseserine-ethanolaminephosphate
phosphodiesterase
acetyl-CoA hydrolaseDipeptidyl-peptidases andlimonin-D-ring-lactonaseSerine-type carboxypeptidases
tripeptidyl-peptidases
acetylesteraseDiphosphoric-monoesterlipoprotein lipaseS-formylglutathione hydrolase
hydrolases
acetylpyruvate hydrolasedisulfoglucosamine-6-sulfataseL-rhamnono-1,4-lactonasesialate O-acetylesterase
acetylsalicylate deacetylasedodecanoyl-[acyl-carrier-lysophospholipasesinapine esterase
protein] hydrolase
acetylxylan esteraseEndodeoxyribonucleasesmannitol-1-phosphataseSite specific
producing 3′-endodeoxyribonucleases:
phosphomonoesterscleavage is not sequence specific
acid phosphataseEndodeoxyribonucleasesMetallocarboxypeptidasesSite-specific
producing 5′-endodeoxyribonucleases that
phosphomonoestersare specific for altered bases.
Acting on acid anhydrides toEndopeptidases of unknownMetalloendopeptidases.Site-specific
catalyse transmembranecatalytic mechanismendodeoxyribonucleases:
movement of substancescleavage is sequence specific
Acting on acid anhydrides toEndoribonucleases producingmethylphosphothioglyceratesphingomyelin
facilitate cellular and3′-phosphomonoestersphosphatasephosphodiesterase
subcellular movement
Acting on GTP to facilitateEndoribonucleases producingmethylumbelliferyl-acetateS-succinylglutathione hydrolase
cellular and subcellular5′-phosphomonoestersdeacetylase
movement
Acting on phosphorus-Endoribonucleases that aremonoterpene e-lactonesteroid-lactonase
nitrogen bondsactive with either ribo- orhydrolase
deoxyribonucleic acids and
produce 3′-
phosphomonoesters
Acting on sulfur-nitrogenEndoribonucleases that areN-acetylgalactosamine-4-sterol esterase
bondsactive with either ribo- orsulfatase
deoxyribonucleic acids and
produce 5′-
phosphomonoesters
actinomycin lactonaseEnzymes acting on acidN-acetylgalactosamine-6-steryl-sulfatase
anhydridessulfatase
acylcarnitine hydrolaseEnzymes Acting on carbon-N-succinyl-CoA hydrolase
carbon bondsacetylgalactosaminoglycan
deacetylase
acyl-CoA hydrolaseEnzymes acting on carbon-N-acetylglucosamine-6-sucrose-phosphate phosphatase
nitrogen bonds, other thansulfatase
peptide bonds
acylglycerol lipaseEnzymes acting on carbon-N-sulfoglucosaminesugar-phosphatase
phosphorus bondssulfohydrolase
acyloxyacyl hydrolaseEnzymes acting on carbon-oleoyl-[acyl-carrier-protein]Sulfuric-ester hydrolases
sulfur bondshydrolase
acylpyruvate hydrolaseEnzymes Acting on ether bondsOmega peptidasestannase
ADAMTS13Enzymes acting on halideorsellinate-depsideThioester hydrolases
bondshydrolase
Adenosine deaminaseEnzymes acting on peptideoxaloacetaseThioether and trialkylsulfonium
bonds (peptidases)hydrolases
adenylyl-[glutamate-Enzymes acting onpalmitoyl[protein] hydrolaseThreonine endopeptidases
ammonia ligase]phosphorus-nitrogen bonds
hydrolase
ADP-dependent medium-Enzymes acting on sulfur-palmitoyl-CoA hydrolasethymidine phosphorylase
chain-acyl-CoA hydrolasenitrogen bonds
ADP-dependent short-chain-Enzymes acting on sulfur-sulfurpectinesterasetrehalose-phosphatase
acyl-CoA hydrolasebonds
ADP-phosphoglycerateEther hydrolases.Peptidyl peptide hydrolasestriacetate-lactonase
phosphatase
alkaline phosphataseExodeoxyribonucleasesPeptidyl-amino-acidTriphosphoric-monoester
producing 5′-hydrolaseshydrolases
phosphomonoesters
all-trans-retinyl-palmitateExonucleases that are activePeptidylamino-acidtrithionate hydrolase
hydrolasewith either ribo- orhydrolases or acylamino-
deoxyribonucleic acids andacid hydrolases
produce 3′-
phosphomonoesters
aminoacyl-tRNA hydrolaseExonucleases that are activePeptidyl-dipeptidasestropinesterase
with either ribo- or
deoxyribonucleic acids and
produce 5′-
phosphomonoesters
AminopeptidasesExoribonucleases producing 3′-phenylacetyl-CoA hydrolaseubiquitin thiolesterase
phosphomonoesters
arylesteraseExoribonucleases producing 5′-Phenylalanine ammoniaUDP-sulfoquinovose synthase
phosphomonoesters.lyase
arylsulfataseFactor IXPhenylalanine hydroxylaseuricase
AsparaginaseFactor VIIIpheophorbidaseuronolactonase
Aspartic endopeptidasesfatty-acyl-ethyl-ester synthasephloretin hydrolasewax-ester hydrolase
b-diketone hydrolasephorbol-diester hydrolasexylono-1,4-lactonase

TABLE 7
Selected Diseases, Exogenous antigens and Targets
CategoryDiseaseExogenous antigenTarget
AmyloidosesAA Amyloidosisan an antibody-like binder to serumSerum amyloid A protein and
amyloid A protein or serum amyloid Pamyloid placques
component
Amyloidosesbeta2 microglobulin amyloidosisan an antibody-like binder to beta-2Beta2 microglobulin or amyloid
microglobulin or serum amyloid Pplacques
component
AmyloidosesLight chain amyloidosisan an antibody-like binder to light chain,Antibody light chain or amyloid
serum amyloid P componentplacques
Cell clearanceCanceran an antibody-like binder to CD44a circulating tumor cell
Cell clearanceCanceran an antibody-like binder to EpCama circulating tumor cell
Cell clearanceCanceran an antibody-like binder to Her2a circulating tumor cell
Cell clearanceCanceran an antibody-like binder to EGFRa circulating tumor cell
Cell clearanceCancer (B cell)an an antibody-like binder to CD20a cancerous B cell
Cell clearanceCancer (B cell)an an antibody-like binder to CD19a cancerous B cell
Clearance AbAntiphospholipid syndromebeta2-glycoprotein-1pathogenic self-antibody
against beta2-glycoprotein-1
Clearance AbCatastrophic antiphospholipidbeta2-glycoprotein-1pathogenic self-antibody
syndromeagainst beta2-glycoprotein-1
Clearance AbCold agglutinin diseaseI/i antigenPathogenic self-antibody
against I/i antigen
Clearance AbGoodpasture syndromea3 NC1 domain of collagen (IV)pathogenic self-antibody
against a3 NC1 domain of
Collagen (IV)
Clearance AbImmune thrombocytopeniaPlatelet Glycoproteins (Ib-IX, IIb-IIIa, IV, Ia-pathogenic self-antibody
purpuraIIa)against platelet glycoprotein
Clearance AbMembranous NephropathyPhospholipase A2 receptorpathogenic self-antibody
against phospholipase A2
receptor
Clearance AbWarm antibody hemolytic anemiaGlycophorin A, glycophorin B, and/orpathogenic self-antibody
glycophorin C, Rh antigenagainst glycophorins and/or Rh
antigen
ComplementAge-related macular degenerationa suitable complement regulatory proteinactive complement
ComplementAtypical hemolytic uremiccomplement factor H, or a suitableactive complement
syndromecomplement regulatory protein
ComplementAutoimmune hemolytic anemiaa suitable complement regulatory moleculeactive complement
ComplementComplement Factor I deficiencyComplement factor I, a suitableactive complement
complement regulatory protein
ComplementNon-alcoholic steatohepatitisa suitable complement regulatory moleculeactive complement
ComplementParoxysmal nocturnala suitable complement regulatory proteinactive complement
hemoglobinuria
Enzyme3-methylcrotonyl-CoA carboxylase3-methylcrotonyl-CoA carboxylase3-hydroxyvalerylcarnitine, 3-
deficiencymethylcrotonylglycine (3-MCG)
and 3-hydroxyisovaleric acid (3-
HIVA)
EnzymeAcute Intermittent PorphyriaPorphobilinogen deaminasePorphobilinogen
EnzymeAcute lymphoblastic leukemiaAsparaginaseAsparagine
EnzymeAcute lymphocytic leukemia,AsparaginaseAsparagine
acute myeloid leukemia
EnzymeAcute myeloblastic leukemiaAsparaginaseAsparagine
EnzymeAdenineadenine phosphoribosyltransferaseInsoluble purine 2,8-
phosphoribosyltransferasedihydroxyadenine
deficiency
EnzymeAdenosine deaminase deficiencyAdenosine deaminaseAdenosine
EnzymeAfibrinogenomiaFIenzyme replacement
EnzymeAlcohol poisoningAlcohol dehydrogenase/oxidaseEthanol
EnzymeAlexander's diseaseFVIIenzyme replacement
EnzymeAlkaptonuriahomogentisate oxidasehomogentisate
EnzymeArgininemiaAmmonia monooxygenaseammonia
Enzymeargininosuccinate aciduriaAmmonia monooxygenaseammonia
Enzymecitrullinemia type IAmmonia monooxygenaseammonia
EnzymeCitrullinemia type IIAmmonia monooxygenaseammonia
EnzymeComplete LCAT deficiency, Fish-Lecithin-cholesterol acyltransferase (LCAT)Cholesterol
eye disease, atherosclerosis,
hypercholesterolemia
EnzymeCyanide poisoningThiosulfate-cyanide sulfurtransferaseCyanide
EnzymeDiabetesHexokinase, glucokinaseGlucose
EnzymeFactor II DeficiencyFIIenzyme replacement
EnzymeFamilial hyperarginemiaArginaseArginine
EnzymeFibrin Stabilizing factor Def.FXIIIenzyme replacement
EnzymeGlutaric acidemia type Ilysine oxidase3-hydroxyglutaric and glutaric
acid (C5-DC), lysine
EnzymeGoutUricaseUric Acid
EnzymeGout - hyperuricemiaUricaseUric acid (Urate crystals)
EnzymeHageman Def.FXIIenzyme replacement
EnzymeHemolytic anemia due topyrimidine 5′ nucleotidasepyrimidines
pyrimidine 5′ nucleotidase
deficiency
EnzymeHemophilia AFactor VIIIThrombin (factor II a) or Factor
X
EnzymeHemophilia BFactor IXFactor XIa or Factor X
EnzymeHemophilia CFXIenzyme replacement
EnzymeHepatocellular carcinoma,Arginine deiminaseArginine
melanoma
EnzymeHomocystinuriaCystathionine B synthasehomocysteine
Enzymehyperammonemia/ornithinemia/Ammonia monooxygenaseAmmonia
citrullinemia (ornithine transporter
defect)
EnzymeIsovaleric acidemiaLeucine metabolizing enzymeleucine
EnzymeLead poisoningd-aminolevulinate dehydrogenaselead
EnzymeLesch-Nyhan syndromeUricaseUric acid
EnzymeMaple syrup urine diseaseLeucine metabolizing enzymeLeucine
EnzymeMethylmalonic acidemia (vitaminmethylmalonyl-CoA mutasemethylmalonate
b12 non-responsive)
EnzymeMitochondrialthymidine phosphorylasethymidine
neurogastrointestinal
encephalomyopathy
EnzymeMitochondrialThymidine phosphorylaseThymidine
neurogastrointestinal
encephalomyopathy (MNGIE)
EnzymeOwren's diseaseFVenzyme replacement
Enzymep53-null solid tumorSerine dehyrdatase or serineserine
hydroxymethyl transferase
EnzymePancreatic adenocarcinomaAsparaginaseasparagine
EnzymePhenylketonuriaPhenylalanine hydroxylase, phenylalaninePhenylalanine
ammonia lyase
EnzymePrimary hyperoxaluriaOxalate oxidaseOxalate
EnzymePropionic acidemiaPropionate conversion enzyme?Proprionyl coA
EnzymePurine nucleoside phosphorylasePurine nucleoside phosphorylaseInosine, dGTP
deficiency
EnzymeStuart-Power Def.FXenzyme replacement
EnzymeThrombotic ThrombocytopenicADAMTS13ultra-large von willebrand
Purpurafactor (ULVWF)
EnzymeTransferase deficientgalactose dehydrogenaseGalactose-1-phosphate
galactosemia (Galactosemia type
1)
EnzymeTyrosinemia type 1tyrosine phenol-lyasetyrosine
Enzymevon Willebrand diseasevWFenzyme replacement
IC clearanceIgA NephropathyComplement receptor 1Immune complexes
IC clearanceLupus nephritisComplement receptor 1immune complex
IC clearanceSystemic lupus erythematosusComplement receptor 1immune complex
InfectiousAnthrax (B. anthracis) infectionan an antibody-like binder to B. anthracisB. anthracis
surface protein
InfectiousC. botulinum infectionan an antibody-like binder to C. botulinumC. botulinum
surface protein
InfectiousC. difficile infectionan antibody-like binder to C. difficileC. difficile
surface protein
InfectiousCandida infectionan antibody-like binder to candida surfacecandida
protein
InfectiousE. coli infectionan antibody-like binder to E. coli surfaceE. coli
protein
InfectiousEbola infectionan antibody-like binder to Ebola surfaceEbola
protein
InfectiousHepatitis B (HBV) infectionan antibody-like binder to HBV surfaceHBV
protein
InfectiousHepatitis C (HCV) infectionan antibody-like binder to HCV surfaceHCV
protein
InfectiousHuman immunodeficiency virusan antibody-like binder to HIV envelopeHIV
(HIV) infectionproteins or CD4 or CCR5 or
InfectiousM. tuberculosis infectionan antibody-like binder to M. tuberculosisM. tuberculosis
surface protein
InfectiousMalaria (P. falciparum) infectionan antibody-like binder to P. falciparumP. falciparum
surface protein
LipidHepatic lipase deficiency,Hepatic lipase (LIPC)Lipoprotein, intermediate
hypercholesterolemiadensity (IDL)
LipidHyperalphalipoproteinemia 1Cholesteryl ester transfer protein(CETP)Lipoprotein, high density (HDL)
Lipidhypercholesterolemiaan antibody-like binder to low-densityLDL
lipoprotein (LDL), LDL receptor
Lipidhypercholesterolemiaan antibody-like binder to high-densityHDL
lipoprotein (HDL) or HDL receptor
Lipidlipoprotein lipase deficiencylipoprotein lipasechilomicrons and very low
density lipoproteins (VLDL)
LipidLipoprotein lipase deficiency,lipoprotein lipase (LPL)Lipoprotein, very low density
disorders of lipoprotein(VLDL)
metabolism
Lysosomal storageAspartylglucosaminuria (208400)N-Aspartylglucosaminidaseglycoproteins
Lysosomal storageCerebrotendinous xanthomatosisSterol 27-hydroxylaselipids, cholesterol, and bile acid
(cholestanol lipidosis; 213700)
Lysosomal storageCeroid lipofuscinosis Adult formPalmitoyl-protein thioesterase-1lipopigments
(CLN4, Kufs' disease; 204300)
Lysosomal storageCeroid lipofuscinosis InfantilePalmitoyl-protein thioesterase-1lipopigments
form (CLN1, Santavuori-Haltia
disease; 256730)
Lysosomal storageCeroid lipofuscinosis Juvenile formLysosomal transmembrane CLN3 proteinlipopigments
(CLN3, Batten disease, Vogt-
Spielmeyer disease; 204200)
Lysosomal storageCeroid lipofuscinosis Late infantileLysosomal pepstatin-insensitive peptidaselipopigments
form (CLN2, Jansky-Bielschowsky
disease; 204500)
Lysosomal storageCeroid lipofuscinosis ProgressiveTransmembrane CLN8 proteinlipopigments
epilepsy with intellectual disability
(600143)
Lysosomal storageCeroid lipofuscinosis Variant lateTransmembrane CLN6 proteinlipopigments
infantile form (CLN6; 601780)
Lysosomal storageCeroid lipofuscinosis Variant lateLysosomal transmembrane CLN5 proteinlipopigments
infantile form, Finnish type (CLN5;
256731)
Lysosomal storageCholesteryl ester storage diseaselisosomal acid lipaselipids and cholesterol
(CESD)
Lysosomal storageCongenital disorders of N-Phosphomannomutase-2N-glycosylated protein
glycosylation CDG Ia (solely
neurologic and neurologic-
multivisceral forms; 212065)
Lysosomal storageCongenital disorders of N-Mannose (Man) phosphate (P) isomeraseN-glycosylated protein
glycosylation CDG Ib (602579)
Lysosomal storageCongenital disorders of N-Dolicho-P-Glc: Man9GlcNAc2-PP-dolicholN-glycosylated protein
glycosylation CDG Ic (603147)glucosyltransferase
Lysosomal storageCongenital disorders of N-Dolicho-P-Man: Man5GlcNAc2-PP-dolicholN-glycosylated protein
glycosylation CDG Id (601110)mannosyltransferase
Lysosomal storageCongenital disorders of N-Dolichol-P-mannose synthaseN-glycosylated protein
glycosylation CDG Ie (608799)
Lysosomal storageCongenital disorders of N-Protein involved in mannose-P-dolicholN-glycosylated protein
glycosylation CDG If (609180)utilization
Lysosomal storageCongenital disorders of N-Dolichyl-P-mannose: Man-7-GlcNAc-2-PP-N-glycosylated protein
glycosylation CDG Ig (607143)dolichyl-α-6-mannosyltransferase
Lysosomal storageCongenital disorders of N-Dolichyl-P-glucose: Glc-1-Man-9-GlcNAc-2-N-glycosylated protein
glycosylation CDG Ih (608104)PP-dolichyl-α-3-glucosyltransferase
Lysosomal storageCongenital disorders of N-α-1,3-MannosyltransferaseN-glycosylated protein
glycosylation CDG Ii (607906)
Lysosomal storageCongenital disorders of N-Mannosyl-α-1,6-glycoprotein-β-1,2-N-N-glycosylated protein
glycosylation CDG IIa (212066)acetylglucosminyltransferase
Lysosomal storageCongenital disorders of N-Glucosidase IN-glycosylated protein
glycosylation CDG IIb (606056)
Lysosomal storageCongenital disorders of N-GDP-fucose transporter-1N-glycosylated protein
glycosylation CDG IIc (Rambam-
Hasharon syndrome; 266265
Lysosomal storageCongenital disorders of N-β-1,4-GalactosyltransferaseN-glycosylated protein
glycosylation CDG IId (607091)
Lysosomal storageCongenital disorders of N-Oligomeric Golgi complex-7N-glycosylated protein
glycosylation CDG IIe (608779)
Lysosomal storageCongenital disorders of N-UDP-GlcNAc: dolichyl-P NAcGlcN-glycosylated protein
glycosylation CDG Ij (608093)phosphotransferase
Lysosomal storageCongenital disorders of N-β-1,4-MannosyltransferaseN-glycosylated protein
glycosylation CDG Ik (608540)
Lysosomal storageCongenital disorders of N-α-1,2-MannosyltransferaseN-glycosylated protein
glycosylation CDG Il (608776)
Lysosomal storageCongenital disorders of N-α-1,2-MannosyltransferaseN-glycosylated protein
glycosylation, type I (pre-Golgi
glycosylation defects)
Lysosomal storageCystinosisCystinosin (lysosomal cystine transporter)Cysteine
Lysosomal storageFabry's disease (301500)Trihexosylceramide α-galactosidaseglobotriaosylceramide
Lysosomal storageFarber's diseaseCeramidaselipids
(lipogranulomatosis; 228000)
Lysosomal storageFucosidosis (230000)α-L-Fucosidasefucose and complex sugars
Lysosomal storageGalactosialidosis (Goldberg'sProtective protein/cathepsin A (PPCA)lysosomal content
syndrome, combined
neuraminidase and β-
galactosidase deficiency; 256540)
Lysosomal storageGaucher's diseaseGlucosylceramide β-glucosidasesphingolipids
Lysosomal storageGlutamyl ribose-5-phosphateADP-ribose protein hydrolaseglutamyl ribose 5-phosphate
storage disease (305920)
Lysosomal storageGlycogen storage disease type 2alpha glucosidaseglycogen
(Pompe's disease)
Lysosomal storageGM1 gangliosidosis, generalizedGanglioside β-galactosidaseacidic lipid material,
gangliosides
Lysosomal storageGM2 activator protein deficiencyGM2 activator proteingangliosides
(Tay-Sachs disease AB variant,
GM2A; 272750)
Lysosomal storageGM2 gangliosidosisGanglioside β-galactosidasegangliosides
Lysosomal storageInfantile sialic acid storageNa phosphate cotransporter, sialinsialic acid
disorder (269920)
Lysosomal storageKrabbe's disease (245200)Galactosylceramide β-galactosidasesphingolipids
Lysosomal storageLysosomal acid lipase deficiencyLysosomal acid lipasecholesteryl
(278000)esters and triglycerides
Lysosomal storageMetachromatic leukodystrophyArylsulfatase Asulfatides
(250100)
Lysosomal storageMucolipidosis ML II (I-cell disease;N-Acetylglucosaminyl-1-N-linked glycoproteins
252500)phosphotransfeerase catalytic subunit
Lysosomal storageMucolipidosis ML III (pseudo-N-acetylglucosaminyl-1-N-linked glycoproteins
Hurler's polydystrophy)phosphotransfeerase
Lysosomal storageMucolipidosis ML III (pseudo-Catalytic subunitN-linked glycoproteins
Hurler's polydystrophy) Type III-A
(252600)
Lysosomal storageMucolipidosis ML III (pseudo-Substrate-recognition subunitN-linked glycoproteins
Hurler's polydystrophy) Type III-C
(252605)
Lysosomal storageMucopolysaccharidosis MPS I H/Sα-I-Iduronidaseglycosaminoglycans
(Hurler-Scheie syndrome; 607015)
Lysosomal storageMucopolysaccharidosis MPS I-Hα-I-Iduronidaseglycosaminoglycans
(Hurler's syndrome; 607014)
Lysosomal storageMucopolysaccharidosis MPS IIIduronate sulfate sulfataseglycosaminoglycans
(Hunter's syndrome; 309900)
Lysosomal storageMucopolysaccharidosis MPS IIIHeparan-S-sulfate sulfamidaseglycosaminoglycans
(Sanfilippo's syndrome) Type III-A
(252900)
Lysosomal storageMucopolysaccharidosis MPS IIIN-acetyl-D-glucosaminidaseglycosaminoglycans
(Sanfilippo's syndrome) Type III-B
(252920)
Lysosomal storageMucopolysaccharidosis MPS IIIAcetyl-CoA-glucosaminide N-glycosaminoglycans
(Sanfilippo's syndrome) Type III-Cacetyltransferase
(252930)
Lysosomal storageMucopolysaccharidosis MPS IIIN-acetyl-glucosaminine-6-sulfate sulfataseglycosaminoglycans
(Sanfilippo's syndrome) Type III-D
(252940)
Lysosomal storageMucopolysaccharidosis MPS I-Sα-I-Iduronidaseglycosaminoglycans
(Scheie's syndrome; 607016)
Lysosomal storageMucopolysaccharidosis MPS IVGalactosamine-6-sulfate sulfataseglycosaminoglycans
(Morquio's syndrome) Type IV-A
(253000)
Lysosomal storageMucopolysaccharidosis MPS IVβ-Galactosidaseglycosaminoglycans
(Morquio's syndrome) Type IV-B
(253010)
Lysosomal storageMucopolysaccharidosis MPS IXHyaluronidase deficiencyglycosaminoglycans
(hyaluronidase deficiency;
601492)
Lysosomal storageMucopolysaccharidosis MPS VIN-Acetyl galactosamine α-4-sulfateglycosaminoglycans
(Maroteaux-Lamy syndrome;sulfatase (arylsulfatase B)
253200)
Lysosomal storageMucopolysaccharidosis MPS VIIβ-Glucuronidaseglycosaminoglycans
(Sly's syndrome; 253220)
Lysosomal storageMucosulfatidosis (multipleSulfatase-modifying factor-1sulfatides
sulfatase deficiency; 272200)
Lysosomal storageNiemann-Pick disease type ASphingomyelinasesphingomyelin
Lysosomal storageNiemann-Pick disease type BSphingomyelinasesphingomyelin
Lysosomal storageNiemann-Pick disease TypeNPC1 proteinsphingomyelin
C1/Type D ((257220)
Lysosomal storageNiemann-Pick disease Type C2Epididymal secretory protein 1 (HE1; NPC2sphingomyelin
(607625)protein)
Lysosomal storageProsaposin deficiency (176801)Prosaposinsphingolipids
Lysosomal storagePycnodysostosis (265800)Cathepsin Kkinins
Lysosomal storageSandhoff's disease; 268800β-Hexosaminidase Bgangliosides
Lysosomal storageSaposin B deficiency (sulfatideSaposin Bsphingolipids
activator deficiency)
Lysosomal storageSaposin C deficiency (Gaucher'sSaposin Csphingolipids
activator deficiency)
Lysosomal storageSchindler's disease Type IN-Acetyl-galactosaminidaseglycoproteins
(infantile severe form; 609241)
Lysosomal storageSchindler's disease Type IIN-Acetyl-galactosaminidaseglycoproteins
(Kanzaki disease, adult-onset
form; 609242)
Lysosomal storageSchindler's disease Type IIIN-Acetyl-galactosaminidaseglycoproteins
(intermediate form; 609241)
Lysosomal storageSialidosis (256550)Neuraminidase 1 (sialidase)mucopolysaccharides and
mucolipids
Lysosomal storageSialuria Finnish type (Salla disease;Na phosphate cotransporter, sialinsialic acid
604369)
Lysosomal storageSialuria French type (269921)UDP-N-acetylglucosamine-2-epimerase/N-sialic acid
acetylmannosamine kinase, sialin
Lysosomal storageSphingolipidosis Type I (230500)Ganglioside β-galactosidasesphingolipids
Lysosomal storageSphingolipidosis Type II (juvenileGanglioside β-galactosidasesphingolipids
type; 230600)
Lysosomal storageSphingolipidosis Type III (adultGanglioside β-galactosidasesphingolipids
type; 230650)
Lysosomal storageTay-Sachs disease; 272800β-Hexosaminidase Agangliosides
Lysosomal storageWinchester syndrome (277950)Metalloproteinase-2mucopolysaccharides
Lysosomal storageWolman's diseaselysosomal acid lipaselipids and cholesterol
Lysosomal storageα-Mannosidosis (248500), type Iα-D-Mannosidasecarbohydrates and
(severe) or II (mild)glycoproteins
Lysosomal storageβ-Mannosidosis (248510)β-D-Mannosidasecarbohydrates and
glycoproteins
Toxic Moleculealpha hemolysin poisoningan antibody-like binder to alpha hemolysinalpha hemolysin
Toxic Moleculeantrax toxin poisoningan antibody-like binder to anthrax toxinanthrax toxin
Toxic Moleculebacterial toxin-induced shockan antibody-like binder to bacterial toxinbacterial toxin
Toxic Moleculebotulinum toxin poisoningan antibody-like binder to botulinum toxinbotulinum toxin
Toxic MoleculeHemochromatosis (ironiron chelatormolecular iron
poisoning)
Toxic MoleculeMethanol poisoningMethanol dehdrogenaseMethanol
Toxic MoleculeNerve gas poisoningButyryl cholinesteraseSarin
Toxic MoleculePrion disease caused by PRPan antibody-like binder to prion proteinPrion protein PRP
PRP
Toxic MoleculePrion disease caused by PRPcan antibody-like binder to prion proteinPrion protein PRPc
PRPc
Toxic MoleculePrion disease caused by PRPscan antibody-like binder to prion proteinPrion protein PRPsc
PRPsc
Toxic MoleculePrion disease cuased by PRPresan antibody-like binder to prion proteinPrion protein PRPres
PRPres
Toxic MoleculeSepsis or cytokine storman antibody-like binder to cytokines orcytokines
Duffy antigen receptor of chemokines
(DARC)
Toxic Moleculespider venom poisoningan antibody-like binder to spider venomspider venom
Toxic MoleculeWilson diseasecopper chelatormolecular copper

TABLE 8
Complement & Complement Regulatory Molecules
Soluble molecules
Alternative Pathway
Factor B
Factor D
Properdin
C3
C3a
C3b
iC3b
C3c
C3dg
C3dk
C3e
Bb
Factor I
Classical Pathway
C1q
C1r
C1s
C4
C4a
C4b
C2
C4bp
Lectin Pathway
Mannose-Binding Lectin (MBL)
MBL-Associated Serine Protease 1 (MASP1)
MBL-Associated Serine Protease 2 (MASP2)
Late Components
C5
C5a
C6
C7
C8
C9
Receptors
CR1
CR2
CR3
CR4
C3aR
C3eR
Decay-accelerating factor (DAF)
Membrane cofactor protein (MCP)
CD59
C3 Beta chain Receptor
Homologous restriction factor
Control Proteins
C1 inhibitor
C4 binding protein
Factor I
Factor H

US11576934B2. Methods and compositions for immunomodulation (2023-02-14). RUBIUS THERAPEUTICS, INC. [US]. Inventors: Jordi Mata-Fink [US], John Round [US], Noubar B. Afeyan [US], Avak Kahvejian [US].
Patent 2023
4
Intranasal Antivirals and Pathway Inhibitors
Not available on PMC !

Example 11

A 44 year-old male executive had to travel to Italy by plane to an area which was considered a hot zone for coronavirus. The person was not complaining or having any symptoms of influenza his blood pressure was normal, no fever or running nose, etc. His temperature was 97 degrees F. and his examination was otherwise normal. He was advised of the option of doing nothing or not traveling or treating himself prophylactically with daily application of combination therapy with oseltamivir (Tamiflu) and Baricitinib, and a GSK inhibitor, intra-nasally followed with deep breathing 3-4 times daily in a semifluorinated alkane for 3 days until he returned, he was then examined for signs of COVID-19 disease. He felt that the medication was well tolerated and no side effects were produced, his repeat examination showed he was normal with no fever, cough, or running nose, etc.

In one embodiment, a method of drug delivery described for treatment of respiratory tract inflammatory diseases caused by various viruses, bacteria, etc. or chronic smoking or exposure to toxic aerosolized nanoparticles and air pollution or asthma and allergens and pathogens, where the inflammation or its consequences are treated with an inflammatory cell pathway inhibitor to block the inflammatory response of the tissue while it does not inhibit an immune response, such as a Rock inhibitor, Wnt inhibitor, GSK inhibitor, or integrin inhibitors IL-1 and IL-6 inhibitors dissolved in liquid semifluorinated alkanes or other liquids as the drug, or in polymeric slow release nanoparticles applied locally as a spray or evaporative solution or in evaporative aerosolized drops that travels through the nasal cavity or mouth to reach the lung alveoli and while on the way attaching to the mucosa, epithelial or endothelial cells of the mouth, nose throat, pharynx, larynx, epiglottis, trachea, bronchi and lung alveoli where the semifluorinated alkanes which is non-toxic or causes irritation to the tissue, rapidly evaporates leaving the medication(s) or slow release nanoparticles, such as polymeric lactic, glycolic acid, or in combination, or porous silicon or polycaprolactone, etc. on the surface of these tissues, releasing the medications over a time of daily inhalation, daily for one week to 3 weeks, then the release of the medication from the nanoparticles continues for months or years to inhibit chronic inflammatory lung diseases.

In one embodiment, the disease process affects many other organs and creates an inflammatory response that can damage these organs, such as in bacterial or viral infections or immune or autoimmune response, chronic inflammation of the prostate, gastro-intestinal tract, joints, one applies a similar strategy for treatment combining anti-bacterial and antiviral with Rock inhibitors, Wnt inhibitors, GSK inhibitors, and integrin inhibitors, IL-6 inhibitors, Baricitinib interleukin antagonists (anakinra), in a known non-toxic dose administered locally, systematically, or orally either with semifluorinated alkane or the standard way in a physiological solution, or in the form of polymeric functionalized nanoparticles for slow release of the medication.

In one embodiment, the patient having a cytokine storm as a result of a viral infection and body's cellular immune/humoral response receiving the inventive therapy, undergoes plasmapheresis to remove, e.g., such cytokines, enzymes, dead cells, etc. from the circulation. Plasmapheresis is a known method to remove unwanted toxic components from blood plasma. Because the patient's plasma is treated extracorporeal, then reinfused, in contrast to reinfusing only cellular components of the patient's blood, plasmapheresis also beneficially detoxifies the patient's plasma without compromising blood volume and with minimal or no fluid loss. This technique avoids the serious complications and side effects of simply returning the cellular components of the blood to the patient. Additionally, all precautions are observed to avoid hypotension and loss of calcium ions in the process of citrate anticoagulation that this procedure requires. The patient can be treated initially with presently available anticoagulants such as heparin, or low molecular weight heparin, polyphenols, such as catechins, coumadin, etc., which can be immediately neutralized post-procedure. Neutralization uses standard techniques known in the art, such as calcium, etc. Hemofiltration treatment is performed with activated carbon, treatment on non-ionic exchange resins, etc. for removing free toxins and also toxin bound with plasma proteins, etc. as in renal dialysis methods. The process may be instituted or repeated as needed. The addition of Rock inhibitors or Wnt inhibitors, GSK inhibitors, integrin inhibitors, IL-1 inhibitors, or IL-6 inhibitors along with other therapeutic agents, such as disulfiram, anakinra, or macrolide immune suppressants such as cyclosporine, Tacrolimus, mycophenolic acid, Ascomycin, Immunomycin, FR-900520, FK520, is an ethyl analog of tacrolimus (FK506) which can be administered in a physiological solution or semifluorinated alkane or a physiological liquid or a suitable medium, systemically or for inhalation dissolved in semifluorinated alkanes or a suitable medium can reduce the overt inflammatory response seen in immune therapy or an autoimmune disease. In some cases with kidney involvement or its protection, kidney dialysis, hemodialysis and or serum electrophoresis is done to remove unwanted toxins and creatinine, etc.

The viral and microbial pathogens can gain access to the brain passing through the damaged endothelial cells of the brain or spinal cord vessels through the circulation or alternatively through the olfactory or trigeminal nerves directly bypassing all barriers of the brain. In one embodiment, a similar route through the nasal mucosa can be utilized to deliver medications to fight the pathogens or provide medications needed to enhance brain nerve survival such as in Alzheimer's disease or Parkinson's disease, etc.

In one embodiment, the viruses are transmitted to brain via circulation using transcellular penetration of the brain capillaries with infected leukocytes.

In one embodiment, the virus gains access to the tissue by using the ACE2 cell receptors of the nasal epithelial cells with the assistance of TMPRSS2 and Purine protein that are found in the mucosa lining of the nose where they reside and multiply before moving toward the respiratory airways and the lung or use the existing channels that lead to the brain through the olfactory nerve or trigeminal nerves. In one embodiment, one can block these enzymes using Rock inhibitors or other protease inhibitors at microgram to milligram concentrations of Rock inhibitors, Wnt inhibitors, GSK inhibitors, or integrin inhibitors, or low concentrations of hydroxychloroquine at 1-6 milligrams in solubilized or aerosolized formulation for inhalation, etc. or blocks the viruses by at least two antivirals such as Tamiflu, Baricitinib, Glidesivir, Tonofovir Disproxil fumarate, lamivudine, efavirenz, Delutegravir and maraviroc, or in combinations, Favipiravir, Xofluza, Remdesivir, nanoviricides, Oya1, umifenovir, tamivir ribavirin dissolved in liquid semifluorinated alkanes or other physiological liquids in combination or sequentially.

In one embodiment, one or at least two antivirals are used with Rock inhibitors, Wnt inhibitors, GSK inhibitors, or integrin inhibitors as polymeric slow release nanoparticles applied as drops or spray or an evaporative solution or dissolved in liquid semifluorinated alkanes or other physiological liquids, in an evaporative aerosolized nano- to micro-drops that travels through the nasal mucosa to reach the branches of trigeminal nerve or olfactory nerve to the brain, brain vasculature, and cerebrospinal fluid where the semifluorinated alkanes rapidly evaporate at body temperature in the tissue leaving the medication(s) or slow release nanoparticles of polylactic, polyglycolic acid, polycaprolactone, porous silicon, micelles or liposomes combination thereof, or the medications move in the respiratory tract, through the nose, throat, and bronchi to the lung alveoli, and release slowly the medications from the nanoparticles over a time period of one day or one week to 3 weeks or months depending on the composition of the nanoparticles.

In one embodiment, the slow release polymeric pluralities of nanoparticles are conjugated with a viral specific antibody while carrying at least one or two antivirals to specifically target the viruses.

In one embodiment, the viral antibody can be obtained from plasma/serum of the patients who have recovered from the infection or the antibody can be produced in the tissue culture against the dead viruses which is cultured with T-cell lymphocytes or natural killers that produce the antibody in addition to producing exosomes or extracellular vesicles (ECV) that can both be harvested to be conjugated with the slow release polymeric nanoparticles or alone to be used for intranasal administration to travel to the brain and lung and kill viruses and the ECV contribute to recovery of the brain and its vasculature by their anti-inflammatory effect.

In one embodiment, the viral antibody coated polymeric nanoparticles are conjugated with antivirals and pluralities of antibodies coated nanoparticles combined with cellular pathway inhibitors or IL-1 and/or IL-6 inhibitors, such as kevzara or nitric oxide (NO) donor (NONOate), interleukin antagonists or rituximab, tocilizumab, etc. administered intra-nasally by inhalation and the same delivery system of semifluorinated alkane or a physiological saline solution with slow release polymeric nanoparticles to seek the viruses, release the medication and block their entry to the endothelial cells, brain, etc. or kill the viruses while releasing the medications and protecting the nose, lung, or brain tissue from further invasion of viruses and reducing the inflammation of the brain and the nerves involved that cause neuralgia and pain.

In one embodiment, pluralities of viral or a fragment of the viral S protein antibody(s) coated polymeric nanoparticles are conjugated with CPP, or ACPP and one or two antivirals with semifluorinated alkanes or a solution is administered intra-nasally, intravenously intramuscularly, topically to enhance cell penetration of the nanoparticle inside the cells to damage the viruses outside the cells and those which have penetrated the cells

In one embodiment, pluralities of ACE-2 or neuropilin receptors antibody(s) coated polymeric nanoparticles are conjugated with CPP, or ACPP, or heparin or catechins or linoleic acid and one or two antivirals to block the viruses to enter the cells via ACE-receptors or neuropilin receptors inside the cells by nasal or topical, or systemic administration.

In one embodiment, after inhalation of antivirals, and cellular pathway inhibitors or IL-1 and/or IL 6 inhibitors, such as kevzara of rituximab, tocilizumab, etc. are absorbed through the lung capillaries in the blood and travel to the heart and brain via circulation first, before they are diluted as is the case with intravenous administration, since in brain vasculitis, the blood brain barrier (BBB) is broken, the medication and nanoparticles gain access rapidly to the inflamed areas of the brain where the medication is released over a long time protecting the brain substance and preventing fibrin induced beta amyloid oligomers production and microglial proliferation that encourages a chronic inflammation leading to Alzheimer disease, dementia or neuralgia, etc.

In one embodiment, the intranasal administration and inhalation reduces the side effects or systemic administration of medications, such as cellular pathway inhibitors or IL-1 and/or IL 6 inhibitors such as kevzara of rituximab, tocilizumab, or antivirals, etc. because the medication reaches directly to the source of inflammation and it is applied at a significantly lower dose than the systemic administration of these medications.

In one embodiment, the medications can be simultaneously administered in a physiological solution or semifluorinated alkane or a physiological liquid or a suitable medium orally, intravenously and nasally as needed for therapy and/or as prophylaxis of the viral infection when traveling, or flying by airplane, etc.

In one embodiment, Hypochlorous acid (HOCL) is produced by myeloid cells such as neutrophils, immune cells, eosinophils, mononuclear phagocytes, and B lymphocytes. The non-myeloid cells such as fibrocytes, etc. can also generate Hypochlorous acid (HOCl) in the presence of a solution of sodium chloride (NaCl) in the tissue.

In one embodiment, the stabilized Hypochlorous acid is in general prepared in a physiological saline solution of 0.9%-1.5%, preferably 1%, with Hypochlorous acid at 0.01%, 0.03%, and 0.1% w/v at pH of 3.0-5.0 and the concentration of 0.1 to 2.8 μg/ml. In the cell, the primary enzyme responsible for production of the Hypochlorous acid in presence of NaCl is myeloperoxidase found in phagosomes. In one embodiment, hypochlorous acid is conjugated with taurine that is an antioxidant reducing to toxicity of Hypochlorous acid when it is used in combination of other medications to treat respiratory disease or medication is intended to reach brain through the nasal administration.

In one embodiment, stabilized Hypochlorous acid or chloramines, the stable N-chloro derivatives or N-chlorotaurine (NTC), dimethylated derivatives of NCT (N-chloro-2,2-dimethyltaurine [DM-NCT] and N,N-dichloro-2,2-dimethyltaurine [DM-NDCT] and slow release polymeric nanoparticles carrying at least two antivirals and Rock inhibitors or GSK inhibitors or Wnt inhibitors and IL-6 inhibitors, interleukin antagonists, etc. are administered in a physiological solution of or Benzalkonium chloride or semifluorinated alkane or a physiological liquid or a suitable solution in the nose as inhalation in spray or nebulized form in viral encephalitis or lung inflammation in (SARS-CoV-2), COVID-19 or their mutations to kill the viruses and prevent the side effects of inflammation in the brain and lung.

In one embodiment, stabilized Hypochlorous acid or chloramines, the stable N-chloro derivatives and slow release polymeric nanoparticles carrying at least two antivirals and Rock inhibitors or GSK inhibitors and IL-6 inhibitors, etc. are administered in a physiological solution or semifluorinated alkane or a physiological liquid along with heparin or low molecular weight heparin, or heparin mimetics or synthetic heparin, such as PG500 and PG545, or polyphenols such as catechins or Ebselen and/or glutathione peroxidase, and superoxide dismutase (SOD)—metabolize oxidative toxic intermediates requiring zinc, selenium, manganese iron, copper, and for ideal catalytic activity applied in the nose as inhalation, in spray or nebulized form to treat viral encephalitis or lung inflammation in (SARS-CoV-2), COVID-19 or their mutations to kill the viruses, etc., such as coronaviruses and prevent the side effects of inflammation or as prophylaxis of viral infection in the respiratory tract, encephalitis, vasculitis, dementia, and neuralgia, etc.

In one embodiment, one can administer prophylactically, one or two antivirals as nasal spray, aerosolized or nebulized form, or oral zinc lozenges, or zinc orally at about 15 mg/day, vitamin D<than 4000 IU/day, atrovastatin or other statins oral 10-50 mg/day more and/or gargle with salt and lukewarm water at a salt concentration of >0.9% to 1.5% or more Na Cl or spray it as aerosolized or nebulized for nasal inhalation, etc. to damage the invading viruses before entering the nasal mucosa, etc.

In one embodiment, increasing the salt concentration enhances the action of the myeloperoxidase to create Hypochlorous acid or chloramines, the stable N-chloro derivatives to fight viruses.

In one embodiment, one can administer prophylactically, antiviral nasal spray, aerosolized or nebulized form of zinc or oral zinc lozenges, or zinc at about 15 mg, vitamin D<than 4000 IU/day and/or with salt and lukewarm water or as spray it as aerosolized or nebulized for nasal inhalation, or hydrogen peroxide at <3% concentration mouthwash or gargle in a short time.

In one embodiment, the mouthwash Listerine in low concentrations or diluted form can be applied to the nose, mouth, or throat mucosa to eliminate viruses.

In one embodiment, povidone iodine toxicity to the eye was tested after injection in the eye 0.1 mL of 50, 100, 200, or 400 micrograms (microg) of PVP-I in 1 eye without toxic effect; higher concentrations of 100 milligrams to 1000 milligrams or more has been used routinely to sterilize the skin prior to surgery.

In one embodiment, povidone iodine at 400 micrograms to 10 milligrams or more can be used as inhalation/day, inhalation through both nostrils for 1-14 days or using Q-tipped applicator with a mixture of 1-20% ethanol and 0.1-1% or more povidone iodide or other iodine preparations, such as cadexomer, Inadine, tincture of iodine iodophor, lugol iodine, etc. can be administered with or without Ebselen and/or glutathione peroxidase, and superoxide dismutase (SOD)—metabolize oxidative toxic intermediates requiring zinc, selenium, manganese iron, copper, and for ideal catalytic activity applied in the nose in a physiological solution or semifluorinated alkane or a physiological liquid or another medium to eliminate viruses and bacteria in the nose respiratory tract.

In one embodiment, Povidone iodine 0.1% is combined with zinc <15 mg in a solution or ointment, etc. applied to the skin of the upper lip, nasal skin, and nose mucosa entrance to damage the invading viruses/bacteria before entering the nasal mucosal cells, etc. reducing the chance of the infection during traveling by plane, etc.

In one embodiment, squalene nanoparticles combined with riboflavin applied to the nose and exposed to a low level of UV radiation of 3 mW/cm2 for one minute damage the viral particles in the nose without crosslinking the nasal proteins.

In one embodiment, the hypochlorous acid (HOCL) is stabilized at PH 5 and less can be applied as drops or spray or nebulized form locally or by inhalation to the nose and its surrounding tissue to eliminate viruses.

In one embodiment, the stabilized hypochlorous solution is acid at a pH 3 to pH 9 and the concentration of 0.01% to about 0.05% or in a semifluorinated alkane or liquid as a slow release nanoparticles of lactic acid, polyglycolic acid, polycaprolactone, or as micelles or in liposomes for nasal or inhalation as spray or aerosolized form.

In one embodiment, the purpose of the invention is to block the viruses, such as (SARS-CoV-2), COVID-19 or their mutations, influenza, herpes, zoster, Zika, Epstein-bar, HIV etc. at different levels of entry in the cell or block the mechanisms involved in its replication and release of the virus including the virucidal activity by preventing attachment or of the viruses' glycoprotein with the glycosylated host protein on the cell membrane surface or inside the cell preventing its capsid formation by inhibiting viral reverse transcriptase, preventing the DNA or RNA transport to the nucleus, or the viral integrase and viral integration in the chromosome, or preventing viral protease to breakdown the cell protein to build viral capsid, or by inducing an innate immune response, such as stimulation of complement C1, C3, C5, toll-like receptors and NK cells and cytotoxic T cells. Other approaches are the use of venom peptides affecting the viral replication cycle, inhibiting viral attachment glycoprotein to the cells, such as ChTx and Scyllatoxin-based mimetics or cecropin A, Magainin or by preventing attachment of virus glycoprotein to CXCR4 and CCR5 co-receptors or disintegration of viral capsid or interfering with the reverse transcription using melittin peptides or preventing the viral assembly of the viral capsid using peptide hacate and interfering in the assembly of the viral capsid and in the organization of the polymerase complex or using peptides derived from Wasp venom to affect Zika virus, chikungunya, dengue, and HIV virus.

In one embodiment, the stabilized hypochlorous or chloramines, the stable N-chloro derivatives or chloramines, the stable N-chloro derivatives or N-chlorotaurine (NTC), dimethylated derivatives of NCT (N-chloro-2,2-dimethyltaurine [DM-NCT] and N,N-dichloro-2,2-dimethyltaurine [DM-NDCT] solution is acid at a pH 3 to pH 9 and the concentration of 0.01% to about 0.05% or with mimetic heparin with or without Benzalkonium chloride in or with catechin combined with LMWH in a semifluorinated alkane or a suitable medium to block viral receptors, heparan sulfate and Sialic acid, present in the mucosa cells, endothelial cells or neuronal cells, or olfactory bulb and the thiol bound of the viruses, etc., as a slow release nanoparticles of lactic acid, polyglycolic acid, polycaprolactone, or as micelles or in liposomes and chitosan and encapsulated in a non-dissolvable compound given orally to pass through the stomach and is released by enzymatic action in the intestinal tract to release the medication and get absorbed in the intestine to kill the viruses such as (SARS-CoV-2), COVID-19 or their mutations locally preventing the intestinal side effect of viral infection.

In one embodiment, certain compounds can be used prophylactically as mouthwash or hand cleansing, nasal spray, such as hydrogen peroxide, povidone-iodine, ethanol, chlorhexidine, cetylpyridinium chloride, to disrupt the SARS-CoV-2 lipid envelope, COVID-19 lipid envelope, or their mutations, etc.

In one embodiment, for prophylaxis such as traveling by airplane, one can combine two or more antivirals with zinc, or povidone iodine, etc. or in a semifluorinated alkane or in a physiologic fluid in the form of slow release polymeric pluralities of nanoparticles, micelles liposomes, polyglycolic acid, or lactic acid, etc. administered through the nose or orally to last one week or more and release medication after administration in the form of spraying or nebulization by an intranasal route and inhalation to prevent viral attachment to the surface of the nose, throat, mucosa or lung alveoli or kill the incoming viruses or prevent their multiplication before reaching the brain and prevent their migration to the brain via the olfactory nerve.

In one embodiment, certain compounds can be used prophylactically as mouthwash or hand cleansing, such as hydrogen peroxide, povidone-iodine, ethanol, chlorhexidine, cetylpyridinium chloride, Hypochlorous acid, or chloramines, the stable N-chloro derivatives, or chloramines, the stable N-chloro derivatives or N-chlorotaurine (NTC), dimethylated derivatives of NCT (N-chloro-2,2-dimethyltaurine [DM-NCT] and N,N-dichloro-2,2-dimethyltaurine [DM-NDCT] alone or in combination to disrupt the (SARS-CoV-2), COVID-19 or their mutations lipid envelope.

In one embodiment, the damage to the capillary endothelial cells causes accumulation of platelets and other blood cells causing vascular occlusion, pain, stroke, paralysis, etc.; therefore, in one embodiment, any treatment to combat viral or bacterial central nervous system (CNS) vasculitis or vasculitis in an autoimmune response, such as lupus or in immunotherapy of cancer, etc. should be treated also with oral or systemic anticoagulants, such as aspirin in low molecular weight heparin, and/or in severe conditions, anticoagulants, such as Coumadin, or heparin, low molecular weight heparin (Lovenox), without or with catechin in a semifluorinated alkane or a suitable medium as slow release nanoparticles of lactic acid, polyglycolic acid, polycaprolactone, or as micelles or in liposomes and chitosan with or without Benzalkonium chloride or to block viral receptors, heparan sulfate and Sialic acid, in the mucosa, endothelial cells or neuronal cells, or olfactory bulb, etc., as slow release nanoparticles of lactic acid (LA), polyglycolic acid (PGLA), polycaprolactone, or as micelles, or in liposomes and chitosan to prevent cellular damage by virus and to enhance nerve repair and prevent blood coagulation or TPA to dissolve the blood clot, etc. followed by plasmapheresis, and/or kidney dialysis to remove excessive cytokines.

In one embodiment, the cytokines can be measured by using either the saliva, expectorations, tear, urine, or nasal secretion, cerebrospinal fluid or aqueous fluid of the eye, or blood circulation, etc., the concentrations of cytokines, such as IL-1 and/or IL-6, IL-8 are higher in the inflammatory diseases, etc., and the increase or decrease of their concentrations are indicative of the progression of viral infection or its prognosis.

In the brain and spinal cord, microglial cells act as immune cells, such as macrophages and respond to any pathogen encountered.

In one embodiment, several viruses can affect the upper respiratory system and brain simultaneously, such as influenza viruses or SARS-CoV-2, COVID-19 viruses, or their mutations, and herpes simplex, mumps, or measles, EBV etc.

In one embodiment, the patient with early cases of viral CNS vasculitis can be treated with one or two or more anti-virals or IL-6 inhibitors, interleukin antagonists via inhalation using aerosolized or nebulized medication, in semifluorinated alkane, as polymeric slow release nanoparticles to cover the nasal passages to the brain from the olfactory epithelium to olfactory bulb, and subsequently to the posterior gyms rectus and the cerebrospinal fluid and simultaneously lower respiratory tract infection is treated as described here, while the presence of the virus and cytokines, such as IL-6, before and after therapy can be verified through the nasal secretion or cerebrospinal fluid (CSF), blood, etc. as prognostic indication of the disease process.

In one embodiment, the persistence of headache is a sign of brain vasculitis and increase in the intracranial pressure associated damage to pericytes of small brain capillaries leading to leakage of the blood enriched fibrinogen and accumulation and activation of microglial cells leading to loss of myelin and white matter and buildup of tau and amyloid oligomers, fibrils, and plaque and Alzheimer's disease or Parkinson's disease, dementia; in one embodiment, the nasal application or inhalation of one or more antivirals and anti-inflammatory agents, such as Rock inhibitors, Wnt inhibitors, GSK inhibitors, and integrin inhibitors with or without complement pathway inhibitors, such as C3 inhibitors—AMY-101 (NCT04395456) and APL-9 (NCT04402060); C5 inhibitors—eculizumab (NCT04346797 and NCT04355494), C1 esterase inhibitors, which block the classical complement pathway with anti-IL6 medication, such as Kevzara, tocilizumab, rituximab, etc., or antiviral, baloxavir marboxil, and antibiotics such as tetracycline derivatives a metalloproteinase inhibitor and/or low molecular weight heparin (Levonox) with or without catechin and LMWH in a semifluorinated alkane or a suitable medium to block viral receptors, heparan sulfate, and Sialic acid, as a slow release nanoparticles of lactic acid, polyglycolic acid, polycaprolactone, or as micelles, or in liposomes and chitosan or tissue plasminogen activator (tpa) in the form of nasal spray or aerosolized medication or nebulized medication to reduce the inflammatory process and low molecular weight heparin assists in clearing the fibrinogen and oligodendrocyte loss preventing future side effects of viral encephalitis, such as dementia, Alzheimer's disease, neuralgia, etc.

In one embodiment, viral infection of the lung and brain vasculitis, produce anoxia and ischemia through HIF-1 factor that induces angiogenesis. TiPARP is activated in the cell nucleus that eliminates the HIF-1alpha and TiPARP. Tamoxifen works similarly for the breast tumor and degrades HIF-1 and prevent ischemia and anoxia. In one embodiment, Tamoxifen is combined with an antiviral in a viral infection of the lung and viral brain encephalitis and brain vasculitis and cell pathway inhibitors, Wnt inhibitor, GSK inhibitors, and integrin inhibitors administered in a physiological solution or semifluorinated alkane or a physiological liquid or a suitable medium combined or sequentially through the nose inhalation by spraying, aerosolization, or nebulization to reach both brain and the lung tissue, reduce the inflammatory process and eliminate the side effects of the infection.

In one embodiment, in respiratory viral infection of the upper or lower respiratory system or brain is associated with significant fibrin formation, the treatment is given as nasal application or inhalation of one or more antivirals and anti-inflammatory agents, such as Rock inhibitors, Wnt inhibitors, GSK inhibitors, and integrin inhibitors with anti-IL6 medication, such as Kevzara, or nitric oxide (NO) donor (NONOate), tocilizumab, etc., or tPA tissue plasminogen activator in nanogram to microgram concentrations in the form of nasal spray or aerosolized medication or nebulized medication to reduce the inflammatory process and tPA assists in clearing the fibrinogen/fibrin preventing future side effects of viral encephalitis, or enhancing the clearing the lung from the fibrinous exudates initiated by the viral inflammatory disease. In one embodiment, Mucinex given orally will work synergistically to cleanse the lung alveoli.

In one embodiment, the TPA can be administered in a physiological solution or semifluorinated alkane or a physiological liquid or a suitable medium intravenously either to dissolve the blood clot in the vessels or prevent coronary stent clot formation.

In one embodiment, the brain vasculitis and viral infection produces headache as a sign of cranial vasculitis and increased intracranial pressure, in addition to other symptoms of fever, shiver, and neck stiffness, or nerve palsy, etc., release of viral cytokines and cellular and humoral immune response enhance the inflammatory process in the brain. In one embodiment, one treats the viral brain and upper respiratory infection by simultaneous administration of antiviral agents, with one or more anti-inflammatory cell pathway inhibitors to block the excessive inflammatory response of the brain tissue and its vasculature while maintaining a normal immune response, with one or more Rock inhibitors antitumor SB 772077B, potent Rho-kinase inhibitor; vasodilator SR 3677 dihydrochloride, potent, selective Rho-kinase (ROCK) inhibitor TC-S7001, potent and highly selective ROCK inhibitor Y-27632 dihydrochloride, Botox or botulinum toxin, ROCK2 inhibitor, KD025, Netarsudil, Fasudil, and its derivatives, and/or Wnt inhibitors, GSK inhibitors, integrin inhibitors, or IL-1 and/or IL-6, IL-8 inhibitors dissolved in liquid semifluorinated alkanes or other liquids as the drug, or in a polymeric slow release nanoparticles administered locally as a spray or evaporative solution or in evaporative aerosolized drops or nebulization that travels through the nasal cavity where the semifluorinated alkanes which is non-toxic or causes irritation to the tissue, rapidly evaporates leaving the medication(s) or slow release nanoparticles, such as polymeric lactic, glycolic acid, or in combination, or porous silicon or polycaprolactone, liposomes, micelles, etc. on the surface of these tissues, or travel to the brain through the olfactory or trigeminal nerves releasing the medications over time to the brain, or simultaneously to the mouth to reach the lung alveoli, and while on the way attaching to the mucosa, epithelial or endothelial cells of the trachea, bronchi and lung alveoli and its vasculature and simultaneous absorption of the medication through the nasal capillaries, and lung capillaries provide the delivery of the medication through the circulation to the heart, and brain to their inflamed vasculature by daily inhalation, for one week to three weeks, or the release of the medication from the nanoparticles continues for months or years to inhibit chronic inflammatory processes in the brain that is associated with silent dementia and Alzheimer's disease, Neuralgia, or Parkinson's disease depending on the location of the inflammation.

In one embodiment, the antiviral delivery and pathway inhibitors are conjugated with antibody coated nanoparticles made of pluralities of dimethyl fumarate (DMF), squalene, lanosterol or squalamine or their derivatives that per se are antibiotic/anti-inflammatory compounds, tetracycline and doxycycline, a metalloproteinase inhibitor, to reduce the excessive inflammatory immune response, combined with semifluorinated alkanes or a physiological solution as aerosolized drops or spray for intranasal administration to the lung, brain, and heart.

In one embodiment, the antiviral delivery and pathway inhibitors are conjugated with antibody coated nanoparticles made of pluralities of heparin or synthetic heparin mimetics or synthetic heparin, such as PG500 and polyphenols, such as catechins or hyaluronic acid or their derivatives that per se are anti-inflammatory compounds to reduce the excessive fibrin release or breakdown the fibrinogen and inflammatory immune response, combined with semifluorinated alkanes or a physiological solution as aerosolized drops or spray for intranasal administration to prevent blood clotting, closure of vasculature or coronary stent, etc.

In one embodiment, the nasal approach to the delivery of antivirals, pathway inhibitors or IL-6 inhibitors, etc. using a semifluorinated alkane compound or in physiologic fluid combined with slow release polymeric nanoparticles or antibody-coated nanoparticles can be considered as a systemic application of the drug delivery in viral diseases involving the lung, heart, and brain or their generalized vascular involvement (vasculitis) of the intestinal tract, brain or increased coagulopathy, a single disease complex that is best treated through judicious intranasal route or inhalation, since the major organs (e.g., heart, lung, intestine, and brain) are reached very fast and the lung absorption provide the circulation route to reach the rest of body's vasculature to be treated immediately and also long term with slow release polymeric nanoparticles.

In one embodiment, the administration of the inflammatory pathway inhibitors, such as a Rock inhibitor, Wnt inhibitor, GSK inhibitor, such as synthetic small-molecule ATP-competitive inhibitors, and substrate-competitive inhibitors, non-ATP-competitive inhibitors, where FRAT/GBP competes with Axin inhibiting GSK-3 activity or integrin inhibitors or IL-1 and/or IL-6 inhibitors via nasal administration and inhalation using a semifluorinated alkane compound or in physiologic fluid with polymeric slow release nanoparticles, block the severe inflammatory response of the brain tissue caused by the invasion of the pathogens, which stimulate glial cells proliferation and migration producing oligomers of amyloid that coalesce building fibrils, tau and amyloid plaques, and the medication over time prevents the consequences of the brain vasculitis and encephalopathy in viral diseases of the brain.

In one embodiment, the viral encephalitis, if not treated in time, causes slow simmering or sui generous inflammatory process that may not become recognized, in time, to be treated leading to glial response, production of oligomers of beta amyloid and to self-sustained progressive Alzheimer's disease years or decades later.

In one embodiment, one or two antivirals, such as Tamiflu, Baricitinib, Glidesivir, Favipiravir, Xofluza Remdesivir, nanoviricides, Lenacapavir/Gilead in picomolar concentrations or GS-CA1, Oya1, interferon, umifenovir, tamivir ribavirin, baloxavir can be used orally, systemically or with or without IL-6 inhibitors, etc. Intranasal and orally as prophylaxis of the viral infection in the winter season or when traveling, or flying etc.

In one embodiment, at least one antiviral is combined with one pathway inhibitor, such as Wnt inhibitor FH535, IWP-2, PNU-74654, IWR-1endo, IWR-exo, Demethoxycurcumin, CCTO36477, KY02111, WAY-316606, SFRP, IWP, LGK974, C59, Ant1.4Br/Ant 1.4C1, Ivermectin, Niclosamide, apicularen and bafilomycin, XAV939, XAV939, G007-LK and G244-LM, NSC668036, SB-216763, gemtuzumab, etc., small molecule Wnt inhibitor PKF118-310, Niclosamide with both antiviral and anti-inflammatory effect, Fasudil, Netarsudil, the Wnt/β-catenin pathway inhibitor or Rock inhibitors with an IL-6 inhibitor or Kevzara, or nitric oxide (NO) donor (NONOate), or Actems are used in combination with interferon which is normally produced by natural killer cells in the body to excite cellular immune response in the body where interferons or pegylated interferon act as antivirals in the upper and lower respiratory tract blocking the replication of the RNA and DNA of the viruses at an early stage of viral infection.

The interferons are released in the body as cytokines to excite protective immune such as natural killers, macrophages, major Histocompatibility complex, etc. The interferons act as an antiviral preventing the virus growth in the cells. Interferon or pegylated interferon attaches to the cell receptors of the nasal or throat of the airway system and brain vasculatures, etc. and prevents DNA or RNA of the virus from replicating, the medication is administered in a physiological solution or semifluorinated alkane or a physiological liquid or a suitable medium as a spray of aerosolized liquid or nebulized liquid with or without semifluorinated alkanes preferably at an early stage in the disease process and not if a cytokine storm is eminent.

In one embodiment, antivirals and pathway inhibitors, such as Wnt inhibitors, such as Ivermectin, Niclosamide, etc. can be given orally specially in children or when intestinal involvement is predicted or intranasal inhalation as slow release polymeric nanoparticles at a significantly lower concentration than systemic administration for both viral infection of the lung and brain vasculitis, etc.

In one embodiment, interferon enhances cellular response while cell pathway inhibitors such as Rock, Wnt, GSK, or integrin inhibitors such as such as abegrin, cilengitide, abciximab, tirofiban, natalizumab, eptifibatide, or risuteganib in a low concentration of 1 microgram to 10 micrograms as a solution and IL-6 inhibitor or Kevzara, and/or nitric oxide (NO) donor (NONOate) or Actems to inhibitors, retuaximab, tocilizumab, control the inflammatory process preventing a cytokine response.

In one embodiment, viruses may affect upper or lower respiratory system followed by a bacterial infection with pathogens such as Streptococcus pneumonia, Haemophilus influenza, Staphylococcus aureus, or E. Coli, etc. However, the bacterial encephalitis, or meningitis is caused more commonly through the circulation. In these cases, a combination use of an antibacterial and one or two antivirals and one pathway inhibitor with or without complement pathway inhibitors, such as C3 inhibitors—AMY-101 (NCT04395456) and APL-9 (NCT04402060); C5 inhibitors—eculizumab (NCT04346797 and NCT04355494); C1 esterase inhibitors, which block the classical complement pathway can be administered in a physiological solution or semifluorinated alkane or a physiological liquid or a suitable medium by inhalation and systemic administration of a non-toxic dose of the antibacterial, antibiotics, or refabutin, etc. medications.

In one embodiment, the TMPRSS2 inhibitor Camostat inhibits entry of the virus in the cells and one or two antivirals nasal combined with Rock inhibitors or GSK inhibitors, or integrin inhibitors, such as abegrin cilengitide, abciximab, tirofiban, natalizumab, eptifibatide, or risuteganib in a low concentration of 1 microgram to 10 micrograms as a solution with or without semifluorinated alkanes or as polymeric nanoparticles can be administered in a physiological solution or semifluorinated alkane or a physiological liquid, simultaneously or sequentially by inhalation for prophylactic as well and treatment of viral infection affecting the brain and its vasculature or the lung.

In one embodiment of viral encephalitis, one can combine intranasal admiration of two antivirals such as lopinavir and ritonavir or Baricitinib, Glidesivir, Favipiravir, Xofluza, Remdesivir, nanoviricides, Oya1, interferon, or pegylated interferon, umifenovir, tamivir, lopinavir, etc. with protease inhibitors such as NSAIDS, or cox-2 inhibitors celecoxib, propanoic acid derivatives, etc. that block the main protease of the virus (M-Pro) essential for virus replication or MicroRNAs or atovaquone with its antiviral effect against RNA viruses, or antisense molecule fomivirsen, antiherpes drugs inhibit viral replication with a Rock inhibitor, or Wnt inhibitor, GSK inhibitor, integrin inhibitor or an IL-6 inhibitor such as kevzara, rituximab, Melatonin, etc. in a semifluorinated alkane or a physiologic solution as polymeric slow release delivery as nasal spray of aerosolized, or nebulized drops to treat or use it as prophylaxis in susceptible patients or those who are exposed, such as health care workers etc., or first responders.

In one embodiment, in end stage viral encephalitis or lung infection, one can combine antivirals with Wnt inhibitors, or integrin inhibitors or Rock inhibitors with IL-6 inhibitors, a macrolide such as tacrolimus, mycophenolic acid, or cyclosporine administered in a physiological solution or semifluorinated alkane or a physiological liquid or a suitable medium intranasal with intravenous administration or orally to suppress cytokine storm with simultaneous kidney dialysis and blood dialysis or plasma electrophoresis.

In one embodiment, antivirals are administered in combination with MPA, an antiviral and TNF inhibitor, and LMWH, catechins, and a Wnt inhibitor, such as niclosamide or ivermectin, or melatonin in polymeric slow release nanoparticles with or without semifluorinated alkanes as a nasal spray or by inhaler to prevent or treat viral encephalitis or prevent the side effect of the viral infection of the brain or after traumatic brain injuries, such as Alzheimer's disease or Parkinson's disease, by eliminating the infection and reducing the endoplasmic reticulum stress in the neuronal cells.

In one embodiment, one administer intranasal antivirals along with medications that block the ACE-2 receptor to which viral particles attach as the compound hydroxyquinoline at low concentration of micro to milligrams, Rock inhibitors where rock inhibition reduces the blood pressure, and while reducing the angiotensin II and increases Ang (1-9) plasma levels and inhibiting the NOX4-Derived ROS-Mediated RhoA/Rho Kinase Pathway, or follicle stimulating hormone or finistride to inhibit testosterone production, along with IL-6 inhibitors or tocilizumab dissolved in a semifluorinated alkane or in a physiologic solution as polymeric slow release antibody coated polymeric nanoparticles as aerosolized delivery system, etc.

In one embodiment, the two viruses such as (SARS-CoV-2), COVID-19 or their mutations and a herpes virus is involved simultaneously or sequentially one can add two antivirals with ganciclovir or acyclovir or valacyclovir, Cidofovir, Vidarabine, Penciclovir, Foscarnet Fomivirsen Famciclovir or Oseltamivir phosphate, Rimantadine, Amantadine, Zanamivir, Telbivudine, Lamivudine, Entecavir, Emtricitabine, Adefovir and heparin mimics containing glucosamine saccharides/acrylamide to bind to 13-Secretase (BACE-1) involved in Alzheimer's disease (AD) administered with or without polyphenols, such as catechins, with or without fluvoxamine, selective serotonin reuptake inhibitors (SSRIs), or tetracycline derivatives, a metalloproteinase inhibitor, or doxycycline, etc., as an antibacterial and anti-inflammatory in a physiological solution or semifluorinated alkane or a physiological liquid or a suitable medium intranasally as slow release polymeric nanoparticles with or without semifluorinated alkanes with a Rock inhibitor and IL-6 inhibitor, or nitric oxide (NO), donor (NONOate) as antiviral and anti-cytokines such as or nitric oxide (NO) donor (NONOate), interleukin antagonists or DMF by inhalation, systemic, oral, topical locally to halt spread of the virus to the brain or its reactivation or to prevent continuation of inflammation as nasal inhalation, etc. in the brain leading to Alzheimer's disease, dementia, and neuralgia, etc.

In one embodiment, two or more antivirals that can be used with the described methodology as a cocktail, in the semifluorinated alkane as a cocktail of antivirals and with pathway inhibitors or complement inhibitors, such as: Fosfonet Sodium; Rimantadine Hydrochloride; Saquinavir Mesylate; Somantadine Hydrochloride; Sorivudine; Statolon; Stavudine; Tilorone Hydrochloride; Trifluridine; Valacyclovir Hydrochloride; Vidarabine; Vidarabine Phosphate; Vidarabine Sodium Phosphate; Viroxime; Zalcitabine; Zidovudine; Zinviroxime, zinc, heparin, anionic polymers. Ganciclovir; Ganciclovir Sodium; Idoxuridine; Kethoxal; Lamivudine; Lobucavir; Memotine Hydrochloride; Methisazone, Adefovir; Alovudine; Alvircept Sudotox; Amantadine Hydrochloride; Aranotin; Arildone; Atevirdine Mesylate; Avridine, Acyclovir; Acyclovir Sodium; Desciclovir; Didanosine; Disoxaril; Edoxudine; Enviradene; Acemannan; Nevirapine; Penciclovir; Pirodavir; Ribavirin; Rimantadine Hydrochloride; Saquinavir Mesylate; Somantadine Hydrochloride; Sorivudine; Statolon; Stavudine; Enviroxime; Famciclovir; Famotine Hydrochloride; Fiacitabine; Fialuridine; Fosarilate; Foscarnet Sodium, Cidofovir; Cipamfylline; Cytarabine Hydrochloride; Delavirdine Mesylate, zanamivir, amantadine, and Palivizumab. Other examples of anti-viral agents include, but are not limited to Acemannan; Nevirapine; Penciclovir; Pirodavir; Ribavirin; Rimantadine Hydrochloride; Saquinavir Mesylate; Somantadine Hydrochloride; Sorivudine; Statolon; Stavudine, etc.

In one embodiment, with a viral infection, the antiviral can be given with an anti-inflammatory compound such as naltrexone, or disulfiram, combined with cox-2 inhibitors or Rock or Wnt or GSK inhibitors or anti-integrin intranasal with a semifluorinated or liquid solution with slow release nanoparticles or polylactic, polyglycolic, polycaprolactone, or porous silicon, micelles, or liposomes, etc. with or without IL-6 inhibitors.

In one embodiment of viral infection, the virus induces a storm cytokine response causing generalized vasculitis and thrombus formation, on treating this condition in addition to the antivirals such as the inhibitor Sofosbuvir, a polymerase inhibitor and ribavirin, umifenovir, tamivir, lopinavir etc., pathway inhibitors, such as Rock inhibitors, with inhibition of cytokine IL-6 with an inhibitor such as Kevzara or nitric oxide (NO), donor (NONOate), or rituximab intranasal administration with semifluorinated or liquid solution with slow release nanoparticles or polylactic, polyglycolic, polycaprolactone, or porous silicon, micelles, or liposomes, etc.

In one embodiment, the medications can be simultaneously administered in a physiological solution or semifluorinated alkane or a physiological liquid or medium orally, intravenously, and nasally as needed for therapy and/or as prophylaxis of the viral infection or when traveling, or flying by airplane, etc.

In one embodiment, one can administer prophylactically, antivirals nasal spray, aerosolized or nebulized form of zinc or oral zinc lozenges, or zinc at about 15 mg, vitamin D<than 4000 IU/day and/or with salt and lukewarm water or spray it as aerosolized or nebulized for nasal inhalation, or hydrogen peroxide at <3% concentration in combination with Listerine mouthwash at low concentration or gargle in a short time.

In one embodiment, the mouthwash Listerine in low concentration or diluted form can be applied to the nose, mouth or throat mucosa with salt water to eliminate viruses.

In one embodiment, povidone iodine toxicity to the eye was tested after injection in the eye 0.1 mL of 50, 100, 200, or 400 micrograms (microg) of PVP-I in one eye without toxic effect; higher concentrations of 100 milligram to 1000 milligram or more has been used routinely to sterilize the skin prior to surgery.

In one embodiment, povidone iodine at 400 micrograms to 10 milligrams or more can be used as inhalation/day through both nostrils for 1-14 days or using Q-tipped applicator with a mixture of 1-20% ethanol and 0.1-1% or more povidone iodide or other iodine preparations such as cadexomer, Inadine, tincture of iodine iodophor, lugol, iodine, with or without LMWH, etc. can be administered in a physiological solution or semifluorinated alkane or a physiological liquid or salt water to eliminate viruses and bacteria in the nose or respiratory tract.

In one embodiment, Povidone iodine 0.1% in salt water is combined with zinc <15 mg in a solution or ointment, etc. applied to the skin of the upper lip, nasal skin, and nose mucosa entrance to damage the invading viruses/bacteria before entering the nasal mucosal cells, etc. reducing the chance of the infection during traveling by plane, etc.

In one embodiment, nanoparticles of squalene nanoparticles combine with riboflavin in salt water 0.9% NaCl applied to the nose and exposure to a low level of UV radiation of 3 mW/cm2 for one minute damage the viral particles in the nose without crosslinking the nasal proteins.

In one embodiment, hypochlorous acid (HOCL) is stabilized at PH 5 and leas in salt water >0.9% NaCl can be applied as drops or spray or nebulized form locally or by inhalation to the nose and its surrounding tissue to eliminate viruses.

In one embodiment, certain compounds can be used prophylactically as mouthwash or hand cleansing, nasal spray, such as hydrogen peroxide, povidone-iodine, ethanol, chlorhexidine, cetylpyridinium chloride to disrupt the COVID-19 lipid envelope.

In one embodiment, for prophylaxis such as traveling by airplane or visiting a patient, or in the office, one can combine two or more antivirals with zinc, or povidone iodine, or another antiseptics, etc. or in semifluorinated alkane or in a physiologic fluid in form of slow release polymeric pluralities of nanoparticles, micelles, liposomes, polyglycolic acid, or lactic acid, etc. administered in form of spraying or nebulization by intranasal route and inhalation to last one week or more and release medication to prevent viral attachment to the surface of the nose, throat, mucosa, or lung alveoli, etc. or kill the incoming viruses or preventing their multiplication before reaching the brain and prevent their migration to the brain via olfactory nerve.

In one embodiment, the stabilized hypochlorous acid or chloramines, the stable N-chloro derivatives or chloramines, the stable N-chloro derivatives or N-chlorotaurine (NTC), dimethylated derivatives of NCT (N-chloro-2,2-dimethyltaurine [DM-NCT] and N,N-dichloro-2,2-dimethyltaurine [DM-NDCT] solution has a pH 3 to pH 9 and a concentration of 0.02% to about 0.05% or in a semifluorinated alkane or liquid such as 1% or more NaCl solution as a slow release nanoparticles of lactic acid, polyglycolic acid, polycaprolactone or as micelles or in liposomes for nasal administration or inhalation as a spray or aerosolized form with or without antivirals.

In one embodiment, the stabilized hypochlorous acid or chloramines, the stable N-chloro derivatives or chloramines, the stable N-chloro derivatives or N-chlorotaurine (NTC), dimethylated derivatives of NCT (N-chloro-2,2-dimethyltaurine [DM-NCT] and N,N-dichloro-2,2-dimethyltaurine [DM-NDCT] at a concentration of 0.025% in 1% sodium chloride with electrolyzed water is obtained from EcoloxTech, Envirolite®, etc. without phosphates, or Phosphate Buffered Saline (PBS) and sodium Hypochloride, phosphate with or without a Rock inhibitor, at 1-20 microgram/ml or more, Wnt inhibitor at pico-nanogram/ml concentrations or more, GSK 50 microgram/ml inhibitor or statins at <100 microgram/ml concentration or integrin inhibitors at 25-200 microgram/ml or more concentration with one or more antivirals or bronchodilators.

In one embodiment, 60 milligrams of iron oxide administered in a physiological solution or semifluorinated alkane or a physiological liquid once every two days enhances the production of hemoglobin.

In one embodiment, the nose can be disinfected with intra-nasal Miramistin solution, an old non-toxic disinfectant that kills the bacteria and viruses without affecting the normal cells.

In one embodiment, one or more convalescent plasma's antibodies are used to coat or conjugate with slow release polymeric nanoparticles which seek and attach to the viruses; where the nanoparticles are made from lactic, polyglycolic acid, polycaprolactone, anhydrides, porous silicon, micelles, liposomes, etc. carrying medications, such as antivirals or pluralities of nanoparticles are used carrying two or more antivirals in a physiological solution or administered in a physiological solution or semifluorinated alkane or a physiological liquid or a suitable medium intra-nasally as spray or drops or nebulization for inhalation to treat the early stage viral infection and reduce both viral infection side effects of the infection in the brain or the lung.

In one embodiment, pluralities of one or more antibody-coated slow release polymeric nanoparticles, such as polylactic acid, polyglycolic acid, porous silicon, micelles, liposomes, polyanhydrides, polyesters, polycaprolactone with cell penetrating peptides carry antivirals, such as nelfinavir, or Remdesivir, etc. along with bronchodilators such as, emetine, hydroxychloroquine or its derivatives, salbutamol, obatoclax, albuterol, with or without Rock inhibitors, Wnt inhibitors, GSK inhibitors or integrin inhibitors, intra-nasally or through the mouth as inhalation, to enhance relaxation of the bronchi that bring air in the lung alveoli by relaxing the smooth muscles of the vessels of the lung and brain.

In one embodiment, a combination of antivirals and salbutamol, and IL-6 inhibitors, Rock inhibitors, Wnt inhibitors, GSK inhibitors, or integrin inhibitors, or nitric oxide (NO), donor (NONOate) with or without DMF to inhibit inflammatory processes of the brain or lung vessels leading to leakage of fibrinogen stimulating production of oligomeric beta-amyloid in the brain or fibrin in the lung and can slow down or inhibit formation of Alzheimer's plaques, tau and tangled fibrils or dementia, etc. or reduce oxygen absorption by the lung capillaries and hemoglobin.

In one embodiment, the combination of antivirals with or without tetracycline derivatives, a metalloproteinase inhibitor which antibacterial and an anti-inflammatory and/or nitric oxide (NO), donor (NONOate), with antibody-coated polymeric slow release nanoparticles, such as polylactic acid, polyglycolic acid, porous silicon, micelles, liposomes, polyanhydrides, polyesters, polycaprolactone and antivirals with pathway inhibitors to reduce the inflammation and with cell penetrating peptides or activatable cell penetrating peptides (ACPPs) or cyclodextrin or low-molecular-weight (2-5 kDa) polyethylene glycol, or low molecular weight heparin, synthetic heparin mimetics heparin mimics containing glucosamine saccharides/acrylamide to bind to 13-Secretase (BACE-1) involved in Alzheimer's disease (AD), or synthetic heparin, such as PG500, etc. or Epigallocatechin gallate (EGCG), a green tea catechin, that binds to heparan sulfate or in combination with low molecular weight heparin or heparin mimetics to bind to heparan sulfate and sialic acid preventing the viral attachment to viral cell receptors, such as Neuroplin-1 and ACE-2 receptors of the mucosa, endothelial cells or neuronal cells, or olfactory bulb, etc. as slow release nanoparticles of lactic acid, polyglycolic acid, polycaprolactone, or as micelles or in liposomes and chitosan administered in semifluorinated alkane or a suitable medium through inhalation or vapor, nasal spray or nebulization to reach the brain directly and lung endothelial cells and cells of alveoli directly to inhibit the intracellular viral replication, in the brain, and lung and kill them with minimal amount of antiviral medication compared to the systemic administration of the antiviral that requires production of a large amount of medication with its associated expenses and complications.

In one embodiment of a method of treating, reducing, or alleviating a medical condition in a patient, the method comprising administering to a patient in need thereof a biocompatible drug comprising one or more antiviral medications together with one or more green tee, oolong, Cinnamon, or orange with or without linoleic acid in the warm to boiling water or a nebulizer creating vapor containing the active ingredient of the cocktail for simultaneous inhalation of the vapor's components to inhibit attachment of viruses to ACE-2 receptors or neuropilins's receptors in the nasal pathway to the lung to through the olfactory nerve and trigeminal nerve to brain thereby preventing the viral attachment to enter the nasal or respiratory pathway to the alveoli cells and olfactory nerve or sensory trigeminal nerves, to gain access to the brain cell producing viral encephalitis, or lung infection, where the cocktail can be consumed orally after it is cooled down to be absorbed through the gut preventing damage to the intestine, liver, kidney and the brain through the blood circulation.

In one embodiment of a method of treating, reducing, or alleviating a medical condition in a patient, the method comprises administering to a patient in need thereof a biocompatible drug cocktail comprising one or more antiviral medications together with or without one or more green tee, oolong, Cinnamon, or orange with or without linoleic acid polyphenyls, epigallocatechin gallate catechins (EGCG) having antioxidants compounds cocktail also and catechins etc. found in black tea, or coffee, oolong, white tea, Pu-reh, Chamomile tea, the vegetable, such as fruits or coco, alone or in combinations as a cocktail, or in addition to it one or more antioxidants, antimicrobial, statins and immunomodulatory mangiferin, genistein, estradiol, berberine and baicalein, sulforaphane, with or without vitamin D and high doses of vitamin C, vitamin E, D, or with or without quercetin, curcumin, resveratrol, Alpha-lipoic acid, tocopherols and tocotrienols, carotenoids, glutathione tocopherols, carotenoids alone or with or without linoleic acid mixed in the warm to boiling water or a nebulizer to create a vapor containing the active ingredients for nasal inhalation of the components of the cocktail which are inhibiting attachment of viruses to ACE-2 receptors or neuropilins's receptors etc. thereby preventing the viral attachment or entering the nasal or respiratory pathway to the alveoli cells and olfactory nerve or sensory trigeminal nerves, to gain access to the brain cell producing viral encephalitis, where the cocktail can also be consumed orally after it is cooled down.

In one embodiment, phosphorylation of endoplasmic reticulum resident kinase (PERK) and increased eIF-2α phosphorylation is a marker of endoplasmic reticulum (ER) stress response. The intranasal application of inhibitors of phosphorylation with medications, such as Baricitinib, a Janus kinases inhibitor as anti-TNF and cycloheximide at low concentrations of nanogram/ml to 1-4 microgram/ml, or naproxen prevents/treats not only the viral growth and infection/inflammation in the lung and brain (encephalitis/Alzheimer disease) but also prevent ER stress induced protein misfolding, such as beta amyloid tangles or plaques, chronic inflammation and neuropathy.

In one embodiment, inhibitors of phosphorylation of endoplasmic reticulum resident kinase (PERK) a marker of endoplasmic reticulum (ER) stress response, and prevention of hyperphosphorylation of eIF-2α, such as with a short lasting cycloheximide in DMSO in nanogram/ml to 1-microgram/ml concentration or Baricitinib, a Janus kinases inhibitor as anti-TNF, or naproxen that interacts with the viral nucleocapsid and anti-inflammatory and an antiviral, such as remdesivir or favipiravir in semifluorinated alkanes is administered in combination with nitric oxide (NO), donor (NONOate), pathway inhibitors and LMWH with antivirals as a topical application or nebulization, spray in the nose to prevent or treat viral replication and protein misfolding in the brain diseases caused by viral encephalitis including influenza viruses, coronaviruses, e.g., (SARS-CoV-2), COVID-19, or their mutations herpes viruses, herpes zoster, Epstein Barr virus, cytomegalovirus and subsequent Alzheimer's disease formation, etc., the medications are used sequentially or combined or at different time of the day preferentially as a nasal inhalation, etc.

In one embodiment, other viruses that can be treated with the described methodology are certain RNA viruses that are antigens in vertebrate animals which include, but are not limited to, the following: members of the family Retroviridae, the genus Orbivirus Colorado Tick Fever virus), the genus Rotavirus (human rotavirus); the family Picomaviridae, including the genus Enterovirus, poliovirus, Coxsackie virus A and B, enteric cytopathic human orphan (ECHO) viruses, hepatitis A virus, Porcine enteroviruses, the genus Cardiovirus (Encephalomyocarditis virus) the genus Rhinovirus (Human rhinoviruses the genus Apthovirus; the family Calciviridae, Feline picornavirus and Norwalk virus; the family Togaviridae, including the genus Alphavirus, Ross river virus, Venezuelan equine encephalitis virus, Western equine encephalitis virus, the genus Flavirius, yellow fever virus; Dengue virus, Japanese encephalitis virus, St. Louis encephalitis virus, Murray Valley encephalitis virus, West Nile virus, Central European tick borne virus, Far Eastern tick borne virus, Omsk hemorrhagic fever virus), the genus Rubivirus (Rubella virus), the genus Pestivirus (Mucosal disease virus, the family Bunyaviridae, including the genus Bunyvirus (Bunyamwera and related viruses, California encephalitis group viruses), the genus Phlebovirus, Sandfly fever Sicilian virus, Rift Valley fever virus, the genus Nairovirus, hemorrhagic fever virus, and the genus Uukuvirus\the family Orthomyxoviridae, including the genus influenza virus (influenza virus type A, many human subtypes; Swine influenza virus, and Avian and Equine Influenza viruses; influenza type B many human subtypes, and influenza type C, the family paramyxoviridae, including the genus Paramyxovirus, Parainfluenza virus type I, Parainfluenza viruses types 2 to 5, Newcastle Disease Virus, Mumps virus, the genus Morbillivirus, Measles virus, subacute sclerosing panencephalitis virus, distemper virus, Rinderpest virus, the genus Pneumovirus respiratory syncytial virus (RSV), Bovine respiratory syncytial virus, forest virus, Sindbis virus, Chikungunya virus, O'Nyong-Nyong virus, Ross river virus, Venezuelan equine encephalitis virus, Western equine encephalitis virus, the genus Flavirius (Mosquito borne yellow fever virus, Dengue virus, Japanese encephalitis virus, St. Louis encephalitis virus, Murray Valley encephalitis virus, West Nile virus, Kunjin virus, Central European tick borne virus, Far Eastern tick borne virus, Kyasanur forest virus, Louping III virus, Powassan virus, Omsk hemorrhagic fever virus), the genus Rubivirus (Rubella virus), the genus Pestivirus (Mucosal disease virus, Hog cholera virus, Border disease virus); the family Bunyaviridae, related viruses, California encephalitis group viruses, the genus Phlebovirus Sandfly fever Sicilian virus, Rift Valley fever, virus, the genus Nairovirus, Crimean-Congo hemorrhagic fever virus, Nairobi sheep disease virus), and the genus Uukuvirus (Uukuniemi and related viruses); the family Orthomyxoviridae, including the genus Influenza virus, Influenza virus type A, many human subtypes; Swine influenza virus, and Avian and Equine Influenza viruses; influenza type B and influenza type C the family paramyxoviridae, including the genus Paramyxovirus, Parainfluenza virus type I, Sendai virus, Hemadsorption virus, Parainfluenza viruses types 2 to 5, Newcastle Disease Virus, Mumps virus, the genus Morbillivirus, Measles virus, subacute sclerosing panencephalitis virus, distemper virus, Rinderpest virus, the genus Pneumovirus, respiratory syncytial virus (RSV), Bovine respiratory syncytial virus and Pneumonia virus of mic); the family Rhabdoviridae, including the genus Vesiculovirus (VSV), Chandipura virus, Flanders-Hart Park virus), the genus Lyssavirus (Rabies virus) (Marburg virus and Ebola virus); the family Arenaviridae, including Lymphocytic choriomeningitis virus (LCM), Tacaribe virus complex, and Lassa virus; the family Coronoaviridae, including Infectious Bronchitis Virus (IBV), Mouse Hepatitis virus, Human enteric coronavirus, and Feline infectious peritonitis (Feline coronavirus). In addition, other viruses that can be treated with the described methodology are certain DNA viruses that are antigens in vertebrate animals which include, but are not limited to: the family Poxviridae, including the genus Orthopoxvirus (Variola major, Variola minor, Monkey pox Vaccinia, Cowpox, the family Herpesviridae, including the alpha-Herpesviruses, Herpes Simplex Types 1 and 2, Varicella-Zoster, Equine abortion virus, Equine herpes virus 2 and 3, pseudorabies virus, infectious bovine keratoconjunctivitis virus, infectious bovine rhinotracheitis virus, feline rhinotracheitis virus, infectious laryngotracheitis virus, the Beta-herpesviruses Human cytomegalovirus and cytomegaloviruses of swine, monkeys and rodents; the gamma-herpes viruses, Epstein-Barr virus (EBV), Marek's disease virus, Herpes saimiri, Herpesvirus ateles, the family Adenoviridae, including the genus Mastadenovirus, Human subgroups A, B, C, D, E and ungrouped; simian adenoviruses, infectious canine hepatitis, (Avian adenoviruses); and non-cultivatable adenoviruses; the family Papoviridae, including the genus Papillomavirus, Human papilloma viruses, bovine papilloma viruses, various pathogenic papilloma viruses of other species), the genus Polyomavirus); the family Parvoviridae including the genus Adeno-associated viruses, the genus Parvovirus, bovine parvovirus, canine parvovirus, Aleutian mink disease virus, DNA viruses may include viruses that do not fit into the above families such as Creutzfeldt-Jacob disease viruses and chronic infectious neuropathic agents.

In one embodiment, one can administer antivirals with pathway inhibitors in combination with TNF alpha inhibitors, such as baricitinib, and Raf inhibitors, such as sorafenib, regorafenib, dabrafenib, with or without anti-VGEFs, aerosolized or in slow release polymeric nanoparticles with or without semifluorinated alkanes by nasal application, inhalation, etc. at low concentrations to inhibit inflammatory processes and excessive activation of glial cell stimulation in viral encephalitis or traumatic brain injuries while protecting the existing neuronal cells and preventing side effects, such as Alzheimer's disease or Parkinson's disease, etc.

In one embodiment, the combination of antivirals and salbutamol with antibody-coated nanoparticles, such as polylactic acid, polyglycolic acid, porous silicon, micelles, liposomes, polyanhydrides, polyesters, polycaprolactone with cell penetrating peptides or activatable cell penetrating peptides (ACPPs) or cyclodextrin or low molecular weight heparin, synthetic heparin mimetics, or synthetic heparin, such as PG500 and semifluorinated alkane or catechins alone or combined with low molecular weight heparin or heparin mimetics that bind to heparan sulfate or to sialic acid which are the component of ACE-2 and neuropilin-1 receptors of the mucosa, endothelial cells or neuronal cells, or olfactory bulb, etc. as slow release nanoparticles of lactic acid, polyglycolic acid, polycaprolactone, or as micelles or in liposomes and chitosan that the site where the influenza, (SARS-CoV-2), COVID-19 or their mutations and other viruses enter the cells, etc. in a hyaluronic acid solution at <1% concentration or LMWH are administered in a physiological solution or semifluorinated alkane or a physiological liquid through inhalation, or by an inhaler or through the nose to reach the brain directly and lung endothelial cells and remain there for a period of time before the semifluorinated alkane evaporates, leaving the antibody-coated polymeric slow release nanoparticles in place to penetrate the alveoli cells or brain vessels cells directly to inhibit the intracellular viral particles, and kill them with a minimal amount of antiviral medication compared to the systemic administration while the nanoparticles can deliver the medication for a long period of time, reducing the need for a production or availability of medication in a pandemic viral infection, while salbutamol and low molecular weight heparin or synthetic heparin mimetics and polyphenols, such as catechins and/or Probenecid inhibits Panex-1 and prevent formation of fibrin and beta-amyloid that encourages tau plaque and neurofibrillary formation as a precursor of dementia or Alzheimer's disease occurring after inflammatory processes of the brain.

In another embodiment, where the disease has progressed, the combination of inhalation and intravenous administration of antibody-coated polymeric slow release nanoparticles/antivirals with cell penetrating peptides or activatable cell penetrating peptides (ACPPs) or cyclodextrin, or polyethylene glycol, or low molecular weight heparin, micelles, etc. is given simultaneously intravenously or orally that enhances also the cellular immune response of the body directly in the gut, lung, or brain directly which clears the dead viruses or dead cells, etc. that can produce toxins and multi-system inflammatory disease in adults or children after viral infection.

In one embodiment, the combination of antivirals and salbutamol, adrenaline, hyaluronic acid, with antibody-coated polymeric slow release nanoparticles, such as polylactic acid, polyglycolic acid, porous silicon, PEG-PLA, micelles, liposomes, polyanhydrides, polyesters, polycaprolactone with cell penetrating peptides or activatable cell penetrating peptides (ACPPs) or cyclodextrin or epigallocatechin gallate (EGCG), that bind to heparan sulfate or to sialic acid preventing the viral attachment to its cell receptors or pegylated heparin or synthetic heparin mimetics, or synthetic heparin, such as PG500, or catechins alone or combined with low molecular weight heparin, or low molecular weight heparin (LMWH), or heparin mimetics that bind to heparan sulfate or to sialic acid which are the component of ACE-2 and neuropilin-1 receptors of the mucosa, endothelial cells or neuronal cells, or olfactory bulb etc. as a slow release nanoparticles of lactic acid, polyglycolic acid, polycaprolactone, or as micelles or in liposomes and chitosan that the site where the influenza, (SARS-CoV-2), COVID-19 or their mutations and other viruses enter the cells, etc. in nanoparticles, micelles, or liposomes are administered with protease (PLpro or Mpro, etc.) blocking agents, such as Ebselen, Ebseleno, or Ebselenum, and or glutathione peroxidase, GPx and superoxide dismutase (SOD)—metabolize oxidative toxic intermediates requiring zinc, selenium, manganese iron, copper, and for ideal catalytic activity applied in the nose etc., which also is an antiviral, antibacterial, anti-inflammatory, anti-prostaglandin, and neuroprotective effect, administered in a physiological solution or semifluorinated alkane or a physiological liquid or as vapor by inhalation through the nose, or through the mouth by an inhaler to reach the brain directly in lung, brain blood vessel endothelial cells, and remain in the nose, alveoli, brain endothelial cells, and to inhibit the replication of intracellular viruses, and kill them with minimal amount of antiviral medications compared to the systemic administration of the medications while improving breathing through the relaxation of bronchi smooth vessels and in the brain enhancing neuronal regeneration and prevention of amyloid plaque formation.

In one embodiment, the combination of antivirals with antibody-coated polymeric slow release nanoparticles, such as polylactic acid, polyglycolic acid, porous silicon, micelles, liposomes, polyanhydrides, polyesters, polycaprolactone with cell penetrating peptides or activatable cell penetrating peptides (ACPPs) or pegylated low-molecular-weight heparin or synthetic heparin mimetics or synthetic heparin, such as PG500, or epigallocatechin gallate (EGCG), that binds to sialic acid, combined low molecular weight heparin (LMWH) or heparin mimetics that bind to heparan sulfate or to sialic acid preventing the viral attachment to its cell receptors in slow release nanoparticles of lactic acid, polyglycolic acid, polycaprolactone, or as micelles or in liposomes and chitosan or cyclodextrin are administered with naturally or synthetically produced compounds to inhibit protease (PLpro or Mpro), such as Ebselen, and/or glutathione peroxidase and superoxide dismutase (SOD)—metabolize oxidative toxic intermediates requiring zinc, selenium, manganese iron, copper, and for ideal catalytic activity applied in the nose, blocking proteases, which also has an antiviral, antibacterial, anti-inflammatory, anti-prostaglandin, and neuroprotective effect, or preventing the (SARS-CoV-2), COVID-19 or their mutations spikes attachment to the cells, by administration in a semifluorinated alkane or a suitable medium through inhalation or through the mouth by an inhaler to reach the brain directly through the nose, lung, brain blood vessel endothelial cells and to remain in the nose, alveoli, brain endothelial cells for a longer period of time to inhibit the cell entry through the ACE-2 or preventing replication of intracellular viruses, and kill them with minimal amount of antiviral medications compared to the systemic administration for a long period of time for the patient to recover.

In one embodiment, one can examine and assess the degree of vascular and brain involvement or damage after viral brain involvement using an electroencephalogram prior and after administration of the antiviral and Rock inhibitors, etc. medications through the nose or orally or intravenously, with the administration of polymeric slow release nanoparticles carrying antivirals with or without Rock inhibitors, Wnt inhibitors, GSK inhibitors, or integrin inhibitors, etc. or salbutamol which indicates the functional recovery of the affected brain cells or treating seizure, sleep difficulty, etc.

In one embodiment, the combination of antivirals with antibody-coated polymeric slow release nanoparticles, such as polylactic acid, polyglycolic acid, porous silicon, PEG-PLA, micelles, liposomes, polyanhydrides, polyesters, polycaprolactone with cell penetrating peptides or activatable cell penetrating peptides (ACPPs) or cyclodextrin or pegylated nanoparticles or PEG-PLA or PGG-PGLA or PEG-Heparin, or synthetic heparin mimetics, or synthetic heparin, such as PG500, nanoparticles with polyphenols, such as catechins alone that bind to sialic acid or combined with low molecular weight heparin that bind to both heparan sulfate and to sialic acid which are the component of ACE-2 and neuropilin-1 receptors of the mucosa, endothelial cells or neuronal cells, or olfactory bulb, etc. that the site where the influenza, COVID-19 and other viruses enter the cells, etc. as slow release antibody-coated nanoparticles of lactic acid, polyglycolic acid, polycaprolactone, or as micelles or in liposomes and chitosan, etc. are administered in a physiological solution or semifluorinated alkane or a physiological liquid by spray or inhalation or through the nose, mouth by an inhaler in combination with bronchodilators, such as xanthine bronchodilators terbutaline, non-selective beta.-stimulants, isoprenaline, adrenaline, Sudafed, beta.sub.2-agonist fenoterol, formoterol, pirbuterol, reproterol, salbutamol, indacaterol, aminophylline and choline theophyllinate and anti-allergic agents, such as ketotifen, cromoglycate, and anti-inflammatory agents, such as Dexamethasone, fluticasone, betamethasone, budesonide, flunisolide, beclomethasone, dipropionate, ciclesonide, triamcinolone acetonide, etc., anticholinergic agents, ipratropium bromide, oxitropium bromide and tiotropiumetc, alone or in combinations as needed to treat viral brain infection, encephalitis or lung viral infections, such as influenza viruses or (SARS-CoV-2), COVID-19, or their mutations etc.

In one embodiment, with encephalitis viral infection, the vasculitis causes severe migraines, which are treated with the combination of antivirals with antibody-coated nanoparticles such as polylactic acid, polyglycolic acid, porous silicon, PEG-PLA, micelles, liposomes, polyanhydrides, polyesters, polycaprolactone with cell penetrating peptides or activatable cell penetrating peptides (ACPPs) or pegylated nanoparticles or PEG-PLA or PGG-PGLA or PEG-Heparin or synthetic heparin mimetics or synthetic heparin, such as PG500, or catechins alone or combined with low molecular weight heparin that bind to heparan sulfate or to sialic acid which are the component of ACE-2 and neuropilin-1 receptors of the mucosa, endothelial cells or neuronal cells, or olfactory bulb, etc. the site where the influenza, (SARS-CoV-2), COVID-19, or their mutations and other viruses enter the cells, etc. as slow release antibody-coated nanoparticles of lactic acid, polyglycolic acid, polycaprolactone, or as micelles or in liposomes and chitosan or nanoparticles or cyclodextrin administered in a physiological solution or semifluorinated alkane or a physiological liquid by spray or inhalation or through the mouth by an inhaler, in combination with bronchodilators, such as isoprenaline, adrenaline, Sudafed, salbutamol, albuterol, indacaterol, glycopyrrolate, formoterol, aminophylline or in combinations and choline theophylline and anti-inflammatory agents, such as Dexamethasone, fluticasone, betamethasone, Rock inhibitors, Wnt inhibitors, GSK inhibitors, or integrin inhibitors or in combinations, anticholinergic agents, ipratropium bromide, oxitropium bromide and tiotropiumetc, alone or in combinations with anti-migraine medications, such as almotriptan, rizatriptan, triptan through inhalation, or orally or NSAIDs, such as propionic acid derived non-steroidal agents.

In one embodiment, the combination of antivirals such as Remdesivir, zanamivir, ribavirin, flumist, ruprintrivir and pleconaril, Favipiravir, etc. and protease inhibitors with antibody-coated polymeric nanoparticles, such as polylactic acid, polyglycolic acid, porous silicon, PEG-PLA, micelles, liposomes, polyanhydrides, polyesters, polycaprolactone conjugated with or without cell penetrating peptides or activatable cell penetrating peptides (ACPPs) or cyclodextrin, or low-molecular-weight (2-5 kDa) polyethylene glycol or PEG-modified NPs densely coated by low MW PEG or Pluronic F-127 modified NPs, as PEG-polyacrylic acid, or papain or pegylated nanoparticles or PEG-PLA or PGG-PGLA or PEG-Heparin or synthetic heparin mimetics or synthetic heparin, such as PG500, or catechins alone or combined with low molecular weight heparin that bind to heparan sulfate or to sialic acid which are the component of ACE-2 and neuropilin-1 receptors of the mucosa, endothelial cells or neuronal cells, or olfactory bulb, etc. that the site where the influenza, COVID-19 and other viruses enter the cells, etc., as nanoparticles, PEG-LA, polysorbates are administered in a physiological solution or semifluorinated alkane or a physiological liquid as drops or spray, orally or intravenously in combination with anti-allergic agents, such as ketotifen, cromoglycate, and anti-inflammatory agents, such as Dexamethasone, fluticasone, budesonide, flunisolide, ciclesonide, beclomethasone, dipropionate, triamcinolone acetonide, fluorocinolone, betamethasone, etc., anticholinergic agents, ipratropium bromide, oxitropium bromide and tiotropiumetc, melatonin, alone or GABA inhibitors such as KDS2010, low molecular weight heparin (Lovenox) to simultaneously act as an antiviral (e.g., (SARS-CoV-2), COVID-19) or their mutations or anti-bacterial and to enhance nerve repair and prevent blood coagulation, NSAIDS in combinations with polyphenols, such as catechins as needed to treat intestinal viral infections (e.g., COVID-19) as inhalation therapy or through the mouth by an inhaler, with or without semifluorinated alkanes.

In one embodiment, end stage viral brain and lung infection antivirals are administered in a physiological solution or semifluorinated alkane or a physiological liquid or a suitable medium by inhalation or intravenously or orally in combination with anticoagulants, aspirin, Coumadin, non-coagulative low molecular weight heparin, or synthetic heparin mimetics or synthetic heparin, such as PG500, etc., and immunomodulators, Rock inhibitors, Wnt inhibitors, integrin inhibitors, cyclosporine, macrolide, mycophenolic acid, ascomycin, tacrolimus, etc. with GABA inhibitors, such as KDS2010, or melatonin that regulates the sleep-wake cycle or low molecular weight heparin (Lovenox) and polyphenols, such as catechins that bind to heparan sulfate or to sialic acid which are the component of ACE-2 and neuropilin-1 receptors of the mucosa, endothelial cells or neuronal cells, or olfactory bulb cells, etc. the site where the influenza, (SARS-CoV-2), COVID-19 or their mutations and other viruses enter the cells, etc. as a polymeric slow release nanoparticles of lactic acid, polyglycolic acid, polycaprolactone, or as micelles or in liposomes and chitosan to enhance nerve repair and prevent blood coagulation in antibody-coated polymeric slow release nanoparticles to combat an overactive immune response.

In one embodiment, when the viral infection is associated with a cytokine storm or multi-organ disease, blood electrophoresis, kidney dialysis, and/or dielectrophoresis are needed to remove excessive cytokine and killed cells and viruses, etc.

In the cells, TRIM proteins are generated by the interferon. A number of TRIMs are needed to block viral infections. Trim2 binds to the antibody conjugated non-enveloped virions in the infected cells and directs the virions to the proteasomes where the virions are degraded.

In one embodiment, since there are no antivirals for newly genetically modified viruses, the body's immune response including cellular response with killer cells is the only way to overcome a viral infection; the immune stimulation is beneficial at the early diseases process but excessive response damages the vital organs of the patient the so called multi-organ disease.

In one embodiment, to stimulate the immune response one can use viral-like particles along with serum antibody(s) obtained from convalescent person or an animal to conjugate with viral-like particles (VLP) that naturally produce a strong cellular immune response and interferon against any invading organism in this case the viral antigen that VLPs are conjugated with the viral antigen e.g., COVID-19 or their mutations, spike protein or multiple antigens, etc. to initiate humoral and cellular response against the recently propagated epidemic viral infection. In one embodiment, this methodology using methylene blue can be used to produce a vaccine in antibody-coated polymeric slow release nanoparticles to produce or enhance the immune system to fight the viral (e.g., COVID-19) infection in general or (SARS-CoV-2), COVID-19 or their mutations or other specific viruses, by inhalation or nasal drops or spray or aerosolized drops.

In one embodiment, using the antibody(s) coated VLPs used with the bethylen blue vaccinane production technology produces a strong cellular immune response by stimulating interferon production against any invading organism in this case the viral antigen, VLPs are conjugated with the viral antigen e.g., (SARS-CoV-2), COVID-19 or their mutations spike protein or RNA or multiple antigens, etc. to initiate humoral and cellular response against the recently propagated epidemic viral infection and natural killer cells that are culture grown with (SARS-CoV-2), COVID-19 or their mutations antigen(s) or protein(s) are administered in a physiological solution or semifluorinated alkane or a physiological liquid with or without antivirals simultaneously with or without Rock inhibitors, or Wnt inhibitors as ivermectin, niclosamide or integrin inhibitors, simultaneously or sequentially by inhalation, subcutaneously, intraperitoneally, intramuscularly or intravenously to initiate a cellular and humoral immune response against the (SARS-CoV-2), COVID-19 virus, or their mutations, or in immunosuppressed patient, where the natural killer cells attack the viruses to eliminate the infected cells and viruses.

In one embodiment, antibody-coated VLP that induces interferon production conjugated with spike protein of the virus is prepared with the known technology in the art for vaccination in antibody and CPP or Mucus penetrating agents coated polymeric slow release nanoparticles, with or without antivirals, and administered in a physiological solution or semifluorinated alkane or a physiological liquid intra-nasally, subcutaneously, or orally or systemically at low concentrations which can be repeated initially monthly, every three months, or six months or yearly by measuring the antibody or neutralizing antibody in a person.

In one embodiment, antibody-coated VLP that induces interferon production conjugated with fragments of RNA of the virus is prepared or after irradiation with UV light to crosslink it to lose its activity, but maintaining its antigenicity for vaccination in antibody (s), ACPP or MPP-coated polymeric slow release polymeric nanoparticles with or without antivirals simultaneously or sequentially and administered in a physiological solution or semifluorinated alkane or a physiological liquid intra-nasally, subcutaneously, or orally or systemically at low concentrations which can be repeated initially monthly, every three months, or six months or yearly by measuring the antibody or neutralizing antibody present in a person.

In one embodiment, using the spike protein or crosslinked DNA or RNA fragments of a number of viruses can be used with an antibody, CPP or MPP-coated VLP that enhance interferon production and to induce a humoral and cellular response against any viruses or other pathogens administered, in a physiological solution or semifluorinated alkane or a physiological liquid initially at very low but gradually increasing concentrations to render immune response against any organism.

In one embodiment, vaccination is performed with multiple viral antibodies, and CPP coated VLPs that induces interferon production conjugated with slow release polymeric nanoparticles with or without antivirals simultaneously or sequentially and administered in a physiological solution or semifluorinated alkane or a physiological liquid, etc. intra-nasally, subcutaneously, or orally or systemically at low concentrations which can be repeated initially monthly, every three months, or six months or yearly by measuring the antibody or neutralizing antibody present in a person.

In one embodiment, the VLPs can be coated with one or more viral (COVID-19) antibodies and another adjuvant, such as acrylic-acid-based adjuvant (ADJ) in antibody-coated polymeric slow release nanoparticles with or without antivirals, or catechins or Lovenox such as Remdesivir, favipiravir, etc. used in vaccine with and or an adjuvant production to create an incremental increase in immune response to the viruses, bacteria, etc. intramuscularly, by inhalation, intranasally without inducing a cytokine storm.

In one embodiment, the VLP or an adjuvant/antigen/antibody/Rock inhibitors, etc. vaccination is done with or without an antibody and ACPP-coated polymeric slow release of viral antibody-coated pluralities of nanoparticles alone or in an oxygenated semifluorinated alkane with adjuvants, such as Analgesic adjuvants, calcium phosphate hydroxide, aluminum phosphate, alum, aluminum hydroxide, paraffin oil, Mycobacterium bovis, squalene detergents, antivirals, catechins and/or Lovenox, antibiotics, such as tetracycline, a metalloproteinase inhibitor which are antibacterial and anti-inflammatory or doxycycline, Egg proteins, yeast proteins, Acidity regulators, or modified sugar molecules against viruses, such as Tamiflu, etc. in a semifluorinated alkane or a liquid for inhalation or intramuscularly, etc.

In one embodiment, the VLP/antigen/antibody/Rock inhibitors, etc. vaccination is done with or without antibody and ACPP, or MPP-coated polymeric slow release nanoparticles having dexamethasone or Rock inhibitors, Wnt inhibitors, integrin inhibitors, or GSK inhibitors with adjuvants such as Analgesic adjuvants, calcium phosphate hydroxide, aluminum phosphate, alum, aluminum hydroxide, paraffin oil, Mycobacterium bovis, squalene detergents, antiviral, antibiotics, antivirals with Tetracycline derivative medications, a metalloproteinase inhibitor which is antibacterial and anti-inflammatory include demeclocycline, doxycycline, Minocycline, Minocin, etc. to treat inflammatory viral lung or brain infection through the nasal inhalation, etc., Egg proteins, yeast proteins, acidity regulators, or modified sugar molecules against viruses, such as Tamiflu, green tee extracts etc. or other antivirals, such as baloxavir marboxil, combined with nanoparticles or polymeric slow release antibody-coated pluralities of nanoparticles coated with a virus, (SARS-CoV-2), COVID-19, or their mutations or influenza or other viruses in combination with LMWH/catechins, LMWH, heparin mimetics or viral-like or antibody coated viral like nanoparticles and an adjuvant such as acrylic-acid-based adjuvant (ADJ) to induce an immunity against the specific virus or treat specific viruses, etc. or vaccination for inhalation, or subcutaneous, intraperitoneal, or intramuscular or intravenous injection monthly, every three months, or six months or yearly by measuring the antibody or neutralizing antibody present in a person.

In one embodiment of viral lung or brain involvement the antibody, CPP or low-molecular-weight (2-5 kDa) polyethylene glycol or poloxamer, Lovenox-coated, VLP that induces interferon production is combined with or without polyphenols such as catechins with LMWH that block ACE-2 and neuropilin-1 receptors for the virus cell entry, and one of Rock inhibitors, Wnt inhibitors, GSK and/or integrin inhibitors, or with therapeutic medications, such an antiviral in a semifluorinated alkane or suitable medium administered by inhalation, with such as salbutamol, fenoterol, adrenalin, dobutamine, in antibody-coated polymeric slow release nanoparticles to reduce the side effect of vaccination and enhance recovery regardless of its application, intranasal, intramuscular, inhalation, or through the mouth by an inhaler, or intraperitoneal or intravenously.

In one embodiment, antivirals combined with antibody (monoclonal or polyclonal antibodies) coated or aptamer or mRNA or in combinations conjugated pluralities of nanoparticles or polymeric slow release nanoparticles coated against a virus, (SARS-CoV-2), COVID-19 or their mutations or influenza or other viruses in combination with LMWH, heparin mimetics/catechins, or a metalloproteinase inhibitor tetracycline derivatives which antibacterial and anti-inflammatory and antibody-coated viral-like nanoparticles or an adjuvant as a vaccine to induce interferon and an immune response to the antigens and a pathway inhibitor, with or without additional adjuvants to induce an immunity against the specific virus/bacteria, etc. or treat specific viruses while blocking excessive type 2 immune response.

In one embodiment, an adjuvant can be used or added to a vaccine to enhance the immune response including amorphous aluminum hydroxyphosphate sulfate (AAHS), aluminum hydroxide, aluminum phosphate, potassium aluminum sulfate (Alum), Oil in water emulsion made of squalene, Monophosphoryl lipid A (MPL), QS-21, extracted from the Chilean soapbark tree in liposomes, Cytosine phosphoguanine (CpG) a synthetic DNA mimicking viral bacteria genetic material, Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE), synthetic Toll-like receptor (TLR)4 agonist, adjuvant Fluzone®. The GLA-SE adjuvant Fluzone vaccine, or saponins, etc.

In one embodiment, one can start with VLP antigen/antibodies vaccination through the inhalation or variation of vaccines repeatedly combined with pathway inhibitors.

In one embodiment, one can start with one mRNA vaccine and move to second application of the same or another vaccine, one such as VLP antigen/antibodies or synthetic toll-like receptor agonist in a semifluorinated alkane or perfluorocarbon liquid through the inhalation or variation of vaccines repeatedly combined with pathway inhibitors in slow release polymeric nanoparticles.

In one embodiment to prevent vasculitis, one can administer two or more antivirals, combined with cell inflammatory pathway inhibitors, with LMWH, or heparin mimetic, linoleic acid etc. complement inhibitors, anti-inflammatory compounds, by inhalation, orally, systemically, intravenously, subcutaneously, intramuscularly, etc.

In one embodiment of viral encephalitis, one prevents Alzheimer's and Parkinson's disease and other viral-related CNS infections with an antiviral in combination with cell inflammatory pathway inhibitors and with LMWH, or a heparin mimetic, complement inhibitors and specific medications such as Bariticinib, Kezara, and with LMWH, or heparin mimetics, complement inhibitors, etc. and GSK inhibitors by inhalation, orally, systemically, intravenously, subcutaneously, intramuscularly, etc.

In one embodiment, the endoplasmic reticulum stress of the neuronal cell in viral diseases and also traumatic brain injuries, etc. is treated by adding anti inflammatory medications, such as such as Bariticinib, Kezara, to pathway inhibitors and combining ACE-2 inhibitors, neuropilin receptor blockage, catechins and linoleic acid, etc.

In one embodiment, as described with the use of methylene blue, for self-vaccination with a single dose unit or vaccine for nasal inhalation with one or multiple vaccines produced for numerous viruses that is obtained or ordered for home delivery from the pharmacists by doctor's prescription by inhalation, orally, systemically, intravenously, subcutaneously, intramuscularly, etc.

US11648261B2. Method of treating, reducing, or alleviating a medical condition in a patient (2023-05-16). None [US]. Inventors: Gholam A. Peyman [US].
Patent 2023
5
Construction and Characterization of Additional Chimeric Proteins
Not available on PMC !

Example 5

Additional constructs were generated which include: additional human PD-1-Fc-OX40L constructs as well as human hCD172a-Fc-OX40L, hPD1-Fc-TL1A, hBTLA-Fc-OX40L, hTMIGD2-Fc-OX40L, hTIM3-Fc-OX40L, mPD1-Fc-GITRL, mPD1-Fc-41BBL, mPD1-Fc-TL1A, mCD172a-Fc-CD40L, hTIGIT-Fc-OX40L and canine PD-1-Fc-OX40L. Each of these constructs was codon optimized for expression in Chinese Hamster Ovary (CHO) cells, transfected into CHO cells and individual clones were selected for high expression. High expressing clones were then used for small-scale manufacturing in stirred bioreactors in serum-free media and the relevant chimeric fusion proteins were purified with Protein A binding resin columns. FIG. 17A shows a Western blot characterization of various chimeric proteins including hCD172a-Fc-OX40L, hPD1-Fc-TL1A, hBTLA-Fc-OX40L, hTMIGD2-Fc-OX40L, hTIM3-Fc-OX40L, mPD1-Fc-GITRL, mPD1-Fc-41BBL, mPD1-Fc-TL1A, mCD172a-Fc-CD40L, hTIGIT-Fc-OX40L.

Binding assays were carried out to characterize the ability of the various human ECD-Fc-OX40L constructs to bind to hOX40. With respect to hXECO-Fc-OX40L, X refers to the ECD of each protein listed in the bracket on the left (with reference to FIG. 17B). FIG. 17B shows a schematic representation of the ELISA method used to detect binding of hXECD-Fc-OX40L to hOX40. Recombinant hOX40 fused to human Fc (hOX40-hFc) was used to capture hXECD-Fc-OX40L in the culture media. Because the hOX40 fusion protein used to capture the target fusion proteins also contains a hIgG region, blocking was performed using a non-HRP conjugated anti-hIgG prior to incubation with the culture supernatants containing the target fusion proteins. A rabbit polyclonal antibody to hIgG was used to detect the hIgG domain in the chimeric protein and subsequently detected using a horseradish peroxidase (HRP)-conjugated polyclonal antibody to rabbit IgG (H+L).

The binding of SL-279252 to cell surface expressed OX40 on Jurkat cells by flow cytometry was compared to two negative control proteins which are not expected to bind human OX40. These data demonstrate that SL-279252 efficiently binds human OX40 (left panel), while neither human PD1-Fc-TL1A or canine PD1-Fc-OX40L were observed to bind human OX40 (FIG. 17C).

The human CD172a-Fc-OX40L construct was imported into the protein tertiary prediction software RaptorX to determine the tertiary structure. The predicted tertiary structure is shown in FIG. 17D.

The codon-optimized DNA sequence of several chimeric fusion proteins were synthesized and directionally cloned into pVITRO2, pcDNA3.4 and other expression vectors. Vectors were then either transiently or stably transfected into CHO or 293 cells and individual clones were selected for high expression. For example, SL-279252 was produced from a transient transfection from 293 cells, purified by affinity chromatography to Protein A columns and evaluated by Coomassie staining, Western blot and quantitated as compared to a BCG standard (FIG. 17E).

In another example, CD172a-Fc-OX40L was produced from a transient transfection from 293 cells, purified by affinity chromatography to Protein A columns and evaluated by Coomassie staining, Western blot and quantitated as compared to a BCG standard (FIG. 17F). In another example, CD172a-Fc-CD40L was produced from a transient transfection from 293 cells, purified by affinity chromatography to Protein A columns and evaluated by the Perkin Elmer LabChip system and quantitated as compared to a BCG standard (FIG. 17G). In another example, human TIGIT-Fc-OX40L was produced from a transient transfection from 293 cells, purified by affinity chromatography to Protein A columns and evaluated by Coomassie staining, Western blot and quantitated as compared to a BCG standard (FIG. 17H).

The binding affinity of human CD172a-Fc-OX40L was evaluated by surface plasmon resonance (SPR) analysis to hCD47, hOX40 and various human Fc receptors (FIG. 17I to FIG. 17M). Specifically, polyhistidine-tagged versions of recombinant human CD47 and human OX40 was bound to ProteOn HTG tris-NTA chips (BIORAD). CD172a-Fc-OX40L was then flowed over the bound ligands over a time course and a relative index of ‘on-rate’ (Ka) and ‘off-rate’ (Kd) was generated to calculate binding affinity (KD) of CD172a-Fc-OX40L to each partner. Recombinant human CD47-Fc and OX40L-Fc were used as positive controls for binding. These controls have a relatively fast ‘on-rate’ and an equally fast ‘off-rate’, resulting in low nanomolar binding affinities. Consistent with these results, the ‘on-rate’ of CD172a-Fc-OX40L to human CD47 was rapid, however the ‘off-rate’ was much lower, in fact ˜40-fold slower than the ‘off-rate’ of recombinant CD47-Fc, indicating that CD172a-Fc-OX40L bound quickly and stably, with long on-target residence time (FIG. 17I). The KD of CD172a-Fc-OX40L binding to human CD47 was calculated to be 3.59 nM. CD172a-Fc-OX40L bound with high affinity to human OX40 (869 pM), again with a fast ‘on-rate’ and slow ‘off-rate’ (FIG. 17J).

To further define the molecular characteristics of CD172a-Fc-OX40L, SPR was performed, analyzing the binding affinities of CD172a-Fc-OX40L to chip-bound, Fcγ receptors FcγR1A and to the neonatal receptor, FcRn. The human immunoglobulin IgG1 was shown to bind with the highest affinities to FcγR1A, followed by FcRn, in addition to low-level binding to FcγR2b (FIG. 17K and FIG. 17L). CD172a-Fc-OX40L did not bind to FcγR1A or FcγR2B, but did bind to FcRn at 790 nM affinity (FIG. 17L). Without wishing to be bound by theory, this binding characteristic may be important to the fusion protein because FcRn is involved in IgG recycling to the surface of a cell, thereby avoiding lysosomal degradation, and potentially extending the in vivo half-life of CD172a-Fc-OX40L. Summary data for CD172a-Fc-OX40L binding affinities are including (FIG. 17M).

The codon-optimized DNA sequence of several additional chimeric fusion proteins were synthesized and directionally cloned into pVITRO2, pcDNA3.4 and other expression vectors. Vectors were then either transiently or stably transfected into CHO or 293 cells and individual clones were selected for high expression. For example, canine PD1-Fc-OX40L was produced from a transient transfection from 293 cells, purified by affinity chromatography to Protein A columns and evaluated by Coomassie staining, Western blot and quantitated as compared to a BCG standard (FIG. 17N). In another example, mouse PD1-Fc-OX40L was produced from a transient transfection from 293 cells, purified by affinity chromatography to Protein A columns and evaluated by Coomassie staining, Western blot and quantitated as compared to a BCG standard (FIG. 17O). In another example, mouse PD1-Fc-GITRL was produced from a transient transfection from 293 cells, purified by affinity chromatography to Protein A columns and evaluated by Coomassie staining, Western blot and quantitated as compared to a BCG standard (FIG. 17P). In another example, mouse PD1-Fc-41BBL was produced from a transient transfection from 293 cells, purified by affinity chromatography to Protein A columns and evaluated by Coomassie staining, Western blot and quantitated as compared to a BCG standard (FIG. 17Q). In another example, mouse PD1-Fc-TL1A was produced from a transient transfection from 293 cells, purified by affinity chromatography to Protein A columns and evaluated by Coomassie staining, Western blot and quantitated as compared to a BCG standard (FIG. 17R). In yet another example, CD115-Fc-CD40L was produced from a transient transfection from 293 cells, purified by affinity chromatography to Protein A columns and evaluated by Coomassie staining, Western blot and quantitated as compared to a BCG standard (FIG. 17S).

Each purified protein is characterized by ELISA assays to bind to the marker, e.g. the intended inhibitory ligand as well as the intended costimulatory receptor. For example, to test the binding of purified human PD-1-Fc-OX40L, recombinant PD-L1-Fc is adsorbed to microtiter plates and used to capture PD-1-Fc-OX40L. Any bound PD-1-Fc-OX40L is then detected by using recombinant human OX40-Fc linked to biotin, which is then detected in a chromogenic assay through binding with streptravidin-HRP.

In addition, each purified protein has been characterized by flow cytometry to bind the intended inhibitory ligand as well as the intended costimulatory receptor. For example, human tumor cell lines are characterized for endogenous expression of PD-L1, which was found to be particularly abundant on several human melanoma tumor cell lines. These same tumor cell lines were shown to be negative for human OX40L. Following incubation with PD-1-Fc-OX40L, any bound chimeric fusion protein is detected with human OX40L specific antibodies. Similarly, human Jurkat cells were transfected with human OX40 and shown to be negative for human PD-L1. Following incubation with the chimeric PD-1-Fc-OX40L constructs, any bound complex is detected using anti-human PD-L1 specific antibodies. A series of screening cell lines were generated in order to detect specific cell surface binding of each chimeric fusion protein to its respective receptor/ligand, these included: CHO-K1-CD47, CHO-K1-PD-L1, CHO-K1-HVEM, CHO-K1-HHLA2, CHO-K1-VISTA, CHO-K1-Gal9, HeLa-PD-L1, HeLa-CD47, HeLa-HVEM, HeLa-HHLA2, HeLa-VISTA, HeLa-Gal9.

To determine the functional activity of each receptor, in vitro T cell proliferation assays are performed in the presence of inhibitory ligand positive human tumor cells. For example, human melanoma tumor cells expressing PD-L1 are pulsed with peptides specific for hen egg lysozyme (HEL) and incubated with human HEL specific T cells expressing OX40 receptor. The proliferation of these cells is monitored in the presence and absence of the PD-1-Fc-OX40L construct and found to be functionally responsive to the presence of the chimeric constructs. In a similar system, human tumors expressing HVEM, CD47, galectin-9, TIGIT receptors or TMIGD2 receptors are used.

In some experiments, mouse PD-1-Fc-OX40L or mouse PD-1-Fc-TL1A are used to treat murine tumors known to be positive for murine PD-L1 (including B16-F10 melanoma, MC38 colon carcinoma and CT26 colon carcinoma). In these systems, established tumors are treated with purified chimeric fusion proteins as compared to PD-1-Fc fusion proteins, anti-PD-1 or anti-PD-L1 monoclonal antibodies or anti-OX40 or anti-GITR monoclonal antibodies. In these experiments, the activity of the chimeric constructs is observed to lead to enhanced antigen-specific T cell responses and increased rates of tumor rejection as compared to the individual therapeutics. In some experiments, nucleic acid constructs encoding PD-1-Fc-OX40L or PD-1-Fc-TL1A are directly electroporated into established tumors. In these experiments, the chimeric constructs are shown to lead to increased rates of tumor rejection as well as increased tumor antigen specific CD8+ T cell proliferation detected both in the peripheral blood and within established tumors.

To determine the binding of purified chimeric fusion proteins to human tumor explants, fresh frozen human tumor samples are obtained and incubated with each chimeric fusion protein. Any bound fusion protein is detected with anti-human OX40L and controlled against background staining by separate staining with anti-human OX40L.

To determine the molecular characteristics of each fusion protein, purified chimeric fusion proteins are characterized by size exclusion chromatography. This analysis is important because, for example, the OX40L ECD is known to form a homo-trimer, while the Fc region is known to form a homo-dimer, while the inhibitory ligand binding receptor may either be monomeric (e.g. PD-1) or form homo-multimers (e.g. TIM3). Thus, there are several possibilities for the individual species that may be formed by these chimeric constructs. Further molecular characterization by mass spec, thermal stability, pH stability, physical stability, charge profile, hydrophobicity, physical stability, buffer compatibility and solubility up to 100 mg/mL are also performed.

TABLE 1
Illustrative human Type I proteins which may be incorporated into the present compositions and methods include (as used herein “Entry”
refers to the human Type I protein entry in the Uniprot database and “Entry name” refers to the human Type I protein entry in the Uniprot database).
EntryEntry nameProtein namesGene namesLength
P044391A03_HUMANHLA class I histocompatibility antigen, A-3 alpha chain (MHC class I antigen A*3)HLA-A HLAA365
P304561A43_HUMANHLA class I histocompatibility antigen, A-43 alpha chain (Aw-43) (MHC class I antigen A*43)HLA-A HLAA365
P103161A69_HUMANHLA class I histocompatibility antigen, A-69 alpha chain (Aw-69) (HLA class IHLA-A HLAA365
histocompatibility antigen, A-28 alpha chain) (MHC class I antigen A*69)
P304601B08_HUMANHLA class I histocompatibility antigen, B-8 alpha chain (MHC class I antigen B*8)HLA-B HLAB362
Q953651B38_HUMANHLA class I histocompatibility antigen, B-38 alpha chain (Bw-4) (MHC class I antigen B*38)HLA-B HLAB362
P184641B51_HUMANHLA class I histocompatibility antigen, B-51 alpha chain (MHC class I antigen B*51)HLA-B HLAB362
P304951B56_HUMANHLA class I histocompatibility antigen, B-56 alpha chain (Bw-22) (Bw-56) (MHC class I antigen B*56)HLA-B HLAB362
P103191B58_HUMANHLA class I histocompatibility antigen, B-58 alpha chain (Bw-58) (MHC class I antigen B*58)HLA-B HLAB362
P305011C02_HUMANHLA class I histocompatibility antigen, Cw-2 alpha chain (MHC class I antigen Cw*2)HLA-C HLAC366
P042221C03_HUMANHLA class I histocompatibility antigen, Cw-3 alpha chain (MHC class I antigen Cw*3)HLA-C HLAC366
Q9TNN71C05_HUMANHLA class I histocompatibility antigen, Cw-5 alpha chain (MHC class I antigen Cw*5)HLA-C HLAC366
P103211C07_HUMANHLA class I histocompatibility antigen, Cw-7 alpha chain (MHC class I antigen Cw*7)HLA-C HLAC366
Q070001C15_HUMANHLA class I histocompatibility antigen, Cw-15 alpha chain (MHC class I antigen Cw*15)HLA-C HLAC366
Q956041C17_HUMANHLA class I histocompatibility antigen, Cw-17 alpha chain (MHC class I antigen Cw*17)HLA-C D6S204372
HLA-JY3 HLAC
P137602B14_HUMANHLA class II histocompatibility antigen, DRB1-4 beta chain (MHC class II antigen DRB1*4) (DR-4) (DR4)HLA-DRB1266
Q9TQE02B19_HUMANHLA class II histocompatibility antigen, DRB1-9 beta chain (MHC class II antigen DRB1*9) (DR-9) (DR9)HLA-DRB1266
Q301672B1A_HUMANHLA class II histocompatibility antigen, DRB1-10 beta chain (DRw10) (MHC class II antigen DRB1*10)HLA-DRB1266
Q299742B1G_HUMANHLA class II histocompatibility antigen, DRB1-16 beta chain (MHC class II antigen DRB1*16) (DR-16) (DR16)HLA-DRB1266
P018891B07_HUMANHLA class I histocompatibility antigen, B-7 alpha chain (MHC class I antigen B*7)HLA-B HLAB362
P304621B14_HUMANHLA class I histocompatibility antigen, B-14 alpha chain (MHC class I antigen B*14)HLA-B HLAB362
P304641B15_HUMANHLA class I histocompatibility antigen, B-15 alpha chain (MHC class I antigen B*15)HLA-B HLAB362
P039891B27_HUMANHLA class I histocompatibility antigen, B-27 alpha chain (MHC class I antigen B*27)HLA-B HLAB362
P184631B37_HUMANHLA class I histocompatibility antigen, B-37 alpha chain (MHC class I antigen B*37)HLA-B HLAB362
P304791B41_HUMANHLA class I histocompatibility antigen, B-41 alpha chain (Bw-41) (MHC class I antigen B*1)HLA-B HLAB362
P304831B45_HUMANHLA class I histocompatibility antigen, B-45 alpha chain (Bw-45) (MHC class I antigen B*45)HLA-B HLAB362
P304851B47_HUMANHLA class I histocompatibility antigen, B-47 alpha chain (Bw-47) (MHC class I antigen B*47)HLA-B HLAB362
P304871B49_HUMANHLA class I histocompatibility antigen, B-49 alpha chain (HLA class I histocompatibilityHLA-B HLAB362
antigen, B-21 alpha chain) (MHC class I antigen B*49)
P304911B53_HUMANHLA class I histocompatibility antigen, B-53 alpha chain (Bw-53) (MHC class I antigen B*53)HLA-B HLAB362
Q299401B59_HUMANHLA class I histocompatibility antigen, B-59 alpha chain (MHC class I antigen B*59)HLA-B HLAB362
P304981B78_HUMANHLA class I histocompatibility antigen, B-78 alpha chain (MHC class I antigen B*78)HLA-B HLAB362
P304991C01_HUMANHLA class I histocompatibility antigen, Cw-1 alpha chain (MHC class I antigen Cw*1)HLA-C HLAC366
P305051C08_HUMANHLA class I histocompatibility antigen, Cw-8 alpha chain (MHC class I antigen Cw*8)HLA-C HLAC366
P305081C12_HUMANHLA class I histocompatibility antigen, Cw-12 alpha chain (MHC class I antigen Cw*12)HLA-C HLAC366
P019122B13_HUMANHLA class II histocompatibility antigen, DRB1-3 chain (Clone P2-beta-3) (MHC class IIHLA-DRB1266
antigen DRB1*3)
Q301342B18_HUMANHLA class II histocompatibility antigen, DRB1-8 beta chain (MHC class II antigenHLA-DRB1266
DRB1*8) (DR-8) (DR8) (DRw8)
Q95IE32B1C_HUMANHLA class II histocompatibility antigen, DRB1-12 beta chain (MHC class II antigenHLA-DRB1266
DRB1*12) (DR-12) (DR12)
Q9BYF1ACE2_HUMANAngiotensin-converting enzyme 2 (EC 3.4.17.23) (ACE-related carboxypeptidase)ACE2 UNQ868/PRO1885805
(Angiotensin-converting enzyme homolog) (ACEH) (Metalloprotease MPROT15)
[Cleaved into: Processed angiotensin-converting enzyme 2]
P161881A30_HUMANHLA class I histocompatibility antigen, A-30 alpha chain (MHC class I antigen A*30)HLA-A HLAA365
P161901A33_HUMANHLA class I histocompatibility antigen, A-33 alpha chain (Aw-19) (Aw-33) (MHC class I antigen A*33)HLA-A HLAA365
P018911A68_HUMANHLA class I histocompatibility antigen, A-68 alpha chain (Aw-68) (HLA class IHLA-A HLAA365
histocompatibility antigen, A-28 alpha chain) (MHC class I antigen A*68)
Q298361B67_HUMANHLA class I histocompatibility antigen, B-67 alpha chain (MHC class I antigen B*67)HLA-B HLAB362
P137612B17_HUMANHLA class II histocompatibility antigen, DRB1-7 beta chain (MHC class II antigen DRB1*7) (DR-7) (DR7)HLA-DRB1266
Q5Y7A72B1D_HUMANHLA class II histocompatibility antigen, DRB1-13 beta chain (MHC class II antigen DRB1*13) (DR-13)HLA-DRB1266
(DR13)
P137461A11_HUMANHLA class I histocompatibility antigen, A-11 alpha chain (MHC class I antigen A*11)HLA-A HLAA365
P055341A24_HUMANHLA class I histocompatibility antigen, A-24 alpha chain (Aw-24) (HLA class IHLA-A HLAA365
histocompatibility antigen, A-9 alpha chain) (MHC class I antigen A*24)
P305121A29_HUMANHLA class I histocompatibility antigen, A-29 alpha chain (Aw-19) (MHC class I antigen A*29)HLA-A HLAA365
P161891A31_HUMANHLA class I histocompatibility antigen, A-31 alpha chain (MHC class I antigen A*31)HLA-A HLAA365
P103141A32_HUMANHLA class I histocompatibility antigen, A-32 alpha chain (MHC class I antigen A*32)HLA-A HLAA365
Q048261B40_HUMANHLA class I histocompatibility antigen, B-40 alpha chain (Bw-60) (MHC class I antigen B*40)HLA-B HLAB362
P304841B46_HUMANHLA class I histocompatibility antigen, B-46 alpha chain (Bw-46) (MHC class I antigen B*46)HLA-B HLAB362
P304861B48_HUMANHLA class I histocompatibility antigen, B-48 alpha chain (Bw-48) (MHC class I antigen B*48)HLA-B HLAB362
P304901B52_HUMANHLA class I histocompatibility antigen, B-52 alpha chain (Bw-52) (HLA class IHLA-B HLAB362
histocompatibility antigen, B-5 alpha chain) (MHC class I antigen B*52)
Q316121B73_HUMANHLA class I histocompatibility antigen, B-73 alpha chain (MHC class I antigen B*73)HLA-B HLAB363
Q316101B81_HUMANHLA class I histocompatibility antigen, B-81 alpha chain (B′DT) (MHC class I antigen B*81)HLA-B HLAB362
Q299601C16_HUMANHLA class I histocompatibility antigen, Cw-16 alpha chain (MHC class I antigen Cw*16)HLA-C HLAC366
Q298651C18_HUMANHLA class I histocompatibility antigen, Cw-18 alpha chain (MHC class I antigen Cw*18)HLA-C HLAC366
Q9GIY32B1E_HUMANHLA class II histocompatibility antigen, DRB1-14 beta chain (MHC class II antigenHLA-DRB1266
DRB1*14) (DR-14) (DR14)
P304431A01_HUMANHLA class I histocompatibility antigen, A-1 alpha chain (MHC class I antigen A*1)HLA-A HLAA365
P018921A02_HUMANHLA class I histocompatibility antigen, A-2 alpha chain (MHC class I antigen A*2)HLA-A HLAA365
P304471A23_HUMANHLA class I histocompatibility antigen, A-23 alpha chain (HLA class I histocompatibilityHLA-A HLAA365
antigen, A-9 alpha chain) (MHC class I antigen A*23)
P184621A25_HUMANHLA class I histocompatibility antigen, A-25 alpha chain (HLA class I histocompatibilityHLA-A HLAA365
antigen, A-10 alpha chain) (MHC class I antigen A*25)
P304501A26_HUMANHLA class I histocompatibility antigen, A-26 alpha chain (MHC class I antigen A*26)HLA-A HLAA365
P304531A34_HUMANHLA class I histocompatibility antigen, A-34 alpha chain (Aw-34) (HLA class IHLA-A HLAA365
histocompatibility antigen, A-10 alpha chain) (MHC class I antigen A*34)
P304571A66_HUMANHLA class I histocompatibility antigen, A-66 alpha chain (Aw-66) (HLA class IHLA-A HLAA365
histocompatibility antigen, A-10 alpha chain) (MHC class I antigen A*66)
Q091601A80_HUMANHLA class I histocompatibility antigen, A-80 alpha chain (Aw-80) (HLA class IHLA-A HLAA365
histocompatibility antigen, A-1 alpha chain) (MHC class I antigen A*80)
P304611B13_HUMANHLA class I histocompatibility antigen, B-13 alpha chain (MHC class I antigen B*13)HLA-B HLAB362
P304661B18_HUMANHLA class I histocompatibility antigen, B-18 alpha chain (MHC class I antigen B*18)HLA-B HLAB362
P306851B35_HUMANHLA class I histocompatibility antigen, B-35 alpha chain (MHC class I antigen B*35)HLA-B HLAB362
P304751B39_HUMANHLA class I histocompatibility antigen, B-39 alpha chain (MHC class I antigen B*39)HLA-B HLAB362
P304801B42_HUMANHLA class I histocompatibility antigen, B-42 alpha chain (MHC class I antigen B*42)HLA-B HLAB362
P304811B44_HUMANHLA class I histocompatibility antigen, B-44 alpha chain (Bw-44) (MHC class I antigen B*44)HLA-B HLAB362
P304881B50_HUMANHLA class I histocompatibility antigen, B-50 alpha chain (Bw-50) (HLA class IHLA-B HLAB362
histocompatibility antigen, B-21 alpha chain) (MHC class I antigen B*50)
P304921B54_HUMANHLA class I histocompatibility antigen, B-54 alpha chain (Bw-22) (Bw-54) (MHC class I antigen B*54)HLA-B HLAB362
P184651B57_HUMANHLA class I histocompatibility antigen, B-57 alpha chain (Bw-57) (MHC class I antigen B*57)HLA-B HLAB362
Q297181B82_HUMANHLA class I histocompatibility antigen, B-82 alpha chain (MHC class I antigen B*82)HLA-B HLAB362
P305041C04_HUMANHLA class I histocompatibility antigen, Cw-4 alpha chain (MHC class I antigen Cw*4)HLA-C HLAC366
Q299631C06_HUMANHLA class I histocompatibility antigen, Cw-6 alpha chain (MHC class I antigen Cw*6)HLA-C HLAC366
P305101C14_HUMANHLA class I histocompatibility antigen, Cw-14 alpha chain (MHC class I antigen Cw*14)HLA-C HLAC366
P042292B11_HUMANHLA class II histocompatibility antigen, DRB1-1 beta chain (MHC class II antigen DRB1*1) (DR-1) (DR1)HLA-DRB1266
P200392B1B_HUMANHLA class II histocompatibility antigen, DRB1-11 beta chain (DR-5) (DR5) (DRw11) (MHCHLA-DRB1266
class II antigen DRB1*11)
P019112B1F_HUMANHLA class II histocompatibility antigen, DRB1-15 beta chain (DW2.2/DR2.2) (MHC class II antigen DRB1*15)HLA-DRB1 HLA-DRB2266
O14672ADA10_HUMANDisintegrin and metalloproteinase domain-containing protein 10 (ADAM 10) (ECADAM10 KUZ MADM748
3.4.24.81) (CDw156) (Kuzbanian protein homolog) (Mammalian disintegrin-
metalloprotease) (CD antigen CD156c)
Q13444ADA15_HUMANDisintegrin and metalloproteinase domain-containing protein 15 (ADAM 15) (EC 3.4.24.-)ADAM15 MDC15863
(Metalloprotease RGD disintegrin protein) (Metalloproteinase-like, disintegrin-like, and
cysteine-rich protein 15) (MDC-15) (Metargidin)
O75077ADA23_HUMANDisintegrin and metalloproteinase domain-containing protein 23 (ADAM 23)ADAM23 MDC3832
(Metalloproteinase-like, disintegrin-like, and cysteine-rich protein 3) (MDC-3)
P304551A36_HUMANHLA class I histocompatibility antigen, A-36 alpha chain (Aw-36) (MHC class I antigen A*36)HLA-A HLAA365
P304591A74_HUMANHLA class I histocompatibility antigen, A-74 alpha chain (Aw-19) (Aw-74) (MHC class I antigen A*74)HLA-A HLAA365
P304931B55_HUMANHLA class I histocompatibility antigen, B-55 alpha chain (Bw-55) (HLA class IHLA-B HLAB CDABP0067362
histocompatibility antigen, B-12 alpha chain) (MHC class I antigen B*55)
O43184ADA12_HUMANDisintegrin and metalloproteinase domain-containing protein 12 (ADAM 12) (EC 3.4.24.-) (Meltrin-alpha)ADAM12 MLTN909
UNQ346/PRO545
Q9Y3Q7ADA18_HUMANDisintegrin and metalloproteinase domain-containing protein 18 (ADAM 18)ADAM18 TMDC3739
(Transmembrane metalloproteinase-like, disintegrin-like, and cysteine-rich protein III) (tMDC III)UNQ858/PRO1867
Q9H013ADA19_HUMANDisintegrin and metalloproteinase domain-containing protein 19 (ADAM 19) (EC 3.4.24.-)ADAM19 MLTNB FKSG34955
(Meltrin-beta) (Metalloprotease and disintegrin dendritic antigen marker) (MADDAM)
Q9UKF5ADA29_HUMANDisintegrin and metalloproteinase domain-containing protein 29 (ADAM 29) (Cancer/testis antigen 73) (CT73)ADAM29820
Q8TC27ADA32_HUMANDisintegrin and metalloproteinase domain-containing protein 32 (ADAM 32)ADAM32 UNQ5982/PRO21340787
Q9BZ11ADA33_HUMANDisintegrin and metalloproteinase domain-containing protein 33 (ADAM 33) (EC 3.4.24.-)ADAM33 C20orf153813
UNQ873/PRO1891
P05067A4_HUMANAmyloid beta A4 protein (ABPP) (APPI) (APP) (Alzheimer disease amyloid protein)APP A4 AD1770
(Amyloid precursor protein) (Beta-amyloid precursor protein) (Cerebral vascular amyloid
peptide) (CVAP) (PreA4) (Protease nexin-II) (PN-II) [Cleaved into: N-APP; Soluble APP-
alpha (S-APP-alpha); Soluble APP-beta (S-APP-beta); C99; Beta-amyloid protein 42
(Beta-APP42); Beta-amyloid protein 40 (Beta-APP40); C83; P3(42); P3(40); C80;
Gamma-secretase C-terminal fragment 59 (Amyloid intracellular domain 59) (AICD-59)
(AID(59)) (Gamma-CTF(59)); Gamma-secretase C-terminal fragment 57 (Amyloid
intracellular domain 57) (AICD-57) (AID(57)) (Gamma-CTF(57)); Gamma-secretase C-
terminal fragment 50 (Amyloid intracellular domain 50) (AICD-50) (AID(50)) (Gamma-CTF(50)); C31]
P12821ACE_HUMANAngiotensin-converting enzyme (ACE) (EC 3.2.1.-) (EC 3.4.15.1) (DipeptidylACE DCP DCP11306
carboxypeptidase I) (Kininase II) (CD antigen CD143) [Cleaved into: Angiotensin-
converting enzyme, soluble form]
Q04771ACVR1_HUMANActivin receptor type-1 (EC 2.7.11.30) (Activin receptor type I) (ACTR-I) (Activin receptor-ACVR1 ACVRLK2509
like kinase 2) (ALK-2) (Serine/threonine-protein kinase receptor R1) (SKR1) (TGF-B
superfamily receptor type I) (TSR-I)
Q8NER5ACV1C_HUMANActivin receptor type-1C (EC 2.7.11.30) (Activin receptor type 1C) (ACTR-IC) (ActivinACVR1C ALK7493
receptor-like kinase 7) (ALK-7)
Q9H2U9ADAM7_HUMANDisintegrin and metalloproteinase domain-containing protein 7 (ADAM 7) (SpermADAM7 GP83754
maturation-related glycoprotein GP-83)
P36896ACV1B_HUMANActivin receptor type-1B (EC 2.7.11.30) (Activin receptor type IB) (ACTR-IB) (ActivinACVR1B ACVRLK4 ALK4505
receptor-like kinase 4) (ALK-4) (Serine/threonine-protein kinase receptor R2) (SKR2)
O75078ADA11_HUMANDisintegrin and metalloproteinase domain-containing protein 11 (ADAM 11)ADAM11 MDC769
(Metalloproteinase-like, disintegrin-like, and cysteine-rich protein) (MDC)
P78536ADA17_HUMANDisintegrin and metalloproteinase domain-containing protein 17 (ADAM 17) (ECADAM17 CSVP TACE824
3.4.24.86) (Snake venom-like protease) (TNF-alpha convertase) (TNF-alpha-converting
enzyme) (CD antigen CD156b)
Q9P0K1ADA22_HUMANDisintegrin and metalloproteinase domain-containing protein 22 (ADAM 22)ADAM22 MDC2906
(Metalloproteinase-disintegrin ADAM22-3) (Metalloproteinase-like, disintegrin-like, and
cysteine-rich protein 2)
Q9UKQ2ADA28_HUMANDisintegrin and metalloproteinase domain-containing protein 28 (ADAM 28) (EC 3.4.24.-)ADAM28 ADAM23775
(Epididymal metalloproteinase-like, disintegrin-like, and cysteine-rich protein II) (eMDC II)MDCL
(Metalloproteinase-like, disintegrin-like, and cysteine-rich protein L) (MDC-L)
Q9UKF2ADA30_HUMANDisintegrin and metalloproteinase domain-containing protein 30 (ADAM 30) (EC 3.4.24.-)ADAM30 UNQ2509/PRO5997790
P19021AMD_HUMANPeptidyl-glycine alpha-amidating monooxygenase (PAM) [Includes: Peptidylglycine alpha-PAM973
hydroxylating monooxygenase (PHM) (EC 1.14.17.3); Peptidyl-alpha-hydroxyglycine
alpha-amidating lyase (EC 4.3.2.5) (Peptidylamidoglycolate lyase) (PAL)]
Q86SJ2AMGO2_HUMANAmphoterin-induced protein 2 (AMIGO-2) (Alivin-1) (Differentially expressed in gastricAMIGO2 ALI1522
adenocarcinomas) (DEGA)
Q16671AMHR2_HUMANAnti-Muellerian hormone type-2 receptor (EC 2.7.11.30) (Anti-Muellerian hormone type IIAMHR2 AMHR MISR2573
receptor) (AMH type II receptor) (MIS type II receptor) (MISRII) (MRII)
P37023ACVL1_HUMANSerine/threonine-protein kinase receptor R3 (SKR3) (EC 2.7.11.30) (Activin receptor-likeACVRL1 ACVRLK1 ALK1503
kinase 1) (ALK-1) (TGF-B superfamily receptor type I) (TSR-I)
Q13443ADAM9_HUMANDisintegrin and metalloproteinase domain-containing protein 9 (ADAM 9) (EC 3.4.24.-)ADAM9 KIAA0021819
(Cellular disintegrin-related protein) (Meltrin-gamma)MCMP MDC9 MLTNG
(Metalloprotease/disintegrin/cysteine-rich protein 9) (Myeloma cell metalloproteinase)
O43506ADA20_HUMANDisintegrin and metalloproteinase domain-containing protein 20 (ADAM 20) (EC 3.4.24.-)ADAM20726
Q9UKJ8ADA21_HUMANDisintegrin and metalloproteinase domain-containing protein 21 (ADAM 21) (EC 3.4.24.-)ADAM21722
Q99965ADAM2_HUMANDisintegrin and metalloproteinase domain-containing protein 2 (ADAM 2) (Cancer/testisADAM2 FTNB735
antigen 15) (CT15) (Fertilin subunit beta) (PH-30) (PH30) (PH30-beta)
P78325ADAM8_HUMANDisintegrin and metalloproteinase domain-containing protein 8 (ADAM 8) (EC 3.4.24.-)ADAM8 MS2824
(Cell surface antigen MS2) (CD antigen CD156a)
Q9H6X2ANTR1_HUMANAnthrax toxin receptor 1 (Tumor endothelial marker 8)ANTXR1 ATR TEM8564
P58335ANTR2_HUMANAnthrax toxin receptor 2 (Capillary morphogenesis gene 2 protein) (CMG-2)ANTXR2 CMG2489
Q86WK6AMGO1_HUMANAmphoterin-induced protein 1 (AMIGO-1) (Alivin-2)AMIGO1 ALI2493
AMIGO KIAA1163
P16066ANPRA_HUMANAtrial natriuretic peptide receptor 1 (EC 4.6.1.2) (Atrial natriuretic peptide receptor type A)NPR1 ANPRA1061
(ANP-A) (ANPR-A) (NPR-A) (Guanylate cyclase A) (GC-A)
Q6UXC1AEGP_HUMANApical endosomal glycoprotein (MAM domain-containing protein 4)MAMDC4 AEGP1216
UNQ3001/PRO9742
Q9BXJ7AMNLS_HUMANProtein amnionlessAMN453
UNQ513/PRO1028
P20594ANPRB_HUMANAtrial natriuretic peptide receptor 2 (EC 4.6.1.2) (Atrial natriuretic peptide receptor type B)NPR2 ANPRB1047
(ANP-B) (ANPR-B) (NPR-B) (Guanylate cyclase B) (GC-B)
Q8J025APCD1_HUMANProtein APCDD1 (Adenomatosis polyposis coli down-regulated 1 protein)APCDD1 DRAPC1 FP7019514
P51693APLP1_HUMANAmyloid-like protein 1 (APLP) (APLP-1) [Cleaved into: C30]APLP1650
Q9UM73ALK_HUMANALK tyrosine kinase receptor (EC 2.7.10.1) (Anaplastic lymphoma kinase) (CD antigen CD246)ALK1620
A6NF34ANTRL_HUMANAnthrax toxin receptor-likeANTXRL631
Q86WK7AMGO3_HUMANAmphoterin-induced protein 3 (AMIGO-3) (Alivin-3)AMIGO3 ALI3 KIAA1851504
UNQ6084/PRO20089
P17342ANPRC_HUMANAtrial natriuretic peptide receptor 3 (Atrial natriuretic peptide clearance receptor) (AtrialNPR3 ANPRC541
natriuretic peptide receptor type C) (ANP-C) (ANPR-C) (NPR-C)C5orf23 NPRC
Q06481APLP2_HUMANAmyloid-like protein 2 (APLP-2) (APPH) (Amyloid protein homolog) (CDEI box-binding protein) (CDEBP)APLP2 APPL2763
Q13705AVR2B_HUMANActivin receptor type-2B (EC 2.7.11.30) (Activin receptor type IIB) (ACTR-IIB)ACVR2B512
P35613BASI_HUMANBasigin (5F7) (Collagenase stimulatory factor) (Extracellular matrix metalloproteinaseBSG UNQ6505/PRO21383385
inducer) (EMMPRIN) (Leukocyte activation antigen M6) (OK blood group antigen) (Tumor
cell-derived collagenase stimulatory factor) (TCSF) (CD antigen CD147)
P50895BCAM_HUMANBasal cell adhesion molecule (Auberger B antigen) (B-CAM cell surface glycoprotein)BCAM LU MSK19628
(F8/G253 antigen) (Lutheran antigen) (Lutheran blood group glycoprotein) (CD antigen CD239)
O75882ATRN_HUMANAttractin (DPPT-L) (Mahogany homolog)ATRN KIAA0548 MGCA1429
Q9Y5Z0BACE2_HUMANBeta-secretase 2 (EC 3.4.23.45) (Aspartic-like protease 56 kDa) (Aspartyl protease 1)BACE2 AEPLC ALP56 ASP21 CDA13518
(ASP1) (Asp 1) (Beta-site amyloid precursor protein cleaving enzyme 2) (Beta-site APPUNQ418/PRO852
cleaving enzyme 2) (Down region aspartic protease) (DRAP) (Memapsin-1) (Membrane-
associated aspartic protease 1) (Theta-secretase)
Q13145BAMBI_HUMANBMP and activin membrane-bound inhibitor homolog (Non-metastatic gene A protein)BAMBI NMA260
(Putative transmembrane protein NMA)
P36894BMR1A_HUMANBone morphogenetic protein receptor type-1A (BMP type-1A receptor) (BMPR-1A) (ECBMPR1A ACVRLK3 ALK3532
2.7.11.30) (Activin receptor-like kinase 3) (ALK-3) (Serine/threonine-protein kinase
receptor R5) (SKR5) (CD antigen CD292)
P56817BACE1_HUMANBeta-secretase 1 (EC 3.4.23.46) (Aspartyl protease 2) (ASP2) (Asp 2) (Beta-site amyloidBACE1 BACE KIAA1149501
precursor protein cleaving enzyme 1) (Beta-site APP cleaving enzyme 1) (Memapsin-2)
(Membrane-associated aspartic protease 2)
Q5VV63ATRN1_HUMANAttractin-like protein 1ATRNL1 KIAA05341379
P27037AVR2A_HUMANActivin receptor type-2A (EC 2.7.11.30) (Activin receptor type IIA) (ACTR-IIA) (ACTRIIA)ACVR2A ACVR2513
Q9BWV1BOC_HUMANBrother of CDO (Protein BOC)BOC UNQ604/PRO11901114
O00238BMR1B_HUMANBone morphogenetic protein receptor type-1B (BMP type-1B receptor) (BMPR-1B) (ECBMPR1B502
2.7.11.30) (CD antigen CDw293)
O00481BT3A1_HUMANButyrophilin subfamily 3 member A1 (CD antigen CD277)BTN3A1 BTF5513
Q7Z6A9BTLA_HUMANB- and T-lymphocyte attenuator (B- and T-lymphocyte-associated protein) (CD antigen CD272)BTLA289
Q96KV6BT2A3_HUMANPutative butyrophilin subfamily 2 member A3BTN2A3P BTN2A3586
P78410BT3A2_HUMANButyrophilin subfamily 3 member A2BTN3A2 BT3.2 BTF3 BTF4334
Q6UXE8BTNL3_HUMANButyrophilin-like protein 3 (Butyrophilin-like receptor)BTNL3 BTNLR COLF4100466
UNQ744/PRO1472
Q6UXG8BTNL9_HUMANButyrophilin-like protein 9BTNL9535
UNQ1900/PRO4346
Q5SY80CA101_HUMANUncharacterized protein C1orf101C1orf101951
F2Z333CA233_HUMANFibronectin type-III domain-containing transmembrane protein C1orf233C1orf233226
Q13410BT1A1_HUMANButyrophilin subfamily 1 member A1 (BT)BTN1A1 BTN526
Q8WVV5BT2A2_HUMANButyrophilin subfamily 2 member A2BTN2A2 BT2.2 BTF2523
O00478BT3A3_HUMANButyrophilin subfamily 3 member A3BTN3A3 BTF3584
Q6UX41BTNL8_HUMANButyrophilin-like protein 8BTNL8 UNQ702/PRO1347500
Q6UWJ8C16L2_HUMANCD164 sialomucin-like 2 proteinCD164L2174
UNQ6122/PRO20044
P55289CAD12_HUMANCadherin-12 (Brain cadherin) (BR-cadherin) (Neural type cadherin 2) (N-cadherin 2)CDH12794
Q9UJ99CAD22_HUMANCadherin-22 (Pituitary and brain cadherin) (PB-cadherin)CDH22 C20orf25828
Q9H251CAD23_HUMANCadherin-23 (Otocadherin)CDH23 KIAA17743354
KIAA1812
UNQ1894/PRO4340
Q8IXH8CAD26_HUMANCadherin-like protein 26 (Cadherin-like protein VR20)CDH26852
P19022CADH2_HUMANCadherin-2 (CDw325) (Neural cadherin) (N-cadherin) (CD antigen CD325)CDH2 CDHN NCAD906
P55285CADH6_HUMANCadherin-6 (Kidney cadherin) (K-cadherin)CDH6790
Q9ULB5CADH7_HUMANCadherin-7CDH7 CDH7L1785
P55286CADH8_HUMANCadherin-8CDH8799
Q9ULX7CAH14_HUMANCarbonic anhydrase 14 (EC 4.2.1.1) (Carbonate dehydratase XIV) (Carbonic anhydrase XIV) (CA-XIV)CA14 UNQ690/PRO1335337
Q5VU97CAHD1_HUMANVWFA and cache domain-containing protein 1 (Cache domain-containing protein 1)CACHD1 KIAA1573 VWCD11274
P27824CALX_HUMANCalnexin (IP90) (Major histocompatibility complex class I antigen-binding protein p88) (p90)CANX592
Q13873BMPR2_HUMANBone morphogenetic protein receptor type-2 (BMP type-2 receptor) (BMPR-2) (ECBMPR2 PPH11038
2.7.11.30) (Bone morphogenetic protein receptor type II) (BMP type II receptor) (BMPR-II)
Q7KYR7BT2A1_HUMANButyrophilin subfamily 2 member A1BTN2A1 BT2.1 BTF1527
P35070BTC_HUMANProbetacellulin [Cleaved into: Betacellulin (BTC)]BTC178
Q86VB7C163A_HUMANScavenger receptor cysteine-rich type 1 protein M130 (Hemoglobin scavenger receptor)CD163 M1301156
(CD antigen CD163) [Cleaved into: Soluble CD163 (sCD163)]
Q8TCZ2C99L2_HUMANCD99 antigen-like protein 2 (MIC2-like protein 1) (CD antigen CD99)CD99L2 MIC2L1262
UNQ1964/PRO4486
Q8IZS8CA2D3_HUMANVoltage-dependent calcium channel subunit alpha-2/delta-3 (Voltage-gated calciumCACNA2D31091
channel subunit alpha-2/delta-3) [Cleaved into: Voltage-dependent calcium channel
subunit alpha-2-3; Voltage-dependent calcium channel subunit delta-3]
Q7Z3S7CA2D4_HUMANVoltage-dependent calcium channel subunit alpha-2/delta-4 (Voltage-gated calciumCACNA2D41137
channel subunit alpha-2/delta-4) [Cleaved into: Voltage-dependent calcium channel
subunit alpha-2-4; Voltage-dependent calcium channel subunit delta-4]
Q9Y6N8CAD10_HUMANCadherin-10 (T2-cadherin)CDH10788
Q12864CAD17_HUMANCadherin-17 (Intestinal peptide-associated transporter HPT-1) (Liver-intestine cadherin) (LI-cadherin)CDH17832
P55283CADH4_HUMANCadherin-4 (Retinal cadherin) (R-CAD) (R-cadherin)CDH4916
P33151CADH5_HUMANCadherin-5 (7B4 antigen) (Vascular endothelial cadherin) (VE-cadherin) (CD antigen CD144)CDH5784
Q8NFZ8CADM4_HUMANCell adhesion molecule 4 (Immunoglobulin superfamily member 4C) (IgSF4C) (Nectin-likeCADM4 IGSF4C NECL4 TSLL2388
protein 4) (NECL-4) (TSLC1-like protein 2)
Q9NPY3C1QR1_HUMANComplement component C1q receptor (C1q/MBL/SPA receptor) (C1qR) (C1qR(p))CD93 C1QR1 MXRA4652
(C1qRp) (CDw93) (Complement component 1 q subcomponent receptor 1) (Matrix-
remodeling-associated protein 4) (CD antigen CD93)
Q9NY47CA2D2_HUMANVoltage-dependent calcium channel subunit alpha-2/delta-2 (Voltage-gated calciumCACNA2D2 KIAA05581150
channel subunit alpha-2/delta-2) [Cleaved into: Voltage-dependent calcium channel
subunit alpha-2-2; Voltage-dependent calcium channel subunit delta-2]
Q8N3J6CADM2_HUMANCell adhesion molecule 2 (Immunoglobulin superfamily member 4D) (IgSF4D) (Nectin-likeCADM2 IGSF4D NECL3435
protein 3) (NECL-3) (Synaptic cell adhesion molecule 2) (SynCAM 2)
Q13634CAD18_HUMANCadherin-18 (Cadherin-14)CDH18 CDH14790
A8MVZ5BTNLA_HUMANButyrophilin-like protein 10BTNL10291
Q9NR16C163B_HUMANScavenger receptor cysteine-rich type 1 protein M160 (CD163 antigen-like 1) (CD antigen CD163b)CD163L1 CD163B M1601453
UNQ6434/PRO23202
P54289CA2D1_HUMANVoltage-dependent calcium channel subunit alpha-2/delta-1 (Voltage-gated calciumCACNA2D11103
channel subunit alpha-2/delta-1) [Cleaved into: Voltage-dependent calcium channelCACNL2A CCHL2A MHS3
subunit alpha-2-1; Voltage-dependent calcium channel subunit delta-1]
Q86UP0CAD24_HUMANCadherin-24CDH24 CDH11L819
UNQ2834/PRO34009
Q9BY67CADM1_HUMANCell adhesion molecule 1 (Immunoglobulin superfamily member 4) (IgSF4) (Nectin-likeCADM1 IGSF4442
protein 2) (NECL-2) (Spermatogenic immunoglobulin superfamily) (SgIgSF) (Synaptic cellIGSF4A NECL2
adhesion molecule) (SynCAM) (Tumor suppressor in lung cancer 1) (TSLC-1)SYNCAM TSLC1
Q9HBT6CAD20_HUMANCadherin-20CDH20 CDH7L3801
Q16790CAH9_HUMANCarbonic anhydrase 9 (EC 4.2.1.1) (Carbonate dehydratase IX) (Carbonic anhydrase IX)CA9 G250 MN459
(CA-IX) (CAIX) (Membrane antigen MN) (P54/58N) (Renal cell carcinoma-associated
antigen G250) (RCC-associated antigen G250) (pMW1)
O75976CBPD_HUMANCarboxypeptidase D (EC 3.4.17.22) (Metallocarboxypeptidase D) (gp180)CPD1380
P55287CAD11_HUMANCadherin-11 (OSF-4) (Osteoblast cadherin) (OB-cadherin)CDH11796
P55291CAD15_HUMANCadherin-15 (Cadherin-14) (Muscle cadherin) (M-cadherin)CDH15 CDH14 CDH3814
O75309CAD16_HUMANCadherin-16 (Kidney-specific cadherin) (Ksp-cadherin)CDH16 UNQ695/PRO1340829
Q9H159CAD19_HUMANCadherin-19CDH19 CDH7L2772
UNQ478/PRO941
P12830CADH1_HUMANCadherin-1 (CAM 120/80) (Epithelial cadherin) (E-cadherin) (Uvomorulin) (CD antigenCDH1 CDHE UVO882
CD324) [Cleaved into: E-Cad/CTF1; E-Cad/CTF2; E-Cad/CTF3]
P22223CADH3_HUMANCadherin-3 (Placental cadherin) (P-cadherin)CDH3 CDHP829
Q9ULB4CADH9_HUMANCadherin-9CDH9789
Q8N126CADM3_HUMANCell adhesion molecule 3 (Brain immunoglobulin receptor) (Immunoglobulin superfamilyCADM3 IGSF4B398
member 4B) (IgSF4B) (Nectin-like protein 1) (NECL-1) (Synaptic cell adhesion moleculeNECL1 SYNCAM3
3) (SynCAM3) (TSLC1-like protein 1) (TSLL1)TSLL1 UNQ225/PRO258
O43570CAH12_HUMANCarbonic anhydrase 12 (EC 4.2.1.1) (Carbonate dehydratase XII) (Carbonic anhydraseCA12354
XII) (CA-XII) (Tumor antigen HOM-RCC-3.1.3)
P15813CD1D_HUMANAntigen-presenting glycoprotein CD1d (R3G1) (CD antigen CD1d)CD1D335
Q9BZW8CD244_HUMANNatural killer cell receptor 2B4 (NK cell activation-inducing ligand) (NAIL) (NK cell type ICD244 2B4370
receptor protein 2B4) (NKR2B4) (h2B4) (SLAM family member 4) (SLAMF4) (Signaling
lymphocytic activation molecule 4) (CD antigen CD244)
Q5ZPR3CD276_HUMANCD276 antigen (4Ig-B7-H3) (B7 homolog 3) (B7-H3) (Costimulatory molecule) (CD antigen CD276)CD276 B7H3 PSEC0249534
UNQ309/PRO352
P34810CD68_HUMANMacrosialin (Gp110) (CD antigen CD68)CD68354
P40259CD79B_HUMANB-cell antigen receptor complex-associated protein beta chain (B-cell-specificCD79B B29 IGB229
glycoprotein B29) (Ig-beta) (Immunoglobulin-associated B29 protein) (CD antigen CD79b)
P01732CD8A_HUMANT-cell surface glycoprotein CD8 alpha chain (T-lymphocyte differentiation antigen T8/Leu-2) (CD antigen CD8a)CD8A MAL235
P06126CD1A_HUMANT-cell surface glycoprotein CD1a (T-cell surface antigen T6/Leu-6) (hTa1 thymocyteCD1A327
antigen) (CD antigen CD1a)
P20273CD22_HUMANB-cell receptor CD22 (B-lymphocyte cell adhesion molecule) (BL-CAM) (Sialic acid-CD22 SIGLEC2847
binding Ig-like lectin 2) (Siglec-2) (T-cell surface antigen Leu-14) (CD antigen CD22)
P06127CD5_HUMANT-cell surface glycoprotein CD5 (Lymphocyte antigen T1/Leu-1) (CD antigen CD5)CD5 LEU1495
P10966CD8B_HUMANT-cell surface glycoprotein CD8 beta chain (CD antigen CD8b)CD8B CD8B1210
P14209CD99_HUMANCD99 antigen (12E7) (E2 antigen) (Protein MIC2) (T-cell surface glycoprotein E2) (CD antigen CD99)CD99 MIC2 MIC2X MIC2Y185
P29017CD1C_HUMANT-cell surface glycoprotein CD1c (CD antigen CD1c)CD1C333
P10747CD28_HUMANT-cell-specific surface glycoprotein CD28 (TP44) (CD antigen CD28)CD28220
A6NJW9CD8BL_HUMANPutative T-cell surface glycoprotein CD8 beta-2 chain (CD8b pseudogene)CD8BP CD8B2211
Q9BYE9CDHR2_HUMANCadherin-related family member 2 (Protocadherin LKC) (PC-LKC) (Protocadherin-24)CDHR2 PCDH24 PCLKC1310
Q9HBB8CDHR5_HUMANCadherin-related family member 5 (Mu-protocadherin) (Mucin and cadherin-like protein)CDHR5 MUCDHL MUPCDH845
(Mucin-like protocadherin) (MLPCDH)UNQ2781/PRO7168
Q6UY09CEA20_HUMANCarcinoembryonic antigen-related cell adhesion molecule 20CEACAM20585
UNQ9366/PRO34155
Q3KPI0CEA21_HUMANCarcinoembryonic antigen-related cell adhesion molecule 21CEACAM21293
UNQ3098/PRO10075
P15391CD19_HUMANB-lymphocyte antigen CD19 (B-lymphocyte surface antigen B4) (Differentiation antigenCD19556
CD19) (T-cell surface antigen Leu-12) (CD antigen CD19)
P15812CD1E_HUMANT-cell surface glycoprotein CD1e, membrane-associated (hCD1e) (R2G1) (CD antigenCD1E388
CD1e) [Cleaved into: T-cell surface glycoprotein CD1e, soluble (sCD1e)]
Q15762CD226_HUMANCD226 antigen (DNAX accessory molecule 1) (DNAM-1) (CD antigen CD226)CD226 DNAM1336
P26842CD27_HUMANCD27 antigen (CD27L receptor) (T-cell activation antigen CD27) (T14) (Tumor necrosisCD27 TNFRSF7260
factor receptor superfamily member 7) (CD antigen CD27)
P06729CD2_HUMANT-cell surface antigen CD2 (Erythrocyte receptor) (LFA-2) (LFA-3 receptor) (RosetteCD2 SRBC351
receptor) (T-cell surface antigen T11/Leu-5) (CD antigen CD2)
Q9NPF0CD320_HUMANCD320 antigen (8D6 antigen) (FDC-signaling molecule 8D6) (FDC-SM-8D6)CD320 8D6A282
(Transcobalamin receptor) (TCbIR) (CD antigen CD320)UNQ198/PRO224
P04234CD3D_HUMANT-cell surface glycoprotein CD3 delta chain (T-cell receptor T3 delta chain) (CD antigen CD3d)CD3D T3D171
P16070CD44_HUMANCD44 antigen (CDw44) (Epican) (Extracellular matrix receptor III) (ECMR-III) (GP90CD44 LHR MDU2742
lymphocyte homing/adhesion receptor) (HUTCH-I) (Heparan sulfate proteoglycan)MDU3 MIC4
(Hermes antigen) (Hyaluronate receptor) (Phagocytic glycoprotein 1) (PGP-1)
(Phagocytic glycoprotein I) (PGP-I) (CD antigen CD44)
P30203CD6_HUMANT-cell differentiation antigen CD6 (T12) (TP120) (CD antigen CD6) [Cleaved into: Soluble CD6]CD6668
P33681CD80_HUMANT-lymphocyte activation antigen CD80 (Activation B7-1 antigen) (BB1) (CTLA-4 counter-CD80 CD28LG288
receptor B7.1) (B7) (CD antigen CD80)CD28LG1 LAB7
P13688CEAM1_HUMANCarcinoembryonic antigen-related cell adhesion molecule 1 (Biliary glycoprotein 1) (BGP-CEACAM1 BGP BGP1526
1) (CD antigen CD66a)
P29016CD1B_HUMANT-cell surface glycoprotein CD1b (CD antigen CD1b)CD1B333
Q9HCU0CD248_HUMANEndosialin (Tumor endothelial marker 1) (CD antigen CD248)CD248 CD164L1 TEM1757
P28906CD34_HUMANHematopoietic progenitor cell antigen CD34 (CD antigen CD34)CD34385
P07766CD3E_HUMANT-cell surface glycoprotein CD3 epsilon chain (T-cell surface antigen T3/Leu-4 epsilonCD3E T3E207
chain) (CD antigen CD3e)
P09693CD3G_HUMANT-cell surface glycoprotein CD3 gamma chain (T-cell receptor T3 gamma chain) (CD antigen CD3g)CD3G T3G182
Q6ZTQ4CDHR3_HUMANCadherin-related family member 3 (Cadherin-like protein 28)CDHR3 CDH28885
P20963CD3Z_HUMANT-cell surface glycoprotein CD3 zeta chain (T-cell receptor T3 zeta chain) (CD antigen CD247)CD247 CD3Z T3Z TCRZ164
P11912CD79A_HUMANB-cell antigen receptor complex-associated protein alpha chain (Ig-alpha) (MB-1CD79A IGA MB1226
membrane glycoprotein) (Membrane-bound immunoglobulin-associated protein) (Surface
IgM-associated protein) (CD antigen CD79a)
O75871CEAM4_HUMANCarcinoembryonic antigen-related cell adhesion molecule 4 (Carcinoembryonic antigenCEACAM4 CGM7244
CGM7) (Non-specific cross-reacting antigen W236)
Q13740CD166_HUMANCD166 antigen (Activated leukocyte cell adhesion molecule) (CD antigen CD166)ALCAM MEMD583
Q99467CD180_HUMANCD180 antigen (Lymphocyte antigen 64) (Radioprotective 105 kDa protein) (CD antigen CD180)CD180 LY64 RP105661
Q8IX05CD302_HUMANCD302 antigen (C-type lectin BIMLEC) (C-type lectin domain family 13 member A)CD302 CLEC13A232
(DEC205-associated C-type lectin 1) (Type I transmembrane C-type lectin receptor DCL-DCL1 KIAA0022
1) (CD antigen CD302)
P20138CD33_HUMANMyeloid cell surface antigen CD33 (Sialic acid-binding Ig-like lectin 3) (Siglec-3) (gp67)CD33 SIGLEC3364
(CD antigen CD33)
P01730CD4_HUMANT-cell surface glycoprotein CD4 (T-cell surface antigen T4/Leu-3) (CD antigen CD4)CD4458
P09564CD7_HUMANT-cell antigen CD7 (GP40) (T-cell leukemia antigen) (T-cell surface antigen Leu-9) (TP41)CD7240
(CD antigen CD7)
Q01151CD83_HUMANCD83 antigen (hCD83) (B-cell activation protein) (Cell surface protein HB15) (CD antigen CD83)CD83205
P42081CD86_HUMANT-lymphocyte activation antigen CD86 (Activation B7-2 antigen) (B70) (BU63) (CTLA-4CD86 CD28LG2329
counter-receptor B7.2) (FUN-1) (CD antigen CD86)
A6H8M9CDHR4_HUMANCadherin-related family member 4 (Cadherin-like protein 29)CDHR4 CDH29788
UNQ9392/PRO34300
Q7Z692CEA19_HUMANCarcinoembryonic antigen-related cell adhesion molecule 19 (Carcinoembryonic antigen-like 1)CEACAM19 CEAL1300
UNQ2973/PRO7436
P40198CEAM3_HUMANCarcinoembryonic antigen-related cell adhesion molecule 3 (Carcinoembryonic antigenCEACAM3 CD66D CGM1252
CGM1) (CD antigen CD66d)
Q9H9P2CHODL_HUMANChondrolectin (Transmembrane protein MT75)CHODL C21orf68 PRED12273
UNQ872/PRO1890
Q08708CLM6_HUMANCMRF35-like molecule 6 (CLM-6) (CD300 antigen-like family member C) (CMRF35-A1)CD300C CMRF35 CMRF35A224
(CMRF-35) (Immunoglobulin superfamily member 16) (IgSF16) (CD antigen CD300c)CMRF35A1 IGSF16
O14967CLGN_HUMANCalmeginCLGN610
Q496F6CLM2_HUMANCMRF35-like molecule 2 (CLM-2) (CD300 antigen-like family member E) (CMRF35-A5)CD300E CD300LE205
(Immune receptor expressed on myeloid cells 2) (IREM-2) (Polymeric immunoglobulinCLM2 CMRF35A5 IREM2
receptor 2) (PIgR-2) (PIgR2) (Poly-Ig receptor 2) (CD antigen CD300e)
Q6UXG3CLM9_HUMANCMRF35-like molecule 9 (CLM-9) (CD300 antigen-like family member G) (TriggeringCD300LG CLM9 TREM4332
receptor expressed on myeloid cells 4) (TREM-4) (CD antigen CD300g)UNQ422/PRO846
Q9UQC9CLCA2_HUMANCalcium-activated chloride channel regulator 2 (EC 3.4.-.-) (Calcium-activated chlorideCLCA2 CACC3943
channel family member 2) (hCLCA2) (Calcium-activated chloride channel protein 3)
(CaCC-3) (hCaCC-3) [Cleaved into: Calcium-activated chloride channel regulator 2, 109
kDa form; Calcium-activated chloride channel regulator 2, 35 kDa form]
Q9H6B4CLMP_HUMANCXADR-like membrane protein (Adipocyte adhesion molecule) (Coxsackie- andCLMP ACAM ASAM373
adenovirus receptor-like membrane protein) (CAR-like membrane protein)UNQ318/PRO363
Q96F05CK024_HUMANUncharacterized protein C11orf24 (Protein DM4E3)C11orf24 FP2568449
UNQ1872/PRO4315
Q6NUJ2CK087_HUMANUncharacterized protein C11orf87C11orf87197
A8K4G0CLM7_HUMANCMRF35-like molecule 7 (CLM-7) (CD300 antigen-like family member B) (CMRF35-A2)CD300LB CD300B201
(Immune receptor expressed on myeloid cells 3) (IREM-3) (Leukocyte mono-Ig-likeCLM7 CMRF35A2
receptor 5) (Triggering receptor expressed on myeloid cells 5) (TREM-5) (CD antigen CD300b)IREM3 LMIR5 TREM5
UNQ2530/PRO6029
Q9UGN4CLM8_HUMANCMRF35-like molecule 8 (CLM-8) (CD300 antigen-like family member A) (CMRF-35-H9)CD300A CMRF35H299
(CMRF35-H9) (CMRF35-H) (IRC1/IRC2) (Immunoglobulin superfamily member 12)IGSF12 HSPC083
(IgSF12) (Inhibitory receptor protein 60) (IRp60) (NK inhibitory receptor) (CD antigen CD300a)
Q96NU0CNT3B_HUMANContactin-associated protein-like 3B (Cell recognition molecule Caspr3b)CNTNAP3B1288
CASPR3B
P78357CNTP1_HUMANContactin-associated protein 1 (Caspr) (Caspr1) (Neurexin IV) (Neurexin-4) (p190)CNTNAP1 CASPR1384
NRXN4
Q9UHC6CNTP2_HUMANContactin-associated protein-like 2 (Cell recognition molecule Caspr2)CNTNAP2 CASPR21331
KIAA0868
Q9C0A0CNTP4_HUMANContactin-associated protein-like 4 (Cell recognition molecule Caspr4)CNTNAP4 CASPR41308
KIAA1763
Q8WYK1CNTP5_HUMANContactin-associated protein-like 5 (Cell recognition molecule Caspr5)CNTNAP5 CASPR51306
Q8TDQ1CLM1_HUMANCMRF35-like molecule 1 (CLM-1) (CD300 antigen-like family member F) (ImmuneCD300LF CD300F290
receptor expressed on myeloid cells 1) (IREM-1) (Immunoglobulin superfamily memberCLM1 IGSF13
13) (IgSF13) (NK inhibitory receptor) (CD antigen CD300f)IREM1 NKIR
UNQ3105/PRO10111
Q5T292CJ128_HUMANPutative uncharacterized protein C10orf128C10orf128105
Q86T13CLC14_HUMANC-type lectin domain family 14 member A (Epidermal growth factor receptor 5) (EGFR-5)CLEC14A C14orf27490
EGFR5 UNQ236/PRO269
Q6UXZ3CLM4_HUMANCMRF35-like molecule 4 (CLM-4) (CD300 antigen-like family member D) (CMRF35-A4)CD300LD CD300D194
(CD antigen CD300d)CMRF35A4
UNQ9218/PRO28686
Q9BZ76CNTP3_HUMANContactin-associated protein-like 3 (Cell recognition molecule Caspr3)CNTNAP3 CASPR31288
KIAA1714
Q86TY3CN037_HUMANUncharacterized protein C14orf37C14orf37774
Q9HC73CRLF2_HUMANCytokine receptor-like factor 2 (Cytokine receptor-like 2) (IL-XR) (Thymic stromalCRLF2 CRL2 ILXR TSLPR371
lymphopoietin protein receptor) (TSLP receptor)
Q9BVV8CS024_HUMANUncharacterized membrane protein C19orf24C19orf24132
P09603CSF1_HUMANMacrophage colony-stimulating factor 1 (CSF-1) (M-CSF) (MCSF) (Lanimostim) [CleavedCSF1554
into: Processed macrophage colony-stimulating factor 1]
Q5IJ48CRUM2_HUMANProtein crumbs homolog 2 (Crumbs-like protein 2)CRB21285
Q96PZ7CSMD1_HUMANCUB and sushi domain-containing protein 1 (CUB and sushi multiple domains protein 1)CSMD1 KIAA18903565
UNQ5952/PRO19863
O95196CSPG5_HUMANChondroitin sulfate proteoglycan 5 (Acidic leucine-rich EGF-like domain-containing brainCSPG5 CALEB NGC566
protein) (Neuroglycan C)
Q9BUF7CRUM3_HUMANProtein crumbs homolog 3CRB3 UNQ588/PRO1158120
O94985CSTN1_HUMANCalsyntenin-1 (Alcadein-alpha) (Alc-alpha) (Alzheimer-related cadherin-like protein) (Non-CLSTN1 CS1981
classical cadherin XB31alpha) [Cleaved into: Soluble Alc-alpha (SAlc-alpha); CTF1-alphaKIAA0911
(C-terminal fragment 1-alpha)]
Q6ZRH7CTSRG_HUMANCation channel sperm-associated protein subunit gammaCATSPERG1159
C19orf15
Q86UP6CUZD1_HUMANCUB and zona pellucida-like domain-containing protein 1 (CUB and ZP domain-CUZD1 UNQ224/PRO257607
containing protein 1) (Transmembrane protein UO-44)
Q5JRM2CX066_HUMANUncharacterized protein CXorf66CXorf66361
Q8NEA5CS018_HUMANUncharacterized protein C19orf18C19orf18215
P17927CR1_HUMANComplement receptor type 1 (C3b/C4b receptor) (CD antigen CD35)CR1 C3BR2039
P20023CR2_HUMANComplement receptor type 2 (Cr2) (Complement C3d receptor) (Epstein-Barr virusCR2 C3DR1033
receptor) (EBV receptor) (CD antigen CD21)
P15509CSF2R_HUMANGranulocyte-macrophage colony-stimulating factor receptor subunit alpha (GM-CSF-R-CSF2RA CSF2R CSF2RY400
alpha) (GMCSFR-alpha) (GMR-alpha) (CDw116) (CD antigen CD116)
Q99062CSF3R_HUMANGranulocyte colony-stimulating factor receptor (G-CSF receptor) (G-CSF-R) (CD antigen CD114)CSF3R GCSFR836
Q9BQT9CSTN3_HUMANCalsyntenin-3 (Alcadein-beta) (Alc-beta)CLSTN3 CS3956
KIAA0726
Q9NZV1CRIM1_HUMANCysteine-rich motor neuron 1 protein (CRIM-1) (Cysteine-rich repeat-containing proteinCRIM1 S521036
S52) [Cleaved into: Processed cysteine-rich motor neuron 1 protein]UNQ1886/PRO4330
P82279CRUM1_HUMANProtein crumbs homolog 1CRB11406
Q6UVK1CSPG4_HUMANChondroitin sulfate proteoglycan 4 (Chondroitin sulfate proteoglycan NG2) (MelanomaCSPG4 MCSP2322
chondroitin sulfate proteoglycan) (Melanoma-associated Chondroitin sulfate proteoglycan)
P16410CTLA4_HUMANCytotoxic T-lymphocyte protein 4 (Cytotoxic T-lymphocyte-associated antigen 4) (CTLA-CTLA4 CD152223
4) (CD antigen CD152)
Q86XM0CTSRD_HUMANCation channel sperm-associated protein subunit delta (CatSper-delta) (CatSperdelta)CATSPERD TMEM146798
(Transmembrane protein 146)
P78310CXAR_HUMANCoxsackievirus and adenovirus receptor (CAR) (hCAR) (CVB3-binding protein)CXADR CAR365
(Coxsackievirus B-adenovirus receptor) (HCVADR)
O95727CRTAM_HUMANCytotoxic and regulatory T-cell molecule (Class-I MHC-restricted T-cell-associatedCRTAM393
molecule) (CD antigen CD355)
P07333CSF1R_HUMANMacrophage colony-stimulating factor 1 receptor (CSF-1 receptor) (CSF-1-R) (CSF-1R)CSF1R FMS972
(M-CSF-R) (EC 2.7.10.1) (Proto-oncogene c-Fms) (CD antigen CD115)
Q4G0I0CSMT1_HUMANProtein CCSMST1CCSMST1 C16orf91132
Q9H4D0CSTN2_HUMANCalsyntenin-2 (Alcadein-gamma) (Alc-gamma)CLSTN2 CS2955
Q9H2A7CXL16_HUMANC-X-C motif chemokine 16 (Scavenger receptor for phosphatidylserine and oxidized lowCXCL16 SCYB16 SRPSOX254
density lipoprotein) (SR-PSOX) (Small-inducible cytokine B16) (Transmembrane chemokine CXCL16)UNQ2759/PRO6714
P08174DAF_HUMANComplement decay-accelerating factor (CD antigen CD55)CD55 CR DAF381
Q14118DAG1_HUMANDystroglycan (Dystrophin-associated glycoprotein 1) [Cleaved into: Alpha-dystroglycanDAG1895
(Alpha-DG); Beta-dystroglycan (Beta-DG)]
Q96J86CYYR1_HUMANCysteine and tyrosine-rich protein 1 (Proline-rich domain-containing protein)CYYR1 C21orf95154
P43146DCC_HUMANNetrin receptor DCC (Colorectal cancer suppressor) (Immunoglobulin superfamily DCCDCC IGDCC11447
subclass member 1) (Tumor suppressor protein DCC)
Q08345DDR1_HUMANEpithelial discoidin domain-containing receptor 1 (Epithelial discoidin domain receptor 1)DDR1 CAK EDDR1913
(EC 2.7.10.1) (CD167 antigen-like family member A) (Cell adhesion kinase) (DiscoidinNEP NTRK4 PTK3A
receptor tyrosine kinase) (HGK2) (Mammary carcinoma kinase 10) (MCK-10) (Protein-RTK6 TRKE
tyrosine kinase 3A) (Protein-tyrosine kinase RTK-6) (TRK E) (Tyrosine kinase DDR)
(Tyrosine-protein kinase CAK) (CD antigen CD167a)
Q16832DDR2_HUMANDiscoidin domain-containing receptor 2 (Discoidin domain receptor 2) (EC 2.7.10.1)DDR2 NTRKR3855
(CD167 antigen-like family member B) (Discoidin domain-containing receptor tyrosineTKT TYRO10
kinase 2) (Neurotrophic tyrosine kinase, receptor-related 3) (Receptor protein-tyrosine
kinase TKT) (Tyrosine-protein kinase TYRO10) (CD antigen CD167b)
Q8N8Z6DCBD1_HUMANDiscoidin, CUB and LCCL domain-containing protein 1DCBLD1715
Q96PD2DCBD2_HUMANDiscoidin, CUB and LCCL domain-containing protein 2 (CUB, LCCL and coagulationDCBLD2 CLCP1 ESDN775
factor V/VIII-homology domains protein 1) (Endothelial and smooth muscle cell-derived
neuropilin-like protein)
P28068DMB_HUMANHLA class II histocompatibility antigen, DM beta chain (MHC class II antigen DMB)HLA-DMB DMB263
(Really interesting new gene 7 protein)RING7
P80370DLK1_HUMANProtein delta homolog 1 (DLK-1) (pG2) [Cleaved into: Fetal antigen 1 (FA1)]DLK1 DLK383
Q9NYJ7DLL3_HUMANDelta-like protein 3 (Drosophila Delta homolog 3) (Delta3)DLL3618
P28067DMA_HUMANHLA class II histocompatibility antigen, DM alpha chain (MHC class II antigen DMA)HLA-DMA DMA261
(Really interesting new gene 6 protein)RING6
P06340DOA_HUMANHLA class II histocompatibility antigen, DO alpha chain (MHC DN-alpha) (MHC DZ alpha)HLA-DOA HLA-DNA250
(MHC class II antigen DOA)HLA-DZA
Q6UY11DLK2_HUMANProtein delta homolog 2 (DLK-2) (Epidermal growth factor-like protein 9) (EGF-like protein 9)DLK2 EGFL9383
UNQ2903/PRO28633
Q8NFT8DNER_HUMANDelta and Notch-like epidermal growth factor-related receptorDNER BET737
UNQ262/PRO299
P20036DPA1_HUMANHLA class II histocompatibility antigen, DP alpha 1 chain (DP(W3)) (DP(W4)) (HLA-SBHLA-DPA1 HLA-260
alpha chain) (MHC class II DP3-alpha) (MHC class II DPA1)DP1A HLASB
P79483DRB3_HUMANHLA class II histocompatibility antigen, DR beta 3 chain (MHC class II antigen DRB3)HLA-DRB3266
Q96KC8DNJC1_HUMANDnaJ homolog subfamily C member 1 (DnaJ protein homolog MTJ1)DNAJC1 HTJ1554
Q8TD84DSCL1_HUMANDown syndrome cell adhesion molecule-like protein 1 (Down syndrome cell adhesion molecule 2)DSCAML12053
DSCAM2 KIAA1132
O00548DLL1_HUMANDelta-like protein 1 (Drosophila Delta homolog 1) (Delta1) (H-Delta-1)DLL1 UNQ146/PRO172723
Q02487DSC2_HUMANDesmocollin-2 (Cadherin family member 2) (Desmocollin-3) (Desmosomal glycoprotein II)DSC2 CDHF2 DSC3901
(Desmosomal glycoprotein III)
O60469DSCAM_HUMANDown syndrome cell adhesion molecule (CHD2)DSCAM2012
Q9NR61DLL4_HUMANDelta-like protein 4 (Drosophila Delta homolog 4) (Delta4)DLL4 UNQ1895/PRO4341685
P13765DOB_HUMANHLA class II histocompatibility antigen, DO beta chain (MHC class II antigen DOB)HLA-DOB273
P01906DQA2_HUMANHLA class II histocompatibility antigen, DQ alpha 2 chain (DX alpha chain) (HLA class IIHLA-DQA2 HLA-DXA255
histocompatibility antigen, DQ(6) alpha chain) (HLA-DQA1) (MHC class II DQA2)
P01920DQB1_HUMANHLA class II histocompatibility antigen, DQ beta 1 chain (MHC class II antigen DQB1)HLA-DQB1 HLA-DQB261
Q30154DRB5_HUMANHLA class II histocompatibility antigen, DR beta 5 chain (DR beta-5) (DR2-beta-2) (Dw2)HLA-DRB5266
(MHC class II antigen DRB5)
Q14574DSC3_HUMANDesmocollin-3 (Cadherin family member 3) (Desmocollin-4) (HT-CP)DSC3 CDHF3 DSC4896
P01909DQA1_HUMANHLA class II histocompatibility antigen, DQ alpha 1 chain (DC-1 alpha chain) (DC-alpha)HLA-DQA1254
(HLA-DCA) (MHC class II DQA1)
P32926DSG3_HUMANDesmoglein-3 (130 kDa pemphigus vulgaris antigen) (PVA) (Cadherin family member 6)DSG3 CDHF6999
Q9NZJ5E2AK3_HUMANEukaryotic translation initiation factor 2-alpha kinase 3 (EC 2.7.11.1) (PRKR-likeEIF2AK3 PEK PERK1116
endoplasmic reticulum kinase) (Pancreatic eIF2-alpha kinase) (HsPEK)
P04440DPB1_HUMANHLA class II histocompatibility antigen, DP beta 1 chain (HLA class II histocompatibilityHLA-DPB1 HLA-DP1B258
antigen, DP(W4) beta chain) (MHC class II antigen DPB1)
P13762DRB4_HUMANHLA class II histocompatibility antigen, DR beta 4 chain (MHC class II antigen DRB4)HLA-DRB4266
Q86SJ6DSG4_HUMANDesmoglein-4 (Cadherin family member 13)DSG4 CDHF131040
Q3MIW9DPCR1_HUMANDiffuse panbronchiolitis critical region protein 1DPCR1 C6orf37 PBLT517
P01903DRA_HUMANHLA class II histocompatibility antigen, DR alpha chain (MHC class II antigen DRA)HLA-DRA HLA-DRA1254
Q08554DSC1_HUMANDesmocollin-1 (Cadherin family member 1) (Desmosomal glycoprotein 2/3) (DG2/DG3)DSC1 CDHF1894
Q02413DSG1_HUMANDesmoglein-1 (Cadherin family member 4) (Desmosomal glycoprotein 1) (DG1) (DGI)DSG1 CDHF41049
(Pemphigus foliaceus antigen)
P05538DQB2_HUMANHLA class II histocompatibility antigen, DQ beta 2 chain (HLA class II histocompatibilityHLA-DQB2 HLA-DXB268
antigen, DX beta chain) (MHC class II antigen DQB2)
Q14126DSG2_HUMANDesmoglein-2 (Cadherin family member 5) (HDGC)DSG2 CDHF51118
P01133EGF_HUMANPro-epidermal growth factor (EGF) [Cleaved into: Epidermal growth factor (Urogastrone)]EGF1207
Q19T08ECSCR_HUMANEndothelial cell-specific chemotaxis regulator (Apoptosis regulator through modulatingECSCR ECSM2205
IAP expression) (ARIA) (Endothelial cell-specific molecule 2)
Q9UNE0EDAR_HUMANTumor necrosis factor receptor superfamily member EDAR (Anhidrotic ectodysplasinEDAR DL448
receptor 1) (Downless homolog) (EDA-A1 receptor) (Ectodermal dysplasia receptor)
(Ectodysplasin-A receptor)
P98172EFNB1_HUMANEphrin-B1 (EFL-3) (ELK ligand) (ELK-L) (EPH-related receptor tyrosine kinase ligand 2) (LERK-2)EFNB1 EFL3346
EPLG2 LERK2
Q15768EFNB3_HUMANEphrin-B3 (EPH-related receptor transmembrane ligand ELK-L3) (EPH-related receptorEFNB3 EPLG8 LERK8340
tyrosine kinase ligand 8) (LERK-8)
Q9NPA0EMC7_HUMANER membrane protein complex subunit 7EMC7 C11orf3242
C15orf24 HT022
UNQ905/PRO1926
Q902F9EN113_HUMANEndogenous retrovirus group K member 113 Env polyprotein (EnvK5 protein) (EnvelopeHERVK_113699
polyprotein) (HERV-K113 envelope protein) (HERV-K_19p13.11 provirus ancestral Env
polyprotein) [Cleaved into: Surface protein (SU); Transmembrane protein (TM)]
Q6UWV6ENPP7_HUMANEctonucleotide pyrophosphatase/phosphodiesterase family member 7 (E-NPP 7) (NPP-7)ENPP7458
(EC 3.1.4.12) (Alkaline sphingomyelin phosphodiesterase) (Intestinal alkaline sphingomyelinase)UNQ3077/PRO9912
(Alk-SMase)
P61566ENK24_HUMANEndogenous retrovirus group K member 24 Env polyprotein (Envelope polyprotein)ERVK-24588
(HERV-K101 envelope protein) (HERV-K_22q11.21 provirus ancestral Env polyprotein)
[Cleaved into: Surface protein (SU); Transmembrane protein (TM)]
Q902F8ENK8_HUMANEndogenous retrovirus group K member 8 Env polyprotein (EnvK6 protein) (EnvelopeERVK-8699
polyprotein) (HERV-K115 envelope protein) (HERV-K_8p23.1 provirus ancestral Env
polyprotein) [Cleaved into: Surface protein (SU); Transmembrane protein (TM)]
P29320EPHA3_HUMANEphrin type-A receptor 3 (EC 2.7.10.1) (EPH-like kinase 4) (EK4) (hEK4) (HEK) (HumanEPHA3 ETK ETK1983
embryo kinase) (Tyrosine-protein kinase TYRO4) (Tyrosine-protein kinase receptorHEK TYRO4
ETK1) (Eph-like tyrosine kinase 1)
P54764EPHA4_HUMANEphrin type-A receptor 4 (EC 2.7.10.1) (EPH-like kinase 8) (EK8) (hEK8) (Tyrosine-EPHA4 HEK8 SEK TYRO1986
protein kinase TYRO1) (Tyrosine-protein kinase receptor SEK)
Q9UF33EPHA6_HUMANEphrin type-A receptor 6 (EC 2.7.10.1) (EPH homology kinase 2) (EHK-2) (EPH-like kinase 12) (EK12)EPHA6 EHK2 HEK121036
Q5JZY3EPHAA_HUMANEphrin type-A receptor 10 (EC 2.7.10.1)EPHA101008
P19235EPOR_HUMANErythropoietin receptor (EPO-R)EPOR508
P04626ERBB2_HUMANReceptor tyrosine-protein kinase erbB-2 (EC 2.7.10.1) (Metastatic lymph node gene 19ERBB2 HER21255
protein) (MLN 19) (Proto-oncogene Neu) (Proto-oncogene c-ErbB-2) (Tyrosine kinase-MLN19 NEU NGL
type cell surface receptor HER2) (p185erbB2) (CD antigen CD340)
P52799EFNB2_HUMANEphrin-B2 (EPH-related receptor tyrosine kinase ligand 5) (LERK-5) (HTK ligand) (HTK-L)EFNB2 EPLG5333
HTKL LERK5
P17813EGLN_HUMANEndoglin (CD antigen CD105)ENG END658
Q5UCC4EMC10_HUMANER membrane protein complex subunit 10 (Hematopoietic signal peptide-containingEMC10 C19orf63262
membrane domain-containing protein 1)HSM1 INM02
UNQ764/PRO1556
Q69384ENK6_HUMANEndogenous retrovirus group K member 6 Env polyprotein (EnvK2 protein) (EnvelopeERVK-6 ERVK6699
polyprotein) (HERV-K(C7) envelope protein) (HERV-K(HML-2.HOM) envelope protein)
(HERV-K108 envelope protein) (HERV-K_7p22.1 provirus ancestral Env polyprotein)
[Cleaved into: Surface protein (SU); Transmembrane protein (TM)]
Q9UKH3ENK9_HUMANEndogenous retrovirus group K member 9 Env polyprotein (EnvK4 protein) (EnvelopeERVK-9698
polyprotein) (HERV-K(C6) envelope protein) (HERV-K109 envelope protein) (HERV-
K_6q14.1 provirus ancestral Env polyprotein) [Cleaved into: Surface protein (SU);
Transmembrane protein (TM)]
Q6UW88EPGN_HUMANEpigen (Epithelial mitogen) (EPG)EPGN154
UNQ3072/PRO9904
P29317EPHA2_HUMANEphrin type-A receptor 2 (EC 2.7.10.1) (Epithelial cell kinase) (Tyrosine-protein kinaseEPHA2 ECK976
receptor ECK)
P54753EPHB3_HUMANEphrin type-B receptor 3 (EC 2.7.10.1) (EPH-like tyrosine kinase 2) (EPH-like kinase 2)EPHB3 ETK2 HEK2 TYRO6998
(Embryonic kinase 2) (EK2) (hEK2) (Tyrosine-protein kinase TYRO6)
O15197EPHB6_HUMANEphrin type-B receptor 6 (HEP) (Tyrosine-protein kinase-defective receptor EPH-6)EPHB61021
O14944EREG_HUMANProepiregulin [Cleaved into: Epiregulin (EPR)]EREG169
B6SEH8ERVV1_HUMANEndogenous retrovirus group V member 1 Env polyprotein (HERV-V_19q13.41 provirusERVV-1 ENVV1477
ancestral Env polyprotein 1)
P00533EGFR_HUMANEpidermal growth factor receptor (EC 2.7.10.1) (Proto-oncogene c-ErbB-1) (ReceptorEGFR ERBB1210
tyrosine-protein kinase erbB-1)ERBB1 HER1
Q8N766EMC1_HUMANER membrane protein complex subunit 1EMC1 KIAA0090993
PSEC0263
O42043ENK18_HUMANEndogenous retrovirus group K member 18 Env polyprotein (Envelope polyprotein)ERVK-18560
(HERV-K(C1a) envelope protein) (HERV-K110 envelope protein) (HERV-K18 envelope
protein) (HERV-K18 superantigen) (HERV-K_1q23.3 provirus ancestral Env polyprotein)
(IDDMK1, 2 22 envelope protein) (IDDMK1, 2 22 superantigen) [Cleaved into: Surface
protein (SU); Transmembrane protein (TM)]
O71037ENK19_HUMANEndogenous retrovirus group K member 19 Env polyprotein (EnvK3 protein) (EnvelopeERVK-19699
polyprotein) (HERV-K(C19) envelope protein) (HERV-K_19q11 provirus ancestral Env
polyprotein) [Cleaved into: Surface protein (SU); Transmembrane protein (TM)]
Q15375EPHA7_HUMANEphrin type-A receptor 7 (EC 2.7.10.1) (EPH homology kinase 3) (EHK-3) (EPH-likeEPHA7 EHK3 HEK11998
kinase 11) (EK11) (hEK11)
Q9NQ60EQTN_HUMANEquatorin (Acrosome formation-associated factor)EQTN AFAF C9orf11294
P61565ENK21_HUMANEndogenous retrovirus group K member 21 Env polyprotein (EnvK1 protein) (EnvelopeERVK-21698
polyprotein) (HERV-K_12q14.1 provirus ancestral Env polyprotein) [Cleaved into: Surface
protein (SU); Transmembrane protein (TM)]
Q9UNN8EPCR_HUMANEndothelial protein C receptor (Activated protein C receptor) (APC receptor) (EndothelialPROCR EPCR238
cell protein C receptor) (CD antigen CD201)
P54762EPHB1_HUMANEphrin type-B receptor 1 (EC 2.7.10.1) (ELK) (EPH tyrosine kinase 2) (EPH-like kinase 6)EPHB1 ELK EPHT2984
(EK6) (hEK6) (Neuronally-expressed EPH-related tyrosine kinase) (NET) (Tyrosine-HEK6 NET
protein kinase receptor EPH-2)
P54760EPHB4_HUMANEphrin type-B receptor 4 (EC 2.7.10.1) (Hepatoma transmembrane kinase) (Tyrosine-EPHB4 HTK MYK1987
protein kinase TYRO11)TYRO11
P21860ERBB3_HUMANReceptor tyrosine-protein kinase erbB-3 (EC 2.7.10.1) (Proto-oncogene-like protein c-ERBB3 HER31342
ErbB-3) (Tyrosine kinase-type cell surface receptor HER3)
A8MVW0F1712_HUMANProtein FAM171A2FAM171A2826
Q5JX69F209B_HUMANProtein FAM209BFAM209B C20orf107171
P0C7U0ELFN1_HUMANProtein ELFN1 (Extracellular leucine-rich repeat and fibronectin type-III domain-ELFN1 PPP1R28828
containing protein 1) (Protein phosphatase 1 regulatory subunit 28)
Q6PCB8EMB_HUMANEmbiginEMB327
Q9Y6X5ENPP4_HUMANBis(5′-adenosyl)-triphosphatase ENPP4 (EC 3.6.1.29) (AP3A hydrolase) (AP3Aase)ENPP4 KIAA0879453
(Ectonucleotide pyrophosphatase/phosphodiesterase family member 4) (E-NPP 4) (NPP-4)NPP4
P21709EPHA1_HUMANEphrin type-A receptor 1 (hEpha1) (EC 2.7.10.1) (EPH tyrosine kinase) (EPH tyrosineEPHA1 EPH EPHT976
kinase 1) (Erythropoietin-producing hepatoma receptor) (Tyrosine-protein kinase receptor EPH)EPHT1
P54756EPHA5_HUMANEphrin type-A receptor 5 (EC 2.7.10.1) (Brain-specific kinase) (EPH homology kinase 1)EPHA5 BSK EHK11037
(EHK-1) (EPH-like kinase 7) (EK7) (hEK7)HEK7 TYRO4
P29322EPHA8_HUMANEphrin type-A receptor 8 (EC 2.7.10.1) (EPH- and ELK-related kinase) (EPH-like kinaseEPHA8 EEK HEK31005
3) (EK3) (hEK3) (Tyrosine-protein kinase receptor EEK)KIAA1459
P29323EPHB2_HUMANEphrin type-B receptor 2 (EC 2.7.10.1) (Developmentally-regulated Eph-related tyrosineEPHB2 DRT EPHT31055
kinase) (ELK-related tyrosine kinase) (EPH tyrosine kinase 3) (EPH-like kinase 5) (EK5)EPTH3 ERK HEK5
(hEK5) (Renal carcinoma antigen NY-REN-47) (Tyrosine-protein kinase TYRO5)TYRO5
(Tyrosine-protein kinase receptor EPH-3)
P03372ESR1_HUMANEstrogen receptor (ER) (ER-alpha) (Estradiol receptor) (Nuclear receptor subfamily 3ESR1 ESR NR3A1595
group A member 1)
Q15884F1892_HUMANProtein FAM189A2 (Protein X123)FAM189A2 C9orf61450
X123
P16422EPCAM_HUMANEpithelial cell adhesion molecule (Ep-CAM) (Adenocarcinoma-associated antigen) (CellEPCAM GA733-2314
surface glycoprotein Trop-1) (Epithelial cell surface antigen) (Epithelial glycoprotein)M1S2 M4S1 MIC18
(EGP) (Epithelial glycoprotein 314) (EGP314) (hEGP314) (KS 1/4 antigen) (KSA) (MajorTACSTD1 TROP1
gastrointestinal tumor-associated protein GA733-2) (Tumor-associated calcium signal
transducer 1) (CD antigen CD326)
Q15303ERBB4_HUMANReceptor tyrosine-protein kinase erbB-4 (EC 2.7.10.1) (Proto-oncogene-like protein c-ERBB4 HER41308
ErbB-4) (Tyrosine kinase-type cell surface receptor HER4) (p180erbB4) [Cleaved into:
ERBB4 intracellular domain (4ICD) (E4ICD) (s80HER4)]
O75460ERN1_HUMANSerine/threonine-protein kinase/endoribonuclease IRE1 (Endoplasmic reticulum-to-ERN1 IRE1977
nucleus signaling 1) (Inositol-requiring protein 1) (hIRE1p) (Ire1-alpha) (IRE1a) [Includes:
Serine/threonine-protein kinase (EC 2.7.11.1); Endoribonuclease (EC 3.1.26.-)]
P58658EVA1C_HUMANProtein eva-1 homolog C (Protein FAM176C) (SUE21)EVA1C C21orf63441
C21orf64 FAM176C
PRED34
UNQ2504/PRO5993
P22794EVI2A_HUMANProtein EVI2A (Ecotropic viral integration site 2A protein homolog) (EVI-2A)EVI2A EVDA EVI2236
Q5VUB5F1711_HUMANProtein FAM171A1 (Astroprincin)FAM171A1 C10orf38890
Q6V0I7FAT4_HUMANProtocadherin Fat 4 (hFat4) (Cadherin family member 14) (FAT tumor suppressorFAT4 CDHF144981
homolog 4) (Fat-like cadherin protein FAT-J)FATJ Nbla00548
Q96PL5ERMAP_HUMANErythroid membrane-associated protein (hERMAP) (Radin blood group antigen) (SciannaERMAP RD SC475
blood group antigen)
Q76MJ5ERN2_HUMANSerine/threonine-protein kinase/endoribonuclease IRE2 (Endoplasmic reticulum-to-ERN2 IRE2926
nucleus signaling 2) (Inositol-requiring protein 2) (hIRE2p) (Ire1-beta) (IRE1b) [Includes:
Serine/threonine-protein kinase (EC 2.7.11.1); Endoribonuclease (EC 3.1.26.-)]
Q96AP7ESAM_HUMANEndothelial cell-selective adhesion moleculeESAM390
UNQ220/PRO246
P34910EVI2B_HUMANProtein EVI2B (Ecotropic viral integration site 2B protein homolog) (EVI-2B) (CD antigen CD361)EVI2B EVDB448
Q3ZCQ3F174B_HUMANMembrane protein FAM174BFAM174B159
Q8WWV6FCAMR_HUMANHigh affinity immunoglobulin alpha and immunoglobulin mu Fc receptor (Fc alpha/muFCAMR FKSG87532
receptor) (CD antigen CD351)
P30273FCERG_HUMANHigh affinity immunoglobulin epsilon receptor subunit gamma (Fc receptor gamma-chain)FCER1G86
(FcRgamma) (Fc-epsilon RI-gamma) (IgE Fc receptor subunit gamma) (FceRI gamma)
Q8TBP5F174A_HUMANMembrane protein FAM174A (Hepatitis C virus NS5A-transactivated protein 6) (HCVFAM174A NS5ATP6190
NS5A-transactivated protein 6) (Transmembrane protein 157)TMEM157
UNQ1912/PRO4371
P31995FCG2C_HUMANLow affinity immunoglobulin gamma Fc region receptor II-c (IgG Fc receptor II-c)FCGR2C CD32323
(CDw32) (Fc-gamma RII-c) (Fc-gamma-RIIc) (FcRII-c) (CD antigen CD32)FCG2 IGFR2
P55899FCGRN_HUMANIgG receptor FcRn large subunit p51 (FcRn) (IgG Fc fragment receptor transporter alphaFCGRT FCRN365
chain) (Neonatal Fc receptor)
Q96LA5FCRL2_HUMANFc receptor-like protein 2 (FcR-like protein 2) (FcRL2) (Fc receptor homolog 2) (FcRH2)FCRL2 FCRH2508
(IFGP family protein 4) (Immunoglobulin receptor translocation-associated protein 4)IFGP4 IRTA4 SPAP1
(SH2 domain-containing phosphatase anchor protein 1) (CD antigen CD307b)UNQ9236/PRO31998
Q96RD9FCRL5_HUMANFc receptor-like protein 5 (FcR-like protein 5) (FcRL5) (BXMAS1) (Fc receptor homolog 5)FCRL5 FCRH5 IRTA2977
(FcRH5) (Immune receptor translocation-associated protein 2) (CD antigen CD307e)UNQ503/PRO820
P31994FCG2B_HUMANLow affinity immunoglobulin gamma Fc region receptor II-b (IgG Fc receptor II-b)FCGR2B CD32310
(CDw32) (Fc-gamma RII-b) (Fc-gamma-RIIb) (FcRII-b) (CD antigen CD32)FCG2 IGFR2
Q96PJ5FCRL4_HUMANFc receptor-like protein 4 (FcR-like protein 4) (FcRL4) (Fc receptor homolog 4) (FcRH4)FCRL4 FCRH4515
(IFGP family protein 2) (hIFGP2) (Immune receptor translocation-associated protein 1)IFGP2 IRTA1
(CD antigen CD307d)
P22607FGFR3_HUMANFibroblast growth factor receptor 3 (FGFR-3) (EC 2.7.10.1) (CD antigen CD333)FGFR3 JTK4806
Q6P995F171B_HUMANProtein FAM171BFAM171B826
KIAA1946 NPD019
A6NFU0F187A_HUMANIg-like V-type domain-containing protein FAM187AFAM187A413
Q17R55F187B_HUMANProtein FAM187B (Transmembrane protein 162)FAM187B TMEM162369
Q5JX71F209A_HUMANProtein FAM209AFAM209A C20orf106171
Q14517FAT1_HUMANProtocadherin Fat 1 (Cadherin family member 7) (Cadherin-related tumor suppressorFAT1 CDHF7 FAT4588
homolog) (Protein fat homolog) [Cleaved into: Protocadherin Fat 1, nuclear form]
Q9NYQ8FAT2_HUMANProtocadherin Fat 2 (hFat2) (Cadherin family member 8) (Multiple epidermal growthFAT2 CDHF84349
factor-like domains protein 1) (Multiple EGF-like domains protein 1)KIAA0811 MEGF1
Q8TDW7FAT3_HUMANProtocadherin Fat 3 (hFat3) (Cadherin family member 15) (FAT tumor suppressor homolog 3)FAT3 CDHF154589
KIAA1989
P24071FCAR_HUMANImmunoglobulin alpha Fc receptor (IgA Fc receptor) (CD antigen CD89)FCAR CD89287
P12314FCGR1_HUMANHigh affinity immunoglobulin gamma Fc receptor I (IgG Fc receptor I) (Fc-gamma RI)FCGR1A FCG1374
(FcRI) (Fc-gamma RIA) (FcgammaRIa) (CD antigen CD64)FCGR1 IGFR1
Q96LA6FCRL1_HUMANFc receptor-like protein 1 (FcR-like protein 1) (FcRL1) (Fc receptor homolog 1) (FcRH1)FCRL1 FCRH1429
(IFGP family protein 1) (hIFGP1) (Immune receptor translocation-associated protein 5)IFGP1 IRTA5
(CD antigen CD307a)
Q96P31FCRL3_HUMANFc receptor-like protein 3 (FcR-like protein 3) (FcRL3) (Fc receptor homolog 3) (FcRH3)FCRL3 FCRH3734
(IFGP family protein 3) (hIFGP3) (Immune receptor translocation-associated protein 3)IFGP3 IRTA3 SPAP2
(SH2 domain-containing phosphatase anchor protein 2) (CD antigen CD307c)
P12318FCG2A_HUMANLow affinity immunoglobulin gamma Fc region receptor II-a (IgG Fc receptor II-a)FCGR2A CD32317
(CDw32) (Fc-gamma RII-a) (Fc-gamma-RIIa) (FcRII-a) (CD antigen CD32)FCG2 FCGR2A1 IGFR2
P08637FCG3A_HUMANLow affinity immunoglobulin gamma Fc region receptor III-A (CD16a antigen) (Fc-gammaFCGR3A CD16A254
RIII-alpha) (Fc-gamma RIII) (Fc-gamma RIIIa) (FcRIII) (FcRIIIa) (FcR-10) (IgG FcFCG3 FCGR3 IGFR3
receptor III-2) (CD antigen CD16a)
Q92637FCGRB_HUMANHigh affinity immunoglobulin gamma Fc receptor IB (IgG Fc receptor IB) (Fc-gamma RIB)FCGR1B IGFRB280
(FcRIB) (hFcgammaRIB)
Q8N441FGRL1_HUMANFibroblast growth factor receptor-like 1 (FGF receptor-like protein 1) (FGF homologousFGFRL1 FGFR5 FHFR504
factor receptor) (FGFR-like protein) (Fibroblast growth factor receptor 5) (FGFR-5)UNQ480/PRO943
P12319FCERA_HUMANHigh affinity immunoglobulin epsilon receptor subunit alpha (Fc-epsilon RI-alpha) (FcERI)FCER1A FCE1A257
(IgE Fc receptor subunit alpha)
Q6DN72FCRL6_HUMANFc receptor-like protein 6 (FcR-like protein 6) (FcRL6) (Fc receptor homolog 6) (FcRH6) (IFGP6)FCRL6 FCRH6434
P11362FGFR1_HUMANFibroblast growth factor receptor 1 (FGFR-1) (EC 2.7.10.1) (Basic fibroblast growth factorFGFR1 BFGFR822
receptor 1) (BFGFR) (bFGF-R-1) (Fms-like tyrosine kinase 2) (FLT-2) (N-sam) (Proto-CEK FGFBR FLG
oncogene c-Fgr) (CD antigen CD331)FLT2 HBGFR
P21802FGFR2_HUMANFibroblast growth factor receptor 2 (FGFR-2) (EC 2.7.10.1) (K-sam) (KGFR)FGFR2 BEK KGFR KSAM821
(Keratinocyte growth factor receptor) (CD antigen CD332)
A6NKC4FCGRC_HUMANPutative high affinity immunoglobulin gamma Fc receptor IC (IgG Fc receptor IC) (Fc-FCGR1C IGFRC280
gamma RIC) (FcRIC) (hFcgammaRIC)
Q9H6D8FNDC4_HUMANFibronectin type III domain-containing protein 4 (Fibronectin type III repeat-containing protein 1)FNDC4 FRCP1234
UNQ6389/PRO21134
Q9P2B2FPRP_HUMANProstaglandin F2 receptor negative regulator (CD9 partner 1) (CD9P-1) (Glu-Trp-Ile EWIPTGFRN CD9P1879
motif-containing protein F) (EWI-F) (Prostaglandin F2-alpha receptor regulatory protein)EWIF FPRP
(Prostaglandin F2-alpha receptor-associated protein) (CD antigen CD315)KIAA1436
Q5SZK8FREM2_HUMANFRAS1-related extracellular matrix protein 2 (ECM3 homolog)FREM23169
P22455FGFR4_HUMANFibroblast growth factor receptor 4 (FGFR-4) (EC 2.7.10.1) (CD antigen CD334)FGFR4 JTK2 TKF802
O95866G6B_HUMANProtein G6bG6B C6orf25241
P49771FLT3L_HUMANFms-related tyrosine kinase 3 ligand (Flt3 ligand) (Flt3L) (SL cytokine)FLT3LG235
P59646FXYD4_HUMANFXYD domain-containing ion transport regulator 4FXYD489
UNQ526/PRO1069
P36888FLT3_HUMANReceptor-type tyrosine-protein kinase FLT3 (EC 2.7.10.1) (FL cytokine receptor) (FetalFLT3 CD135 FLK2 STK1993
liver kinase-2) (FLK-2) (Fms-like tyrosine kinase 3) (FLT-3) (Stem cell tyrosine kinase 1)
(STK-1) (CD antigen CD135)
Q8NAU1FNDC5_HUMANFibronectin type III domain-containing protein 5 (Fibronectin type III repeat-containingFNDC5 FRCP2212
protein 2) [Cleaved into: Irisin]
Q86XX4FRAS1_HUMANExtracellular matrix protein FRAS1FRAS1 KIAA15004008
P09958FURIN_HUMANFurin (EC 3.4.21.75) (Dibasic-processing enzyme) (Paired basic amino acid residue-FURIN FUR PACE PCSK3794
cleaving enzyme) (PACE)
Q14802FXYD3_HUMANFXYD domain-containing ion transport regulator 3 (Chloride conductance inducer proteinFXYD3 MAT8 PLML87
Mat-8) (Mammary tumor 8 kDa protein) (Phospholemman-like)
Q9H0Q3FXYD6_HUMANFXYD domain-containing ion transport regulator 6 (Phosphohippolin)FXYD6 UNQ521/PRO105695
Q96DB9FXYD5_HUMANFXYD domain-containing ion transport regulator 5 (Dysadherin)FXYD5 DYSAD178
IWU1 HSPC113
UNQ2561/PRO6241
P58550FXYD8_HUMANPutative FXYD domain-containing ion transport regulator 8FXYD6P3 FXYD894
I3L273GFY_HUMANGolgi-associated olfactory signaling regulator (Protein Goofy)GFY518
P06028GLPB_HUMANGlycophorin-B (PAS-3) (SS-active sialoglycoprotein) (Sialoglycoprotein delta) (CD antigen CD235b)GYPB GPB91
P10912GHR_HUMANGrowth hormone receptor (GH receptor) (Somatotropin receptor) [Cleaved into: GrowthGHR638
hormone-binding protein (GH-binding protein) (GHBP) (Serum-binding protein)]
P15421GLPE_HUMANGlycophorin-EGYPE GPE78
P13224GP1BB_HUMANPlatelet glycoprotein Ib beta chain (GP-Ib beta) (GPIb-beta) (GPIbB) (Antigen CD42b-GP1BB206
beta) (CD antigen CD42c)
Q9NU53GINM1_HUMANGlycoprotein integral membrane protein 1GINM1 C6orf72330
UNQ710/PRO1361
P02724GLPA_HUMANGlycophorin-A (MN sialoglycoprotein) (PAS-2) (Sialoglycoprotein alpha) (CD antigen CD235a)GYPA GPA150
Q3T906GNPTA_HUMANN-acetylglucosamine-1-phosphotransferase subunits alpha/beta (EC 2.7.8.17) (GlcNAc-GNPTAB GNPTA1256
1-phosphotransferase subunits alpha/beta) (Stealth protein GNPTAB) (UDP-N-KIAA1208
acetylglucosamine-1-phosphotransferase subunits alpha/beta) [Cleaved into: N-
acetylglucosamine-1-phosphotransferase subunit alpha; N-acetylglucosamine-1-
phosphotransferase subunit beta]
Q8WWB7GLMP_HUMANGlycosylated lysosomal membrane protein (Lysosomal protein NCU-G1)GLMP C1orf85406
PSEC0030
UNQ2553/PRO6182
P07359GP1BA_HUMANPlatelet glycoprotein Ib alpha chain (GP-Ib alpha) (GPIb-alpha) (GPIbA) (GlycoproteinGP1BA652
Ibalpha) (Antigen CD42b-alpha) (CD antigen CD42b) [Cleaved into: Glycocalicin]
P40197GPV_HUMANPlatelet glycoprotein V (GPV) (Glycoprotein 5) (CD antigen CD42d)GP5560
Q99795GPA33_HUMANCell surface A33 antigen (Glycoprotein A33)GPA33319
P14770GPIX_HUMANPlatelet glycoprotein IX (GP-IX) (GPIX) (Glycoprotein 9) (CD antigen CD42a)GP9177
Q86XS8GOLI_HUMANE3 ubiquitin-protein ligase RNF130 (EC 6.3.2.-) (Goliath homolog) (H-Goliath) (RINGRNF130419
finger protein 130)
P25092GUC2C_HUMANHeat-stable enterotoxin receptor (STA receptor) (hSTAR) (EC 4.6.1.2) (Guanylyl cyclaseGUCY2C GUC2C STAR1073
C) (GC-C) (Intestinal guanylate cyclase)
Q14789GOGB1_HUMANGolgin subfamily B member 1 (372 kDa Golgi complex-associated protein) (GCP372) (Giantin)GOLGB13259
(Macrogolgin)
Q14956GPNMB_HUMANTransmembrane glycoprotein NMB (Transmembrane glycoprotein HGFIN)GPNMB HGFIN NMB572
UNQ1725/PRO9925
P51841GUC2F_HUMANRetinal guanylyl cyclase 2 (RETGC-2) (EC 4.6.1.2) (Guanylate cyclase 2F, retinal)GUCY2F GUC2F1108
(Guanylate cyclase F) (GC-F) (Rod outer segment membrane guanylate cyclase 2) (ROS-GC2)RETGC2
Q92643GPI8_HUMANGPI-anchor transamidase (GPI transamidase) (EC 3.-.-.-) (GPI8 homolog) (hGPI8)PIGK GPI8395
(Phosphatidylinositol-glycan biosynthesis class K protein) (PIG-K)
Q02846GUC2D_HUMANRetinal guanylyl cyclase 1 (RETGC-1) (EC 4.6.1.2) (Guanylate cyclase 2D, retinal) (RodGUCY2D CORD61103
outer segment membrane guanylate cyclase) (ROS-GC)GUC1A4 GUC2D
RETGC RETGC1
Q9UBK5HCST_HUMANHematopoietic cell signal transducer (DNAX-activation protein 10) (Membrane proteinHCST DAP1093
DAP10) (Transmembrane adapter protein KAP10)KAP10 PIK3AP
UNQ587/PRO1157
Q14CZ8HECAM_HUMANHepatocyte cell adhesion molecule (Protein hepaCAM)HEPACAM416
A8MVW5HECA2_HUMANHEPACAM family member 2 (Mitotic kinetics regulator)HEPACAM2 MIKI462
UNQ305/PRO346
Q9ULI3HEG1_HUMANProtein HEG homolog 1HEG1 KIAA12371381
Q92896GSLG1_HUMANGolgi apparatus protein 1 (CFR-1) (Cysteine-rich fibroblast growth factor receptor) (E-GLG1 CFR1 ESL11179
selectin ligand 1) (ESL-1) (Golgi sialoglycoprotein MG-160)MG160
Q99075HBEGF_HUMANProheparin-binding EGF-like growth factor [Cleaved into: Heparin-binding EGF-likeHBEGF DTR DTS HEGFL208
growth factor (HB-EGF) (HBEGF) (Diphtheria toxin receptor) (DT-R)]
Q96D42HAVR1_HUMANHepatitis A virus cellular receptor 1 (HAVcr-1) (Kidney injury molecule 1) (KIM-1) (T-cellHAVCR1 KIM1359
immunoglobulin and mucin domain-containing protein 1) (TIMD-1) (T-cell immunoglobulinTIM1 TIMD1
mucin receptor 1) (TIM) (TIM-1) (T-cell membrane protein 1)
Q8TDQ0HAVR2_HUMANHepatitis A virus cellular receptor 2 (HAVcr-2) (T-cell immunoglobulin and mucin domain-HAVCR2 TIM3 TIMD3301
containing protein 3) (TIMD-3) (T-cell immunoglobulin mucin receptor 3) (TIM-3) (T-cell
membrane protein 3)
Q30201HFE_HUMANHereditary hemochromatosis protein (HLA-H)HFE HLAH348
P30511HLAF_HUMANHLA class I histocompatibility antigen, alpha chain F (CDA12) (HLA F antigen)HLA-F HLA-5.4 HLAF346
(Leukocyte antigen F) (MHC class I antigen F)
A8MVS5HIDE1_HUMANProtein HIDE1HIDE1 C19orf38230
P13747HLAE_HUMANHLA class I histocompatibility antigen, alpha chain E (MHC class I antigen E)HLA-E HLA-6.2 HLAE358
Q9BQS7HEPH_HUMANHephaestin (EC 1.-.-.-)HEPH KIAA06981158
UNQ2562/PRO6242
Q95460HMR1_HUMANMajor histocompatibility complex class I-related gene protein (MHC class I-related geneMR1341
protein) (Class I histocompatibility antigen-like protein)
Q6MZM0HPHL1_HUMANHephaestin-like protein 1 (EC 1.-.-.-)HEPHL11159
Q9UM44HHLA2_HUMANHERV-H LTR-associating protein 2 (Human endogenous retrovirus-H long terminalHHLA2414
repeat-associating protein 2)
P17693HLAG_HUMANHLA class I histocompatibility antigen, alpha chain G (HLA G antigen) (MHC class I antigen G)HLA-G HLA-6.0 HLAG338
Q08334I10R2_HUMANInterleukin-10 receptor subunit beta (IL-10 receptor subunit beta) (IL-10R subunit beta)IL10RB CRFB4325
(IL-10RB) (Cytokine receptor class-II member 4) (Cytokine receptor family 2 member 4)D21S58 D21S66
(CRF2-4) (Interleukin-10 receptor subunit 2) (IL-10R subunit 2) (IL-10R2) (CD antigen CDw210b)
Q96F46I17RA_HUMANInterleukin-17 receptor A (IL-17 receptor A) (IL-17RA) (CDw217) (CD antigen CD217)IL17RA IL17R866
Q99665I12R2_HUMANInterleukin-12 receptor subunit beta-2 (IL-12 receptor subunit beta-2) (IL-12R subunitIL12RB2862
beta-2) (IL-12R-beta-2) (IL-12RB2)
Q14627I13R2_HUMANInterleukin-13 receptor subunit alpha-2 (IL-13 receptor subunit alpha-2) (IL-13R subunitIL13RA2 IL13R380
alpha-2) (IL-13R-alpha-2) (IL-13RA2) (Interleukin-13-binding protein) (CD antigen CD213a2)
Q9NRM6I17RB_HUMANInterleukin-17 receptor B (IL-17 receptor B) (IL-17RB) (Cytokine receptor-like 4) (IL-17IL17RB CRL4502
receptor homolog 1) (IL-17RM) (IL17Rh1) (Interleukin-17B receptor) (IL-17B receptor)EVI27 IL17BR
UNQ2501/PRO19612
Q8NFM7I17RD_HUMANInterleukin-17 receptor D (IL-17 receptor D) (IL-17RD) (IL17Rhom) (Interleukin-17IL17RD IL17RLM SEF739
receptor-like protein) (Set homolog) (hSef)UNQ6115/PRO20026
Q8N6P7I22R1_HUMANInterleukin-22 receptor subunit alpha-1 (IL-22 receptor subunit alpha-1) (IL-22R-alpha-1)IL22RA1 IL22R574
(IL-22RA1) (Cytokine receptor class-II member 9) (Cytokine receptor family 2 member 9)
(CRF2-9) (ZcytoR11)
Q9UMF0ICAM5_HUMANIntercellular adhesion molecule 5 (ICAM-5) (Telencephalin)ICAM5 TLCN TLN924
P42701I12R1_HUMANInterleukin-12 receptor subunit beta-1 (IL-12 receptor subunit beta-1) (IL-12R subunitIL12RB1 IL12R662
beta-1) (IL-12R-beta-1) (IL-12RB1) (IL-12 receptor beta component) (CD antigen CD212)IL12RB
P78552I13R1_HUMANInterleukin-13 receptor subunit alpha-1 (IL-13 receptor subunit alpha-1) (IL-13R subunitIL13RA1 IL13R427
alpha-1) (IL-13R-alpha-1) (IL-13RA1) (Cancer/testis antigen 19) (CT19) (CD antigen CD213a1)IL13RA
Q8NFR9I17RE_HUMANInterleukin-17 receptor E (IL-17 receptor E) (IL-17RE)IL17RE667
UNQ3056/PRO9877
O95256I18RA_HUMANInterleukin-18 receptor accessory protein (IL-18 receptor accessory protein) (IL-18RAcP)IL18RAP IL1R7599
(Accessory protein-like) (AcPL) (CD218 antigen-like family member B) (CDw218b) (IL-1R
accessory protein-like) (IL-1RAcPL) (Interleukin-1 receptor 7) (IL-1R-7) (IL-1R7)
(Interleukin-18 receptor accessory protein-like) (Interleukin-18 receptor beta) (IL-18R-
beta) (IL-18Rbeta) (CD antigen CD218b)
Q6UXL0I20RB_HUMANInterleukin-20 receptor subunit beta (IL-20 receptor subunit beta) (IL-20R-beta) (IL-20RB)IL20RB DIRS1311
(Fibronectin type III domain containing 6) (FNDC6) (IL-20R2)UNQ557/PRO1114
P32942ICAM3_HUMANIntercellular adhesion molecule 3 (ICAM-3) (CDw50) (ICAM-R) (CD antigen CD50)ICAM3547
Q13261I15RA_HUMANInterleukin-15 receptor subunit alpha (IL-15 receptor subunit alpha) (IL-15R-alpha) (IL-IL15RA267
15RA) (CD antigen CD215) [Cleaved into: Soluble interleukin-15 receptor subunit alpha
(sIL-15 receptor subunit alpha) (sIL-15R-alpha) (sIL-15RA)]
Q9H2X8I27L2_HUMANInterferon alpha-inducible protein 27-like protein 2 (Interferon-stimulated gene 12bIFI27L2 FAM14A130
protein) (ISG12(b)) (Protein TLH29) (pIFI27-like protein)TLH29
Q9Y6W8ICOS_HUMANInducible T-cell costimulator (Activation-inducible lymphocyte immunomediatoryICOS AILIM199
molecule) (CD antigen CD278)
P13598ICAM2_HUMANIntercellular adhesion molecule 2 (ICAM-2) (CD antigen CD102)ICAM2275
P98153IDD_HUMANIntegral membrane protein DGCR2/IDDDGCR2 IDD550
KIAA0163
O75054IGSF3_HUMANImmunoglobulin superfamily member 3 (IgSF3) (Glu-Trp-Ile EWI motif-containing protein 3) (EWI-3)IGSF3 EWI31194
KIAA0466
P01589IL2RA_HUMANInterleukin-2 receptor subunit alpha (IL-2 receptor subunit alpha) (IL-2-RA) (IL-2R subunitIL2RA272
alpha) (IL2-RA) (TAC antigen) (p55) (CD antigen CD25)
P26951IL3RA_HUMANInterleukin-3 receptor subunit alpha (IL-3 receptor subunit alpha) (IL-3R subunit alpha)IL3RA IL3R378
(IL-3R-alpha) (IL-3RA) (CD antigen CD123)
P24394IL4RA_HUMANInterleukin-4 receptor subunit alpha (IL-4 receptor subunit alpha) (IL-4R subunit alpha)IL4R IL4RA 582J2.1825
(IL-4R-alpha) (IL-4RA) (CD antigen CD124) [Cleaved into: Soluble interleukin-4 receptor
subunit alpha (Soluble IL-4 receptor subunit alpha) (Soluble IL-4R-alpha)
(sIL4Ralpha/prot) (IL-4-binding protein) (IL4-BP)]
Q8NAC3I17RC_HUMANInterleukin-17 receptor C (IL-17 receptor C) (IL-17RC) (Interleukin-17 receptor homolog)IL17RC UNQ6118/PRO20040/791
(IL17Rhom) (Interleukin-17 receptor-like protein) (IL-17RL) (ZcytoR14)PRO38901
Q9UHF4I20RA_HUMANInterleukin-20 receptor subunit alpha (IL-20 receptor subunit alpha) (IL-20R-alpha) (IL-IL20RA553
20RA) (Cytokine receptor class-II member 8) (Cytokine receptor family 2 member 8)UNQ681/PRO1315
(CRF2-8) (IL-20R1) (ZcytoR7)
Q6UWB1I27RA_HUMANInterleukin-27 receptor subunit alpha (IL-27 receptor subunit alpha) (IL-27R subunitIL27RA CRL1636
alpha) (IL-27R-alpha) (IL-27RA) (Cytokine receptor WSX-1) (Cytokine receptor-like 1)TCCR WSX1
(Type I T-cell cytokine receptor) (TCCR) (ZcytoR1)UNQ296/PRO336
Q9H665IGFR1_HUMANIGF-like family receptor 1 (Transmembrane protein 149) (U2 small nuclear RNA auxiliaryIGFLR1 TMEM149355
factor 1-like 4)U2AF1L4
P01880IGHD_HUMANIg delta chain C regionIGHD384
Q5DX21IGS11_HUMANImmunoglobulin superfamily member 11 (IgSF11) (Brain and testis-specificIGSF11 BTIGSF431
immunoglobulin superfamily protein) (Bt-IGSF) (V-set and immunoglobulin domain-containing protein 3)CXADRL1 VSIG3
Q93033IGSF2_HUMANImmunoglobulin superfamily member 2 (IgSF2) (Cell surface glycoprotein V7) (Glu-Trp-IleCD101 EWI1011021
EWI motif-containing protein 101) (EWI-101) (CD antigen CD101)IGSF2 V7
Q9HBE5IL21R_HUMANInterleukin-21 receptor (IL-21 receptor) (IL-21R) (Novel interleukin receptor) (CD antigen CD360)IL21R NILR538
UNQ3121/PRO10273
Q71H61ILDR2_HUMANImmunoglobulin-like domain-containing receptor 2ILDR2 C1orf32639
O75144ICOSL_HUMANICOS ligand (B7 homolog 2) (B7-H2) (B7-like protein GI50) (B7-related protein 1) (B7RP-ICOSLG B7H2302
1) (CD antigen CD275)B7RP1 ICOSL
KIAA0653
Q8TDY8IGDC4_HUMANImmunoglobulin superfamily DCC subclass member 4 (Neighbor of punc e11) (Protein DDM36) (hDDM36)IGDCC4 DDM361250
KIAA1628 NOPE
P01871IGHM_HUMANIg mu chain C regionIGHM452
O95976IGSF6_HUMANImmunoglobulin superfamily member 6 (IgSF6) (Protein DORA)IGSF6 DORA241
Q9NPH3IL1AP_HUMANInterleukin-1 receptor accessory protein (IL-1 receptor accessory protein) (IL-1RAcP)IL1RAP C3orf13570
(Interleukin-1 receptor 3) (IL-1R-3) (IL-1R3)IL1R3
P31785IL2RG_HUMANCytokine receptor common subunit gamma (Interleukin-2 receptor subunit gamma) (IL-2IL2RG369
receptor subunit gamma) (IL-2R subunit gamma) (IL-2RG) (gammaC) (p64) (CD antigen CD132)
P32927IL3RB_HUMANCytokine receptor common subunit beta (CDw131) (GM-CSF/IL-3/IL-5 receptor commonCSF2RB IL3RB897
beta subunit) (CD antigen CD131)IL5RB
Q01113IL9R_HUMANInterleukin-9 receptor (IL-9 receptor) (IL-9R) (CD antigen CD129)IL9R521
Q9HB29ILRL2_HUMANInterleukin-1 receptor-like 2 (IL-36 receptor) (IL-36R) (Interleukin-1 receptor-relatedIL1RL2 IL1RRP2575
protein 2) (IL-1Rrp2) (IL1R-rp2)
P15260INGR1_HUMANInterferon gamma receptor 1 (IFN-gamma receptor 1) (IFN-gamma-R1) (CDw119) (CD antigen CD119)IFNGR1489
Q13651I10R1_HUMANInterleukin-10 receptor subunit alpha (IL-10 receptor subunit alpha) (IL-10R subunitIL10RA IL10R578
alpha) (IL-10RA) (CDw210a) (Interleukin-10 receptor subunit 1) (IL-10R subunit 1) (IL-
10R1) (CD antigen CD210)
Q14626I11RA_HUMANInterleukin-11 receptor subunit alpha (IL-11 receptor subunit alpha) (IL-11R subunitIL11RA422
alpha) (IL-11R-alpha) (IL-11RA)
P05362ICAM1_HUMANIntercellular adhesion molecule 1 (ICAM-1) (Major group rhinovirus receptor) (CD antigen CD54)ICAM1532
Q14773ICAM4_HUMANIntercellular adhesion molecule 4 (ICAM-4) (Landsteiner-Wiener blood groupICAM4 LW271
glycoprotein) (LW blood group protein) (CD antigen CD242)
Q9NSI5IGSF5_HUMANImmunoglobulin superfamily member 5 (IgSF5) (Junctional adhesion molecule 4) (JAM-4)IGSF5 JAM4407
P14778IL1R1_HUMANInterleukin-1 receptor type 1 (IL-1R-1) (IL-1RT-1) (IL-1RT1) (CD121 antigen-like familyIL1R1 IL1R IL1RA569
member A) (Interleukin-1 receptor alpha) (IL-1R-alpha) (Interleukin-1 receptor type I)IL1RT1
(p80) (CD antigen CD121a) [Cleaved into: Interleukin-1 receptor type 1, membrane form
(mIL-1R1) (mIL-1RI); Interleukin-1 receptor type 1, soluble form (sIL-1R1) (sIL-1RI)]
Q8NI17IL31R_HUMANInterleukin-31 receptor subunit alpha (IL-31 receptor subunit alpha) (IL-31R subunitIL31RA CRL3 GPL732
alpha) (IL-31R-alpha) (IL-31RA) (Cytokine receptor-like 3) (GLM-R) (hGLM-R) (Gp130-UNQ6368/PRO21073/
like monocyte receptor) (Gp130-like receptor) (ZcytoR17)PRO21384
Q01344IL5RA_HUMANInterleukin-5 receptor subunit alpha (IL-5 receptor subunit alpha) (IL-5R subunit alpha)IL5RA IL5R420
(IL-5R-alpha) (IL-5RA) (CDw125) (CD antigen CD125)
P16871IL7RA_HUMANInterleukin-7 receptor subunit alpha (IL-7 receptor subunit alpha) (IL-7R subunit alpha)IL7R459
(IL-7R-alpha) (IL-7RA) (CDw127) (CD antigen CD127)
P08887IL6RA_HUMANInterleukin-6 receptor subunit alpha (IL-6 receptor subunit alpha) (IL-6R subunit alpha)IL6R468
(IL-6R-alpha) (IL-6RA) (IL-6R 1) (Membrane glycoprotein 80) (gp80) (CD antigen CD126)
Q01638ILRL1_HUMANInterleukin-1 receptor-like 1 (Protein ST2)IL1RL1 DER4 ST2 T1556
P06213INSR_HUMANInsulin receptor (IR) (EC 2.7.10.1) (CD antigen CD220) [Cleaved into: Insulin receptorINSR1382
subunit alpha; Insulin receptor subunit beta]
P08069IGF1R_HUMANInsulin-like growth factor 1 receptor (EC 2.7.10.1) (Insulin-like growth factor I receptor)IGF1R1367
(IGF-I receptor) (CD antigen CD221) [Cleaved into: Insulin-like growth factor 1 receptor
alpha chain; Insulin-like growth factor 1 receptor beta chain]
P14784IL2RB_HUMANInterleukin-2 receptor subunit beta (IL-2 receptor subunit beta) (IL-2R subunit beta) (IL-IL2RB551
2RB) (High affinity IL-2 receptor subunit beta) (p70-75) (p75) (CD antigen CD122)
Q86SU0ILDR1_HUMANImmunoglobulin-like domain-containing receptor 1ILDR1546
P14616INSRR_HUMANInsulin receptor-related protein (IRR) (EC 2.7.10.1) (IR-related receptor) [Cleaved into:INSRR IRR1297
Insulin receptor-related protein alpha chain; Insulin receptor-related protein beta chain]
Q13478IL18R_HUMANInterleukin-18 receptor 1 (IL-18R-1) (IL-18R1) (CD218 antigen-like family member A)IL18R1 IL1RRP541
(CDw218a) (IL1 receptor-related protein) (IL-1Rrp) (IL1R-rp) (CD antigen CD218a)
Q5VWK5IL23R_HUMANInterleukin-23 receptor (IL-23 receptor) (IL-23R)IL23R629
Q9BZV3IMPG2_HUMANInterphotoreceptor matrix proteoglycan 2 (Interphotoreceptor matrix proteoglycan of 200IMPG2 IPM2001241
kDa) (IPM 200) (Sialoprotein associated with cones and rods proteoglycan) (Spacrcan)
Q8IU57INLR1_HUMANInterferon lambda receptor 1 (IFN-lambda receptor 1) (IFN-lambda-R1) (CytokineIFNLR1 IL28RA520
receptor class-II member 12) (Cytokine receptor family 2 member 12) (CRF2-12)LICR2
(Interleukin-28 receptor subunit alpha) (IL-28 receptor subunit alpha) (IL-28R-alpha) (IL-
28RA) (Likely interleukin or cytokine receptor 2) (LICR2)
Q6GPH6IPIL1_HUMANInositol 1,4,5-trisphosphate receptor-interacting protein-like 1ITPRIPL1 KIAA1754L555
Q9NP60IRPL2_HUMANX-linked interleukin-1 receptor accessory protein-like 2 (IL-1 receptor accessory protein-IL1RAPL2 IL1R9686
like 2) (IL-1-RAPL-2) (IL-1RAPL-2) (IL1RAPL-2) (IL1RAPL-2-related protein) (Interleukin-
1 receptor 9) (IL-1R-9) (IL-1R9) (Three immunoglobulin domain-containing IL-1 receptor-
related 1) (TIGIRR-1)
Q8IVU1IGDC3_HUMANImmunoglobulin superfamily DCC subclass member 3 (Putative neuronal cell adhesion molecule)IGDCC3 PUNC814
P17181INAR1_HUMANInterferon alpha/beta receptor 1 (IFN-R-1) (IFN-alpha/beta receptor 1) (Cytokine receptorIFNAR1 IFNAR557
class-II member 1) (Cytokine receptor family 2 member 1) (CRF2-1) (Type I interferon receptor 1)
Q13683ITA7_HUMANIntegrin alpha-7 [Cleaved into: Integrin alpha-7 heavy chain; Integrin alpha-7 light chain;ITGA71181
Integrin alpha-7 70 kDa form]UNQ406/PRO768
P53708ITA8_HUMANIntegrin alpha-8 [Cleaved into: Integrin alpha-8 heavy chain; Integrin alpha-8 light chain]ITGA81063
Q13349ITAD_HUMANIntegrin alpha-D (ADB2) (CD11 antigen-like family member D) (Leukointegrin alpha D)ITGAD1161
(CD antigen CD11d)
P06756ITAV_HUMANIntegrin alpha-V (Vitronectin receptor subunit alpha) (CD antigen CD51) [Cleaved into:ITGAV MSK8 VNRA1048
Integrin alpha-V heavy chain; Integrin alpha-V light chain]
Q6UXV1IZUM2_HUMANIzumo sperm-egg fusion protein 2IZUMO2 C19orf41 SCRL221
UNQ6978/PRO21961
P27930IL1R2_HUMANInterleukin-1 receptor type 2 (IL-1R-2) (IL-1RT-2) (IL-1RT2) (CD121 antigen-like familyIL1R2 IL1RB398
member B) (CDw121b) (IL-1 type II receptor) (Interleukin-1 receptor beta) (IL-1R-beta)
(Interleukin-1 receptor type II) (CD antigen CD121b) [Cleaved into: Interleukin-1 receptor
type 2, membrane form (mIL-1R2) (mIL-1RII); Interleukin-1 receptor type 2, soluble form
(sIL-1R2) (sIL-1RII)]
P40189IL6RB_HUMANInterleukin-6 receptor subunit beta (IL-6 receptor subunit beta) (IL-6R subunit beta) (IL-IL6ST918
6R-beta) (IL-6RB) (CDw130) (Interleukin-6 signal transducer) (Membrane glycoprotein
130) (gp130) (Oncostatin-M receptor subunit alpha) (CD antigen CD130)
P17301ITA2_HUMANIntegrin alpha-2 (CD49 antigen-like family member B) (Collagen receptor) (PlateletITGA2 CD49B1181
membrane glycoprotein Ia) (GPIa) (VLA-2 subunit alpha) (CD antigen CD49b)
P26006ITA3_HUMANIntegrin alpha-3 (CD49 antigen-like family member C) (FRP-2) (Galactoprotein B3)ITGA3 MSK181051
(GAPB3) (VLA-3 subunit alpha) (CD antigen CD49c) [Cleaved into: Integrin alpha-3
heavy chain; Integrin alpha-3 light chain]
P11215ITAM_HUMANIntegrin alpha-M (CD11 antigen-like family member B) (CR-3 alpha chain) (Cell surfaceITGAM CD11B CR3A1152
glycoprotein MAC-1 subunit alpha) (Leukocyte adhesion receptor M01) (Neutrophil
adherence receptor) (CD antigen CD11b)
P16144ITB4_HUMANIntegrin beta-4 (GP150) (CD antigen CD104)ITGB41822
O75578ITA10_HUMANIntegrin alpha-10ITGA101167
UNQ468/PRO827
P56199ITA1_HUMANIntegrin alpha-1 (CD49 antigen-like family member A) (Laminin and collagen receptor)ITGA11179
(VLA-1) (CD antigen CD49a)
P08514ITA2B_HUMANIntegrin alpha-IIb (GPalpha IIb) (GPIIb) (Platelet membrane glycoprotein IIb) (CD antigenITGA2B GP2B1039
CD41) [Cleaved into: Integrin alpha-IIb heavy chain; Integrin alpha-IIb light chain, form 1;ITGAB
Integrin alpha-IIb light chain, form 2]
P08648ITA5_HUMANIntegrin alpha-5 (CD49 antigen-like family member E) (Fibronectin receptor subunit alpha)ITGA5 FNRA1049
(Integrin alpha-F) (VLA-5) (CD antigen CD49e) [Cleaved into: Integrin alpha-5 heavy
chain; Integrin alpha-5 light chain]
P38570ITAE_HUMANIntegrin alpha-E (HML-1 antigen) (Integrin alpha-IEL) (Mucosal lymphocyte 1 antigen)ITGAE1179
(CD antigen CD103) [Cleaved into: Integrin alpha-E light chain: Integrin alpha-E heavy
chain]
P20702ITAX_HUMANIntegrin alpha-X (CD11 antigen-like family member C) (Leu M5) (Leukocyte adhesionITGAX CD11C1163
glycoprotein p150, 95 alpha chain) (Leukocyte adhesion receptor p150, 95) (CD antigen CD11c)
P05106ITB3_HUMANIntegrin beta-3 (Platelet membrane glycoprotein IIIa) (GPIIIa) (CD antigen CD61)ITGB3 GP3A788
Q5VZ72IZUM3_HUMANIzumo sperm-egg fusion protein 3IZUMO3 C9orf134239
P78504JAG1_HUMANProtein jagged-1 (Jagged1) (hJ1) (CD antigen CD339)JAG1 JAGL11218
A8MWY0K132L_HUMANUPF0577 protein KIAA1324-like (Estrogen-induced gene 121-like protein) (hEIG121L)KIAA1324L1029
EIG121L
P48551INAR2_HUMANInterferon alpha/beta receptor 2 (IFN-R-2) (IFN-alpha binding protein) (IFN-alpha/betaIFNAR2 IFNABR515
receptor 2) (Interferon alpha binding protein) (Type I interferon receptor 2)IFNARB
P38484INGR2_HUMANInterferon gamma receptor 2 (IFN-gamma receptor 2) (IFN-gamma-R2) (InterferonIFNGR2 IFNGT1337
gamma receptor accessory factor 1) (AF-1) (Interferon gamma transducer 1)
Q3MIP1IPIL2_HUMANInositol 1,4,5-trisphosphate receptor-interacting protein-like 2ITPRIPL2535
Q6UXG2K1324_HUMANUPF0577 protein KIAA1324 (Estrogen-induced gene 121 protein)KIAA1324 EIG1211013
UNQ2426/PRO4985
Q3SXP7K1644_HUMANUncharacterized protein KIAA1644KIAA1644199
Q9NZN1IRPL1_HUMANInterleukin-1 receptor accessory protein-like 1 (IL-1-RAPL-1) (IL-1RAPL-1) (IL1RAPL-1)IL1RAPL1 OPHN4696
(Oligophrenin-4) (Three immunoglobulin domain-containing IL-1 receptor-related 2)
(TIGIRR-2) (X-linked interleukin-1 receptor accessory protein-like 1)
Q9UKX5ITA11_HUMANIntegrin alpha-11ITGA11 MSTP0181188
P05556ITB1_HUMANIntegrin beta-1 (Fibronectin receptor subunit beta) (Glycoprotein IIa) (GPIIA) (VLA-4ITGB1 FNRB MDF2798
subunit beta) (CD antigen CD29)MSK12
P05107ITB2_HUMANIntegrin beta-2 (Cell surface adhesion glycoproteins LFA-1/CR3/p150, 95 subunit beta)ITGB2 CD18 MFI7769
(Complement receptor C3 subunit beta) (CD antigen CD18)
P18564ITB6_HUMANIntegrin beta-6ITGB6788
P26010ITB7_HUMANIntegrin beta-7 (Gut homing receptor beta subunit)ITGB7798
P26012ITB8_HUMANIntegrin beta-8ITGB8769
Q9Y624JAM1_HUMANJunctional adhesion molecule A (JAM-A) (Junctional adhesion molecule 1) (JAM-1)F11R JAM1 JCAM299
(Platelet F11 receptor) (Platelet adhesion molecule 1) (PAM-1) (CD antigen CD321)UNQ264/PRO301
Q9BX67JAM3_HUMANJunctional adhesion molecule C (JAM-C) (JAM-2) (Junctional adhesion molecule 3)JAM3310
(JAM-3)UNQ859/PRO1868
Q8IYV9IZUM1_HUMANIzumo sperm-egg fusion protein 1 (Oocyte binding/fusion factor) (OBF) (Sperm-specificIZUMO1350
protein izumo)
Q9UJ90KCNE5_HUMANPotassium voltage-gated channel subfamily E regulatory beta subunit 5 (AMMEKCNE5 AMMECR2142
syndrome candidate gene 2 protein) (Potassium channel subunit beta MiRP4) (PotassiumKCNE1L
voltage-gated channel subfamily E member 1-like protein)
P13612ITA4_HUMANIntegrin alpha-4 (CD49 antigen-like family member D) (Integrin alpha-IV) (VLA-4 subunitITGA4 CD49D1032
alpha) (CD antigen CD49d)
P23229ITA6_HUMANIntegrin alpha-6 (CD49 antigen-like family member F) (VLA-6) (CD antigen CD49f)ITGA61130
[Cleaved into: Integrin alpha-6 heavy chain; Integrin alpha-6 light chain; Processed
integrin alpha-6 (Alpha6p)]
Q13797ITA9_HUMANIntegrin alpha-9 (Integrin alpha-RLC)ITGA91035
P20701ITAL_HUMANIntegrin alpha-L (CD11 antigen-like family member A) (Leukocyte adhesion glycoproteinITGAL CD11A1170
LFA-1 alpha chain) (LFA-1A) (Leukocyte function-associated molecule 1 alpha chain)
(CD antigen CD11a)
P18084ITB5_HUMANIntegrin beta-5ITGB5799
Q9Y219JAG2_HUMANProtein jagged-2 (Jagged2) (hJ2)JAG21238
Q5VV43K0319_HUMANDyslexia-associated protein KIAA0319KIAA03191072
Q8IYS2K2013_HUMANUncharacterized protein KIAA2013KIAA2013634
P57087JAM2_HUMANJunctional adhesion molecule B (JAM-B) (Junctional adhesion molecule 2) (JAM-2)JAM2 C21orf43 VEJAM298
(Vascular endothelial junction-associated molecule) (VE-JAM) (CD antigen CD322)UNQ219/PRO245
Q86YT9JAML_HUMANJunctional adhesion molecule-like (Adhesion molecule interacting with CXADR antigen 1)JAML AMICA1394
(Dendritic cell-specific protein CREA7-1)UNQ722/PRO1387
A0A087WTH5KCE1B_HUMANPotassium voltage-gated channel subfamily E member 1BKCNE1B132
Q8NC54KCT2_HUMANKeratinocyte-associated transmembrane protein 2KCT2 C5orf15265
HTGN29
Q6UWL6KIRR2_HUMANKin of IRRE-like protein 2 (Kin of irregular chiasm-like protein 2) (Nephrin-like protein 3)KIRREL2 NEPH3708
UNQ5827/PRO19646
O76095JTB_HUMANProtein JTB (Jumping translocation breakpoint protein) (Prostate androgen-regulatedJTB HSPC222146
protein) (PAR protein)
Q9Y6J6KCNE2_HUMANPotassium voltage-gated channel subfamily E member 2 (MinK-related peptide 1)KCNE2123
(Minimum potassium ion channel-related peptide 1) (Potassium channel subunit beta MiRP1)
Q9Y6H6KCNE3_HUMANPotassium voltage-gated channel subfamily E member 3 (MinK-related peptide 2)KCNE3103
(Minimum potassium ion channel-related peptide 2) (Potassium channel subunit beta MiRP2)
Q8NHK3KI2LB_HUMANKiller cell immunoglobulin-like receptor 2DL5B (CD158 antigen-like family member F2)KIR2DL5B CD158F375
(Killer cell immunoglobulin-like receptor 2DLX) (CD antigen CD158f2)CD158F2 KIR2DL5
KIR2DLX
Q14952KI2S3_HUMANKiller cell immunoglobulin-like receptor 2DS3 (MHC class I NK cell receptor) (NaturalKIR2DS3 NKAT7304
killer-associated transcript 7) (NKAT-7)
Q14943KI3S1_HUMANKiller cell immunoglobulin-like receptor 3DS1 (MHC class I NK cell receptor) (NaturalKIR3DS1 NKAT10387
killer-associated transcript 10) (NKAT-10)
Q9NRX6KISHB_HUMANProtein kish-B (Transmembrane protein 167B)TMEM167B74
C1orf119 AD-020
P15382KCNE1_HUMANPotassium voltage-gated channel subfamily E member 1 (Delayed rectifier potassiumKCNE1129
channel subunit IsK) (IKs producing slow voltage-gated potassium channel subunit beta
Mink) (Minimal potassium channel)
P43626KI2L1_HUMANKiller cell immunoglobulin-like receptor 2DL1 (CD158 antigen-like family member A)KIR2DL1 CD158A348
(MHC class I NK cell receptor) (Natural killer-associated transcript 1) (NKAT-1) (p58NKAT1
natural killer cell receptor clones CL-42/47.11) (p58 NK receptor CL-42/47.11) (p58.1
MHC class-I-specific NK receptor) (CD antigen CD158a)
Q99706KI2L4_HUMANKiller cell immunoglobulin-like receptor 2DL4 (CD158 antigen-like family member D)KIR2DL4 CD158D377
(G9P) (Killer cell inhibitory receptor 103AS) (KIR-103AS) (MHC class I NK cell receptorKIR103AS
KIR103AS) (CD antigen CD158d)
P43632KI2S4_HUMANKiller cell immunoglobulin-like receptor 2DS4 (CD158 antigen-like family member I) (MHCKIR2DS4 CD158I304
class I NK cell receptor) (Natural killer-associated transcript 8) (NKAT-8) (P58 naturalKKA3 NKAT8
killer cell receptor clones CL-39/CL-17) (p58 NK receptor CL-39/CL-17) (CD antigen CD158i)
Q8IZU9KIRR3_HUMANKin of IRRE-like protein 3 (Kin of irregular chiasm-like protein 3) (Nephrin-like protein 2)KIRREL3 KIAA1867778
[Cleaved into: Processed kin of IRRE-like protein 3]NEPH2
UNQ5923/PRO4502/
PRO19814
P32004L1CAM_HUMANNeural cell adhesion molecule L1 (N-CAM-L1) (NCAM-L1) (CD antigen CD171)L1CAM CAML1 MIC51257
Q6GTX8LAIR1_HUMANLeukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) (hLAIR1) (CD antigen CD305)LAIR1 CD305287
P43628KI2L3_HUMANKiller cell immunoglobulin-like receptor 2DL3 (CD158 antigen-like family member B2)KIR2DL3 CD158B2341
(KIR-023GB) (Killer inhibitory receptor cl 2-3) (MHC class I NK cell receptor) (NKAT2a)KIRCL23 NKAT2
(NKAT2b) (Natural killer-associated transcript 2) (NKAT-2) (p58 natural killer cell receptor
clone CL-6) (p58 NK receptor CL-6) (p58.2 MHC class-I-specific NK receptor) (CD antigen CD158b2)
Q14954KI2S1_HUMANKiller cell immunoglobulin-like receptor 2DS1 (CD158 antigen-like family member H)KIR2DS1 CD158H304
(MHC class I NK cell receptor Eb6 Actl) (CD antigen CD158h)
Q14953KI2S5_HUMANKiller cell immunoglobulin-like receptor 2DS5 (CD158 antigen-like family member G)KIR2DS5 CD158G304
(MHC class I NK cell receptor) (Natural killer-associated transcript 9) (NKAT-9) (CD antigen CD158g)NKAT9
P43629KI3L1_HUMANKiller cell immunoglobulin-like receptor 3DL1 (CD158 antigen-like family member E)KIR3DL1 CD158E444
(HLA-BW4-specific inhibitory NK cell receptor) (MHC class I NK cell receptor) (NaturalNKAT3 NKB1
killer-associated transcript 3) (NKAT-3) (p70 natural killer cell receptor clones CL-2/CL-
11) (p70 NK receptor CL-2/CL-11) (CD antigen CD158e)
Q8N743KI3L3_HUMANKiller cell immunoglobulin-like receptor 3DL3 (CD158 antigen-like family member Z)KIR3DL3 CD158Z410
(Killer cell inhibitory receptor 1) (CD antigen CD158z)KIR3DL7 KIRC1
Q96J84KIRR1_HUMANKin of IRRE-like protein 1 (Kin of irregular chiasm-like protein 1) (Nephrin-like protein 1)KIRREL KIRREL1757
NEPH1
P10721KIT_HUMANMast/stem cell growth factor receptor Kit (SCFR) (EC 2.7.10.1) (Piebald trait protein)KIT SCFR976
(PBT) (Proto-oncogene c-Kit) (Tyrosine-protein kinase Kit) (p145 c-kit) (v-kit Hardy-
Zuckerman 4 feline sarcoma viral oncogene homolog) (CD antigen CD117)
Q86UK5LBN_HUMANLimbin (Ellis-van Creveld syndrome protein 2) (EVC2)EVC2 LBN1308
P43627KI2L2_HUMANKiller cell immunoglobulin-like receptor 2DL2 (CD158 antigen-like family member B1)KIR2DL2 CD158B1348
(MHC class I NK cell receptor) (Natural killer-associated transcript 6) (NKAT-6) (p58NKAT6
natural killer cell receptor clone CL-43) (p58 NK receptor CL-43) (CD antigen CD158b1)
Q8N109KI2LA_HUMANKiller cell immunoglobulin-like receptor 2DL5A (CD antigen CD158f1)KIR2DL5A CD158F375
CD158F1 KIR2DL5
P43631KI2S2_HUMANKiller cell immunoglobulin-like receptor 2DS2 (CD158 antigen-like family member J)KIR2DS2 CD158J304
(MHC class I NK cell receptor) (NK receptor 183 Actl) (Natural killer-associated transcriptNKAT5
5) (NKAT-5) (p58 natural killer cell receptor clone CL-49) (p58 NK receptor CL-49) (CD antigen CD158j)
P43630KI3L2_HUMANKiller cell immunoglobulin-like receptor 3DL2 (CD158 antigen-like family member K)KIR3DL2 CD158K455
(MHC class I NK cell receptor) (Natural killer-associated transcript 4) (NKAT-4) (p70NKAT4
natural killer cell receptor clone CL-5) (p70 NK receptor CL-5) (CD antigen CD158k)
Q8TBQ9KISHA_HUMANProtein kish-A (Transmembrane protein 167) (Transmembrane protein 167A)TMEM167A TMEM16772
Q96MU8KREM1_HUMANKremen protein 1 (Dickkopf receptor) (Kringle domain-containing transmembrane proteinKREMEN1473
1) (Kringle-containing protein marking the eye and the nose)KREMEN KRM1
P11279LAMP1_HUMANLysosome-associated membrane glycoprotein 1 (LAMP-1) (Lysosome-associatedLAMP1417
membrane protein 1) (CD107 antigen-like family member A) (CD antigen CD107a)
P13473LAMP2_HUMANLysosome-associated membrane glycoprotein 2 (LAMP-2) (Lysosome-associatedLAMP2410
membrane protein 2) (CD107 antigen-like family member B) (CD antigen CD107b)
P01130LDLR_HUMANLow-density lipoprotein receptor (LDL receptor)LDLR860
Q9UEF7KLOT_HUMANKlotho (EC 3.2.1.31) [Cleaved into: Klotho peptide]KL1012
A6NM11L37A2_HUMANLeucine-rich repeat-containing protein 37A2LRRC37A21700
Q9UJQ1LAMP5_HUMANLysosome-associated membrane glycoprotein 5 (Brain and dendritic cell-associatedLAMP5 C20orf103280
LAMP) (Brain-associated LAMP-like protein) (BAD-LAMP) (Lysosome-associated
membrane protein 5) (LAMP-5)
P19256LFA3_HUMANLymphocyte function-associated antigen 3 (Ag3) (Surface glycoprotein LFA-3) (CD antigen CD58)CD58 LFA3250
Q8NCW0KREM2_HUMANKremen protein 2 (Dickkopf receptor 2) (Kringle domain-containing transmembraneKREMEN2 KRM2462
protein 2) (Kringle-containing protein marking the eye and the nose)
A6NMS7L37A1_HUMANLeucine-rich repeat-containing protein 37ALRRC37A LRRC37A11700
O60309L37A3_HUMANLeucine-rich repeat-containing protein 37A3LRRC37A3 KIAA05631634
P18627LAG3_HUMANLymphocyte activation gene 3 protein (LAG-3) (Protein FDC) (CD antigen CD223)LAG3 FDC525
Q6UX15LAYN_HUMANLayilinLAYN382
UNQ208/PRO234
P48357LEPR_HUMANLeptin receptor (LEP-R) (HuB219) (OB receptor) (OB-R) (CD antigen CD295)LEPR DB OBR1165
Q8N149LIRA2_HUMANLeukocyte immunoglobulin-like receptor subfamily A member 2 (CD85 antigen-like familyLILRA2 ILT1 LIR7483
member H) (Immunoglobulin-like transcript 1) (ILT-1) (Leukocyte immunoglobulin-like
receptor 7) (LIR-7) (CD antigen CD85h)
A6NI73LIRA5_HUMANLeukocyte immunoglobulin-like receptor subfamily A member 5 (CD85 antigen-like familyLILRA5 ILT11299
member F) (Immunoglobulin-like transcript 11) (ILT-11) (Leukocyte immunoglobulin-likeLILRB7 LIR9
receptor 9) (LIR-9) (CD antigen CD85f)
Q8N423LIRB2_HUMANLeukocyte immunoglobulin-like receptor subfamily B member 2 (LIR-2) (LeukocyteLILRB2 ILT4 LIR2598
immunoglobulin-like receptor 2) (CD85 antigen-like family member D) (Immunoglobulin-MIR10
like transcript 4) (ILT-4) (Monocyte/macrophage immunoglobulin-like receptor 10) (MIR-
10) (CD antigen CD85d)
P42702LIFR_HUMANLeukemia inhibitory factor receptor (LIF receptor) (LIF-R) (CD antigen CD118)LIFR1097
Q6UY18LIGO4_HUMANLeucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interactingLINGO4 LRRN6D593
protein 4 (Leucine-rich repeat neuronal protein 6D)UNQ9248/PRO34002
Q6PI73LIRA6_HUMANLeukocyte immunoglobulin-like receptor subfamily A member 6 (Immunoglobulin-likeLILRA6 ILT8481
transcript 8) (ILT-8) (Leukocyte Ig-like receptor)
O75022LIRB3_HUMANLeukocyte immunoglobulin-like receptor subfamily B member 3 (LIR-3) (LeukocyteLILRB3 ILT5 LIR3631
immunoglobulin-like receptor 3) (CD85 antigen-like family member A) (Immunoglobulin-
like transcript 5) (ILT-5) (Monocyte inhibitory receptor HL9) (CD antigen CD85a)
P49257LMAN1_HUMANProtein ERGIC-53 (ER-Golgi intermediate compartment 53 kDa protein) (Gp58)LMAN1 ERGIC53510
(Intracellular mannose-specific lectin MR60) (Lectin mannose-binding 1)F5F8D
Q9UQV4LAMP3_HUMANLysosome-associated membrane glycoprotein 3 (LAMP-3) (Lysosomal-associatedLAMP3 DCLAMP416
membrane protein 3) (DC-lysosome-associated membrane glycoprotein) (DC LAMP)TSC403
(Protein TSC403) (CD antigen CD208)
Q7L985LIGO2_HUMANLeucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interactingLINGO2 LERN3 LRRN6C606
protein 2 (Leucine-rich repeat neuronal protein 3) (Leucine-rich repeat neuronal protein 6C)UNQ9234/PRO31993
Q9H0V9LMA2L_HUMANVIP36-like protein (Lectin mannose-binding 2-like) (LMAN2-like protein)LMAN2L VIPL348
PSEC0028
UNQ368/PRO704
P09848LPH_HUMANLactase-phlorizin hydrolase (Lactase-glycosylceramidase) [Includes: Lactase (ECLCT LPH1927
3.2.1.108); Phlorizin hydrolase (EC 3.2.1.62)]
Q96FE5LIGO1_HUMANLeucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interactingLINGO1 LERN1 LRRN6A620
protein 1 (Leucine-rich repeat and immunoglobulin domain-containing protein 1) (Leucine-UNQ201/PRO227
rich repeat neuronal protein 1) (Leucine-rich repeat neuronal protein 6A)
Q12907LMAN2_HUMANVesicular integral-membrane protein VIP36 (Glycoprotein GP36b) (Lectin mannose-LMAN2 C5orf8356
binding 2) (Vesicular integral-membrane protein 36) (VIP36)
Q9H756LRC19_HUMANLeucine-rich repeat-containing protein 19LRRC19370
Q5VT99LRC38_HUMANLeucine-rich repeat-containing protein 38 (BK channel auxiliary gamma subunit LRRC38)LRRC38294
A6NDA9LRIT2_HUMANLeucine-rich repeat, immunoglobulin-like domain and transmembrane domain-containingLRIT2 LRRC22550
protein 2 (Leucine-rich repeat-containing protein 22)
P16150LEUK_HUMANLeukosialin (Galactoglycoprotein) (GALGP) (Leukocyte sialoglycoprotein) (Sialophorin)SPN CD43400
(CD antigen CD43)
P0C6S8LIGO3_HUMANLeucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interactingLINGO3 LERN2592
protein 3 (Leucine-rich repeat neuronal protein 2) (Leucine-rich repeat neuronal protein 6B)LRRN6B
O75023LIRB5_HUMANLeukocyte immunoglobulin-like receptor subfamily B member 5 (CD85 antigen-like familyLILRB5 LIR8590
member C) (Leukocyte immunoglobulin-like receptor 8) (LIR-8) (CD antigen CD85c)
Q9HAT1LMA1L_HUMANProtein ERGIC-53-like (ERGIC53-like protein) (Lectin mannose-binding 1-like) (LMAN1-like protein)LMAN1L ERGL526
UNQ2784/PRO7174
O75197LRP5_HUMANLow-density lipoprotein receptor-related protein 5 (LRP-5)LRP5 LR3 LRP71615
O75581LRP6_HUMANLow-density lipoprotein receptor-related protein 6 (LRP-6)LRP61613
Q9H3W5LRRN3_HUMANLeucine-rich repeat neuronal protein 3 (Neuronal leucine-rich repeat protein 3) (NLRR-3)LRRN3 Nbla10363708
UNQ194/PRO220
P59901LIRA4_HUMANLeukocyte immunoglobulin-like receptor subfamily A member 4 (CD85 antigen-like familyLILRA4 ILT7499
member G) (Immunoglobulin-like transcript 7) (ILT-7) (CD antigen CD85g)
Q8NHL6LIRB1_HUMANLeukocyte immunoglobulin-like receptor subfamily B member 1 (LIR-1) (LeukocyteLILRB1 ILT2 LIR1650
immunoglobulin-like receptor 1) (CD85 antigen-like family member J) (Immunoglobulin-MIR7
like transcript 2) (ILT-2) (Monocyte/macrophage immunoglobulin-like receptor 7) (MIR-7)
(CD antigen CD85j)
Q96QE4LR37B_HUMANLeucine-rich repeat-containing protein 37B (C66 SLIT-like testicular protein)LRRC37B947
Q9HCJ2LRC4C_HUMANLeucine-rich repeat-containing protein 4C (Netrin-G1 ligand) (NGL-1)LRRC4C KIAA1580640
NGL1 UNQ292/PRO331
Q9P2V4LRIT1_HUMANLeucine-rich repeat, immunoglobulin-like domain and transmembrane domain-containingLRIT1 LRRC21 PAL623
protein 1 (Leucine-rich repeat-containing protein 21) (Photoreceptor-associated LRR
superfamily protein) (Retina-specific protein PAL)
P29376LTK_HUMANLeukocyte tyrosine kinase receptor (EC 2.7.10.1) (Protein tyrosine kinase 1)LTK TYK1864
Q9HBG7LY9_HUMANT-lymphocyte surface antigen Ly-9 (Cell surface molecule Ly-9) (Lymphocyte antigen 9)LY9 CDABP0070655
(SLAM family member 3) (SLAMF3) (Signaling lymphocytic activation molecule 3) (CD
antigen CD229)
P14151LYAM1_HUMANL-selectin (CD62 antigen-like family member L) (Leukocyte adhesion molecule 1) (LAM-1)SELL LNHR LYAM1372
(Leukocyte surface antigen Leu-8) (Leukocyte-endothelial cell adhesion molecule 1)
(LECAM1) (Lymph node homing receptor) (TQ1) (gp90-MEL) (CD antigen CD62L)
Q5SZI1LRAD2_HUMANLow-density lipoprotein receptor class A domain-containing protein 2LDLRAD2272
Q8TF66LRC15_HUMANLeucine-rich repeat-containing protein 15 (Leucine-rich repeat protein induced by beta-LRRC15 LIB581
amyloid homolog) (hLib)
Q2I0M4LRC26_HUMANLeucine-rich repeat-containing protein 26 (BK channel auxiliary gamma subunit LRRC26)LRRC26 CAPC334
(Cytokeratin-associated protein in cancer)
Q9P244LRFN1_HUMANLeucine-rich repeat and fibronectin type III domain-containing protein 1 (SynapticLRFN1 KIAA1484771
adhesion-like molecule 2)SALM2
Q9ULH4LRFN2_HUMANLeucine-rich repeat and fibronectin type-III domain-containing protein 2 (SynapticLRFN2 KIAA1246789
adhesion-like molecule 1)SALM1
Q9BTN0LRFN3_HUMANLeucine-rich repeat and fibronectin type-III domain-containing protein 3 (SynapticLRFN3 SALM4628
adhesion-like molecule 4)UNQ5865/PRO34192
Q6PJG9LRFN4_HUMANLeucine-rich repeat and fibronectin type-III domain-containing protein 4LRFN4 SALM3635
Q96NI6LRFN5_HUMANLeucine-rich repeat and fibronectin type-III domain-containing protein 5LRFN5 C14orf146719
SALM5
Q96JA1LRIG1_HUMANLeucine-rich repeats and immunoglobulin-like domains protein 1 (LIG-1)LRIG1 LIG11093
O94898LRIG2_HUMANLeucine-rich repeats and immunoglobulin-like domains protein 2 (LIG-2)LRIG2 KIAA08061065
LIG2
Q6UXM1LRIG3_HUMANLeucine-rich repeats and immunoglobulin-like domains protein 3 (LIG-3)LRIG3 LIG31119
UNQ287/PRO326/
PRO335
Q9HBW1LRRC4_HUMANLeucine-rich repeat-containing protein 4 (Brain tumor-associated protein BAG)LRRC4 BAG653
(Nasopharyngeal carcinoma-associated gene 14 protein) (Netrin-G2 ligand) (NGL-2)NAG14
UNQ554/PRO1111
Q6UXK5LRRN1_HUMANLeucine-rich repeat neuronal protein 1 (Neuronal leucine-rich repeat protein 1) (NLRR-1)LRRN1 KIAA1497716
Nbla10449
UNQ693/PRO1338
Q86VH5LRRT3_HUMANLeucine-rich repeat transmembrane neuronal protein 3LRRTM3581
UNQ803/PRO1693
P16581LYAM2_HUMANE-selectin (CD62 antigen-like family member E) (Endothelial leukocyte adhesionSELE ELAM1610
molecule 1) (ELAM-1) (Leukocyte-endothelial cell adhesion molecule 2) (LECAM2) (CD antigen CD62E)
P16109LYAM3_HUMANP-selectin (CD62 antigen-like family member P) (Granule membrane protein 140) (GMP-SELP GMRP GRMP830
140) (Leukocyte-endothelial cell adhesion molecule 3) (LECAM3) (Platelet activation
dependent granule-external membrane protein) (PADGEM) (CD antigen CD62P)
O75019LIRA1_HUMANLeukocyte immunoglobulin-like receptor subfamily A member 1 (CD85 antigen-like familyLILRA1 LIR6489
member I) (Leukocyte immunoglobulin-like receptor 6) (LIR-6) (CD antigen CD85i)
Q8NHJ6LIRB4_HUMANLeukocyte immunoglobulin-like receptor subfamily B member 4 (CD85 antigen-like familyLILRB4 ILT3 LIR5448
member K) (Immunoglobulin-like transcript 3) (ILT-3) (Leukocyte immunoglobulin-like
receptor 5) (LIR-5) (Monocyte inhibitory receptor HM18) (CD antigen CD85k)
Q6ZMQ8LMTK1_HUMANSerine/threonine-protein kinase LMTK1 (EC 2.7.11.1) (Apoptosis-associated tyrosineAATK AATYK1374
kinase) (AATYK) (Brain apoptosis-associated tyrosine kinase) (CDK5-binding protein)KIAA0641 LMR1 LMTK1
(Lemur tyrosine kinase 1) (p35-binding protein) (p35BP)
Q8N386LRC25_HUMANLeucine-rich repeat-containing protein 25 (Monocyte and plasmacytoid-activated protein)LRRC25 MAPA305
UNQ6169/PRO20174
Q8ND94LRN4L_HUMANLRRN4 C-terminal-like proteinLRRN4CL238
UNQ728/PRO1410
Q86VZ4LRP11_HUMANLow-density lipoprotein receptor-related protein 11 (LRP-11)LRP11500
Q07954LRP1_HUMANProlow-density lipoprotein receptor-related protein 1 (LRP-1) (Alpha-2-macroglobulinLRP1 A2MR APR4544
receptor) (A2MR) (Apolipoprotein E receptor) (APOER) (CD antigen CD91) [Cleaved into:
Low-density lipoprotein receptor-related protein 1 85 kDa subunit (LRP-85); Low-density
lipoprotein receptor-related protein 1 515 kDa subunit (LRP-515); Low-density lipoprotein
receptor-related protein 1 intracellular domain (LRPICD)]
O75074LRP3_HUMANLow-density lipoprotein receptor-related protein 3 (LRP-3) (105 kDa low-densityLRP3770
lipoprotein receptor-related protein) (hLRp105)
O75096LRP4_HUMANLow-density lipoprotein receptor-related protein 4 (LRP-4) (Multiple epidermal growthLRP4 KIAA08161905
factor-like domains 7)LRP10 MEGF7
Q14114LRP8_HUMANLow-density lipoprotein receptor-related protein 8 (LRP-8) (Apolipoprotein E receptor 2)LRP8 APOER2963
O43300LRRT2_HUMANLeucine-rich repeat transmembrane neuronal protein 2 (Leucine-rich repeat neuronal 2LRRTM2 KIAA0416516
protein)LRRN2
Q9HBL6LRTM1_HUMANLeucine-rich repeat and transmembrane domain-containing protein 1LRTM1 HT017345
Q7Z4F1LRP10_HUMANLow-density lipoprotein receptor-related protein 10 (LRP-10)LRP10 MSTP087 SP220713
UNQ389/PRO724
Q8N967LRTM2_HUMANLeucine-rich repeat and transmembrane domain-containing protein 2LRTM2370
Q9Y561LRP12_HUMANLow-density lipoprotein receptor-related protein 12 (LRP-12) (Suppressor ofLRP12 ST7859
tumorigenicity 7 protein)
P98164LRP2_HUMANLow-density lipoprotein receptor-related protein 2 (LRP-2) (Glycoprotein 330) (gp330) (Megalin)LRP24655
Q9H8J5MANS1_HUMANMANSC domain-containing protein 1 (Loss of heterozygosity 12 chromosomal region 3MANSC1 LOH12CR3431
protein)UNQ316/PRO361
Q86YD5LRAD3_HUMANLow-density lipoprotein receptor class A domain-containing protein 3LDLRAD3345
Q14392LRC32_HUMANLeucine-rich repeat-containing protein 32 (Garpin) (Glycoprotein A repetitionsLRRC32 D11S833E662
predominant) (GARP)GARP
Q9NZR2LRP1B_HUMANLow-density lipoprotein receptor-related protein 1B (LRP-1B) (Low-density lipoproteinLRP1B LRPDIT4599
receptor-related protein-deleted in tumor) (LRP-DIT)
O75325LRRN2_HUMANLeucine-rich repeat neuronal protein 2 (Glioma amplified on chromosome 1 protein)LRRN2 GAC1 LRRN5713
(Leucine-rich repeat neuronal protein 5)UNQ256/PRO293
Q8WUT4LRRN4_HUMANLeucine-rich repeat neuronal protein 4 (Neuronal leucine-rich repeat protein 4) (NLRR-4)LRRN4 C20orf75740
Q86UE6LRRT1_HUMANLeucine-rich repeat transmembrane neuronal protein 1LRRTM1522
UNQ675/PRO1309
A6NHS7MANS4_HUMANMANSC domain-containing protein 4MANSC4340
P15529MCP_HUMANMembrane cofactor protein (TLX) (Trophoblast leukocyte common antigen) (CD antigen CD46)CD46 MCP MIC10392
Q86VH4LRRT4_HUMANLeucine-rich repeat transmembrane neuronal protein 4LRRTM4590
UNQ3075/PRO9907
Q13477MADCA_HUMANMucosal addressin cell adhesion molecule 1 (MAdCAM-1) (hMAdCAM-1)MADCAM1382
Q5SQ64LY66F_HUMANLymphocyte antigen 6 complex locus protein G6fLY6G6F C6orf21297
G6F LY6G6D NG32
O60449LY75_HUMANLymphocyte antigen 75 (Ly-75) (C-type lectin domain family 13 member B) (DEC-205)LY75 CD2051722
(gp200-MR6) (CD antigen CD205)CLEC13B
Q9Y5Y7LYVE1_HUMANLymphatic vessel endothelial hyaluronic acid receptor 1 (LYVE-1) (Cell surface retentionLYVE1 CRSBP1322
sequence-binding protein 1) (CRSBP-1) (Extracellular link domain-containing protein 1)HAR XLKD1
(Hyaluronic acid receptor)UNQ230/PRO263
P20916MAG_HUMANMyelin-associated glycoprotein (Siglec-4a)MAG GMA626
Q16820MEP1B_HUMANMeprin A subunit beta (EC 3.4.24.63) (Endopeptidase-2) (Meprin B) (N-benzoyl-L-tyrosyl-MEP1B701
P-amino-benzoic acid hydrolase subunit beta) (PABA peptide hydrolase) (PPH beta)
Q9H9K5MER34_HUMANEndogenous retrovirus group MER34 member 1 Env polyprotein (HERV-MER_4q12ERVMER34-1563
provirus ancestral Env polyprotein)LP9056
Q14703MBTP1_HUMANMembrane-bound transcription factor site-1 protease (EC 3.4.21.112) (EndopeptidaseMBTPS1 KIAA00911052
S1P) (Subtilisin/kexin-isozyme 1) (SKI-1)S1P SKI1
Q12866MERTK_HUMANTyrosine-protein kinase Mer (EC 2.7.10.1) (Proto-oncogene c-Mer) (Receptor tyrosine kinase MerTK)MERTK MER999
Q7Z7M0MEGF8_HUMANMultiple epidermal growth factor-like domains protein 8 (Multiple EGF-like domainsMEGF8 C19orf492845
protein 8) (Epidermal growth factor-like protein 4) (EGF-like protein 4)EGFL4 KIAA0817
P55082MFAP3_HUMANMicrofibril-associated glycoprotein 3MFAP3362
Q96KG7MEG10_HUMANMultiple epidermal growth factor-like domains protein 10 (Multiple EGF-like domains protein 10)MEGF10 KIAA17801140
A6BM72MEG11_HUMANMultiple epidermal growth factor-like domains protein 11 (Multiple EGF-like domains protein 11)MEGF11 KIAA17811044
UNQ1949/PRO4432
Q16819MEP1A_HUMANMeprin A subunit alpha (EC 3.4.24.18) (Endopeptidase-2) (N-benzoyl-L-tyrosyl-P-amino-MEP1A746
benzoic acid hydrolase subunit alpha) (PABA peptide hydrolase) (PPH alpha)
P51512MMP16_HUMANMatrix metalloproteinase-16 (MMP-16) (EC 3.4.24.-) (MMP-X2) (Membrane-type matrixMMP16 MMPX2607
metalloproteinase 3) (MT-MMP 3) (MTMMP3) (Membrane-type-3 matrix
metalloproteinase) (MT3-MMP) (MT3MMP)
Q9H1U4MEGF9_HUMANMultiple epidermal growth factor-like domains protein 9 (Multiple EGF-like domainsMEGF9 EGFL5602
protein 9) (Epidermal growth factor-like protein 5) (EGF-like protein 5)KIAA0818
UNQ671/PRO1305
Q5JRA6MIA3_HUMANMelanoma inhibitory activity protein 3 (C219-reactive peptide) (D320) (Transport andMIA3 KIAA02681907
Golgi organization protein 1)TANGO TANGO1
UNQ6077/PRO20088
P51511MMP15_HUMANMatrix metalloproteinase-15 (MMP-15) (EC 3.4.24.-) (Membrane-type matrixMMP15669
metalloproteinase 2) (MT-MMP 2) (MTMMP2) (Membrane-type-2 matrix
metalloproteinase) (MT2-MMP) (MT2MMP) (SMCP-2)
O75121MFA3L_HUMANMicrofi brillar-associated protein 3-like (Testis development protein NYD-SP9)MFAP3L KIAA0626409
HSD-39 HSD39
P08581MET_HUMANHepatocyte growth factor receptor (HGF receptor) (EC 2.7.10.1) (HGF/SF receptor)MET1390
(Proto-oncogene c-Met) (Scatter factor receptor) (SF receptor) (Tyrosine-protein kinase Met)
Q29983MICA_HUMANMHC class I polypeptide-related sequence A (MIC-A)MICA PERB11.1383
Q8TD46MO2R1_HUMANCell surface glycoprotein CD200 receptor 1 (CD200 cell surface glycoprotein receptor)CD200R1 CD200R325
(Cell surface glycoprotein OX2 receptor 1)CRTR2 MOX2R OX2R
UNQ2522/PRO6015
Q29980MICB_HUMANMHC class I polypeptide-related sequence B (MIC-B)MICB PERB11.2383
P50281MMP14_HUMANMatrix metalloproteinase-14 (MMP-14) (EC 3.4.24.80) (MMP-X1) (Membrane-type matrixMMP14582
metalloproteinase 1) (MT-MMP 1) (MTMMP1) (Membrane-type-1 matrix
metalloproteinase) (MT1-MMP) (MT1MMP)
Q2M385MPEG1_HUMANMacrophage-expressed gene 1 protein (Macrophage gene 1 protein) (Mpg-1)MPEG1716
Q7Z6M3MILR1_HUMANAllergin-1 (Allergy inhibitory receptor 1) (Mast cell antigen 32) (MCA-32) (Mast cellMILR1 C17orf60343
immunoglobulin-like receptor 1)MCA32
P20645MPRD_HUMANCation-dependent mannose-6-phosphate receptor (CD Man-6-P receptor) (CD-MPR) (46M6PR MPR46277
kDa mannose 6-phosphate receptor) (MPR 46)MPRD
P11717MPRI_HUMANCation-independent mannose-6-phosphate receptor (CI Man-6-P receptor) (CI-MPR)IGF2R MPRI2491
(M6PR) (300 kDa mannose 6-phosphate receptor) (MPR 300) (Insulin-like growth factor 2
receptor) (Insulin-like growth factor II receptor) (IGF-II receptor) (M6P/IGF2 receptor)
(M6P/IGF2R) (CD antigen CD222)
Q14165MLEC_HUMANMalectinMLEC KIAA0152292
Q9Y5R2MMP24_HUMANMatrix metalloproteinase-24 (MMP-24) (EC 3.4.24.-) (Membrane-type matrixMMP24 MT5MMP645
metalloproteinase 5) (MT-MMP 5) (MTMMP5) (Membrane-type-5 matrix
metalloproteinase) (MT5-MMP) (MT5MMP) [Cleaved into: Processed matrix
metalloproteinase-24]
Q16653MOG_HUMANMyelin-oligodendrocyte glycoproteinMOG247
Q6UWV2MPZL3_HUMANMyelin protein zero-like protein 3MPZL3235
UNQ2966/PRO7425
Q6UVY6MOXD1_HUMANDBH-like monooxygenase protein 1 (EC 1.14.17.-) (Monooxygenase X)MOXD1 MOX613
UNQ2493/PRO5780
Q6Q8B3MO2R2_HUMANCell surface glycoprotein CD200 receptor 2 (CD200 cell surface glycoprotein receptor-likeCD200R1L271
2) (CD200 receptor-like 2) (HuCD200R2) (CD200 cell surface glycoprotein receptor-likeCD200R2
a) (CD200RLa) (Cell surface glycoprotein CD200 receptor 1-like) (Cell surface
glycoprotein OX2 receptor 2)
O60487MPZL2_HUMANMyelin protein zero-like protein 2 (Epithelial V-like antigen 1)MPZL2 EVA EVA1215
UNQ606/PRO1192
Q96KJ4MSLNL_HUMANMesothelin-like protein (Pre-pro-megakaryocyte-potentiating-factor-like)MSLNL C16orf37702
MPFL
P43121MUC18_HUMANCell surface glycoprotein MUC18 (Cell surface glycoprotein P1H12) (Melanoma cellMCAM MUC18646
adhesion molecule) (Melanoma-associated antigen A32) (Melanoma-associated antigen
MUC18) (S-endo 1 endothelial-associated antigen) (CD antigen CD146)
P15941MUC1_HUMANMucin-1 (MUC-1) (Breast carcinoma-associated antigen DF3) (Cancer antigen 15-3) (CAMUC1 PUM1255
15-3) (Carcinoma-associated mucin) (Episialin) (H23AG) (Krebs von den Lungen-6) (KL-
6) (PEMT) (Peanut-reactive urinary mucin) (PUM) (Polymorphic epithelial mucin) (PEM)
(Tumor-associated epithelial membrane antigen) (EMA) (Tumor-associated mucin) (CD
antigen CD227) [Cleaved into: Mucin-1 subunit alpha (MUC1-NT) (MUC1-alpha); Mucin-1
subunit beta (MUC1-beta) (MUC1-CT)]
O95297MPZL1_HUMANMyelin protein zero-like protein 1 (Protein zero-related)MPZL1 PZR269
UNQ849/PRO1787
P22897MRC1_HUMANMacrophage mannose receptor 1 (MMR) (C-type lectin domain family 13 member D) (C-MRC1 CLEC13D1456
type lectin domain family 13 member D-like) (Human mannose receptor) (hMR)CLEC13DL
(Macrophage mannose receptor 1-like protein 1) (CD antigen CD206)MRC1L1
Q9UBG0MRC2_HUMANC-type mannose receptor 2 (C-type lectin domain family 13 member E) (EndocyticMRC2 CLEC13E1479
receptor 180) (Macrophage mannose receptor 2) (Urokinase-type plasminogen activatorENDO180
receptor-associated protein) (UPAR-associated protein) (Urokinase receptor-associatedKIAA0709 UPARAP
protein) (CD antigen CD280)
Q9UKN1MUC12_HUMANMucin-12 (MUC-12) (Mucin-11) (MUC-11)MUC12 MUC115478
Q8N387MUC15_HUMANMucin-15 (MUC-15)MUC15334
UNQ750/PRO1481
Q8WXI7MUC16_HUMANMucin-16 (MUC-16) (Ovarian cancer-related tumor marker CA125) (CA-125) (OvarianMUC16 CA12514507
carcinoma antigen CA125)
Q5SSG8MUC21_HUMANMucin-21 (MUC-21) (Epiglycanin)MUC21 C6orf205566
UNQ697/PRO1342
Q9H3R2MUC13_HUMANMucin-13 (MUC-13) (Down-regulated in colon cancer 1)MUC13 DRCC1 RECC512
UNQ6194/PRO20221
O15146MUSK_HUMANMuscle, skeletal receptor tyrosine-protein kinase (EC 2.7.10.1) (Muscle-specific tyrosine-MUSK869
protein kinase receptor) (MuSK) (Muscle-specific kinase receptor)
Q13505MTX1_HUMANMetaxin-1 (Mitochondrial outer membrane import complex protein 1)MTX1 MTX MTXN466
Q9ULC0MUCEN_HUMANEndomucin (Endomucin-2) (Gastric cancer antigen Ga34) (Mucin-14) (MUC-14)EMCN EMCN2 MUC14261
Q04900MUC24_HUMANSialomucin core protein 24 (MUC-24) (Endolyn) (Multi-glycosylated core protein 24)CD164197
(MGC-24) (MGC-24v) (CD antigen CD164)
P25189MYP0_HUMANMyelin protein P0 (Myelin peripheral protein) (MPP) (Myelin protein zero)MPZ248
Q9BRK3MXRA8_HUMANMatrix-remodeling-associated protein 8 (Limitrin)MXRA8442
Q9UK23NAGPA_HUMANN-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase (EC 3.1.4.45)NAGPA515
(Mannose 6-phosphate-uncovering enzyme) (Phosphodiester alpha-GlcNAcase)
O15394NCAM2_HUMANNeural cell adhesion molecule 2 (N-CAM-2) (NCAM-2)NCAM2 NCAM21837
O76036NCTR1_HUMANNatural cytotoxicity triggering receptor 1 (Lymphocyte antigen 94 homolog) (NK cell-NCR1 LY94304
activating receptor) (Natural killer cell p46-related protein) (NK-p46) (NKp46) (hNKp46)
(CD antigen CD335)
Q8NC67NETO2_HUMANNeuropilin and tolloid-like protein 2 (Brain-specific transmembrane protein containing 2NETO2 BTCL2525
CUB and 1 LDL-receptor class A domains protein 2)UNQ1926/PRO4401
Q8TD07N2DL4_HUMANNKG2D ligand 4 (N2DL-4) (NKG2DL4) (Lymphocyte effector toxicity activation ligand)RAET1E LETAL263
(RAE-1-like transcript 4) (RL-4) (Retinoic acid early transcript 1E)N2DL4 ULBP4
UNQ1867/PRO4303
O14931NCTR3_HUMANNatural cytotoxicity triggering receptor 3 (Activating natural killer receptor p30) (NaturalNCR3 1C7 LY117201
killer cell p30-related protein) (NK-p30) (NKp30) (CD antigen CD337)
Q8TDF5NETO1_HUMANNeuropilin and tolloid-like protein 1 (Brain-specific transmembrane protein containing 2NETO1 BTCL1533
CUB and 1 LDL-receptor class A domains protein 1)
Q92542NICA_HUMANNicastrinNCSTN KIAA0253709
UNQ1874/PRO4317
P13591NCAM1_HUMANNeural cell adhesion molecule 1 (N-CAM-1) (NCAM-1) (CD antigen CD56)NCAM1 NCAM858
Q5T1S8NCMAP_HUMANNoncompact myelin-associated protein (Myelin protein of 11 kDa) (MP11)NCMAP C1orf130102
O95944NCTR2_HUMANNatural cytotoxicity triggering receptor 2 (Lymphocyte antigen 95 homolog) (NK cell-NCR2 LY95276
activating receptor) (Natural killer cell p44-related protein) (NK-p44) (NKp44) (CD antigen CD336)
Q15223NECT1_HUMANNectin-1 (Herpes virus entry mediator C) (Herpesvirus entry mediator C) (HveC)NECTIN1 HVEC517
(Herpesvirus Ig-like receptor) (HIgR) (Nectin cell adhesion molecule 1) (PoliovirusPRR1 PVRL1
receptor-related protein 1) (CD antigen CD111)
Q92859NEO1_HUMANNeogenin (Immunoglobulin superfamily DCC subclass member 2)NEO1 IGDCC2 NGN1461
O00533NCHL1_HUMANNeural cell adhesion molecule L1-like protein (Close homolog of L1) [Cleaved into:CHL1 CALL1208
Processed neural cell adhesion molecule L1-like protein]
Q8N2Q7NLGN1_HUMANNeuroligin-1NLGN1 KIAA1070840
Q8N0W4NLGNX_HUMANNeuroligin-4, X-linked (Neuroligin X) (HNLX)NLGN4X KIAA1260816
NLGN4
UNQ365/PRO701
O60500NPHN_HUMANNephrin (Renal glomerulus-specific cell adhesion receptor)NPHS1 NPHN1241
Q96NY8NECT4_HUMANNectin-4 (Ig superfamily receptor LNIR) (Nectin cell adhesion molecule 4) (PoliovirusNECTIN4 LNIR510
receptor-related protein 4) [Cleaved into: Processed poliovirus receptor-related protein 4]PRR4 PVRL4
Q8NET5NFAM1_HUMANNFAT activation molecule 1 (Calcineurin/NFAT-activating ITAM-containing protein)NFAM1 CNAIP270
(NFAT-activating protein with ITAM motif 1)
O94856NFASC_HUMANNeurofascinNFASC KIAA07561347
Q9UM47NOTC3_HUMANNeurogenic locus notch homolog protein 3 (Notch 3) [Cleaved into: Notch 3 extracellularNOTCH32321
truncation; Notch 3 intracellular domain]
O14511NRG2_HUMANPro-neuregulin-2, membrane-bound isoform (Pro-NRG2) [Cleaved into: Neuregulin-2NRG2 NTAK850
(NRG-2) (Divergent of neuregulin-1) (DON-1) (Neural- and thymus-derived activator for
ERBB kinases) (NTAK)]
Q02297NRG1_HUMANPro-neuregulin-1, membrane-bound isoform (Pro-NRG1) [Cleaved into: Neuregulin-1NRG1 GGF HGL640
(Acetylcholine receptor-inducing activity) (ARIA) (Breast cancer cell differentiation factorHRGA NDF SMDF
p45) (Glial growth factor) (Heregulin) (HRG) (Neu differentiation factor) (Sensory and
motor neuron-derived factor)]
Q9Y4C0NRX3A_HUMANNeurexin-3 (Neurexin III-alpha) (Neurexin-3-alpha)NRXN3 C14orf601643
KIAA0743
Q92692NECT2_HUMANNectin-2 (Herpes virus entry mediator B) (Herpesvirus entry mediator B) (HveB) (NectinNECTIN2 HVEB538
cell adhesion molecule 2) (Poliovirus receptor-related protein 2) (CD antigen CD112)PRR2 PVRL2
Q8NFZ4NLGN2_HUMANNeuroligin-2NLGN2 KIAA1366835
Q8NFZ3NLGNY_HUMANNeuroligin-4, Y-linked (Neuroligin Y)NLGN4Y KIAA0951816
Q15155NOMO1_HUMANNodal modulator 1 (pM5 protein)NOMO1 PM51222
P69849NOMO3_HUMANNodal modulator 3 (pM5 protein 3)NOMO31222
Q9NZ94NLGN3_HUMANNeuroligin-3 (Gliotactin homolog)NLGN3 KIAA1480848
NL3
P46531NOTC1_HUMANNeurogenic locus notch homolog protein 1 (Notch 1) (hN1) (Translocation-associatedNOTCH1 TAN12555
notch protein TAN-1) [Cleaved into: Notch 1 extracellular truncation (NEXT); Notch 1
intracellular domain (NICD)]
Q04721NOTC2_HUMANNeurogenic locus notch homolog protein 2 (Notch 2) (hN2) [Cleaved into: Notch 2NOTCH22471
extracellular truncation (N2ECD); Notch 2 intracellular domain (N2ICD)]
Q92823NRCAM_HUMANNeuronal cell adhesion molecule (Nr-CAM) (Neuronal surface protein Bravo) (hBravo)NRCAM KIAA03431304
(NgCAM-related cell adhesion molecule) (Ng-CAM-related)
O60462NRP2_HUMANNeuropilin-2 (Vascular endothelial cell growth factor 165 receptor 2)NRP2 VEGF165R2931
Q9Y639NPTN_HUMANNeuroplastin (Stromal cell-derived receptor 1) (SDR-1)NPTN SDFR1 SDR1398
Q68D85NR3L1_HUMANNatural cytotoxicity triggering receptor 3 ligand 1 (B7 homolog 6) (B7-H6)NCR3LG1 B7H6454
O14786NRP1_HUMANNeuropilin-1 (Vascular endothelial cell growth factor 165 receptor) (CD antigen CD304)NRP1 NRP923
VEGF165R
P56975NRG3_HUMANPro-neuregulin-3, membrane-bound isoform (Pro-NRG3) [Cleaved into: Neuregulin-3 (NRG-3)]NRG3720
Q86YC3NRROS_HUMANNegative regulator of reactive oxygen species (Leucine-rich repeat-containing protein 33)NRROS LRRC33692
UNQ3030/PRO9833
P58400NRX1B_HUMANNeurexin-1-beta (Neurexin 1-beta)NRXN1442
Q9HDB5NRX3B_HUMANNeurexin-3-beta (Neurexin III-beta) [Cleaved into: Neurexin-3-beta, soluble form;NRXN3 KIAA0743637
Neurexin-3-beta, C-terminal fragment (NRXN3-CTF)]
Q16620NTRK2_HUMANBDNF/NT-3 growth factors receptor (EC 2.7.10.1) (GP145-TrkB) (Trk-B) (NeurotrophicNTRK2 TRKB822
tyrosine kinase receptor type 2) (TrkB tyrosine kinase) (Tropomyosin-related kinase B)
Q16288NTRK3_HUMANNT-3 growth factor receptor (EC 2.7.10.1) (GP145-TrkC) (Trk-C) (Neurotrophic tyrosineNTRK3 TRKC839
kinase receptor type 3) (TrkC tyrosine kinase)
Q99466NOTC4_HUMANNeurogenic locus notch homolog protein 4 (Notch 4) (hNotch4) [Cleaved into: Notch 4NOTCH4 INT32003
extracellular truncation; Notch 4 intracellular domain]
Q8WWG1NRG4_HUMANPro-neuregulin-4, membrane-bound isoform (Pro-NRG4) [Cleaved into: Neuregulin-4 (NRG-4)]NRG4115
Q9P2S2NRX2A_HUMANNeurexin-2 (Neurexin II-alpha) (Neurexin-2-alpha)NRXN2 KIAA09211712
Q9ULB1NRX1A_HUMANNeurexin-1 (Neurexin I-alpha) (Neurexin-1-alpha)NRXN1 KIAA05781477
P58401NRX2B_HUMANNeurexin-2-beta (Neurexin II-beta)NRXN2666
P04629NTRK1_HUMANHigh affinity nerve growth factor receptor (EC 2.7.10.1) (Neurotrophic tyrosine kinaseNTRK1 MTC TRK796
receptor type 1) (TRK1-transforming tyrosine kinase protein) (Tropomyosin-related kinaseTRKA
A) (Tyrosine kinase receptor) (Tyrosine kinase receptor A) (Trk-A) (gp140trk) (p140-TrkA)
Q96PE5OPALI_HUMANOpalin (Oligodendrocytic myelin paranodal and inner loop protein) (Transmembrane protein 10)OPALIN HTMP10141
TMEM10
P41217OX2G_HUMANOX-2 membrane glycoprotein (CD antigen CD200)CD200 MOX1278
MOX2 My033
Q8NBR0P5I13_HUMANTumor protein p53-inducible protein 13 (Damage-stimulated cytoplasmic protein 1)TP53I13 DSCP1393
Q99650OSMR_HUMANOncostatin-M-specific receptor subunit beta (Interleukin-31 receptor subunit beta) (IL-31OSMR OSMRB979
receptor subunit beta) (IL-31R subunit beta) (IL-31R-beta) (IL-31RB)
Q8IYS5OSCAR_HUMANOsteoclast-associated immunoglobulin-like receptor (Osteoclast-associated receptor)OSCAR282
(hOSCAR) (Polymeric immunoglobulin receptor 3) (PIgR-3) (PIgR3) (Poly-Ig receptor 3)
P39656OST48_HUMANDolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunit (DDOSTDDOST KIAA0115456
48 kDa subunit) (Oligosaccharyl transferase 48 kDa subunit) (EC 2.4.99.18)OST48 OK/SW-cl.45
Q86WC4OSTM1_HUMANOsteopetrosis-associated transmembrane protein 1 (Chloride channel 7 beta subunit)OSTM1 GL334
HSPC019
UNQ6098/PRO21201
Q9BZA7PC11X_HUMANProtocadherin-11 X-linked (Protocadherin-11) (Protocadherin on the X chromosome)PCDH11X1347
(PCDH-X) (Protocadherin-S)KIAA1326 PCDH11
PCDHX
Q9P2E7PCD10_HUMANProtocadherin-10PCDH10 KIAA14001040
Q96QU1PCD15_HUMANProtocadherin-15PCDH15 USH1F1955
Q8N6Y1PCD20_HUMANProtocadherin-20 (Protocadherin-13)PCDH20 PCDH13951
Q9UN67PCDBA_HUMANProtocadherin beta-10 (PCDH-beta-10)PCDHB10800
UNQ1906/PRO4352
Q9Y5E8PCDBF_HUMANProtocadherin beta-15 (PCDH-beta-15)PCDHB15787
Q9Y5I4PCDC2_HUMANProtocadherin alpha-C2 (PCDH-alpha-C2)PCDHAC21007
Q9Y5H0PCDG3_HUMANProtocadherin gamma-A3 (PCDH-gamma-A3)PCDHGA3932
Q9Y5G8PCDG5_HUMANProtocadherin gamma-A5 (PCDH-gamma-A5)PCDHGA5931
Q9Y5G6PCDG7_HUMANProtocadherin gamma-A7 (PCDH-gamma-A7)PCDHGA7932
Q9Y5G1PCDGF_HUMANProtocadherin gamma-B3 (PCDH-gamma-B3)PCDHGB3929
Q96FE7P3IP1_HUMANPhosphoinositide-3-kinase-interacting protein 1 (Kringle domain-containing protein HGFL)PIK3IP1 HGFL263
Q9HCL0PCD18_HUMANProtocadherin-18PCDH18 KIAA15621135
Q9Y5H7PCDA5_HUMANProtocadherin alpha-5 (PCDH-alpha-5)PCDHA5 CNRS6936
Q9Y5I1PCDAB_HUMANProtocadherin alpha-11 (PCDH-alpha-11)PCDHA11 CNRS7949
Q9Y5E7PCDB2_HUMANProtocadherin beta-2 (PCDH-beta-2)PCDHB2798
Q9Y5E5PCDB4_HUMANProtocadherin beta-4 (PCDH-beta-4)PCDHB4795
Q9HC56PCDH9_HUMANProtocadherin-9PCDH91237
Q92824PCSK5_HUMANProprotein convertase subtilisin/kexin type 5 (EC 3.4.21.-) (Proprotein convertase 5)PCSK5 PC5 PC61860
(PC5) (Proprotein convertase 6) (PC6) (hPC6) (Subtilisin/kexin-like protease PC5)
Q96JQ0PCD16_HUMANProtocadherin-16 (Cadherin-19) (Cadherin-25) (Fibroblast cadherin-1) (Protein dachsousDCHS1 CDH193298
homolog 1)CDH25 FIB1
KIAA1773 PCDH16
Q9Y5I0PCDAD_HUMANProtocadherin alpha-13 (PCDH-alpha-13)PCDHA13 CNRS5950
Q9Y5E6PCDB3_HUMANProtocadherin beta-3 (PCDH-beta-3)PCDHB3796
Q9Y5E3PCDB6_HUMANProtocadherin beta-6 (PCDH-beta-6)PCDHB6794
Q9Y5F1PCDBC_HUMANProtocadherin beta-12 (PCDH-beta-12)PCDHB12795
Q9Y5G7PCDG6_HUMANProtocadherin gamma-A6 (PCDH-gamma-A6)PCDHGA6932
Q9Y5G5PCDG8_HUMANProtocadherin gamma-A8 (PCDH-gamma-A8)PCDHGA8 KIAA0327932
Q9Y5H3PCDGA_HUMANProtocadherin gamma-A10 (PCDH-gamma-A10)PCDHGA10936
Q9Y5H2PCDGB_HUMANProtocadherin gamma-A11 (PCDH-gamma-A11)PCDHGA11935
Q9Y5F6PCDGM_HUMANProtocadherin gamma-C5 (PCDH-gamma-C5)PCDHGC5944
Q08174PCDH1_HUMANProtocadherin-1 (Cadherin-like protein 1) (Protocadherin-42) (PC42)PCDH11060
O95206PCDH8_HUMANProtocadherin-8 (Arcadlin)PCDH81070
Q9NZQ7PD1L1_HUMANProgrammed cell death 1 ligand 1 (PD-L1) (PDCD1 ligand 1) (Programmed death ligandCD274 B7H1290
1) (B7 homolog 1) (B7-H1) (CD antigen CD274)PDCD1L1
PDCD1LG1 PDL1
Q6UWI2PARM1_HUMANProstate androgen-regulated mucin-like protein 1 (PARM-1)PARM1310
UNQ1879/PRO4322
Q9Y5I3PCDA1_HUMANProtocadherin alpha-1 (PCDH-alpha-1)PCDHA1950
Q9Y5H8PCDA3_HUMANProtocadherin alpha-3 (PCDH-alpha-3)PCDHA3950
Q9UN74PCDA4_HUMANProtocadherin alpha-4 (PCDH-alpha-4)PCDHA4947
Q86YL7PDPN_HUMANPodoplanin (Aggrus) (Glycoprotein 36) (Gp36) (PA2.26 antigen) (T1-alpha) (T1A)PDPN GP36162
PSEC0003
PSEC0025
P07202PERT_HUMANThyroid peroxidase (TPO) (EC 1.11.1.8)TPO933
Q9BZA8PC11Y_HUMANProtocadherin-11 Y-linked (Protocadherin-11) (Protocadherin on the Y chromosome)PCDH11Y PCDH111340
(PCDH-Y) (Protocadherin prostate cancer) (Protocadherin-PC) (Protocadherin-22)PCDH22 PCDHY
O14917PCD17_HUMANProtocadherin-17 (Protocadherin-68)PCDH17 PCDH681159
PCH68
Q8TAB3PCD19_HUMANProtocadherin-19PCDH19 KIAA13131148
Q9UN73PCDA6_HUMANProtocadherin alpha-6 (PCDH-alpha-6)PCDHA6 CNRS2950
Q9Y5I2PCDAA_HUMANProtocadherin alpha-10 (PCDH-alpha-10)PCDHA10 CNRS8948
Q9UN75PCDAC_HUMANProtocadherin alpha-12 (PCDH-alpha-12)PCDHA12941
Q9Y5F3PCDB1_HUMANProtocadherin beta-1 (PCDH-beta-1)PCDHB1818
Q9Y5E4PCDB5_HUMANProtocadherin beta-5 (PCDH-beta-5)PCDHB5795
Q9UN66PCDB8_HUMANProtocadherin beta-8 (PCDH-beta-8) (Protocadherin-3I)PCDHB8 PCDH3I801
Q9Y5F2PCDBB_HUMANProtocadherin beta-11 (PCDH-beta-11)PCDHB11797
Q9Y5F0PCDBD_HUMANProtocadherin beta-13 (PCDH-beta-13)PCDHB13798
UNQ332/PRO531
Q9Y5H1PCDG2_HUMANProtocadherin gamma-A2 (PCDH-gamma-A2)PCDHGA2932
Q9Y5G4PCDG9_HUMANProtocadherin gamma-A9 (PCDH-gamma-A9)PCDHGA9932
O60330PCDGC_HUMANProtocadherin gamma-A12 (PCDH-gamma-A12) (Cadherin-21) (Fibroblast cadherin-3)PCDHGA12 CDH21932
FIB3 KIAA0588
UNQ371/PRO707
Q9Y5G2PCDGE_HUMANProtocadherin gamma-B2 (PCDH-gamma-B2)PCDHGB2931
Q9Y5F9PCDGI_HUMANProtocadherin gamma-B6 (PCDH-gamma-B6)PCDHGB6930
Q9UN70PCDGK_HUMANProtocadherin gamma-C3 (PCDH-gamma-C3) (Protocadherin-2) (Protocadherin-43) (PC-43)PCDHGC3 PCDH2934
O60245PCDH7_HUMANProtocadherin-7 (Brain-heart protocadherin) (BH-Pcdh)PCDH7 BHPCDH1069
Q16549PCSK7_HUMANProprotein convertase subtilisin/kexin type 7 (EC 3.4.21.-) (Lymphoma proproteinPCSK7 LPC PC7785
convertase) (Prohormone convertase 7) (Proprotein convertase 7) (PC7) (ProproteinPC8 SPC7
convertase 8) (PC8) (hPC8) (Subtilisin/kexin-like protease PC7)
Q9BQ51PD1L2_HUMANProgrammed cell death 1 ligand 2 (PD-1 ligand 2) (PD-L2) (PDCD1 ligand 2)PDCD1LG2 B7DC273
(Programmed death ligand 2) (Butyrophilin B7-DC) (B7-DC) (CD antigen CD273)CD273 PDCD1L2 PDL2
P16284PECA1_HUMANPlatelet endothelial cell adhesion molecule (PECAM-1) (EndoCAM) (GPIIA′) (PECA1)PECAM1738
(CD antigen CD31)
Q9NPG4PCD12_HUMANProtocadherin-12 (Vascular cadherin-2) (Vascular endothelial cadherin-2) (VE-cad-2)PCDH121184
(VE-cadherin-2)UNQ395/PRO731
Q9Y5H9PCDA2_HUMANProtocadherin alpha-2 (PCDH-alpha-2)PCDHA2948
Q9UN72PCDA7_HUMANProtocadherin alpha-7 (PCDH-alpha-7)PCDHA7 CNRS4937
Q9Y5H6PCDA8_HUMANProtocadherin alpha-8 (PCDH-alpha-8)PCDHA8950
Q9Y5H5PCDA9_HUMANProtocadherin alpha-9 (PCDH-alpha-9)PCDHA9 KIAA0345950
Q9Y5E2PCDB7_HUMANProtocadherin beta-7 (PCDH-beta-7)PCDHB7793
Q9Y5E1PCDB9_HUMANProtocadherin beta-9 (PCDH-beta-9) (Protocadherin-3H)PCDHB9 PCDH3H797
Q9Y5E9PCDBE_HUMANProtocadherin beta-14 (PCDH-beta-14)PCDHB14798
Q9NRJ7PCDBG_HUMANProtocadherin beta-16 (PCDH-beta-16) (Protocadherin-3X)PCDHB16776
KIAA1621 PCDH3X
Q9H158PCDC1_HUMANProtocadherin alpha-C1 (PCDH-alpha-C1)PCDHAC1963
Q9Y5H4PCDG1_HUMANProtocadherin gamma-A1 (PCDH-gamma-A1)PCDHGA1931
Q9Y5G9PCDG4_HUMANProtocadherin gamma-A4 (PCDH-gamma-A4)PCDHGA4931
Q9Y5G3PCDGD_HUMANProtocadherin gamma-B1 (PCDH-gamma-B1)PCDHGB1927
Q9UN71PCDGG_HUMANProtocadherin gamma-B4 (PCDH-gamma-B4) (Cadherin-20) (Fibroblast cadherin-2)PCDHGB4 CDH20923
FIB2
Q9Y5G0PCDGH_HUMANProtocadherin gamma-B5 (PCDH-gamma-B5)PCDHGB5923
Q9Y5F8PCDGJ_HUMANProtocadherin gamma-B7 (PCDH-gamma-B7)PCDHGB7929
Q9Y5F7PCDGL_HUMANProtocadherin gamma-C4 (PCDH-gamma-C4)PCDHGC4938
P09619PGFRB_HUMANPlatelet-derived growth factor receptor beta (PDGF-R-beta) (PDGFR-beta) (EC 2.7.10.1)PDGFRB PDGFR1106
(Beta platelet-derived growth factor receptor) (Beta-type platelet-derived growth factorPDGFR1
receptor) (CD140 antigen-like family member B) (Platelet-derived growth factor receptor
1) (PDGFR-1) (CD antigen CD140b)
Q15116PDCD1_HUMANProgrammed cell death protein 1 (Protein PD-1) (hPD-1) (CD antigen CD279)PDCD1 PD1288
P16234PGFRA_HUMANPlatelet-derived growth factor receptor alpha (PDGF-R-alpha) (PDGFR-alpha) (ECPDGFRA PDGFR21089
2.7.10.1) (Alpha platelet-derived growth factor receptor) (Alpha-type platelet-derivedRHEPDGFRA
growth factor receptor) (CD140 antigen-like family member A) (CD140a antigen)
(Platelet-derived growth factor alpha receptor) (Platelet-derived growth factor receptor 2)
(PDGFR-2) (CD antigen CD140a)
Q9NZ53PDXL2_HUMANPodocalyxin-like protein 2 (Endoglycan)PODXL2605
UNQ1861/PRO3742
Q6UXB8PI16_HUMANPeptidase inhibitor 16 (PI-16) (Cysteine-rich secretory protein 9) (CRISP-9) (PSP94-PI16 CRISP9463
binding protein)PSPBP PSEC0164
UNQ289/PRO328
Q9UKJ0PILRB_HUMANPaired immunoglobulin-like type 2 receptor beta (Activating receptor PILR-beta) (CellPILRB FDFACT227
surface receptor FDFACT)PP1551
Q8IYJ0PIANP_HUMANPILR alpha-associated neural protein (PILR-associating neural protein) (PairedPIANP C12orf53282
immunoglobin-like type 2 receptor-associating neural protein)PANP
UNQ828/PRO1755
P01833PIGR_HUMANPolymeric immunoglobulin receptor (PIgR) (Poly-Ig receptor) (Hepatocellular carcinoma-PIGR764
associated protein TB6) [Cleaved into: Secretory component]
Q9UKJ1PILRA_HUMANPaired immunoglobulin-like type 2 receptor alpha (Cell surface receptor FDF03)PILRA303
(Inhibitory receptor PILR-alpha)
Q13018PLA2R_HUMANSecretory phospholipase A2 receptor (PLA2-R) (PLA2R) (180 kDa secretoryPLA2R1 CLEC13C1463
phospholipase A2 receptor) (C-type lectin domain family 13 member C) (M-type receptor)
[Cleaved into: Soluble secretory phospholipase A2 receptor (Soluble PLA2-R) (Soluble PLA2R)]
Q8IUK5PLDX1_HUMANPlexin domain-containing protein 1 (Tumor endothelial marker 3) (Tumor endothelial marker 7)PLXDC1 TEM3500
TEM7
O43157PLXB1_HUMANPlexin-B1 (Semaphorin receptor SEP)PLXNB1 KIAA04072135
PLXN5 SEP
O60486PLXC1_HUMANPlexin-C1 (Virus-encoded semaphorin protein receptor) (CD antigen CD232)PLXNC1 VESPR1568
Q969N2PIGT_HUMANGPI transamidase component PIG-T (Phosphatidylinositol-glycan biosynthesis class T protein)PIGT CGI-06578
PSEC0163
UNQ716/PRO1379
P08F94PKHD1_HUMANFibrocystin (Polycystic kidney and hepatic disease 1 protein) (Polyductin) (Tigmin)PKHD1 FCYT4074
TIGM1
Q6P1J6PLB1_HUMANPhospholipase B1, membrane-associated (Phospholipase B) (hPLB) (PhospholipasePLB1 PLB1458
B/lipase) (PLB/LIP) [Includes: Phospholipase A2 (EC 3.1.1.4); Lysophospholipase (EC 3.1.1.5)]
Q8TEM1PO210_HUMANNuclear pore membrane glycoprotein 210 (Nuclear pore protein gp210) (NuclearNUP210 KIAA09061887
envelope pore membrane protein POM 210) (POM210) (Nucleoporin Nup210) (PorePSEC0245
membrane protein of 210 kDa)
O00168PLM_HUMANPhospholemman (FXYD domain-containing ion transport regulator 1)FXYD1 PLM92
P51805PLXA3_HUMANPlexin-A3 (Plexin-4) (Semaphorin receptor SEX)PLXNA3 PLXN41871
SEX
Q9UIW2PLXA1_HUMANPlexin-A1 (Semaphorin receptor NOV)PLXNA1 NOV1896
PLXN1
O75051PLXA2_HUMANPlexin-A2 (Semaphorin receptor OCT)PLXNA2 KIAA04631894
OCT PLXN2
UNQ209/PRO235
Q8TBF5PIGX_HUMANPhosphatidylinositol-glycan biosynthesis class X protein (PIG-X)PIGX258
P40967PMEL_HUMANMelanocyte protein PMEL (ME20-M) (ME20M) (Melanocyte protein Pmel 17)PMEL D12S53E661
(Melanocytes lineage-specific antigen GP100) (Melanoma-associated ME20 antigen)PMEL17 SILV
(P1) (P100) (Premelanosome protein) (Silver locus protein homolog) [Cleaved into: M-
alpha (95 kDa melanocyte-specific secreted glycoprotein) (P26) (Secreted melanoma-
associated ME20 antigen) (ME20-S) (ME20S); M-beta]
Q8IY17PLPL6_HUMANNeuropathy target esterase (EC 3.1.1.5) (Patatin-like phospholipase domain-containing protein 6)PNPLA6 NTE1366
Q9BZG2PPAT_HUMANTesticular acid phosphatase (EC 3.1.3.2)ACPT426
Q86XR5PRIMA_HUMANProline-rich membrane anchor 1 (PRiMA)PRIMA1153
Q9HCM2PLXA4_HUMANPlexin-A4PLXNA4 KIAA15501894
PLXNA4A PLXNA4B
UNQ2820/PRO34003
O15031PLXB2_HUMANPlexin-B2 (MM1)PLXNB2 KIAA03151838
Q9ULL4PLXB3_HUMANPlexin-B3PLXNB3 KIAA12061909
PLXN6
O00592PODXL_HUMANPodocalyxin (GCTM-2 antigen) (Gp200) (Podocalyxin-like protein 1) (PC) (PCLP-1)PODXL PCLP558
PCLP1
Q8N131PORIM_HUMANPorimin (Keratinocytes-associated transmembrane protein 3) (KCT-3) (Pro-oncosisTMEM123 KCT3208
receptor inducing membrane injury) (Transmembrane protein 123)PSEC0111
UNQ641/PRO1271
P15309PPAP_HUMANProstatic acid phosphatase (PAP) (EC 3.1.3.2) (5′-nucleotidase) (5′-NT) (EC 3.1.3.5)ACPP386
(Ecto-5′-nucleotidase) (Thiamine monophosphatase) (TMPase) [Cleaved into: PAPf39]
Q5SGD2PPM1L_HUMANProtein phosphatase 1L (EC 3.1.3.16) (Protein phosphatase 1-like) (Protein phosphatasePPM1L PP2CE360
2C isoform epsilon) (PP2C-epsilon)
P16471PRLR_HUMANProlactin receptor (PRL-R)PRLR622
Q6UWB4PRS55_HUMANSerine protease 55 (EC 3.4.21.-) (Testis serine protease 1) (T-SP1)PRSS55 TSP1352
UNQ9391/PRO34284
P10586PTPRF_HUMANReceptor-type tyrosine-protein phosphatase F (EC 3.1.3.48) (Leukocyte common antigen related) (LAR)PTPRF LAR1907
P28827PTPRM_HUMANReceptor-type tyrosine-protein phosphatase mu (Protein-tyrosine phosphatase mu) (R-PTP-mu) (EC 3.1.3.48)PTPRM PTPRL11452
Q16849PTPRN_HUMANReceptor-type tyrosine-protein phosphatase-like N (R-PTP-N) (Islet cell antigen 512) (ICAPTPRN ICA3979
512) (Islet cell autoantigen 3) (PTP IA-2)ICA512
Q13332PTPRS_HUMANReceptor-type tyrosine-protein phosphatase S (R-PTP-S) (EC 3.1.3.48) (Receptor-typePTPRS1948
tyrosine-protein phosphatase sigma) (R-PTP-sigma)
Q6ISU1PTCRA_HUMANPre T-cell antigen receptor alpha (pT-alpha) (pTa) (pT-alpha-TCR)PTCRA281
P53801PTTG_HUMANPituitary tumor-transforming gene 1 protein-interacting protein (Pituitary tumor-PTTG1IP C21orf1180
transforming gene protein-binding factor) (PBF) (PTTG-binding factor)C21orf3
Q13308PTK7_HUMANInactive tyrosine-protein kinase 7 (Colon carcinoma kinase 4) (CCK-4) (Protein-tyrosinePTK7 CCK41070
kinase 7) (Pseudo tyrosine kinase receptor 7) (Tyrosine-protein kinase-like 7)
P23468PTPRD_HUMANReceptor-type tyrosine-protein phosphatase delta (Protein-tyrosine phosphatase delta)PTPRD1912
(R-PTP-delta) (EC 3.1.3.48)
Q15262PTPRK_HUMANReceptor-type tyrosine-protein phosphatase kappa (Protein-tyrosine phosphatase kappa)PTPRK PTPK1439
(R-PTP-kappa) (EC 3.1.3.48)
Q9UMZ3PTPRQ_HUMANPhosphatidylinositol phosphatase PTPRQ (EC 3.1.3.-) (Receptor-type tyrosine-proteinPTPRQ2332
phosphatase Q) (PTP-RQ) (R-PTP-Q) (EC 3.1.3.48)
P23467PTPRB_HUMANReceptor-type tyrosine-protein phosphatase beta (Protein-tyrosine phosphatase beta) (R-PTPRB PTPB1997
PTP-beta) (EC 3.1.3.48) (Vascular endothelial protein tyrosine phosphatase) (VE-PTP)
Q9HD43PTPRH_HUMANReceptor-type tyrosine-protein phosphatase H (R-PTP-H) (EC 3.1.3.48) (StomachPTPRH SAP11115
cancer-associated protein tyrosine phosphatase 1) (SAP-1) (Transmembrane-type
protein-tyrosine phosphatase type H)
Q16827PTPRO_HUMANReceptor-type tyrosine-protein phosphatase O (R-PTP-O) (EC 3.1.3.48) (GlomerularPTPRO GLEPP11216
epithelial protein 1) (Protein tyrosine phosphatase U2) (PTP-U2) (PTPase U2)PTPU2
Q15256PTPRR_HUMANReceptor-type tyrosine-protein phosphatase R (R-PTP-R) (EC 3.1.3.48) (Ch-1PTPase)PTPRR ECPTP657
(NC-PTPCOM1) (Protein-tyrosine phosphatase PCPTP1)PTPRQ
P15151PVR_HUMANPoliovirus receptor (Nectin-like protein 5) (NECL-5) (CD antigen CD155)PVR PVS417
P18433PTPRA_HUMANReceptor-type tyrosine-protein phosphatase alpha (Protein-tyrosine phosphatase alpha)PTPRA PTPA802
(R-PTP-alpha) (EC 3.1.3.48)PTPRL2
P08575PTPRC_HUMANReceptor-type tyrosine-protein phosphatase C (EC 3.1.3.48) (Leukocyte commonPTPRC CD451304
antigen) (L-CA) (T200) (CD antigen CD45)
O14522PTPRT_HUMANReceptor-type tyrosine-protein phosphatase T (R-PTP-T) (EC 3.1.3.48) (Receptor-typePTPRT KIAA02831441
tyrosine-protein phosphatase rho) (RPTP-rho)
Q92729PTPRU_HUMANReceptor-type tyrosine-protein phosphatase U (R-PTP-U) (EC 3.1.3.48) (PancreaticPTPRU FMI PCP21446
carcinoma phosphatase 2) (PCP-2) (Protein-tyrosine phosphatase J) (PTP-J) (hPTP-J)PTPRO
(Protein-tyrosine phosphatase pi) (PTP pi) (Protein-tyrosine phosphatase receptor
omicron) (PTP-RO) (Receptor-type protein-tyrosine phosphatase psi) (R-PTP-psi)
P23471PTPRZ_HUMANReceptor-type tyrosine-protein phosphatase zeta (R-PTP-zeta) (EC 3.1.3.48) (Protein-PTPRZ1 HTPZP22315
tyrosine phosphatase receptor type Z polypeptide 1) (Protein-tyrosine phosphatasePTPRZ PTPRZ2
receptor type Z polypeptide 2) (R-PTP-zeta-2)PTPZ
Q9NXS2QPCTL_HUMANGlutaminyl-peptide cyclotransferase-like protein (EC 2.3.2.5) (Golgi-resident glutaminyl-QPCTL382
peptide cyclotransferase) (isoQC) (gQC)
Q92932PTPR2_HUMANReceptor-type tyrosine-protein phosphatase N2 (R-PTP-N2) (EC 3.1.3.48) (Islet cellPTPRN2 KIAA03871015
autoantigen-related protein) (IAR) (ICAAR) (Phogrin)
P23469PTPRE_HUMANReceptor-type tyrosine-protein phosphatase epsilon (Protein-tyrosine phosphatasePTPRE700
epsilon) (R-PTP-epsilon) (EC 3.1.3.48)
P23470PTPRG_HUMANReceptor-type tyrosine-protein phosphatase gamma (Protein-tyrosine phosphatasePTPRG PTPG1445
gamma) (R-PTP-gamma) (EC 3.1.3.48)
Q12913PTPRJ_HUMANReceptor-type tyrosine-protein phosphatase eta (Protein-tyrosine phosphatase eta) (R-PTPRJ DEP11337
PTP-eta) (EC 3.1.3.48) (Density-enhanced phosphatase 1) (DEP-1) (HPTP eta) (Protein-
tyrosine phosphatase receptor type J) (R-PTP-J) (CD antigen CD148)
Q15109RAGE_HUMANAdvanced glycosylation end product-specific receptor (Receptor for advancedAGER RAGE404
glycosylation end products)
Q6UX71PXDC2_HUMANPlexin domain-containing protein 2 (Tumor endothelial marker 7-related protein)PLXDC2 TEM7R529
UNQ2514/PRO6003
O60894RAMP1_HUMANReceptor activity-modifying protein 1 (Calcitonin-receptor-like receptor activity-modifyingRAMP1148
protein 1) (CRLR activity-modifying protein 1)
O60895RAMP2_HUMANReceptor activity-modifying protein 2 (Calcitonin-receptor-like receptor activity-modifyingRAMP2175
protein 2) (CRLR activity-modifying protein 2)
O60896RAMP3_HUMANReceptor activity-modifying protein 3 (Calcitonin-receptor-like receptor activity-modifyingRAMP3148
protein 3) (CRLR activity-modifying protein 3)
Q8IUW5RELL1_HUMANRELT-like protein 1RELL1 PSEC0162271
O75787RENR_HUMANRenin receptor (ATPase H(+)-transporting lysosomal accessory protein 2) (ATPase H(+)-ATP6AP2 ATP6IP2350
transporting lysosomal-interacting protein 2) (ER-localized type I transmembrane adaptor)CAPER ELDF10
(Embryonic liver differentiation factor 10) (N14F) (Renin/prorenin receptor) (Vacuolar ATPHT028 MSTP009
synthase membrane sector-associated protein M8-9) (ATP6M8-9) (V-ATPase M8.9 subunit)PSEC0072
Q6H3X3RET1G_HUMANRetinoic acid early transcript 1G protein (UL-16 binding protein 5) (ULBP5)RAET1G334
P07949RET_HUMANProto-oncogene tyrosine-protein kinase receptor Ret (EC 2.7.10.1) (Cadherin familyRET CDHF121114
member 12) (Proto-oncogene c-Ret) [Cleaved into: Soluble RET kinase fragment;CDHR16 PTC
Extracellular cell-membrane anchored RET cadherin 120 kDa fragment]RET51
Q9ULK6RN150_HUMANRING finger protein 150RNF150 KIAA1214438
Q9Y6N7ROBO1_HUMANRoundabout homolog 1 (Deleted in U twenty twenty) (H-Robo-1)ROBO1 DUTT11651
Q01974ROR2_HUMANTyrosine-protein kinase transmembrane receptor ROR2 (EC 2.7.10.1) (NeurotrophicROR2 NTRKR2943
tyrosine kinase, receptor-related 2)
P04843RPN1_HUMANDolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 (EC 2.4.99.18)RPN1607
(Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 67 kDa subunit)
(Ribophorin I) (RPN-I) (Ribophorin-1)
Q68DV7RNF43_HUMANE3 ubiquitin-protein ligase RNF43 (EC 6.3.2.-) (RING finger protein 43)RNF43783
Q04912RON_HUMANMacrophage-stimulating protein receptor (MSP receptor) (EC 2.7.10.1) (CDw136)MST1R PTK8 RON1400
(Protein-tyrosine kinase 8) (p185-Ron) (CD antigen CD136) [Cleaved into: Macrophage-
stimulating protein receptor alpha chain; Macrophage-stimulating protein receptor beta chain]
Q96MS0ROBO3_HUMANRoundabout homolog 3 (Roundabout-like protein 3)ROBO31386
Q01973ROR1_HUMANInactive tyrosine-protein kinase transmembrane receptor ROR1 (Neurotrophic tyrosineROR1 NTRKR1937
kinase, receptor-related 1)
P08922ROS1_HUMANProto-oncogene tyrosine-protein kinase ROS (EC 2.7.10.1) (Proto-oncogene c-Ros)ROS1 MCF3 ROS2347
(Proto-oncogene c-Ros-1) (Receptor tyrosine kinase c-ros oncogene 1) (c-Ros receptor
tyrosine kinase)
Q9HCK4ROBO2_HUMANRoundabout homolog 2ROBO2 KIAA15681378
P34925RYK_HUMANTyrosine-protein kinase RYK (EC 2.7.10.1)RYK JTK5A604
Q9HBV2SACA1_HUMANSperm acrosome membrane-associated protein 1 (Sperm acrosomal membrane-SPACA1 SAMP32294
associated protein 32)
P31431SDC4_HUMANSyndecan-4 (SYND4) (Amphiglycan) (Ryudocan core protein)SDC4198
P21583SCF_HUMANKit ligand (Mast cell growth factor) (MGF) (Stem cell factor) (SCF) (c-Kit ligand) [CleavedKITLG MGF SCF273
into: Soluble KIT ligand (sKITLG)]
O60939SCN2B_HUMANSodium channel subunit beta-2SCN2B215
UNQ326/PRO386
Q8IWT1SCN4B_HUMANSodium channel subunit beta-4SCN4B228
P18827SDC1_HUMANSyndecan-1 (SYND1) (CD antigen CD138)SDC1 SDC310
O75056SDC3_HUMANSyndecan-3 (SYND3)SDC3 KIAA0468442
Q9NTN9SEM4G_HUMANSemaphorin-4GSEMA4G KIAA1619838
W5XKT8SACA6_HUMANSperm acrosome membrane-associated protein 6 (BACHELOR-like protein)SPACA6 SPACA6P324
UNQ2487/PRO5774
Q96BY9SARAF_HUMANStore-operated calcium entry-associated regulatory factor (SARAF) (SOCE-associatedSARAF TMEM66339
regulatory factor) (HBV X-transactivated gene 3 protein) (HBV XAg-transactivated proteinXTP3 HSPC035
3) (Protein FOAP-7) (Transmembrane protein 66)NPD003 PSEC0019
UNQ1967/PRO4499
Q13591SEM5A_HUMANSemaphorin-5A (Semaphorin-F) (Sema F)SEMA5A SEMAF1074
Q53EL9SEZ6_HUMANSeizure protein 6 homolog (SEZ-6) (hSEZ-6)SEZ6994
Q9NY72SCN3B_HUMANSodium channel subunit beta-3SCN3B KIAA1158215
Q8WVN6SCTM1_HUMANSecreted and transmembrane protein 1 (Protein K-12)SECTM1 K12248
Q9UBV2SE1L1_HUMANProtein sel-1 homolog 1 (Suppressor of lin-12-like protein 1) (Sel-1L)SEL1L TSA305794
UNQ128/PRO1063
Q9NPR2SEM4B_HUMANSemaphorin-4BSEMA4B KIAA1745832
SEMAC
UNQ749/PRO1480
O95754SEM4F_HUMANSemaphorin-4F (Semaphorin-M) (Sema M) (Semaphorin-W) (Sema W)SEMA4F SEMAM770
SEMAW
Q96RL6SIG11_HUMANSialic acid-binding Ig-like lectin 11 (Sialic acid-binding lectin 11) (Siglec-11)SIGLEC11698
UNQ9222/PRO28718
Q07699SCN1B_HUMANSodium channel subunit beta-1SCN1B218
P34741SDC2_HUMANSyndecan-2 (SYND2) (Fibroglycan) (Heparan sulfate proteoglycan core protein) (HSPG)SDC2 HSPG1201
(CD antigen CD362)
Q7Z5N4SDK1_HUMANProtein sidekick-1SDK12213
Q58EX2SDK2_HUMANProtein sidekick-2SDK2 KIAA15142172
Q5TEA6SE1L2_HUMANProtein sel-1 homolog 2 (Suppressor of lin-12-like protein 2) (Sel-1L2)SEL1L2 C20orf50688
Q9BYH1SE6L1_HUMANSeizure 6-like proteinSEZ6L KIAA09271024
UNQ2542/PRO6094
Q14242SELPL_HUMANP-selectin glycoprotein ligand 1 (PSGL-1) (Selectin P ligand) (CD antigen CD162)SELPLG412
Q9H3T2SEM6C_HUMANSemaphorin-6C (Semaphorin-Y) (Sema Y)SEMA6C KIAA1869930
SEMAY
Q96DD7SHSA4_HUMANProtein shisa-4 (Transmembrane protein 58)SHISA4 C1orf40197
TMEM58
UNQ583/PRO1153
Q9P0V8SLAF8_HUMANSLAM family member 8 (B-lymphocyte activator macrophage expressed) (BCM-likeSLAMF8 BLAME285
membrane protein) (CD antigen CD353)
Q9H3T3SEM6B_HUMANSemaphorin-6B (Semaphorin-Z) (Sema Z)SEMA6B SEMAN888
SEMAZ
UNQ1907/PRO4353
Q8NFY4SEM6D_HUMANSemaphorin-6DSEMA6D KIAA14791073
O94933SLIK3_HUMANSLIT and NTRK-like protein 3SLITRK3 KIAA0848977
Q6UXD5SE6L2_HUMANSeizure 6-like protein 2SEZ6L2 PSK910
UNQ1903/PRO4349
Q9C0C4SEM4C_HUMANSemaphorin-4CSEMA4C KIAA1739833
SEMAI
UNQ5855/PRO34487
Q92854SEM4D_HUMANSemaphorin-4D (A8) (BB18) (GR3) (CD antigen CD100)SEMA4D C9orf164862
CD100 SEMAJ
P78324SHPS1_HUMANTyrosine-protein phosphatase non-receptor type substrate 1 (SHP substrate 1) (SHPS-1)SIRPA BIT MFR504
(Brain Ig-like molecule with tyrosine-based activation motifs) (Bit) (CD172 antigen-likeMYD1 PTPNS1
family member A) (Inhibitory receptor SHPS-1) (Macrophage fusion receptor) (MyD-1SHPS1 SIRP
antigen) (Signal-regulatory protein alpha-1) (Sirp-alpha-1) (Signal-regulatory protein
alpha-2) (Sirp-alpha-2) (Signal-regulatory protein alpha-3) (Sirp-alpha-3) (p84) (CD
antigen CD172a)
Q8N114SHSA5_HUMANProtein shisa-5 (Putative NF-kappa-B-activating protein 120) (Scotin)SHISA5 SCOTIN240
PSEC0133
B8ZZ34SHSA8_HUMANPutative protein shisa-8SHISA8 C22orf17492
Q96PQ1SIG12_HUMANSialic acid-binding Ig-like lectin 12 (Siglec-12) (Sialic acid-binding Ig-like lectin-like 1)SIGLEC12595
(Siglec-L1)SIGLECL1 SLG
UNQ9215/PRO34042
Q5JXA9SIRB2_HUMANSignal-regulatory protein beta-2 (SIRP-beta-2) (Protein tyrosine phosphatase non-SIRPB2 PTPN1L342
receptor type substrate 1-like 3) (Protein tyrosine phosphatase non-receptor type substrate protein)PTPNS1L3
Q9P1W8SIRPG_HUMANSignal-regulatory protein gamma (SIRP-gamma) (CD172 antigen-like family member B)SIRPG SIRPB2387
(Signal-regulatory protein beta-2) (SIRP-b2) (SIRP-beta-2) (CD antigen CD172g)
Q9BQ49SMIM7_HUMANSmall integral membrane protein 7SMIM7 C19orf4275
Q9H3S1SEM4A_HUMANSemaphorin-4A (Semaphorin-B) (Sema B)SEMA4A SEMAB SEMB761
UNQ783/PRO1317
Q9H2E6SEM6A_HUMANSemaphorin-6A (Semaphorin VIA) (Sema VIA) (Semaphorin-6A-1) (SEMA6A-1)SEMA6A KIAA13681030
SEMAQ
B4DS77SHSA9_HUMANProtein shisa-9SHISA9424
A6NMB1SIG16_HUMANSialic acid-binding Ig-like lectin 16 (Siglec-16) (Siglec-P16)SIGLEC16481
SIGLECP16
Q9NYZ4SIGL8_HUMANSialic acid-binding Ig-like lectin 8 (Siglec-8) (Sialoadhesin family member 2) (SAF-2)SIGLEC8 SAF2499
Q9UIB8SLAF5_HUMANSLAM family member 5 (Cell surface antigen MAX.3) (Hly9-beta) (LeukocyteCD84 SLAMF5345
differentiation antigen CD84) (Signaling lymphocytic activation molecule 5) (CD antigen CD84)
Q16586SGCA_HUMANAlpha-sarcoglycan (Alpha-SG) (50 kDa dystrophin-associated glycoprotein) (50DAG)SGCA ADL DAG2387
(Adhalin) (Dystroglycan-2)
A0PJX4SHSA3_HUMANProtein shisa-3 homologSHISA3238
Q96LC7SIG10_HUMANSialic acid-binding Ig-like lectin 10 (Siglec-10) (Siglec-like protein 2)SIGLEC10 SLG2697
UNQ477/PRO940
O15389SIGL5_HUMANSialic acid-binding Ig-like lectin 5 (Siglec-5) (CD33 antigen-like 2) (Obesity-binding proteinSIGLEC5 CD33L2551
2) (OB-BP2) (OB-binding protein 2) (CD antigen CD170)OBBP2
O43699SIGL6_HUMANSialic acid-binding Ig-like lectin 6 (Siglec-6) (CD33 antigen-like 1) (CDw327) (Obesity-SIGLEC6 CD33L453
binding protein 1) (OB-BP1) (CD antigen CD327)CD33L1 OBBP1
Q9Y336SIGL9_HUMANSialic acid-binding Ig-like lectin 9 (Siglec-9) (CDw329) (Protein FOAP-9) (CD antigen CD329)SIGLEC9463
UNQ668/PRO1302
O00241SIRB1_HUMANSignal-regulatory protein beta-1 (SIRP-beta-1) (CD172 antigen-like family member B) (CD antigen CD172b)SIRPB1398
Q13291SLAF1_HUMANSignaling lymphocytic activation molecule (CDw150) (IPO-3) (SLAM family member 1) (CD antigen CD150)SLAMF1 SLAM335
Q96DU3SLAF6_HUMANSLAM family member 6 (Activating NK receptor) (NK-T-B-antigen) (NTB-A) (CD antigen CD352)SLAMF6 KALI332
UNQ6123/PRO20080
O94991SLIK5_HUMANSLIT and NTRK-like protein 5 (Leucine-rich repeat-containing protein 11)SLITRK5 KIAA0918958
LRRC11
Q96PQ0SORC2_HUMANVPS10 domain-containing receptor SorCS2SORCS2 KIAA13291159
Q6UWI4SHSA2_HUMANProtein shisa-2 homolog (Transmembrane protein 46)SHISA2 C13orf13295
TMEM46
UNQ9166/PRO28631
Q6ZMC9SIG15_HUMANSialic acid-binding Ig-like lectin 15 (Siglec-15) (CD33 antigen-like 3)SIGLEC15 CD33L3328
Q9Y286SIGL7_HUMANSialic acid-binding Ig-like lectin 7 (Siglec-7) (Adhesion inhibitory receptor molecule 1)SIGLEC7 AIRM1467
(AIRM-1) (CDw328) (D-siglec) (QA79 membrane protein) (p75) (CD antigen CD328)
Q96A28SLAF9_HUMANSLAM family member 9 (CD2 family member 10) (CD2F-10) (CD84 homolog 1) (CD84-H1)SLAMF9 CD2F10289
UNQ1938/PRO4421
Q9H156SLIK2_HUMANSLIT and NTRK-like protein 2SLITRK2 CXorf2845
KIAA1854 SLITL1
UNQ9197/PRO34756
Q8IW52SLIK4_HUMANSLIT and NTRK-like protein 4SLITRK4837
A6NGZ8SMIM9_HUMANSmall integral membrane protein 9SMIM9 CXorf6899
Q8WY21SORC1_HUMANVPS10 domain-containing receptor SorCS1 (hSorCS)SORCS1 SORCS1168
Q92673SORL_HUMANSortilin-related receptor (Low-density lipoprotein receptor relative with 11 ligand-bindingSORL1 C11orf322214
repeats) (LDLR relative with 11 ligand-binding repeats) (LR11) (SorLA-1) (Sorting protein-
related receptor containing LDLR class A repeats) (SorLA)
Q99523SORT_HUMANSortilin (100 kDa NT receptor) (Glycoprotein 95) (Gp95) (Neurotensin receptor 3) (NT3) (NTR3)SORT1831
Q9Y3P8SIT1_HUMANSignaling threshold-regulating transmembrane adapter 1 (SHP2-interactingSIT1 SIT196
transmembrane adapter protein) (Suppression-inducing transmembrane adapter 1) (gp30/40)
Q9NQ25SLAF7_HUMANSLAM family member 7 (CD2 subset 1) (CD2-like receptor-activating cytotoxic cells)SLAMF7 CS1335
(CRACC) (Membrane protein FOAP-12) (Novel Ly9) (Protein 19A) (CD antigen CD319)UNQ576/PRO1138
Q96PX8SLIK1_HUMANSLIT and NTRK-like protein 1 (Leucine-rich repeat-containing protein 12)SLITRK1 KIAA1910696
LRRC12
UNQ233/PRO266
Q9H5Y7SLIK6_HUMANSLIT and NTRK-like protein 6SLITRK6841
Q6ZSJ9SHSA6_HUMANProtein shisa-6 homologSHISA6500
Q08ET2SIG14_HUMANSialic acid-binding Ig-like lectin 14 (Siglec-14)SIGLEC14396
UNQ294/PRO333
Q5TFQ8SIRBL_HUMANSignal-regulatory protein beta-1 isoform 3 (SIRP-beta-1 isoform 3)SIRPB1398
Q9UPU3SORC3_HUMANVPS10 domain-containing receptor SorCS3SORCS3 KIAA10591222
O43291SPIT2_HUMANKunitz-type protease inhibitor 2 (Hepatocyte growth factor activator inhibitor type 2) (HAI-SPINT2 HAI2 KOP252
2) (Placental bikunin)
Q9BZZ2SN_HUMANSialoadhesin (Sialic acid-binding Ig-like lectin 1) (Siglec-1) (CD antigen CD169)SIGLEC1 SN1709
Q9P246STIM2_HUMANStromal interaction molecule 2STIM2 KIAA1482746
Q9UBS9SUCO_HUMANSUN domain-containing ossification factor (Membrane protein CH1) (ProteinSUCO C1orf9 CH11254
osteopotentia homolog) (SUN-like protein 1)OPT SLP1
Q96GP6SREC2_HUMANScavenger receptor class F member 2 (SRECRP-1) (Scavenger receptor expressed bySCARF2 SREC2870
endothelial cells 2 protein) (SREC-II)SREPCR
P43307SSRA_HUMANTranslocon-associated protein subunit alpha (TRAP-alpha) (Signal sequence receptorSSR1 TRAPA PSEC0262286
subunit alpha) (SSR-alpha)
Q5VX71SUSD4_HUMANSushi domain-containing protein 4SUSD4490
UNQ196/PRO222
P43308SSRB_HUMANTranslocon-associated protein subunit beta (TRAP-beta) (Signal sequence receptorSSR2 TRAPB183
subunit beta) (SSR-beta)HSD25
P51571SSRD_HUMANTranslocon-associated protein subunit delta (TRAP-delta) (Signal sequence receptorSSR4 TRAPD173
subunit delta) (SSR-delta)
Q13586STIM1_HUMANStromal interaction molecule 1STIM1 GOK685
Q14162SREC_HUMANScavenger receptor class F member 1 (Acetyl LDL receptor) (Scavenger receptorSCARF1 KIAA0149830
expressed by endothelial cells 1) (SREC-I)SREC
Q92537SUSD6_HUMANSushi domain-containing protein 6 (Drug-activated gene overexpressed protein)SUSD6 DRAGO303
KIAA0247
Q9NY15STAB1_HUMANStabilin-1 (Fasciclin, EGF-like, laminin-type EGF-like and link domain-containingSTAB1 FEEL12570
scavenger receptor 1) (FEEL-1) (MS-1 antigen)KIAA0246
Q8WWQ8STAB2_HUMANStabilin-2 (FAS1 EGF-like and X-link domain-containing adhesion molecule 2) (Fasciclin,STAB2 FEEL22551
EGF-like, laminin-type EGF-like and link domain-containing scavenger receptor 2) (FEEL-FELL FEX2 HARE
2) (Hyaluronan receptor for endocytosis) [Cleaved into: 190 kDa form stabilin-2 (190 kDa
hyaluronan receptor for endocytosis)]
O60279SUSD5_HUMANSushi domain-containing protein 5SUSD5 KIAA0527629
Q9UGT4SUSD2_HUMANSushi domain-containing protein 2SUSD2822
Q9UQF0SYCY1_HUMANSyncytin-1 (Endogenous retrovirus group W member 1) (Env-W) (Envelope polyproteinERVW-1 ERVWE1538
gPr73) (Enverin) (HERV-7q Envelope protein) (HERV-W envelope protein) (HERV-
W_7q21.2 provirus ancestral Env polyprotein) (Syncytin) [Cleaved into: Surface protein
(SU) (gp50); Transmembrane protein (TM) (gp24)]
Q6UWL2SUSD1_HUMANSushi domain-containing protein 1SUSD1747
UNQ2438/PRO4999
Q8N3T6T132C_HUMANTransmembrane protein 132CTMEM132C1108
A2VDJ0T131L_HUMANTransmembrane protein 131-likeKIAA09221609
TMEM131L
Q6IEE7T132E_HUMANTransmembrane protein 132ETMEM132E984
Q14DG7T132B_HUMANTransmembrane protein 132BTMEM132B KIAA17861078
KIAA1906
P09758TACD2_HUMANTumor-associated calcium signal transducer 2 (Cell surface glycoprotein Trop-2)TACSTD2 GA733-1323
(Membrane component chromosome 1 surface marker 1) (Pancreatic carcinoma markerM1S1 TROP2
protein GA733-1)
Q14C87T132D_HUMANTransmembrane protein 132D (Mature oligodendrocytes transmembrane protein) (MatureTMEM132D1099
OL transmembrane protein)HBE120 KIAA1944
MOLT
Q96GX1TECT2_HUMANTectonic-2TCTN2 C12orf38697
TECT2
Q24JP5T132A_HUMANTransmembrane protein 132A (HSPA5-binding protein 1)TMEM132A1023
HSPA5BP1
KIAA1583
B6A8C7TARM1_HUMANT-cell-interacting, activating receptor on myeloid cells protein 1 (OSCAR-like transcript-2TARM1271
protein) (OLT-2)
P40200TACT_HUMANT-cell surface protein tactile (Cell surface antigen CD96) (T cell-activated increased lateCD96585
expression protein) (CD antigen CD96)
Q9UIK5TEFF2_HUMANTomoregulin-2 (TR-2) (Hyperplastic polyposis protein 1) (Transmembrane protein withTMEFF2 HPP1374
EGF-like and two follistatin-like domains)TENB2 TPEF
UNQ178/PRO204
P36897TGFR1_HUMANTGF-beta receptor type-1 (TGFR-1) (EC 2.7.11.30) (Activin A receptor type II-like proteinTGFBR1 ALK5 SKR4503
kinase of 53 kD) (Activin receptor-like kinase 5) (ALK-5) (ALK5) (Serine/threonine-protein
kinase receptor R4) (SKR4) (TGF-beta type I receptor) (Transforming growth factor-beta
receptor type I) (TGF-beta receptor type I) (TbetaR-I)
Q9NS62THSD1_HUMANThrombospondin type-1 domain-containing protein 1 (Transmembrane molecule withTHSD1 TMTSP852
thrombospondin module)UNQ3010/PRO9769
Q02763TIE2_HUMANAngiopoietin-1 receptor (EC 2.7.10.1) (Endothelial tyrosine kinase) (Tunica internaTEK TIE2 VMCM1124
endothelial cell kinase) (Tyrosine kinase with Ig and EGF homology domains-2)VMCM1
(Tyrosine-protein kinase receptor TEK) (Tyrosine-protein kinase receptor TIE-2) (hTIE2)
(p140 TEK) (CD antigen CD202b)
P13726TF_HUMANTissue factor (TF) (Coagulation factor III) (Thromboplastin) (CD antigen CD142)F3295
Q495A1TIGIT_HUMANT-cell immunoreceptor with Ig and ITIM domains (V-set and immunoglobulin domain-TIGIT VSIG9244
containing protein 9) (V-set and transmembrane domain-containing protein 3)VSTM3
Q03167TGBR3_HUMANTransforming growth factor beta receptor type 3 (TGF-beta receptor type 3) (TGFR-3)TGFBR3851
(Betaglycan) (Transforming growth factor beta receptor III) (TGF-beta receptor type III)
O43493TGON2_HUMANTrans-Golgi network integral membrane protein 2 (TGN38 homolog) (TGN46) (TGN48)TGOLN2 TGN46480
(Trans-Golgi network protein TGN51)TGN51
Q9BXR5TLR10_HUMANToll-like receptor 10 (CD antigen CD290)TLR10811
UNQ315/PRO358
Q8IYR6TEFF1_HUMANTomoregulin-1 (TR-1) (H7365) (Transmembrane protein with EGF-like and one follistatin-like domain)TMEFF1 C9orf2380
Q8N3G9TM130_HUMANTransmembrane protein 130TMEM130435
UNQ719/PRO1383
Q4KMG9TM52B_HUMANTransmembrane protein 52BTMEM52B C12orf59183
UNQ5927/PRO19821
Q9BZD6TMG4_HUMANTransmembrane gamma-carboxyglutamic acid protein 4 (Praline-rich gamma-PRRG4 PRGP4 TMG4226
carboxyglutamic acid protein 4) (Proline-rich Gla protein 4)
Q8NEW7TMIE_HUMANTransmembrane inner ear expressed proteinTMIE156
Q9HBJ8TMM27_HUMANCollectrin (Transmembrane protein 27)TMEM27222
UNQ679/PRO1312
Q6UXU6TMM92_HUMANTransmembrane protein 92TMEM92159
UNQ5801/PRO19608
Q6NUS6TECT3_HUMANTectonic-3TCTN3 C10orf61607
TECT3 PSEC0041
UNQ1881/PRO4324
P35590TIE1_HUMANTyrosine-protein kinase receptor Tie-1 (EC 2.7.10.1)TIE1 TIE1138
Q15363TMED2_HUMANTransmembrane emp24 domain-containing protein 2 (Membrane protein p24A) (p24)TMED2 RNP24201
(p24 family protein beta-1) (p24beta1)
Q7Z7H5TMED4_HUMANTransmembrane emp24 domain-containing protein 4 (Endoplasmic reticulum stress-TMED4 ERS25227
response protein 25) (ERS25) (GMP25iso) (Putative NF-kappa-B-activating protein 156)
(p24 family protein alpha-3) (p24alpha3)
Q9Y3B3TMED7_HUMANTransmembrane emp24 domain-containing protein 7 (p24 family protein gamma-3)TMED7 CGI-109224
(p24gamma3) (p27)
Q07011TNR9_HUMANTumor necrosis factor receptor superfamily member 9 (4-1BB ligand receptor) (CDw137)TNFRSF9 CD137 ILA255
(T-cell antigen 4-1BB homolog) (T-cell antigen ILA) (CD antigen CD137)
P01135TGFA_HUMANProtransforming growth factor alpha [Cleaved into: Transforming growth factor alphaTGFA160
(TGF-alpha) (EGF-like TGF) (ETGF) (TGF type 1)]
P37173TGFR2_HUMANTGF-beta receptor type-2 (TGFR-2) (EC 2.7.11.30) (TGF-beta type II receptor)TGFBR2567
(Transforming growth factor-beta receptor type II) (TGF-beta receptor type II) (TbetaR-II)
Q9UPZ6THS7A_HUMANThrombospondin type-1 domain-containing protein 7ATHSD7A KIAA09601657
Q9C0I4THS7B_HUMANThrombospondin type-1 domain-containing protein 7BTHSD7B KIAA16791608
Q96H15TIMD4_HUMANT-cell immunoglobulin and mucin domain-containing protein 4 (TIMD-4) (T-cellTIMD4 TIM4378
immunoglobulin mucin receptor 4) (TIM-4) (T-cell membrane protein 4)
Q15399TLR1_HUMANToll-like receptor 1 (Toll/interleukin-1 receptor-like protein) (TIL) (CD antigen CD281)TLR1 KIAA0012786
O15455TLR3_HUMANToll-like receptor 3 (CD antigen CD283)TLR3904
O60602TLR5_HUMANToll-like receptor 5 (Toll/interleukin-1 receptor-like protein 3)TLR5 TIL3858
Q4V9L6TM119_HUMANTransmembrane protein 119 (Osteoblast induction factor) (OBIF)TMEM119 PSEC0199283
UNQ731/PRO1415
Q13445TMED1_HUMANTransmembrane emp24 domain-containing protein 1 (Interleukin-1 receptor-like 1 ligand)TMED1 IL1RL1L227
(Putative T1/ST2 receptor-binding protein) (p24 family protein gamma-1) (Tp24) (p24gamma1)IL1RL1LG
Q9Y3A6TMED5_HUMANTransmembrane emp24 domain-containing protein 5 (p24 family protein gamma-2) (p24gamma2) (p28)TMED5 CGI-100229
UNQ397/PRO733
P49755TMEDA_HUMANTransmembrane emp24 domain-containing protein 10 (21 kDa transmembrane-traffickingTMED10 TMP21219
protein) (S31III125) (S31I125) (Tmp-21-I) (Transmembrane protein Tmp21) (p23) (p24
family protein delta-1) (p24delta1) (p24delta)
Q86V40TIKI1_HUMANMetalloprotease TIKI1 (EC 3.4.-.-) (TRAB domain-containing protein 2A)TRABD2A C2orf89505
TIKI1
Q9Y2C9TLR6_HUMANToll-like receptor 6 (CD antigen CD286)TLR6796
Q9NR97TLR8_HUMANToll-like receptor 8 (CD antigen CD288)TLR81041
UNQ249/PRO286
Q8WZ59TM190_HUMANTransmembrane protein 190TMEM190 MDAC1177
Q6UWW9TM207_HUMANTransmembrane protein 207TMEM207146
UNQ846/PRO1784
Q9UK28TM59L_HUMANTransmembrane protein 59-like (Brain-specific membrane-anchored protein)TMEM59L BSMAP342
C19orf4
Q8WW62TMED6_HUMANTransmembrane emp24 domain-containing protein 6 (p24 family protein gamma-5) (p24gamma5)TMED6240
UNQ9146/PRO34237
Q9BVK6TMED9_HUMANTransmembrane emp24 domain-containing protein 9 (GMP25) (Glycoprotein 25L2) (p24TMED9 GP25L2235
family protein alpha-2) (p24alpha2) (p25)
O14668TMG1_HUMANTransmembrane gamma-carboxyglutamic acid protein 1 (Proline-rich gamma-PRRG1 PRGP1218
carboxyglutamic acid protein 1) (Proline-rich Gla protein 1)TMG1
Q96BF3TMIG2_HUMANTransmembrane and immunoglobulin domain-containing protein 2 (CD28 homolog)TMIGD2 CD28H282
(Immunoglobulin and proline-rich receptor 1) (IGPR-1)IGPR1
UNQ3059/PRO9879
P43489TNR4_HUMANTumor necrosis factor receptor superfamily member 4 (ACT35 antigen) (OX40L receptor)TNFRSF4 TXGP1L111
(TAX transcriptionally-activated glycoprotein 1 receptor) (CD antigen CD134)
P25942TNR5_HUMANTumor necrosis factor receptor superfamily member 5 (B-cell surface antigen CD40)CD40 TNFRSF5277
(Bp50) (CD40L receptor) (CDw40) (CD antigen CD40)
P25445TNR6_HUMANTumor necrosis factor receptor superfamily member 6 (Apo-1 antigen) (Apoptosis-FAS APT1 FAS1335
mediating surface antigen FAS) (FASLG receptor) (CD antigen CD95)TNFRSF6
O14763TR10B_HUMANTumor necrosis factor receptor superfamily member 10B (Death receptor 5) (TNF-relatedTNFRSF10B DR5440
apoptosis-inducing ligand receptor 2) (TRAIL receptor 2) (TRAIL-R2) (CD antigen CD262)KILLER TRAILR2
TRICK2 ZTNFR9
UNQ160/PRO186
Q8TB96TIP_HUMANT-cell immunomodulatory protein (Protein TIP) (Integrin-alpha FG-GAP repeat-containingITFG1 LNKN-1 TIP612
protein 1) (Linkin)CDA08
O00206TLR4_HUMANToll-like receptor 4 (hToll) (CD antigen CD284)TLR4839
Q6P9G4TM154_HUMANTransmembrane protein 154TMEM154183
Q9BXS4TMM59_HUMANTransmembrane protein 59 (Liver membrane-bound protein)TMEM59 C1orf8323
HSPC001
UNQ169/PRO195
Q9NP84TNR12_HUMANTumor necrosis factor receptor superfamily member 12A (Fibroblast growth factor-TNFRSF12A FN14129
inducible immediate-early response protein 14) (FGF-inducible 14) (Tweak-receptor)
(TweakR) (CD antigen CD266)
Q9Y5U5TNR18_HUMANTumor necrosis factor receptor superfamily member 18 (Activation-inducible TNFR familyTNFRSF18 AITR241
receptor) (Glucocorticoid-induced TNFR-related protein) (CD antigen CD357)GITR UNQ319/PRO364
P20333TNR1B_HUMANTumor necrosis factor receptor superfamily member 1B (Tumor necrosis factor receptorTNFRSF1B TNFBR461
2) (TNF-R2) (Tumor necrosis factor receptor type II) (TNF-RII) (TNFR-II) (p75) (p80 TNF-TNFR2
alpha receptor) (CD antigen CD120b) (Etanercept) [Cleaved into: Tumor necrosis factor
receptor superfamily member 1b, membrane form; Tumor necrosis factor-binding protein
2 (TBP-2) (TBPII)]
Q9UBN6TR10D_HUMANTumor necrosis factor receptor superfamily member 10D (Decoy receptor 2) (DcR2)TNFRSF10D DCR2386
(TNF-related apoptosis-inducing ligand receptor 4) (TRAIL receptor 4) (TRAIL-R4)TRAILR4 TRUNDD
(TRAIL receptor with a truncated death domain) (CD antigen CD264)UNQ251/PRO288
Q9NZC2TREM2_HUMANTriggering receptor expressed on myeloid cells 2 (TREM-2) (Triggering receptorTREM2230
expressed on monocytes 2)
A6NFA1TIKI2_HUMANMetalloprotease TIKI2 (EC 3.4.-.-) (Heart, kidney and adipose-enriched transmembraneTRABD2B HKAT517
protein homolog) (TRAB domain-containing protein 2B)TIKI2
Q9NYK1TLR7_HUMANToll-like receptor 7TLR71049
UNQ248/PRO285
Q9NR96TLR9_HUMANToll-like receptor 9 (CD antigen CD289)TLR91032
UNQ5798/PRO19605
A2RRL7TM213_HUMANTransmembrane protein 213TMEM213107
Q9P0T7TMEM9_HUMANTransmembrane protein 9 (Dermal papilla-derived protein 4)TMEM9 DERP4183
TMEM9A HSPC186
PSEC0012
UNQ631/PRO1248
A2RUT3TMM89_HUMANTransmembrane protein 89TMEM89159
Q9H3N1TMX1_HUMANThioredoxin-related transmembrane protein 1 (Thioredoxin domain-containing protein 1)TMX1 TMX TXNDC280
(Transmembrane Trx-related protein)TXNDC1 PSEC0085
UNQ235/PRO268
Q92956TNR14_HUMANTumor necrosis factor receptor superfamily member 14 (Herpes virus entry mediator A)TNFRSF14 HVEA283
(Herpesvirus entry mediator A) (HveA) (Tumor necrosis factor receptor-like 2) (TR2) (CDHVEM
antigen CD270)UNQ329/PRO509
Q9NS68TNR19_HUMANTumor necrosis factor receptor superfamily member 19 (TRADE) (Toxicity and JNKTNFRSF19 TAJ423
inducer)TROY
UNQ1888/PRO4333
P19438TNR1A_HUMANTumor necrosis factor receptor superfamily member 1A (Tumor necrosis factor receptorTNFRSF1A TNFAR455
1) (TNF-R1) (Tumor necrosis factor receptor type I) (TNF-RI) (TNFR-I) (p55) (p60) (CDTNFR1
antigen CD120a) [Cleaved into: Tumor necrosis factor receptor superfamily member 1A,
membrane form; Tumor necrosis factor-binding protein 1 (TBPI)]
Q93038TNR25_HUMANTumor necrosis factor receptor superfamily member 25 (Apo-3) (Apoptosis-inducingTNFRSF25 APO3417
receptor AIR) (Apoptosis-mediating receptor DR3) (Apoptosis-mediating receptorDDR3 DR3
TRAMP) (Death receptor 3) (Lymphocyte-associated receptor of death) (LARD) (ProteinTNFRSF12 WSL
WSL) (Protein WSL-1)WSL1 UNQ455/PRO779
P0DKB5TPBGL_HUMANTrophoblast glycoprotein-likeTPBGL382
Q9BX59TPSNR_HUMANTapasin-related protein (TAPASIN-R) (TAP-binding protein-like) (TAP-binding protein-TAPBPL468
related protein) (TAPBP-R) (Tapasin-like)
O60603TLR2_HUMANToll-like receptor 2 (Toll/interleukin-1 receptor-like protein 4) (CD antigen CD282)TLR2 TIL4784
Q6UXF1TM108_HUMANTransmembrane protein 108TMEM108575
KIAA1690
UNQ1875/PRO4318
Q8IV31TM139_HUMANTransmembrane protein 139TMEM139216
UNQ1932/PRO4407
A6NLX4TM210_HUMANTransmembrane protein 210TMEM210147
Q9Y3Q3TMED3_HUMANTransmembrane emp24 domain-containing protein 3 (Membrane protein p24B) (p24TMED3 C15orf22217
family protein gamma-4) (p24gamma4) (p26)UNQ5357/PRO1078
O14669TMG2_HUMANTransmembrane gamma-carboxyglutamic acid protein 2 (Praline-rich gamma-PRRG2 PRGP2202
carboxyglutamic acid protein 2) (Proline-rich Gla protein 2)TMG2
Q9BZD7TMG3_HUMANTransmembrane gamma-carboxyglutamic acid protein 3 (Proline-rich gamma-PRRG3 PRGP3231
carboxyglutamic acid protein 3) (Proline-rich Gla protein 3)TMG3
Q9Y320TMX2_HUMANThioredoxin-related transmembrane protein 2 (Cell proliferation-inducing gene 26 protein)TMX2 TXNDC14296
(Thioredoxin domain-containing protein 14)CGI-31 My009
PIG26 PSEC0045
UNQ237/PRO270
P36941TNR3_HUMANTumor necrosis factor receptor superfamily member 3 (Lymphotoxin-beta receptor)LTBR D12S370435
(Tumor necrosis factor C receptor) (Tumor necrosis factor receptor 2-related protein)TNFCR TNFR3
(Tumor necrosis factor receptor type III) (TNF-RIII) (TNFR-III)TNFRSF3
Q13641TPBG_HUMANTrophoblast glycoprotein (5T4 oncofetal antigen) (5T4 oncofetal trophoblast glycoprotein)TPBG 5T4420
(5T4 oncotrophoblast glycoprotein) (M6P1) (Wnt-activated inhibitory factor 1) (WAIF1)
P40238TPOR_HUMANThrombopoietin receptor (TPO-R) (Myeloproliferative leukemia protein) (Proto-oncogeneMPL TPOR635
c-MpI) (CD antigen CD110)
P07204TRBM_HUMANThrombomodulin (TM) (Fetomodulin) (CD antigen CD141)THBD THRM575
Q5T2D2TRML2_HUMANTrem-like transcript 2 protein (TLT-2) (Triggering receptor expressed on myeloid cells-likeTREML2 C6orf76321
protein 2)TLT2 UNQ6268/PRO20473
Q6UXZ0TMIG1_HUMANTransmembrane and immunoglobulin domain-containing protein 1TMIGD1 TMIGD262
UNQ9372/PRO34164
Q86YD3TMM25_HUMANTransmembrane protein 25TMEM25366
UNQ2531/PRO6030
Q6P7N7TMM81_HUMANTransmembrane protein 81TMEM81255
UNQ2788/PRO7178
Q3KNT9TMM95_HUMANTransmembrane protein 95TMEM95176
UNQ9390/PRO34281
Q9H1E5TMX4_HUMANThioredoxin-related transmembrane protein 4 (Thioredoxin domain-containing protein 13)TMX4 KIAA1162349
TXNDC13 PSEC0095
UNQ475/PRO938
Q9Y6Q6TNR11_HUMANTumor necrosis factor receptor superfamily member 11A (Osteoclast differentiation factorTNFRSF11A RANK616
receptor) (ODFR) (Receptor activator of NF-KB) (CD antigen CD265)
Q86YW5TRML1_HUMANTrem-like transcript 1 protein (TLT-1) (Triggering receptor expressed on myeloid cells-likeTREML1 TLT1311
protein 1)UNQ1825/PRO3438
P08138TNR16_HUMANTumor necrosis factor receptor superfamily member 16 (Gp80-LNGFR) (Low affinityNGFR TNFRSF16427
neurotrophin receptor p75NTR) (Low-affinity nerve growth factor receptor) (NGF receptor)
(P75 ICD) (CD antigen CD271)
O75509TNR21_HUMANTumor necrosis factor receptor superfamily member 21 (Death receptor 6) (CD antigen CD358)TNFRSF21 DR6655
UNQ437/PRO868
P28908TNR8_HUMANTumor necrosis factor receptor superfamily member 8 (CD30L receptor) (Ki-1 antigen)TNFRSF8 CD30595
(Lymphocyte activation antigen CD30) (CD antigen CD30)D1S166E
O00220TR10A_HUMANTumor necrosis factor receptor superfamily member 10A (Death receptor 4) (TNF-relatedTNFRSF10A APO2468
apoptosis-inducing ligand receptor 1) (TRAIL receptor 1) (TRAIL-R1) (CD antigen CD261)DR4 TRAILR1
Q9NP99TREM1_HUMANTriggering receptor expressed on myeloid cells 1 (TREM-1) (Triggering receptorTREM1234
expressed on monocytes 1) (CD antigen CD354)
O15533TPSN_HUMANTapasin (TPN) (TPSN) (NGS-17) (TAP-associated protein) (TAP-binding protein)TAPBP NGS17448
TAPA
Q969Z4TR19L_HUMANTumor necrosis factor receptor superfamily member 19L (Receptor expressed inRELT TNFRSF19L430
lymphoid tissues)
Q7L0X0TRIL_HUMANTLR4 interactor with leucine rich repeats (Leucine-rich repeat-containing protein KIAA0644)TRIL KIAA0644811
Q5BVD1TTMP_HUMANTPA-induced transmembrane proteinTTMP C3orf52217
Q96J42TXD15_HUMANThioredoxin domain-containing protein 15TXNDC15 C5orf14360
UNQ335/PRO534
Q9P2J2TUTLA_HUMANProtein turtle homolog A (Immunoglobulin superfamily member 9A) (IgSF9A)IGSF9 IGSF9A1179
KIAA1355 NRT1
Q9UPX0TUTLB_HUMANProtein turtle homolog B (Immunoglobulin superfamily member 9B) (IgSF9B)IGSF9B KIAA10301349
Q3SY77UD3A2_HUMANUDP-glucuronosyltransferase 3A2 (UDPGT 3A2) (EC 2.4.1.17)UGT3A2 PSEC0073523
UNQ842/PRO1780
P14679TYRO_HUMANTyrosinase (EC 1.14.18.1) (LB24-AB) (Monophenol monooxygenase) (SK29-AB) (TumorTYR529
rejection antigen AB)
P40126TYRP2_HUMANL-dopachrome tautomerase (DCT) (DT) (EC 5.3.3.12) (L-dopachrome Delta-isomerase)DCT TYRP2519
(Tyrosinase-related protein 2) (TRP-2) (TRP2)
O95185UNC5C_HUMANNetrin receptor UNC5C (Protein unc-5 homolog 3) (Protein unc-5 homolog C)UNC5C UNC5H3931
Q06418TYRO3_HUMANTyrosine-protein kinase receptor TYRO3 (EC 2.7.10.1) (Tyrosine-protein kinase BYK)TYRO3 BYK DTK890
(Tyrosine-protein kinase DTK) (Tyrosine-protein kinase RSE) (Tyrosine-protein kinaseRSE SKY TIF
SKY) (Tyrosine-protein kinase TIP)
Q9Y4X1UD2A1_HUMANUDP-glucuronosyltransferase 2A1 (UDPGT 2A1) (EC 2.4.1.17)UGT2A1 UGT2A2527
Q9BT76UPK3B_HUMANUroplakin-3b (UP3b) (Uroplakin IIIb) (UPIIIb) (p35)UPK3B320
O43914TYOBP_HUMANTYRO protein tyrosine kinase-binding protein (DNAX-activation protein 12) (Killer-TYROBP DAP12113
activating receptor-associated protein) (KAR-associated protein)KARAP
Q6NUS8UD3A1_HUMANUDP-glucuronosyltransferase 3A1 (UDPGT 3A1) (EC 2.4.1.17)UGT3A1523
O00526UPK2_HUMANUroplakin-2 (UP2) (Uroplakin II) (UPII)UPK2184
B0FP48UPK3L_HUMANUroplakin-3b-like proteinUPK3BL UPLP263
P17643TYRP1_HUMAN5,6-dihydroxyindole-2-carboxylicacid oxidase (DHICA oxidase) (EC 1.14.18.-) (CatalaseTYRP1 CAS2 TYRP537
B) (Glycoprotein 75) (Melanoma antigen gp75) (Tyrosinase-related protein 1) (TRP) (TRP-1) (TRP1)TYRRP
O75631UPK3A_HUMANUroplakin-3a (UP3a) (Uroplakin III) (UPIII)UPK3A UPK3287
O75445USH2A_HUMANUsherin (Usher syndrome type IIa protein) (Usher syndrome type-2A protein)USH2A5202
P30530UFO_HUMANTyrosine-protein kinase receptor UFO (EC 2.7.10.1) (AXL oncogene)AXL UFO894
Q8IZJ1UNC5B_HUMANNetrin receptor UNC5B (Protein unc-5 homolog 2) (Protein unc-5 homolog B) (p53-UNC5B P53RDL1945
regulated receptor for death and life protein 1) (p53RDL1)UNC5H2
UNQ1883/PRO4326
Q6UWM9UD2A3_HUMANUDP-glucuronosyltransferase 2A3 (UDPGT 2A3) (EC 2.4.1.17)UGT2A3527
UNQ2559/PRO6239
Q5DID0UROL1_HUMANUromodulin-like 1 (Olfactorin)UMODL11318
Q6ZN44UNC5A_HUMANNetrin receptor UNC5A (Protein unc-5 homolog 1) (Protein unc-5 homolog A)UNC5A KIAA1976842
UNC5H1
Q6UXZ4UNC5D_HUMANNetrin receptor UNC5D (Protein unc-5 homolog 4) (Protein unc-5 homolog D)UNC5D KIAA1777953
UNC5H4
UNQ6012/PRO34692
P19320VCAM1_HUMANVascular cell adhesion protein 1 (V-CAM 1) (VCAM-1) (INCAM-100) (CD antigen CD106)VCAM1 L1CAM739
P35916VGFR3_HUMANVascular endothelial growth factor receptor 3 (VEGFR-3) (EC 2.7.10.1) (Fms-like tyrosineFLT4 VEGFR31363
kinase 4) (FLT-4) (Tyrosine-protein kinase receptor FLT4)
Q7Z7D3VTCN1_HUMANV-set domain-containing T-cell activation inhibitor 1 (B7 homolog 4) (B7-H4) (B7h.5)VTCN1 B7H4282
(Immune costimulatory protein B7-H4) (Protein B7S1) (T-cell costimulatory molecule B7x)UNQ659/PRO1291
Q6EMK4VASN_HUMANVasorin (Protein slit-like 2)VASN SLITL2673
UNQ314/PRO357/
PRO1282
Q96AW1VOPP1_HUMANVesicular, overexpressed in cancer, prosurvival protein 1 (EGFR-coamplified andVOPP1 ECOP172
overexpressed protein) (ECop) (Glioblastoma-amplified secreted protein) (Putative NF-GASP
kappa-B-activating protein 055N)
P17948VGFR1_HUMANVascular endothelial growth factor receptor 1 (VEGFR-1) (EC 2.7.10.1) (Fms-like tyrosineFLT1 FLT FRT1338
kinase 1) (FLT-1) (Tyrosine-protein kinase FRT) (Tyrosine-protein kinase receptor FLT)VEGFR1
(FLT) (Vascular permeability factor receptor)
Q9H7M9VISTA_HUMANV-type immunoglobulin domain-containing suppressor of T-cell activation (PlateletC10orf54 SISP1311
receptor Gi24) (Stress-induced secreted protein-1) (Sisp-1) (V-set domain-containingVISTA PP2135
immunoregulatory receptor)UNQ730/PRO1412
Q86VR7VS10L_HUMANV-set and immunoglobulin domain-containing protein 10-likeVSIG10L867
Q96IQ7VSIG2_HUMANV-set and immunoglobulin domain-containing protein 2 (Cortical thymocyte-like protein)VSIG2 CTH CTXL327
(CT-like protein)UNQ2770/PRO7154
Q5VU13VSIG8_HUMANV-set and immunoglobulin domain-containing protein 8VSIG8 C1orf204414
P78423X3CL1_HUMANFractalkine (C-X3-C motif chemokine 1) (CX3C membrane-anchored chemokine)CX3CL1 FKN NTT397
(Neurotactin) (Small-inducible cytokine D1) [Cleaved into: Processed fractalkine]SCYD1 A-152E5.2
P35968VGFR2_HUMANVascular endothelial growth factor receptor 2 (VEGFR-2) (EC 2.7.10.1) (Fetal liver kinaseKDR FLK1 VEGFR21356
1) (FLK-1) (Kinase insert domain receptor) (KDR) (Protein-tyrosine kinase receptor flk-1)
(CD antigen CD309)
Q8N0Z9VSI10_HUMANV-set and immunoglobulin domain-containing protein 10VSIG10540
Q8IW00VSTM4_HUMANV-set and transmembrane domain-containing protein 4 [Cleaved into: Peptide Lv]VSTM4 C10orf72320
P55808XG_HUMANGlycoprotein Xg (Protein PBDX)XG PBDX180
P98155VLDLR_HUMANVery low-density lipoprotein receptor (VLDL receptor) (VLDL-R)VLDLR873
Q86XK7VSIG1_HUMANV-set and immunoglobulin domain-containing protein 1 (Cell surface A33 antigen)VSIG1 GPA34387
(Glycoprotein A34)
Q9Y279VSIG4_HUMANV-set and immunoglobulin domain-containing protein 4 (Protein Z39Ig)VSIG4 CRIg Z39IG399
UNQ317/PRO362
A6NLU5VTM2B_HUMANV-set and transmembrane domain-containing protein 2BVSTM2B285
A8MXK1VSTM5_HUMANV-set and transmembrane domain-containing protein 5VSTM5 C11orf90200
Q8N1Y9YI025_HUMANPutative uncharacterized protein FLJ37218231
P60852ZP1_HUMANZona pellucida sperm-binding protein 1 (Zona pellucida glycoprotein 1) (Zp-1) [CleavedZP1638
into: Processed zona pellucida sperm-binding protein 1]
Q05996ZP2_HUMANZona pellucida sperm-binding protein 2 (Zona pellucida glycoprotein 2) (Zp-2) (ZonaZP2 ZPA745
pellucida protein A) [Cleaved into: Processed zona pellucida sperm-binding protein 2]
Q9Y493ZAN_HUMANZonadhesinZAN2812
Q9ULT6ZNRF3_HUMANE3 ubiquitin-protein ligase ZNRF3 (EC 6.3.2.-) (RING finger protein 203) (Zinc/RINGZNRF3 KIAA1133936
finger protein 3)RNF203
Q8TCW7ZPLD1_HUMANZona pellucida-like domain-containing protein 1 (ZP domain-containing protein 1)ZPLD1415
Q8WWF5ZNRF4_HUMANE3 ubiquitin-protein ligase ZNRF4 (EC 6.3.2.-) (Nixin) (RING finger protein 204)ZNRF4 RNF204429
(Zinc/RING finger protein 4)
P21754ZP3_HUMANZona pellucida sperm-binding protein 3 (Sperm receptor) (ZP3A/ZP3B) (Zona pellucidaZP3 ZP3A ZP3B424
glycoprotein 3) (Zp-3) (Zona pellucida protein C) [Cleaved into: Processed zona pellucidaZPC
sperm-binding protein 3]
Q12836ZP4_HUMANZona pellucida sperm-binding protein 4 (Zona pellucida glycoprotein 4) (Zp-4) (ZonaZP4 ZPB540
pellucida protein B) [Cleaved into: Processed zona pellucida sperm-binding protein 4]
K9MUJ5K9MUJ5_HUMANToll-like receptor 4 (Fragment)TLR4138
K9MUQ3K9MUQ3_HUMANToll-like receptor 4 (Fragment)TLR4138
D3DNA1D3DNA1_HUMANIntegrin betaITGB5 hCG_17803691
K9MTL8K9MTL8_HUMANToll-like receptor 4 (Fragment)TLR4138
K9MSZ3K9MSZ3_HUMANToll-like receptor 4 (Fragment)TLR4138
K9MT91K9MT91_HUMANToll-like receptor 4 (Fragment)TLR4138
D3DSM0D3DSM0_HUMANIntegrin betaITGB2 hCG_401305712
K9MT22K9MT22_HUMANToll-like receptor 4 (Fragment)TLR4138
K9MUK7K9MUK7_HUMANToll-like receptor 4 (Fragment)TLR4138
D0EWT7D0EWT7_HUMANToll-like receptor 4 (Fragment)TLR-4 TLR4169
G3V1J9G3V1J9_HUMANTransmembrane emp24 domain-containing protein 3 (Transmembrane emp24 proteinTMED3 hCG_24828146
transport domain containing 3, isoform CRA_b)
L7RT22L7RT22_HUMANIntegrin betaITGB5799
G3V1W8G3V1W8_HUMANSerine/threonine-protein kinase receptor (EC 2.7.11.30)ACVRL1517
hCG_37967
A3QNQ0A3QNQ0_HUMANTGF-beta receptor type-2 (TGFR-2) (EC 2.7.11.30) (TGF-beta type II receptor)TGFBR2567
(Transforming growth factor-beta receptor type II)hCG_1997782
B4E1S6B4E1S6_HUMANSyndecanSDC4 hCG_38363126
A0A024R8T0A0A024R8T0_HUMANIntegrin betaITGB4 hCG_275381822
D3DPA4D3DPA4_HUMANSerine/threonine-protein kinase receptor (EC 2.7.11.30)ACVR1509
hCG_1811747
A0A024R6I3A0A024R6I3_HUMANTesticular tissue protein Li 206 (Transmembrane emp24-like trafficking protein 10TMED10219
(Yeast), isoform CRA_a)hCG_22348
A0A024RB01A0A024RB01_HUMANIntegrin, alpha 5 (Fibronectin receptor, alpha polypeptide), isoform CRA_bITGA5 hCG_219391098
A0A024R7M0A0A024R7M0_HUMANTransmembrane emp24 protein transport domain containing 9, isoform CRA_aTMED9 hCG_41592235
B7Z4L4B7Z4L4_HUMANDolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 (EC 2.4.99.18)RPN1435
A0A024DBF0A0A024DBF0_HUMANIntegrin beta (Fragment)ITGB280
A0A024RDA0A0A024RDA0_HUMANV-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog, isoform CRA_aKIT hCG_22160976
Q9BUG9Q9BUG9_HUMANIntegrin betaITGB8 hCG_37311439
D3DPN2D3DPN2_HUMANSyndecanSDC3 hCG_15913384
A0A024RC30A0A024RC30_HUMANDesmoglein 3 (Pemphigus vulgaris antigen), isoform CRA_aDSG3 hCG_25473999
E9PBI9E9PBI9_HUMANSyndecanSDC2172
A0A024RC29A0A024RC29_HUMANDesmocollin 3, isoform CRA_bDSC3896
hCG_2022649
X5D8X5X5D8X5_HUMANCadherin 10 type 2 isoform A (Cadherin 10, type 2 (T2-cadherin)) (Fragment)CDH10 hCG_36812788
B2R627B2R627_HUMANcDNA, FLJ92752, highly similar to Homo sapiens integrin, alpha 5 (fibronectin receptor,1049
alphapolypeptide) (ITGA5), mRNA
Q6FHT8Q6FHT8_HUMANRNP24 protein (Transmembrane emp24 domain trafficking protein 2, isoform CRA_a)RNP24 TMED2201
(cDNA, FLJ93436, Homo sapiens coated vesicle membrane protein (RNP24), mRNA)hCG_1743563
B4DTY8B4DTY8_HUMANcDNA FLJ61587, highly similar to Integrin alpha-1 (Fragment)1173
Q96CZ9Q96CZ9_HUMANCadherin 11, type 2, OB-cadherin (Osteoblast) (Cadherin 11, type 2, OB-cadherinCDH11 hCG_26636796
(Osteoblast), isoform CRA_c)
A0A024RD88A0A024RD88_HUMANKinase insert domain receptor (A type III receptor tyrosine kinase), isoform CRA_aKDR hCG_315721356
A0A024R8N2A0A024R8N2_HUMANIntegrin betaITGB4 hCG_275381875
A0A024R2B2A0A024R2B2_HUMANCadherin 7, type 2, isoform CRA_aCDH7 hCG_32903785
E7EQW5E7EQW5_HUMANIntegrin beta (Fragment)ITGB1163
Q59F03Q59F03_HUMANIntegrin alpha 3 isoform b, variant (Fragment)749
A0A0G2JRA4A0A0G2JRA4_HUMANCadherin-4 (Fragment)CDH4566
U3KQ84U3KQ84_HUMANDolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunitDDOST155
(Oligosaccharyl transferase 48 kDa subunit) (EC 2.4.99.18) (Fragment)
B4E2C1B4E2C1_HUMANcDNA FLJ57776, highly similar to Transmembrane emp24 domain-containing protein 7136
J3KRI5J3KRI5_HUMANCadherin-8CDH8744
E9PD35E9PD35_HUMANVascular endothelial growth factor receptor 3FLT41306
E7EQ72E7EQ72_HUMANTransmembrane emp24 domain-containing protein 2 (Fragment)TMED2166
D2JYI3D2JYI3_HUMANToll-like receptor 4 (Fragment)TLR4121
J3KT08J3KT08_HUMANUncharacterized protein (Fragment)172
A8K0L1A8K0L1_HUMANcDNA FLJ77485, highly similar to Homo sapiens cadherin-like 24 (CDH24), transcript781
variant 2, mRNA
D2JYI2D2JYI2_HUMANToll-like receptor 4 (Fragment)TLR4122
E7EP60E7EP60_HUMANIntegrin alpha-4 (Fragment)ITGA4614
Q59H01Q59H01_HUMANProtocadherin gamma subfamily A, 7 isoform 1 variant (Fragment)895
D2JYI5D2JYI5_HUMANToll-like receptor 4 (Fragment)TLR4124
J3KNV4J3KNV4_HUMANIntegrin alpha-7ITGA71131
H3BM21H3BM21_HUMANIntegrin beta (Fragment)787
B4DN28B4DN28_HUMANcDNA FLJ54639, highly similar to Integrin alpha-8 (Fragment)1048
A0A0S2Z4U3A0A0S2Z4U3_HUMANSyndecan (Fragment)SDC3370
B4DL99B4DL99_HUMANDolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 (EC 2.4.99.18)581
B4DLF0B4DLF0_HUMANcDNA FLJ50795, highly similar to Cadherin-3774
Q6P4R2Q6P4R2_HUMANProtocadherin alpha subfamily C, 2PCDHAC21007
V9GYZ1V9GYZ1_HUMANIntegrin beta (Fragment)ITGB5139
D1CS55D1CS55_HUMANToll-like receptor 4TLR4839
D0EWT8D0EWT8_HUMANToll-like receptor 4 (Fragment)TLR-4 TLR4169
A8K2C5A8K2C5_HUMANcDNA FLJ78159, highly similar to Homo sapiens cadherin 20, type 2 (CDH20), mRNA801
Q59GD1Q59GD1_HUMANProtocadherin gamma subfamily A, 6 isoform 1 variant (Fragment)950
L7RSL3L7RSL3_HUMANFms-related tyrosine kinase 1 (Vascular endothelial growth factor/vascular permeabilityFLT11338
factor receptor)
A8K8T0A8K8T0_HUMANcDNA FLJ78760, highly similar to Homo sapiens integrin, alpha 11 (ITGA11), transcript1188
variant 1, mRNA
Q4VAU9Q4VAU9_HUMANSerine/threonine-protein kinase receptor (EC 2.7.11.30)ACVR2B303
Q5T3E5Q5T3E5_HUMANIntegrin beta (Fragment)ITGB189
E5RK25E5RK25_HUMANIntegrin beta (Fragment)ITGB2160
A8KAM8A8KAM8_HUMANPlatelet-derived growth factor receptor beta (PDGF-R-beta) (PDGFR-beta) (EC 2.7.10.1)1106
(Beta platelet-derived growth factor receptor) (Beta-type platelet-derived growth factor receptor)
E9PQJ2E9PQJ2_HUMANIntegrin beta (Fragment)ITGB1104
B4E2S6B4E2S6_HUMANSerine/threonine-protein kinase receptor (EC 2.7.11.30)397
A0A087WXP3A0A087WXP3_HUMANIntegrin betaITGB6693
A8K0L9A8K0L9_HUMANcDNA FLJ76999, highly similar to Homo sapiens cadherin-like 22 (CDH22), mRNA828
D2JYI1D2JYI1_HUMANTGF-beta receptor type-2 (TGFR-2) (EC 2.7.11.30) (TGF-beta type II receptor)TGFBR2592
(Transforming growth factor-beta receptor type II)
B7ZLD8B7ZLD8_HUMANIntegrin betaITGB41752
L7UW06L7UW06_HUMANIntegrin betaITGB3470
B4E3M0B4E3M0_HUMANcDNA FLJ58807, highly similar to Integrin alpha-11650
B4DNJ5B4DNJ5_HUMANDolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 (EC 2.4.99.18)378
Q96HX3Q96HX3_HUMANDolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 (EC 2.4.99.18)568
(Fragment)
X5DNG6X5DNG6_HUMANCadherin 10 type 2 isoform B (Fragment)CDH10786
B7Z5H2B7Z5H2_HUMANSyndecan172
F8VNX4F8VNX4_HUMANIntegrin beta (Fragment)ITGB7158
B4DPP4B4DPP4_HUMANcDNA FLJ56646, highly similar to Transmembrane emp24 domain-containing protein 9121
B2RCN5B2RCN5_HUMANcDNA, FLJ96176, highly similar to Homo sapiens cadherin 4, type 1, R-cadherin (retinal)916
(CDH4), mRNA
G3V2K7G3V2K7_HUMANTransmembrane emp24 domain-containing protein 10TMED10153
A8K6T3A8K6T3_HUMANcDNA FLJ78674, highly similar to Homo sapiens desmocollin type 4896
E9PLR6E9PLR6_HUMANIntegrin beta (Fragment)ITGB1143
D3XNU5D3XNU5_HUMANE-cadherin 1CDH1882
B4E2A1B4E2A1_HUMANcDNA FLJ54402, highly similar to Integrin alpha-101095
C9JPK5C9JPK5_HUMANIntegrin beta (Fragment)ITGB198
B2R8A2B2R8A2_HUMANcDNA, FLJ93804, highly similar to Homo sapiens gp25L2 protein (HSGP25L2G), mRNA214
L7UUZ7L7UUZ7_HUMANIntegrin betaITGB3788
Q53EP4Q53EP4_HUMANDolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 (EC 2.4.99.18)607
(Fragment)
Q59H32Q59H32_HUMANProtocadherin gamma subfamily A, 3 isoform 1 variant (Fragment)961
K9MUK4K9MUK4_HUMANToll-like receptor 4 (Fragment)TLR4138
B3KMS6B3KMS6_HUMANcDNA FLJ12486 fis, clone NT2RM2000566, highly similar to Integrin alpha-7973
B4E045B4E045_HUMANcDNA FLJ59131, highly similar to Integrin alpha-4174
B7ZLD5B7ZLD5_HUMANIntegrin betaITGB41752
Q59EA3Q59EA3_HUMANCadherin 5, type 2 preproprotein variant (Fragment)807
E7ESK6E7ESK6_HUMANSyndecanSDC2165
B4DTP0B4DTP0_HUMANcDNA FLJ51087, highly similar to Cadherin-5525
B4E3N0B4E3N0_HUMANIntegrin beta628
A7U833A7U833_HUMANIntegrin beta (Fragment)ITGB365
A0A024R8K7A0A024R8K7_HUMANIntegrin betaITGB4 hCG_275381752
H7C580H7C580_HUMANIntegrin beta (Fragment)ITGB579
H0YA32H0YA32_HUMANIntegrin alpha-3 (Fragment)ITGA384
Q59H14Q59H14_HUMANPREDICTED: integrin, alpha D variant (Fragment)1177
E9PDS3E9PDS3_HUMANIntegrin alpha-9ITGA9632
B2R6U9B2R6U9_HUMANDelta-like protein1218
B4E0R1B4E0R1_HUMANIntegrin beta700
A5YM53A5YM53_HUMANITGAV proteinITGAV1048
Q6IBR0Q6IBR0_HUMANDolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 (EC 2.4.99.18)RPN1607
B4DP27B4DP27_HUMANcDNA FLJ52153, highly similar to Transmembrane emp24 domain-containing protein 2169
A0A0U2ZQU7A0A0U2ZQU7_HUMANE-cadherin 1CDH1882
B4DYQ7B4DYQ7_HUMANcDNA FLJ57822, highly similar to Integrin alpha-V482
B2RAL6B2RAL6_HUMANcDNA, FLJ94991, highly similar to Homo sapiens integrin, alpha L (antigen CD11A1170
(p180), lymphocyte function-associated antigen 1; alpha polypeptide) (ITGAL), mRNA
E7ERX5E7ERX5_HUMANIntegrin beta (Fragment)ITGB1125
F8WF32F8WF32_HUMANDolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 (EC 2.4.99.18)RPN1121
B4E0Q2B4E0Q2_HUMANcDNA FLJ60208, highly similar to Integrin alpha-4366
B4DDT0B4DDT0_HUMANcDNA FLJ59664, highly similar to Integrin alpha-3294
B7Z769B7Z769_HUMANIntegrin beta228
E9PEE8E9PEE8_HUMANIntegrin betaITGB6746
H7C4W1H7C4W1_HUMANIntegrin beta (Fragment)ITGB5263
E9PB77E9PB77_HUMANIntegrin alpha-2ITGA2641
B7Z8B0B7Z8B0_HUMANcDNA FLJ50317, highly similar to Integrin alpha-IIb219
D6RA20D6RA20_HUMANProtocadherin alpha-4PCDHA4901
Q5T3E6Q5T3E6_HUMANIntegrin beta (Fragment)ITGB1136
B4DQ56B4DQ56_HUMANSyndecan192
C9JA99C9JA99_HUMANProtocadherin alpha-13PCDHA13904
Q9UII7Q9UII7_HUMANE-cadherin901
B3KRT0B3KRT0_HUMANcDNA FLJ34857 fis, clone NT2NE2012533, highly similar to Cadherin-12404
Q8N6H6Q8N6H6_HUMANITGA9 protein632
A0A0B5HR54A0A0B5HR54_HUMANSerine/threonine-protein kinase receptor (EC 2.7.11.30)509
C9JXX7C9JXX7_HUMANIntegrin alpha-6 (Fragment)ITGA6231
B4DLJ5B4DLJ5_HUMANcDNA FLJ55716, highly similar to Desmocollin-2912
V9GZ57V9GZ57_HUMANIntegrin beta (Fragment)ITGB5324
Q4LE35Q4LE35_HUMANITGA7 variant protein (Fragment)ITGA7 variant protein1200
B4DIN4B4DIN4_HUMANSyndecan346
J3KNI6J3KNI6_HUMANIntegrin beta (Fragment)ITGB2322
A8K2P8A8K2P8_HUMANcDNA FLJ76245, highly similar to Homo sapiens desmocollin 2 (DSC2), transcript variant901
Dsc2a, mRNA
B4DLU2B4DLU2_HUMANcDNA FLJ56496, highly similar to Integrin alpha-IIb521
F5H4M7F5H4M7_HUMANTransmembrane emp24 domain-containing protein 3TMED3155
D0EWT9D0EWT9_HUMANToll-like receptor 4 (Fragment)TLR-4 TLR4169
Q6PJE7Q6PJE7_HUMANITGA4 protein (Fragment)ITGA4617
E7ESP4E7ESP4_HUMANIntegrin alpha-2ITGA2942
B4E277B4E277_HUMANcDNA FLJ58873, highly similar to Transmembrane emp24 domain-containing protein 3155
B4DU18B4DU18_HUMANcDNA FLJ51093, highly similar to Cadherin-5750
B2R9J8B2R9J8_HUMANcDNA, FLJ94427, highly similar to Homo sapiens cadherin 20, type 2 (CDH20), mRNA801
B4E282B4E282_HUMANcDNA FLJ52401, highly similar to Integrin alpha-101036
F5H6T4F5H6T4_HUMANIntegrin betaITGB7471
G3V2Y2G3V2Y2_HUMANTransmembrane emp24 domain-containing protein 7 (Fragment)TMED782
B4DDR7B4DDR7_HUMANcDNA FLJ54845, highly similar to Transmembrane emp24 domain-containing protein 5178
A0A087WT05A0A087WT05_HUMANProtocadherin gamma-A4PCDHGA4962
B4DMA7B4DMA7_HUMANcDNA FLJ58514, highly similar to Cadherin-11779
A0A0U2N547A0A0U2N547_HUMANMast/stem cell growth factor receptor Kit isoform 3 (EC 2.7.10.1)KIT971
B2R9L8B2R9L8_HUMANDelta-like protein685
E7EVZ9E7EVZ9_HUMANIntegrin beta (Fragment)ITGB2166
B4E2B8B4E2B8_HUMANIntegrin beta746
F5GX39F5GX39_HUMANTransmembrane emp24 domain-containing protein 2TMED2116
Q2VP98Q2VP98_HUMANIntegrin beta (Fragment)ITGB4644
A0A0S2Z310A0A0S2Z310_HUMANSerine/threonine-protein kinase receptor (EC 2.7.11.30) (Fragment)ACVRL1503
H3BRM2H3BRM2_HUMANIntegrin beta (Fragment)ITGB793
A9X9L0A9X9L0_HUMANDesmocollin 2DSC2901
B7Z6U6B7Z6U6_HUMANIntegrin beta471
B4DT61B4DT61_HUMANSyndecan81
D2JYI4D2JYI4_HUMANToll-like receptor 4 (Fragment)TLR4124
E5RIG7E5RIG7_HUMANIntegrin beta (Fragment)ITGB2120
E5RFI0E5RFI0_HUMANIntegrin beta (Fragment)ITGB270
B7Z506B7Z506_HUMANIntegrin beta626
B4DTY9B4DTY9_HUMANIntegrin beta751
G3V2C6G3V2C6_HUMANIntegrin alpha-7 (Fragment)ITGA7153
Q6PJ75Q6PJ75_HUMANIntegrin beta (Fragment)ITGB2758
B4DDX0B4DDX0_HUMANcDNA FLJ59843, highly similar to Integrin alpha-X264
A9X9K9A9X9K9_HUMANDesmocollin 2DSC2901
H3BN02H3BN02_HUMANIntegrin alpha-XITGAX1169
A0A024RAD5A0A024RAD5_HUMANDolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunitDDOST hCG_38871456
(Oligosaccharyl transferase 48 kDa subunit) (EC 2.4.99.18)
A0A0C4DGS1A0A0C4DGS1_HUMANDolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa subunitDDOST439
(Oligosaccharyl transferase 48 kDa subunit) (EC 2.4.99.18)
B4DFP0B4DFP0_HUMANcDNA FLJ57804, highly similar to Cadherin-9382
Q53GF9Q53GF9_HUMANFull-length cDNA 5-PRIME end of clone CSODF013YM24 of Fetal brain of Homo sapiens225
(Human) variant (Fragment)
A8K2N5A8K2N5_HUMANIntegrin beta788
E7EUI6E7EUI6_HUMANIntegrin beta (Fragment)ITGB1152
Q4KMR2Q4KMR2_HUMANDelta-like proteinJAG11218
Q59FA8Q59FA8_HUMANIntegrin alpha-IIb variant (Fragment)551
J3QQL2J3QQL2_HUMANIntegrin beta (Fragment)ITGB4114
L7RXH0L7RXH0_HUMANIntegrin, alpha VITGAV1048
A0A0A6YYA0A0A0A6YYA0_HUMANProtein TMED7-TICAM2TMED7-TICAM2188
B4DL12B4DL12_HUMANcDNA FLJ53754, highly similar to Transmembrane emp24 domain-containing protein 10177
B1AKT3B1AKT3_HUMANTransmembrane emp24 domain-containing protein 5TMED5162
H7C5U2H7C5U2_HUMANIntegrin beta (Fragment)ITGB5401
F8W7F7F8W7F7_HUMANTransmembrane emp24 domain-containing protein 4TMED4178
Q59H50Q59H50_HUMANIntegrin beta (Fragment)475
H3BUU9H3BUU9_HUMANCadherin-11CDH11670
B4E0H8B4E0H8_HUMANcDNA FLJ60385, highly similar to Integrin alpha-31037
A8K6A5A8K6A5_HUMANcDNA FLJ77742, highly similar to Homo sapiens integrin, alpha 5 (fibronectin receptor,1049
alpha polypeptide), mRNA
O60574O60574_HUMANCadherin-7 (Fragment)CDH7317
Q53HR4Q53HR4_HUMANChromosome 15 open reading frame 22 variant (Fragment)217
Q59H35Q59H35_HUMANProtocadherin alpha 13 isoform 1 variant (Fragment)921
A0A024DAS2A0A024DAS2_HUMANIntegrin beta (Fragment)ITGB280
A0A024RC42A0A024RC42_HUMANCadherin 2, type 1, N-cadherin (Neuronal), isoform CRA_bCDH2 hCG_22518906
E7EMF1E7EMF1_HUMANIntegrin alpha-2ITGA2815
A0A024R9D1A0A024R9D1_HUMANSyndecanSDC2 hCG_15745201
Q1PBM2Q1PBM2_HUMANIntegrin beta (Fragment)ITGB365
Q8NB64Q8NB64_HUMANcDNA FLJ34177 fis, clone FCBBF3016451, highly similar to RETINAL-CADHERIN824
Q59EB0Q59EB0_HUMANKinase insert domain receptor (A type III receptor tyrosine kinase) variant (Fragment)1451
Q2YFE1Q2YFE1_HUMANIntegrin beta443
Q3B7W7Q3B7W7_HUMANTMED7 protein (Fragment)TMED7134
K7EQ63K7EQ63_HUMANTransmembrane emp24 domain-containing protein 1 (Fragment)TMED1191
A0A087WTR7A0A087WTR7_HUMANCadherin-24CDH24314
K7EMU3K7EMU3_HUMANIntegrin alpha-3 (Fragment)ITGA3117
Q49AG2Q49AG2_HUMANTMED5 proteinTMED5172
A0A087WX36A0A087WX36_HUMANIntegrin betaITGB2378
Q9HAX1Q9HAX1_HUMANDesmocollin 3 (Fragment)DSC3316
A0A087WXI5A0A087WXI5_HUMANCadherin-1CDH1903
M0R072M0R072_HUMANTransmembrane emp24 domain-containing protein 5TMED5120
Q8N9J3Q8N9J3_HUMANcDNA FLJ37047 fis, clone BRACE2012232, highly similar to Homo sapiens cadherin 20335
(CDH20) mRNA
Q8WWJ8Q8WWJ8_HUMANIntegrin beta378
Q59H34Q59H34_HUMANProtocadherin alpha 4 isoform 1 variant (Fragment)921
A0A024DAE5A0A024DAE5_HUMANIntegrin beta (Fragment)ITGB280
Q59H46Q59H46_HUMANIntegrin beta (Fragment)1515
Q4VAI4Q4VAI4_HUMANCDH5 proteinCDH5662
Q59FL1Q59FL1_HUMANSerine/threonine-protein kinase receptor (EC 2.7.11.30) (Fragment)514
Q2TAL1Q2TAL1_HUMANCDH24 proteinCDH24314
Q59H74Q59H74_HUMANIntegrin alpha 4 variant (Fragment)854
A0A087WX99A0A087WX99_HUMANCadherin-4CDH4822
Q59FN1Q59FN1_HUMANIntegrin beta (Fragment)166
X6R3Y6X6R3Y6_HUMANCadherin-8CDH8745
Q59EQ1Q59EQ1_HUMANCadherin 11, type 2 isoform 1 preproprotein variant (Fragment)798
X5DQT8X5DQT8_HUMANCadherin 10 type 2 isoform C (Fragment)CDH10243
Q8N2D9Q8N2D9_HUMANcDNA PSEC0228 fis, clone HEMBA1006099, weakly similar to COP-COATED VESICLE146
MEMBRANE PROTEIN P24
Q63HM4Q63HM4_HUMANPutative uncharacterized protein DKFZp686P18250DKFZp686P18250758
A0A0E3XJU3A0A0E3XJU3_HUMANE-cadherin 1CDH1882
Q68DY8Q68DY8_HUMANPutative uncharacterized protein DKFZp686I11137DKFZp686I11137667

TABLE 2
Illustrative human Type II proteins which may be incorporated into the present compositions and methods include (as used herein “Entry”
refers to the human Type II protein entry in the UniProt database and “Entry name” refers to the human Type II protein entry in the UniProt database):
EntryEntry nameProtein namesGene namesLength
Q9BUJ0ABHEA_HUMANProtein ABHD14A (EC 3.-.-.-) (Alpha/beta hydrolase domain-containing protein 14A)ABHD14A UNQ1913/PRO4373271
(Abhydrolase domain-containing protein 14A)
P081954F2_HUMAN4F2 cell-surface antigen heavy chain (4F2hc) (4F2 heavy chain antigen) (LymphocyteSLC3A2 MDU1630
activation antigen 4F2 large subunit) (Solute carrier family 3 member 2) (CD antigen CD98)
Q9NPC4A4GAT_HUMANLactosylceramide 4-alpha-galactosyltransferase (EC 2.4.1.228) (Alpha-1,4-N-A4GALT A14GALT A4GALT1353
acetylglucosaminyltransferase) (Alpha-1,4-galactosyltransferase) (Alpha4Gal-T1) (CD77
synthase) (Globotriaosylceramide synthase) (Gb3 synthase) (P1/Pk synthase) (UDP-
galactose:beta-D-galactosyl-beta1-R 4-alpha-D-galactosyltransferase)
Q9UNA3A4GCT_HUMANAlpha-1,4-N-acetylglucosaminyltransferase (Alpha4GnT) (EC 2.4.1.-)A4GNT340
Q96SE0ABHD1_HUMANProtein ABHD1 (EC 3.1.1.-) (Alpha/beta hydrolase domain-containing protein 1)ABHD1 LABH1405
(Abhydrolase domain-containing protein 1) (Lung alpha/beta hydrolase 1)
P08910ABHD2_HUMANMonoacylglycerol lipase ABHD2 (EC 3.1.1.23) (2-arachidonoylglycerol hydrolase)ABHD2 LABH2425
(Abhydrolase domain-containing protein 2) (Lung alpha/beta hydrolase 2) (Protein PHPS1-2)
Q9BV23ABHD6_HUMANMonoacylglycerol lipase ABHD6 (EC 3.1.1.23) (2-arachidonoylglycerol hydrolase)ABHD6337
(Abhydrolase domain-containing protein 6)
Q7L211ABHDD_HUMANProtein ABHD13 (EC 3.-.-.-) (Alpha/beta hydrolase domain-containing protein 13)ABHD13 C13orf6337
(Abhydrolase domain-containing protein 13)
P22760AAAD_HUMANArylacetamide deacetylase (EC 3.1.1.3)AADAC DAC399
Q5VUY2ADCL4_HUMANArylacetamide deacetylase-like 4 (EC 3.1.1.-)AADACL4407
Q8WU67ABHD3_HUMANPhospholipase ABHD3 (EC 3.1.1.32) (EC 3.1.1.4) (Abhydrolase domain-containing protein 3)ABHD3409
O00468AGRIN_HUMANAgrin [Cleaved into: Agrin N-terminal 110 kDa subunit; Agrin C-terminal 110 kDa subunit;AGRN AGRIN2067
Agrin C-terminal 90 kDa fragment (C90); Agrin C-terminal 22 kDa fragment (C22)]
Q9Y673ALG5_HUMANDolichyl-phosphate beta-glucosyltransferase (DolP-glucosyltransferase) (EC 2.4.1.117)ALG5 HSPC149324
(Asparagine-linked glycosylation protein 5 homolog)
P15144AMPN_HUMANAminopeptidase N (AP-N) (hAPN) (EC 3.4.11.2) (Alanyl aminopeptidase)ANPEP APN CD13 PEPN967
(Aminopeptidase M) (AP-M) (Microsomal aminopeptidase) (Myeloid plasma membrane
glycoprotein CD13) (gp150) (CD antigen CD13)
Q6Q4G3AMPQ_HUMANAminopeptidase Q (AP-Q) (APQ) (EC 3.4.11.-) (CHL2 antigen) (Laeverin)LVRN AQPEP990
Q16853AOC3_HUMANMembrane primary amine oxidase (EC 1.4.3.21) (Copper amine oxidase) (HPAO)AOC3 VAP1763
(Semicarbazide-sensitive amine oxidase) (SSAO) (Vascular adhesion protein 1) (VAP-1)
Q9BT22ALG1_HUMANChitobiosyldiphosphodolichol beta-mannosyltransferase (EC 2.4.1.142) (Asparagine-ALG1 HMAT1 HMT1 PSEC0061 UNQ861/464
linked glycosylation protein 1 homolog) (Beta-1,4-mannosyltransferase) (GDP-PRO1870
Man:GlcNAc2-PP-dolichol mannosyltransferase) (GDP-mannose-dolichol
diphosphochitobiose mannosyltransferase) (Mannosyltransferase-1) (MT-1) (hMat-1)
Q07075AMPE_HUMANGlutamyl aminopeptidase (EAP) (EC 3.4.11.7) (Aminopeptidase A) (AP-A) (DifferentiationENPEP957
antigen gp160) (CD antigen CD249)
Q9HDC9APMAP_HUMANAdipocyte plasma membrane-associated protein (Protein BSCv)APMAP C20orf3 UNQ1869/PRO4305416
P07306ASGR1_HUMANAsialoglycoprotein receptor 1 (ASGP-R 1) (ASGPR 1) (C-type lectin domain family 4ASGR1 CLEC4H1291
member H1) (Hepatic lectin H1) (HL-1)
Q9NR71ASAH2_HUMANNeutral ceramidase (N-CDase) (NCDase) (EC 3.5.1.23) (Acylsphingosine deacylase 2)ASAH2 HNAC1780
(BCDase) (LCDase) (hCD) (N-acylsphingosine amidohydrolase 2) (Non-lysosomal
ceramidase) [Cleaved into: Neutral ceramidase soluble form]
Q5U4P2ASPH1_HUMANAspartate beta-hydroxylase domain-containing protein 1 (EC 1.14.11.-)ASPHD1390
Q9UN42AT1B4_HUMANProtein ATP1B4 (X,K-ATPase subunit beta-m) (X/potassium-transporting ATPase subunit beta-m)ATP1B4357
Q99941ATF6B_HUMANCyclic AMP-dependent transcription factor ATF-6 beta (cAMP-dependent transcriptionATF6B CREBL1 G13703
factor ATF-6 beta) (Activating transcription factor 6 beta) (ATF6-beta) (Protein G13)
(cAMP response element-binding protein-related protein) (Creb-rp) (cAMP-responsive
element-binding protein-like 1) [Cleaved into: Processed cyclic AMP-dependent
transcription factor ATF-6 beta]
Q6ICH7ASPH2_HUMANAspartate beta-hydroxylase domain-containing protein 2 (EC 1.14.11.-)ASPHD2369
P51164ATP4B_HUMANPotassium-transporting ATPase subunit beta (Gastric H(+)/K(+) ATPase subunit beta)ATP4B291
(Proton pump beta chain)
Q12797ASPH_HUMANAspartyl/asparaginyl beta-hydroxylase (EC 1.14.11.16) (Aspartate beta-hydroxylase)ASPH BAH758
(ASP beta-hydroxylase) (Peptide-aspartate beta-dioxygenase)
P07307ASGR2_HUMANAsialoglycoprotein receptor 2 (ASGP-R 2) (ASGPR 2) (C-type lectin domain family 4ASGR2 CLEC4H2311
member H2) (Hepatic lectin H2) (HL-2)
P05026AT1B1_HUMANSodium/potassium-transporting ATPase subunit beta-1 (Sodium/potassium-dependentATP1B1 ATP1B303
ATPase subunit beta-1)
P14415AT1B2_HUMANSodium/potassium-transporting ATPase subunit beta-2 (Adhesion molecule in glia)ATP1B2290
(AMOG) (Sodium/potassium-dependent ATPase subunit beta-2)
P54709AT1B3_HUMANSodium/potassium-transporting ATPase subunit beta-3 (Sodium/potassium-dependentATP1B3279
ATPase subunit beta-3) (ATPB-3) (CD antigen CD298)
P18850ATF6A_HUMANCyclic AMP-dependent transcription factor ATF-6 alpha (cAMP-dependent transcriptionATF6670
factor ATF-6 alpha) (Activating transcription factor 6 alpha) (ATF6-alpha) [Cleaved into:
Processed cyclic AMP-dependent transcription factor ATF-6 alpha]
Q9P2W7B3GA1_HUMANGalactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 (EC 2.4.1.135)B3GAT1 GLCATP334
(Beta-1,3-glucuronyltransferase 1) (Glucuronosyltransferase P) (GlcAT-P) (UDP-
GlcUA:glycoprotein beta-1,3-glucuronyltransferase) (GlcUAT-P)
Q9NPZ5B3GA2_HUMANGalactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 2 (EC 2.4.1.135)B3GAT2 GLCATS KIAA1963323
(Beta-1,3-glucuronyltransferase 2) (GlcAT-D) (UDP-glucuronosyltransferase S) (GlcAT-S)
(Glucuronosyltransferase S)
O94766B3GA3_HUMANGalactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3 (EC 2.4.1.135)B3GAT3335
(Beta-1,3-glucuronyltransferase 3) (Glucuronosyltransferase I) (GlcAT-I) (UDP-GlcUA:Gal
beta-1,3-Gal-R glucuronyltransferase) (GlcUAT-I)
Q9Y2A9B3GN3_HUMANN-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 3 (EC 2.4.1.149) (Beta-B3GNT3 B3GALT8 TMEM3 UNQ637/372
1,3-galactosyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase) (ECPRO1266
2.4.1.146) (Beta-1,3-galactosyltransferase 8) (Beta-1,3-GalTase 8) (Beta3Gal-T8)
(Beta3GalT8) (b3Gal-T8) (Beta-3-Gx-T8) (Core 1 extending beta-1,3-N-
acetylglucosaminyltransferase) (Core1-beta3GlcNAcT) (Transmembrane protein 3)
(UDP-Gal:beta-GlcNAc beta-1,3-galactosyltransferase 8) (UDP-GlcNAc:betaGal beta-1,3-
N-acetylglucosaminyltransferase 3) (BGnT-3) (Beta-1,3-Gn-T3) (Beta-1,3-N-
acetylglucosaminyltransferase 3) (Beta3Gn-T3) (UDP-galactose:beta-N-
acetylglucosamine beta-1,3-galactosyltransferase 8)
Q96L58B3GT6_HUMANBeta-1,3-galactosyltransferase 6 (Beta-1,3-GalTase 6) (Beta3Gal-T6) (Beta3GalT6) (ECB3GALT6329
2.4.1.134) (GAG GalTII) (Galactosyltransferase II) (Galactosylxylosylprotein 3-beta-
galactosyltransferase) (UDP-Gal:betaGal beta 1,3-galactosyltransferase polypeptide 6)
O43505B4GA1_HUMANBeta-1,4-glucuronyltransferase 1 (EC 2.4.1.-) (I-beta-1,3-N-B4GAT1 B3GNT1 B3GNT6415
acetylglucosaminyltransferase) (iGnT) (N-acetyllactosaminide beta-1,3-N-
acetylglucosaminyltransferase) (Poly-N-acetyllactosamine extension enzyme) (UDP-
GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1)
O75752B3GL1_HUMANUDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 1 (Beta-1,3-GalNAc-T1) (ECB3GALNT1 B3GALT3 UNQ531/PRO1074331
2.4.1.79) (Beta-1,3-galactosyltransferase 3) (Beta-1,3-GalTase 3) (Beta3Gal-T3)
(Beta3GalT3) (b3Gal-T3) (Beta-3-Gx-T3) (Galactosylgalactosylglucosylceramide beta-D-
acetyl-galactosaminyltransferase) (Globoside synthase) (UDP-N-
acetylgalactosamine:globotriaosylceramide beta-1,3-N-acetylgalactosaminyltransferase)
Q7Z7M8B3GN8_HUMANUDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8 (BGnT-8) (Beta-1,3-B3GNT8 B3GALT7 BGALT15397
Gn-T8) (Beta-1,3-N-acetylglucosaminyltransferase 8) (Beta3Gn-T8) (EC 2.4.1.-)
Q9Y2C3B3GT5_HUMANBeta-1,3-galactosyltransferase 5 (Beta-1,3-GalTase 5) (Beta3Gal-T5) (Beta3GalT5)B3GALT5310
(b3Gal-T5) (EC 2.4.1.-) (Beta-3-Gx-T5) (UDP-Gal:beta-GlcNAc beta-1,3-
galactosyltransferase 5) (UDP-galactose:beta-N-acetylglucosamine beta-1,3-
galactosyltransferase 5)
Q8NFL0B3GN7_HUMANUDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 (BGnT-7) (Beta-1,3-B3GNT7401
Gn-T7) (Beta-1,3-N-acetylglucosaminyltransferase 7) (Beta3Gn-T7) (EC 2.4.1.-)
O43825B3GT2_HUMANBeta-1,3-galactosyltransferase 2 (Beta-1,3-GalTase 2) (Beta3Gal-T2) (Beta3GalT2) (ECB3GALT2422
2.4.1.-) (UDP-galactose:2-acetamido-2-deoxy-D-glucose 3beta-galactosyltransferase 2)
Q00973B4GN1_HUMANBeta-1,4 N-acetylgalactosaminyltransferase 1 (EC 2.4.1.92) ((N-acetylneuraminyl)-B4GALNT1 GALGT SIAT2533
galactosylglucosylceramide) (GM2/GD2 synthase) (GalNAc-T)
P15291B4GT1_HUMANBeta-1,4-galactosyltransferase 1 (Beta-1,4-GalTase 1) (Beta4Gal-T1) (b4Gal-T1) (ECB4GALT1 GGTB2398
2.4.1.-) (UDP-Gal:beta-GlcNAc beta-1,4-galactosyltransferase 1) (UDP-galactose:beta-N-
acetylglucosamine beta-1,4-galactosyltransferase 1) [Cleaved into: Processed beta-1,4-
galactosyltransferase 1] [Includes: Lactose synthase A protein (EC 2.4.1.22); N-
acetyllactosamine synthase (EC 2.4.1.90) (Nal synthase); Beta-N-
acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase (EC 2.4.1.38); Beta-N-
acetylglucosaminyl-glycolipid beta-1,4-galactosyltransferase (EC 2.4.1.-)]
O60513B4GT4_HUMANBeta-1,4-galactosyltransferase 4 (Beta-1,4-GalTase 4) (Beta4Gal-T4) (b4Gal-T4) (ECB4GALT4 UNQ552/PRO1109344
2.4.1.-) (UDP-Gal:beta-GlcNAc beta-1,4-galactosyltransferase 4) (UDP-galactose:beta-N-
acetylglucosamine beta-1,4-galactosyltransferase 4) [Includes: N-acetyllactosamine
synthase (EC 2.4.1.90) (Nal synthase); Lactotriaosylceramide beta-1,4-
galactosyltransferase (EC 2.4.1.275) (Beta-N-acetylglucosaminyl-glycolipid beta-1,4-
galactosyltransferase)]
O43286B4GT5_HUMANBeta-1,4-galactosyltransferase 5 (Beta-1,4-GalTase 5) (Beta4Gal-T5) (b4Gal-T5) (ECB4GALT5388
2.4.1.-) (Beta-1,4-GalT II) (UDP-Gal:beta-GlcNAc beta-1,4-galactosyltransferase 5)
(UDP-galactose:beta-N-acetylglucosamine beta-1,4-galactosyltransferase 5)
Q9NY97B3GN2_HUMANN-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 2 (EC 2.4.1.149) (Beta-B3GNT2 B3GALT7 B3GNT1397
1,3-N-acetylglucosaminyltransferase 1) (BGnT-1) (Beta-1,3-Gn-T1) (Beta3Gn-T1) (Beta-
1,3-galactosyltransferase 7) (Beta-1,3-GalTase 7) (Beta3Gal-T7) (Beta3GalT7) (b3Gal-
T7) (Beta-3-Gx-T7) (UDP-Gal:beta-GlcNAc beta-1,3-galactosyltransferase 7) (UDP-
GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2) (BGnT-2) (Beta-1,3-Gn-T2)
(Beta-1,3-N-acetylglucosaminyltransferase 2) (Beta3Gn-T2) (UDP-galactose:beta-N-
acetylglucosamine beta-1,3-galactosyltransferase 7)
O60512B4GT3_HUMANBeta-1,4-galactosyltransferase 3 (Beta-1,4-GalTase 3) (Beta4Gal-T3) (b4Gal-T3) (ECB4GALT3393
2.4.1.-) (UDP-Gal:beta-GlcNAc beta-1,4-galactosyltransferase 3) (UDP-galactose:beta-N-
acetylglucosamine beta-1,4-galactosyltransferase 3) [Includes: N-acetyllactosamine
synthase (EC 2.4.1.90) (Nal synthase); Beta-N-acetylglucosaminylglycopeptide beta-1,4-
galactosyltransferase (EC 2.4.1.38); Beta-N-acetylglucosaminyl-glycolipid beta-1,4-
galactosyltransferase (EC 2.4.1.-)]
Q9Y5Z6B3GT1_HUMANBeta-1,3-galactosyltransferase 1 (Beta-1,3-GalTase 1) (Beta3Gal-T1) (Beta3GalT1) (ECB3GALT1326
2.4.1.-) (UDP-galactose:beta-N-acetyl-glucosamine-beta-1,3-galactosyltransferase 1)
O96024B3GT4_HUMANBeta-1,3-galactosyltransferase 4 (Beta-1,3-GalTase 4) (Beta3Gal-T4) (Beta3GalT4)B3GALT4 GALT4378
(GalT4) (b3Gal-T4) (EC 2.4.1.62) (Gal-T2) (Ganglioside galactosyltransferase) (UDP-
galactose:beta-N-acetyl-galactosamine-beta-1,3-galactosyltransferase)
Q76KP1B4GN4_HUMANN-acetyl-beta-glucosaminyl-glycoprotein 4-beta-N-acetylgalactosaminyltransferase 1B4GALNT41039
(NGalNAc-T1) (EC 2.4.1.244) (Beta-1,4-N-acetylgalactosaminyltransferase IV)
(Beta4GalNAc-T4) (Beta4GalNAcT4)
O60909B4GT2_HUMANBeta-1,4-galactosyltransferase 2 (Beta-1,4-GalTase 2) (Beta4Gal-T2) (b4Gal-T2) (ECB4GALT2372
2.4.1.-) (UDP-Gal:beta-GlcNAc beta-1,4-galactosyltransferase 2) (UDP-galactose:beta-N-
acetylglucosamine beta-1,4-galactosyltransferase 2) [Includes: Lactose synthase A
protein (EC 2.4.1.22); N-acetyllactosamine synthase (EC 2.4.1.90) (Nal synthase); Beta-
N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase (EC 2.4.1.38); Beta-N-
acetylglucosaminyl-glycolipid beta-1,4-galactosyltransferase (EC 2.4.1.-)]
Q9UBX8B4GT6_HUMANBeta-1,4-galactosyltransferase 6 (Beta-1,4-GalTase 6) (Beta4Gal-T6) (b4Gal-T6) (UDP-B4GALT6382
Gal:beta-GlcNAc beta-1,4-galactosyltransferase 6) (UDP-galactose:beta-N-
acetylglucosamine beta-1,4-galactosyltransferase 6) [Includes: Glucosylceramide beta-
1,4-galactosyltransferase (EC 2.4.1.274) (Lactosylceramide synthase) (LacCer synthase)
(UDP-Gal:glucosylceramide beta-1,4-galactosyltransferase)]
Q9UBV7B4GT7_HUMANBeta-1,4-galactosyltransferase 7 (Beta-1,4-GalTase 7) (Beta4Gal-T7) (b4Gal-T7) (ECB4GALT7 XGALT1 UNQ748/PRO1478327
2.4.1.-) (UDP-Gal:beta-GlcNAc beta-1,4-galactosyltransferase 7) (UDP-galactose:beta-N-
acetylglucosamine beta-1,4-galactosyltransferase 7) [Includes: Xylosylprotein 4-beta-
galactosyltransferase (EC 2.4.1.133) (Proteoglycan UDP-galactose:beta-xylose beta1,4-
galactosyltransferase I) (UDP-galactose:beta-xylose beta-1,4-galactosyltransferase)
(XGPT) (XGalT-1) (Xylosylprotein beta-1,4-galactosyltransferase)]
Q8NCR0B3GL2_HUMANUDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2 (Beta-1,3-GalNAc-T2) (ECB3GALNT2500
2.4.1.-) (Beta-1,3-N-acetylgalactosaminyltransferase II)
Q9C0J1B3GN4_HUMANN-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 4 (EC 2.4.1.149) (UDP-B3GNT4 UNQ1898/PRO4344378
GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 4) (BGnT-4) (Beta-1,3-Gn-T4)
(Beta-1,3-N-acetylglucosaminyltransferase 4) (Beta3Gn-T4)
Q6ZMB0B3GN6_HUMANAcetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferaseB3GNT6384
(EC 2.4.1.147) (Core 3 synthase) (UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 6) (BGnT-6) (Beta-1,3-Gn-T6) (Beta-1,3-N-
acetylglucosaminyltransferase 6) (Beta3Gn-T6)
Q9BYG0B3GN5_HUMANLactosylceramide 1,3-N-acetyl-beta-D-glucosaminyltransferase (EC 2.4.1.206)B3GNT5378
(Lactotriaosylceramide synthase) (Lc(3)Cer synthase) (Lc3 synthase) (UDP-GlcNAc:beta-
Gal beta-1,3-N-acetylglucosaminyltransferase 5) (BGnT-5) (Beta-1,3-Gn-T5) (Beta-1,3-N-
acetylglucosaminyltransferase 5) (Beta3Gn-T5)
Q6UX72B3GN9_HUMANUDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 9 (BGnT-9) (Beta-1,3-B3GNT9 UNQ1922/PRO4397402
Gn-T9) (Beta-1,3-N-acetylglucosaminyltransferase 9) (Beta3Gn-T9) (EC 2.4.1.-)
Q6L9W6B4GN3_HUMANBeta-1,4-N-acetylgalactosaminyltransferase 3 (B4GalNAcT3) (Beta4GalNAc-T3)B4GALNT3998
(Beta4GalNAcT3) (EC 2.4.1.244) (Beta-1,4-N-acetylgalactosaminyltransferase III) (N-
acetyl-beta-glucosaminyl-glycoprotein 4-beta-N-acetylgalactosaminyltransferase 2) (NGalNAc-T2)
Q6Y288B3GLT_HUMANBeta-1,3-glucosyltransferase (Beta3Glc-T) (EC 2.4.1.-) (Beta 3-glucosyltransferase)B3GLCT B3GALTL B3GTL498
(Beta-3-glycosyltransferase-like)
Q8NHY0B4GN2_HUMANBeta-1,4 N-acetylgalactosaminyltransferase 2 (EC 2.4.1.-) (Sd(a) beta-1,4-GalNAcB4GALNT2 GALGT2566
transferase) (UDP-GalNAc:Neu5Aca2-3Galb-R b1,4-N-acetylgalactosaminyltransferase)
P0DN25C1C1L_HUMANC1GALT1-specific chaperone 1-like proteinC1GALT1C1L315
P16442BGAT_HUMANHisto-blood group ABO system transferase (Fucosylglycoprotein 3-alpha-ABO354
galactosyltransferase) (Fucosylglycoprotein alpha-N-acetylgalactosaminyltransferase)
(Glycoprotein-fucosylgalactoside alpha-N-acetylgalactosaminyltransferase) (EC 2.4.1.40)
(Glycoprotein-fucosylgalactoside alpha-galactosyltransferase) (EC 2.4.1.37) (Histo-blood
group A transferase) (A transferase) (Histo-blood group B transferase) (B transferase)
(NAGAT) [Cleaved into: Fucosylglycoprotein alpha-N-acetylgalactosaminyltransferase
soluble form]
Q9NS00C1GLT_HUMANGlycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (EC 2.4.1.122)C1GALT1363
(B3Gal-T8) (Core 1 O-glycan T-synthase) (Core 1 UDP-galactose:N-
acetylgalactosamine-alpha-R beta 1,3-galactosyltransferase 1) (Beta-1,3-
galactosyltransferase) (Core 1 beta1,3-galactosyltransferase 1) (C1GalT1) (Core 1 beta3-
Gal-T1)
Q10589BST2_HUMANBone marrow stromal antigen 2 (BST-2) (HM1.24 antigen) (Tetherin) (CD antigen CD317)BST2180
Q96EU7C1GLC_HUMANC1GALT1-specific chaperone 1 (C38H2-like protein 1) (C38H2-L1) (Core 1 beta1,3-C1GALT1C1 COSMC HSPC067318
galactosyltransferase 2) (C1Gal-T2) (C1GalT2) (Core 1 beta3-Gal-T2) (Core 1 beta3-MSTP143 UNQ273/PRO310
galactosyltransferase-specific molecular chaperone)
Q9UIR0BTNL2_HUMANButyrophilin-like protein 2 (BTL-II)BTNL2455
Q6P4E1CASC4_HUMANProtein CASC4 (Cancer susceptibility candidate gene 4 protein)CASC4 UNQ2573/PRO6308433
Q9NNX6CD209_HUMANCD209 antigen (C-type lectin domain family 4 member L) (Dendritic cell-specific ICAM-3-CD209 CLEC4L404
grabbing non-integrin 1) (DC-SIGN) (DC-SIGN1) (CD antigen CD209)
Q8WVQ1CANT1_HUMANSoluble calcium-activated nucleotidase 1 (SCAN-1) (EC 3.6.1.6) (Apyrase homolog)CANT1 SHAPY401
(Putative MAPK-activating protein PM09) (Putative NF-kappa-B-activating protein 107)
P29965CD40L_HUMANCD40 ligand (CD40-L) (T-cell antigen Gp39) (TNF-related activation protein) (TRAP)CD40LG CD40L TNFSF5 TRAP261
(Tumor necrosis factor ligand superfamily member 5) (CD antigen CD154) [Cleaved into:
CD40 ligand, membrane form; CD40 ligand, soluble form]
P21854CD72_HUMANB-cell differentiation antigen CD72 (Lyb-2) (CD antigen CD72)CD72359
Q07108CD69_HUMANEarly activation antigen CD69 (Activation inducer molecule) (AIM) (BL-AC/P26) (C-typeCD69 CLEC2C199
lectin domain family 2 member C) (EA1) (Early T-cell activation antigen p60) (GP32/28)
(Leukocyte surface antigen Leu-23) (MLR-3) (CD antigen CD69)
Q9ULG6CCPG1_HUMANCell cycle progression protein 1 (Cell cycle progression restoration protein 8)CCPG1 CCP8 CPR8 KIAA1254757
Q8TDX6CGAT1_HUMANChondroitin sulfate N-acetylgalactosaminyltransferase 1 (CsGalNAcT-1) (EC 2.4.1.174)CSGALNACT1 CHGN GALNACT1532
(Chondroitin beta-1,4-N-acetylgalactosaminyltransferase 1) (Beta4GalNAcT-1)UNQ656/PRO1287
P32970CD70_HUMANCD70 antigen (CD27 ligand) (CD27-L) (Tumor necrosis factor ligand superfamily member 7)CD70 CD27L CD27LG TNFSF7193
(CD antigen CD70)
Q8IZ52CHSS2_HUMANChondroitin sulfate synthase 2 (EC 2.4.1.175) (EC 2.4.1.226) (ChondroitinCHPF CSS2 UNQ651/PRO1281775
glucuronyltransferase 2) (Chondroitin-polymerizing factor) (ChPF) (Glucuronosyl-N-
acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase II) (N-
acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase II) (N-
acetylgalactosaminyltransferase 2)
Q9GZX3CHST6_HUMANCarbohydrate sulfotransferase 6 (EC 2.8.2.-) (Corneal N-acetylglucosamine-6-O-CHST6395
sulfotransferase) (C-GlcNAc6ST) (hCGn6ST) (Galactose/N-acetylglucosamine/N-
acetylglucosamine 6-O-sulfotransferase 4-beta) (GST4-beta) (N-acetylglucosamine 6-O-
sulfotransferase 5) (GlcNAc6ST-5) (Gn6st-5)
Q9NRB3CHSTC_HUMANCarbohydrate sulfotransferase 12 (EC 2.8.2.5) (Chondroitin 4-O-sulfotransferase 2)CHST12 UNQ500/PRO1017414
(Chondroitin 4-sulfotransferase 2) (C4ST-2) (C4ST2) (Sulfotransferase Hlo)
P28907CD38_HUMANADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (EC 3.2.2.6) (2′-phospho-ADP-ribosylCD38300
cyclase) (2′-phospho-ADP-ribosyl cyclase/2′-phospho-cyclic-ADP-ribose transferase) (EC
2.4.99.20) (2′-phospho-cyclic-ADP-ribose transferase) (ADP-ribosyl cyclase 1) (ADPRC
1) (Cyclic ADP-ribose hydrolase 1) (cADPr hydrolase 1) (T10) (CD antigen CD38)
Q8N6G5CGAT2_HUMANChondroitin sulfate N-acetylgalactosaminyltransferase 2 (EC 2.4.1.174) (ChondroitinCSGALNACT2 CHGN2 GALNACT2 PRO0082542
beta-1,4-N-acetylgalactosaminyltransferase 2) (Beta4GalNAcT-2) (GalNAcT-2)
Q5QGZ9CL12A_HUMANC-type lectin domain family 12 member A (C-type lectin-like molecule 1) (CLL-1)CLEC12A CLL1 DCAL2 MICL265
(Dendritic cell-associated lectin 2) (DCAL-2) (Myeloid inhibitory C-type lectin-like
receptor) (MICL)
Q9P2E5CHPF2_HUMANChondroitin sulfate glucuronyltransferase (EC 2.4.1.226) (CSGlcA-T) (ChondroitinCHPF2 CHSY3 CSGLCAT KIAA1402772
glucuronyltransferase) (Chondroitin polymerizing factor 2) (ChPF-2) (ChondroitinUNQ299/PRO339
synthase 3) (ChSy-3) (N-acetylgalactosaminyl-proteoglycan 3-beta-
glucuronosyltransferase)
Q70JA7CHSS3_HUMANChondroitin sulfate synthase 3 (EC 2.4.1.175) (EC 2.4.1.226) (Carbohydrate synthase 2)CHSY3 CHSY2 CSS3882
(Chondroitin glucuronyltransferase 3) (Chondroitin synthase 2) (ChSy-2) (Glucuronosyl-
N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase II) (N-
acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase 3) (N-
acetylgalactosaminyltransferase 3)
Q9Y4C5CHST2_HUMANCarbohydrate sulfotransferase 2 (EC 2.8.2.-) (Galactose/N-acetylglucosamine/N-CHST2 GN6ST530
acetylglucosamine 6-O-sulfotransferase 2) (GST-2) (N-acetylglucosamine 6-O-
sulfotransferase 1) (GlcNAc6ST-1) (Gn6ST-1)
Q8NCG5CHST4_HUMANCarbohydrate sulfotransferase 4 (EC 2.8.2.-) (Galactose/N-acetylglucosamine/N-CHST4386
acetylglucosamine 6-O-sulfotransferase 3) (GST-3) (High endothelial cells N-
acetylglucosamine 6-O-sulfotransferase) (HEC-GlcNAc6ST) (L-selectin ligand
sulfotransferase) (LSST) (N-acetylglucosamine 6-O-sulfotransferase 2) (GlcNAc6ST-2)
(Gn6st-2)
O43529CHSTA_HUMANCarbohydrate sulfotransferase 10 (EC 2.8.2.-) (HNK-1 sulfotransferase) (HNK-1ST)CHST10356
(HNK1ST) (HuHNK-1ST)
Q92478CLC2B_HUMANC-type lectin domain family 2 member B (Activation-induced C-type lectin) (C-type lectinCLEC2B AICL CLECSF2 IFNRG1149
superfamily member 2) (IFN-alpha-2b-inducing-related protein 1)
Q6UXN8CLC9A_HUMANC-type lectin domain family 9 member ACLEC9A UNQ9341/PRO34046241
Q6UWU4CF089_HUMANBombesin receptor-activated protein C6orf89 (Amfion)C6orf89 BRAP UNQ177/PRO203347
Q86X52CHSS1_HUMANChondroitin sulfate synthase 1 (EC 2.4.1.175) (EC 2.4.1.226) (ChondroitinCHSY1 CHSY CSS1 KIAA0990802
glucuronyltransferase 1) (Chondroitin synthase 1) (ChSy-1) (Glucuronosyl-N-UNQ756/PRO1487
acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase 1) (N-
acetylgalactosaminyl-proteoglycan 3-beta-glucuronosyltransferase 1) (N-
acetylgalactosaminyltransferase 1)
Q8NET6CHSTD_HUMANCarbohydrate sulfotransferase 13 (EC 2.8.2.5) (Chondroitin 4-O-sulfotransferase 3)CHST13341
(Chondroitin 4-sulfotransferase 3) (C4ST-3) (C4ST3)
Q7LFX5CHSTF_HUMANCarbohydrate sulfotransferase 15 (EC 2.8.2.33) (B-cell RAG-associated gene protein)CHST15 BRAG GALNAC4S6ST KIAA0598561
(hBRAG) (N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase) (GalNAc4S-6ST)
Q9P126CLC1B_HUMANC-type lectin domain family 1 member B (C-type lectin-like receptor 2) (CLEC-2)CLEC1B CLEC2 UNQ721/PRO1384229
Q8IZS7CLCL1_HUMANC-type lectin-like domain family 1 (Dendritic cell-associated lectin 1) (DC-associatedCLECL1 DCAL1167
lectin-1) (DCAL-1)
O43916CHST1_HUMANCarbohydrate sulfotransferase 1 (EC 2.8.2.21) (Galactose/N-acetylglucosamine/N-CHST1411
acetylglucosamine 6-O-sulfotransferase 1) (GST-1) (Keratan sulfate Gal-6
sulfotransferase) (KS6ST) (KSGal6ST) (KSST)
Q7LGC8CHST3_HUMANCarbohydrate sulfotransferase 3 (EC 2.8.2.17) (Chondroitin 6-O-sulfotransferase 1)CHST3479
(C6ST-1) (Chondroitin 6-sulfotransferase) (Galactose/N-acetylglucosamine/N-
acetylglucosamine 6-O-sulfotransferase 0) (GST-0)
Q9GZS9CHST5_HUMANCarbohydrate sulfotransferase 5 (EC 2.8.2.-) (Galactose/N-acetylglucosamine/N-CHST5411
acetylglucosamine 6-O-sulfotransferase 4-alpha) (GST4-alpha) (Intestinal N-
acetylglucosamine-6-O-sulfotransferase) (I-GlcNAc6ST) (Intestinal GlcNAc-6-
sulfotransferase) (hIGn6ST) (N-acetylglucosamine 6-O-sulfotransferase 3) (GlcNAc6ST-
3) (Gn6st-3)
Q9NPF2CHSTB_HUMANCarbohydrate sulfotransferase 11 (EC 2.8.2.5) (Chondroitin 4-O-sulfotransferase 1)CHST11352
(Chondroitin 4-sulfotransferase 1) (C4S-1) (C4ST-1) (C4ST1)
Q9UMR7CLC4A_HUMANC-type lectin domain family 4 member A (C-type lectin DDB27) (C-type lectin superfamilyCLEC4A CLECSF6 DCIR LLIR HDCGC13P237
member 6) (Dendritic cell immunoreceptor) (Lectin-like immunoreceptor)
Q8WXI8CLC4D_HUMANC-type lectin domain family 4 member D (C-type lectin superfamily member 8) (C-typeCLEC4D CLECSF8 MCL215
lectin-like receptor 6) (CLEC-6)
Q8N1N0CLC4F_HUMANC-type lectin domain family 4 member F (C-type lectin superfamily member 13) (C-typeCLEC4F CLECSF13589
lectin 13)
Q6UXB4CLC4G_HUMANC-type lectin domain family 4 member G (Liver and lymph node sinusoidal endothelial cellCLEC4G UNQ431/PR0792293
C-type lectin) (LSECtin)
Q9BXN2CLC7A_HUMANC-type lectin domain family 7 member A (Beta-glucan receptor) (C-type lectin superfamilyCLEC7A BGR CLECSF12 DECTIN1247
member 12) (Dendritic cell-associated C-type lectin 1) (DC-associated C-type lectin 1)UNQ539/PRO1082
(Dectin-1)
Q86VU5CMTD1_HUMANCatechol O-methyltransferase domain-containing protein 1 (EC 2.1.1.-)COMTD1 UNQ766/PRO1558262
Q9NS84CHST7_HUMANCarbohydrate sulfotransferase 7 (EC 2.8.2.-) (EC 2.8.2.17) (Chondroitin 6-CHST7486
sulfotransferase 2) (C6ST-2) (Galactose/N-acetylglucosamine/N-acetylglucosamine 6-O-
sulfotransferase 5) (GST-5) (N-acetylglucosamine 6-O-sulfotransferase 4) (GlcNAc6ST-4)
(Gn6st-4)
Q8NCH0CHSTE_HUMANCarbohydrate sulfotransferase 14 (EC 2.8.2.35) (Dermatan 4-sulfotransferase 1) (D4ST-CHST14 D4ST1 UNQ1925/PRO4400376
1) (hD4ST1)
Q6UVW9CLC2A_HUMANC-type lectin domain family 2 member A (Keratinocyte-associated C-type lectin) (KACL)CLEC2A KACL UNQ5792/PRO19597174
(Proliferation-induced lymphocyte-associated receptor) (PILAR)
Q8WTT0CLC4C_HUMANC-type lectin domain family 4 member C (Blood dendritic cell antigen 2) (BDCA-2) (C-typeCLEC4C BDCA2 CLECSF11 CLECSF7213
lectin superfamily member 7) (Dendritic lectin) (CD antigen CD303)DLEC HECL UNQ9361/PRO34150
Q9ULY5CLC4E_HUMANC-type lectin domain family 4 member E (C-type lectin superfamily member 9)CLEC4E CLECSF9 MINCLE UNQ218/219
(Macrophage-inducible C-type lectin)PRO244
Q9H2A9CHST8_HUMANCarbohydrate sulfotransferase 8 (EC 2.8.2.-) (GalNAc-4-O-sulfotransferase 1) (GalNAc-4-CHST8424
ST1) (GalNAc4ST-1) (N-acetylgalactosamine-4-O-sulfotransferase 1)
Q8IUN9CLC10_HUMANC-type lectin domain family 10 member A (C-type lectin superfamily member 14)CLEC10A CLECSF13 CLECSF14 HML316
(Macrophage lectin 2) (CD antigen CD301)
Q8NC01CLC1A_HUMANC-type lectin domain family 1 member A (C-type lectin-like receptor 1) (CLEC-1)CLEC1A CLEC1 UNQ569/PRO1131280
Q9UJ71CLC4K_HUMANC-type lectin domain family 4 member K (Langerin) (CD antigen CD207)CD207 CLEC4K328
Q7L1S5CHST9_HUMANCarbohydrate sulfotransferase 9 (EC 2.8.2.-) (GalNAc-4-O-sulfotransferase 2) (GalNAc-4-CHST9 UNQ2549/PRO6175443
ST2) (GalNAc4ST-2) (N-acetylgalactosamine-4-O-sulfotransferase 2)
Q07065CKAP4_HUMANCytoskeleton-associated protein 4 (63-kDa cytoskeleton-linking membrane protein)CKAP4602
(Climp-63) (p63)
Q2HXU8CL12B_HUMANC-type lectin domain family 12 member B (Macrophage antigen H)CLEC12B UNQ5782/PRO16089276
Q6ZS10CL17A_HUMANC-type lectin domain family 17, member A (Prolectin)CLEC17A378
Q9NY25CLC5A_HUMANC-type lectin domain family 5 member A (C-type lectin superfamily member 5) (MyeloidCLEC5A CLECSF5 MDL1188
DAP12-associating lectin 1) (MDL-1)
Q6EIG7CLC6A_HUMANC-type lectin domain family 6 member A (C-type lectin superfamily member 10) (DendriticCLEC6A CLECSF10 DECTIN2209
cell-associated C-type lectin 2) (DC-associated C-type lectin 2) (Dectin-2)
P21964COMT_HUMANCatechol O-methyltransferase (EC 2.1.1.6)COMT271
Q9UHP7CLC2D_HUMANC-type lectin domain family 2 member D (Lectin-like NK cell receptor) (Lectin-likeCLEC2D CLAX LLT1 OCIL191
transcript 1) (LLT-1) (Osteoclast inhibitory lectin)
Q9H2X3CLC4M_HUMANC-type lectin domain family 4 member M (CD209 antigen-like protein 1) (DC-SIGN-CLEC4M CD209L CD209L1 CD299399
related protein) (DC-SIGNR) (Dendritic cell-specific ICAM-3-grabbing non-integrin 2) (DC-
SIGN2) (Liver/lymph node-specific ICAM-3-grabbing non-integrin) (L-SIGN) (CD antigen CD299)
Q5KU26COL12_HUMANCollectin-12 (Collectin placenta protein 1) (CL-P1) (hCL-P1) (Nurse cell scavengerCOLEC12 CLP1 NSR2 SCARA4 SRCL742
receptor 2) (Scavenger receptor class A member 4) (Scavenger receptor with C-type lectin)
Q5TAT6CODA1_HUMANCollagen alpha-1(XIII) chain (COLXIIIA1)COL13A1717
Q96BA8CR3L1_HUMANCyclic AMP-responsive element-binding protein 3-like protein 1 (cAMP-responsiveCREB3L1 OASIS PSEC0238519
element-binding protein 3-like protein 1) (Old astrocyte specifically-induced substance)
(OASIS) [Cleaved into: Processed cyclic AMP-responsive element-binding protein 3-like
protein 1]
Q86Y22CONA1_HUMANCollagen alpha-1(XXIII) chainCOL23A1540
Q70SY1CR3L2_HUMANCyclic AMP-responsive element-binding protein 3-like protein 2 (cAMP-responsiveCREB3L2 BBF2H7520
element-binding protein 3-like protein 2) (BBF2 human homolog on chromosome 7)
[Cleaved into: Processed cyclic AMP-responsive element-binding protein 3-like protein 2]
Q9UMD9COHA1_HUMANCollagen alpha-1(XVII) chain (180 kDa bullous pemphigoid antigen 2) (BullousCOL17A1 BP180 BPAG21497
pemphigoid antigen 2) [Cleaved into: 120 kDa linear IgA disease antigen (120 kDa linear
IgA dermatosis antigen) (Linear IgA disease antigen 1) (LAD-1); 97 kDa linear IgA
disease antigen (97 kDa linear IgA bullous dermatosis antigen) (97 kDa LAD antigen)
(97-LAD) (Linear IgA bullous disease antigen of 97 kDa) (LABD97)]
Q8N1L4CP4Z2_HUMANPutative inactive cytochrome P450 family member 4Z2CYP4Z2P340
Q9BXS0COPA1_HUMANCollagen alpha-1(XXV) chain (Alzheimer disease amyloid-associated protein) (AMY)COL25A1654
(CLAC-P) [Cleaved into: Collagen-like Alzheimer amyloid plaque component (CLAC)]
Q9Y5Q5CORIN_HUMANAtrial natriuretic peptide-converting enzyme (EC 3.4.21.-) (Corin) (Heart-specific serineCORIN CRN TMPRSS101042
proteinase ATC2) (Pro-ANP-converting enzyme) (Transmembrane protease serine 10)
[Cleaved into: Atrial natriuretic peptide-converting enzyme, N-terminal propeptide; Atrial
natriuretic peptide-converting enzyme, activated protease fragment; Atrial natriuretic
peptide-converting enzyme, 180 kDa soluble fragment; Atrial natriuretic peptide-
converting enzyme, 160 kDa soluble fragment; Atrial natriuretic peptide-converting
enzyme, 100 kDa soluble fragment]
Q86W10CP4Z1_HUMANCytochrome P4504Z1 (EC 1.14.14.1) (CYPIVZ1)CYP4Z1 UNQ3060/PRO9882505
O43889CREB3_HUMANCyclic AMP-responsive element-binding protein 3 (CREB-3) (cAMP-responsive element-CREB3 LZIP395
binding protein 3) (Leucine zipper protein) (Luman) (Transcription factor LZIP-alpha)
[Cleaved into: Processed cyclic AMP-responsive element-binding protein 3 (N-terminal
Luman) (Transcriptionally active form)]
Q8TEY5CR3L4_HUMANCyclic AMP-responsive element-binding protein 3-like protein 4 (cAMP-responsiveCREB3L4 AIBZIP CREB4 JAL395
element-binding protein 3-like protein 4) (Androgen-induced basic leucine zipper protein)
(AIbZIP) (Attaching to CRE-like 1) (ATCE1) (Cyclic AMP-responsive element-binding
protein 4) (CREB-4) (cAMP-responsive element-binding protein 4) (Transcript induced in
spermiogenesis protein 40) (Tisp40) (hJAL) [Cleaved into: Processed cyclic AMP-
responsive element-binding protein 3-like protein 4]
Q68CJ9CR3L3_HUMANCyclic AMP-responsive element-binding protein 3-like protein 3 (cAMP-responsiveCREB3L3 CREBH HYST1481461
element-binding protein 3-like protein 3) (Transcription factor CREB-H) [Cleaved into:
Processed cyclic AMP-responsive element-binding protein 3-like protein 3]
P37059DHB2_HUMANEstradiol 17-beta-dehydrogenase 2 (EC 1.1.1.62) (17-beta-hydroxysteroidHSD17B2 EDH17B2 SDR9C2387
dehydrogenase type 2) (17-beta-HSD 2) (20 alpha-hydroxysteroid dehydrogenase) (20-
alpha-HSD) (E2DH) (Microsomal 17-beta-hydroxysteroid dehydrogenase) (Short chain
dehydrogenase/reductase family 9C member 2) (Testosterone 17-beta-dehydrogenase)
(EC 1.1.1.239)
P27487DPP4_HUMANDipeptidyl peptidase 4 (EC 3.4.14.5) (ADABP) (Adenosine deaminase complexing proteinDPP4 ADCP2 CD26766
2) (ADCP-2) (Dipeptidyl peptidase IV) (DPP IV) (T-cell activation antigen CD26) (TP103)
(CD antigen CD26) [Cleaved into: Dipeptidyl peptidase 4 membrane form (Dipeptidyl
peptidase IV membrane form); Dipeptidyl peptidase 4 soluble form (Dipeptidyl peptidase
IV soluble form)]
P28845DHI1_HUMANCorticosteroid 11-beta-dehydrogenase isozyme 1 (EC 1.1.1.146) (11-beta-hydroxysteroidHSD11B1 HSD11 HSD11L SDR26C1292
dehydrogenase 1) (11-DH) (11-beta-HSD1) (Short chain dehydrogenase/reductase family
26C member 1)
P09172DOPO_HUMANDopamine beta-hydroxylase (EC 1.14.17.1) (Dopamine beta-monooxygenase) [CleavedDBH617
into: Soluble dopamine beta-hydroxylase]
Q8N608DPP10_HUMANInactive dipeptidyl peptidase 10 (Dipeptidyl peptidase IV-related protein 3) (DPRP-3)DPP10 DPRP3 KIAA1492796
(Dipeptidyl peptidase X) (DPP X) (Dipeptidyl peptidase-like protein 2) (DPL2)
P42658DPP6_HUMANDipeptidyl aminopeptidase-like protein 6 (DPPX) (Dipeptidyl aminopeptidase-relatedDPP6865
protein) (Dipeptidyl peptidase 6) (Dipeptidyl peptidase IV-like protein) (Dipeptidyl
peptidase VI) (DPP VI)
Q6IAN0DRS7B_HUMANDehydrogenase/reductase SDR family member 7B (EC 1.1.-.-) (Short-chainDHRS7B SDR32C1 CGI-93 UNQ212/325
dehydrogenase/reductase family 32C member 1)PRO238
O60344ECE2_HUMANEndothelin-converting enzyme 2 (ECE-2) [Includes: Methyltransferase-like region (ECECE2 KIAA0604 UNQ403/PRO740883
2.1.1.-); Endothelin-converting enzyme 2 region (EC 3.4.24.71)]
O75923DYSF_HUMANDysferlin (Dystrophy-associated fer-1-like protein) (Fer-1-like protein 1)DYSF FER1L12080
O95672ECEL1_HUMANEndothelin-converting enzyme-like 1 (EC 3.4.24.-) (Xce protein)ECEL1 XCE UNQ2431/PRO4991775
Q92838EDA_HUMANEctodysplasin-A (Ectodermal dysplasia protein) (EDA protein) [Cleaved into:EDA ED1 EDA2391
Ectodysplasin-A, membrane form; Ectodysplasin-A, secreted form]
P42892ECE1_HUMANEndothelin-converting enzyme 1 (ECE-1) (EC 3.4.24.71)ECE1770
Q92611EDEM1_HUMANER degradation-enhancing alpha-mannosidase-like protein 1EDEM1 EDEM KIAA0212657
O75354ENTP6_HUMANEctonucleoside triphosphate diphosphohydrolase 6 (NTPDase 6) (EC 3.6.1.6) (CD39ENTPD6 CD39L2 IL6ST2484
antigen-like 2)
P98073ENTK_HUMANEnteropeptidase (EC 3.4.21.9) (Enterokinase) (Serine protease 7) (TransmembraneTMPRSS15 ENTK PRSS71019
protease serine 15) [Cleaved into: Enteropeptidase non-catalytic heavy chain;
Enteropeptidase catalytic light chain]
P22413ENPP1_HUMANEctonucleotide pyrophosphatase/phosphodiesterase family member 1 (E-NPP 1)ENPP1 M6S1 NPPS PC1 PDNP1925
(Membrane component chromosome 6 surface marker 1) (Phosphodiesterase
I/nucleotide pyrophosphatase 1) (Plasma-cell membrane glycoprotein PC-1) [Includes:
Alkaline phosphodiesterase I (EC 3.1.4.1); Nucleotide pyrophosphatase (NPPase) (EC
3.6.1.9)]
O14638ENPP3_HUMANEctonucleotide pyrophosphatase/phosphodiesterase family member 3 (E-NPP 3)ENPP3 PDNP3875
(Phosphodiesterase I beta) (PD-Ibeta) (Phosphodiesterase I/nucleotide pyrophosphatase
3) (CD antigen CD203c) [Includes: Alkaline phosphodiesterase I (EC 3.1.4.1); Nucleotide
pyrophosphatase (NPPase) (EC 3.6.1.9)]
O43909EXTL3_HUMANExostosin-like 3 (EC 2.4.1.223) (EXT-related protein 1) (Glucuronyl-galactosyl-EXTL3 EXTL1L EXTR1 KIAA0519919
proteoglycan 4-alpha-N-acetylglucosaminyltransferase) (Hereditary multiple exostoses
gene isolog) (Multiple exostosis-like protein 3) (Putative tumor suppressor protein EXTL3)
Q6UWH4F198B_HUMANProtein FAM198B (Expressed in nerve and epithelium during development)FAM198B C4orf18 ENED AD021519
UNQ2512/PRO6001
Q9H0X4F234A_HUMANProtein FAM234A (Protein ITFG3)FAM234A C16orf9 ITFG3552
Q5VUD6FA69B_HUMANProtein FAM69BFAM69B C9orf136 PP6977431
Q8IUS5EPHX4_HUMANEpoxide hydrolase 4 (EC 3.3.-.-) (Abhydrolase domain-containing protein 7) (EpoxideEPHX4 ABHD7 EPHXRP362
hydrolase-related protein)
O94905ERLN2_HUMANErlin-2 (Endoplasmic reticulum lipid raft-associated protein 2) (Stomatin-prohibitin-flotillin-ERLIN2 C8orf2 SPFH2 UNQ2441/339
HflC/K domain-containing protein 2) (SPFH domain-containing protein 2)PRO5003/PRO9924
Q93063EXT2_HUMANExostosin-2 (EC 2.4.1.224) (EC 2.4.1.225) (Glucuronosyl-N-acetylglucosaminyl-EXT2718
proteoglycan/N-acetylglucosaminyl-proteoglycan 4-alpha-N-
acetylglucosaminyltransferase) (Multiple exostoses protein 2) (Putative tumor suppressor
protein EXT2)
Q9NZ08ERAP1_HUMANEndoplasmic reticulum aminopeptidase 1 (EC 3.4.11.-) (ARTS-1) (Adipocyte-derivedERAP1 APPILS ARTS1 KIAA0525941
leucine aminopeptidase) (A-LAP) (Aminopeptidase PILS) (Puromycin-insensitive leucyl-UNQ584/PRO1154
specific aminopeptidase) (PILS-AP) (Type 1 tumor necrosis factor receptor shedding
aminopeptidase regulator)
Q6P179ERAP2_HUMANEndoplasmic reticulum aminopeptidase 2 (EC 3.4.11.-) (Leukocyte-derived arginineERAP2 LRAP960
aminopeptidase) (L-RAP)
O75477ERLN1_HUMANErlin-1 (Endoplasmic reticulum lipid raft-associated protein 1) (Protein KE04) (Stomatin-ERLIN1 C10orf69 KE04 KEO4 SPFH1346
prohibitin-flotillin-HflC/K domain-containing protein 1) (SPFH domain-containing protein 1)
Q92935EXTL1_HUMANExostosin-like 1 (EC 2.4.1.224) (Exostosin-L) (Glucuronosyl-N-acetylglucosaminyl-EXTL1 EXTL676
proteoglycan 4-alpha-N-acetylglucosaminyltransferase) (Multiple exostosis-like protein)
Q16394EXT1_HUMANExostosin-1 (EC 2.4.1.224) (EC 2.4.1.225) (Glucuronosyl-N-acetylglucosaminyl-EXT1746
proteoglycan/N-acetylglucosaminyl-proteoglycan 4-alpha-N-
acetylglucosaminyltransferase) (Multiple exostoses protein 1) (Putative tumor suppressor
protein EXT1)
Q9UBQ6EXTL2_HUMANExostosin-like 2 (EC 2.4.1.223) (Alpha-1,4-N-acetylhexosaminyltransferase EXTL2)EXTL2 EXTR2330
(Alpha-GalNAcT EXTL2) (EXT-related protein 2) (Glucuronyl-galactosyl-proteoglycan 4-
alpha-N-acetylglucosaminyltransferase) [Cleaved into: Processed exostosin-like 2]
Q0P6D2FA69C_HUMANProtein FAM69CFAM69C C18orf51419
Q5T7M9FA69A_HUMANProtein FAM69AFAM69A428
Q9H9S5FKRP_HUMANFukutin-related protein (EC 2.-.-.-)FKRP495
Q8N539FBCD1_HUMANFibrinogen C domain-containing protein 1FIBCD1 UNQ701/PRO1346461
P06734FCER2_HUMANLow affinity immunoglobulin epsilon Fc receptor (BLAST-2) (C-type lectin domain family 4FCER2 CD23A CLEC4J FCE2 IGEBF321
member J) (Fc-epsilon-RII) (Immunoglobulin E-binding factor) (Lymphocyte IgE receptor)
(CD antigen CD23) [Cleaved into: Low affinity immunoglobulin epsilon Fc receptor
membrane-bound form; Low affinity immunoglobulin epsilon Fc receptor soluble form]
O75072FKTN_HUMANFukutin (EC 2.-.-.-) (Fukuyama-type congenital muscular dystrophy protein)FKTN FCMD461
Q04609FOLH1_HUMANGlutamate carboxypeptidase 2 (EC 3.4.17.21) (Cell growth-inhibiting gene 27 protein)FOLH1 FOLH NAALAD1 PSM PSMA GIG27750
(Folate hydrolase 1) (Folylpoly-gamma-glutamate carboxypeptidase) (FGCP) (Glutamate
carboxypeptidase II) (GCPII) (Membrane glutamate carboxypeptidase) (mGCP) (N-
acetylated-alpha-linked acidic dipeptidase I) (NAALADase I) (Prostate-specific membrane
antigen) (PSM) (PSMA) (Pteroylpoly-gamma-glutamate carboxypeptidase)
Q9BYC5FUT8_HUMANAlpha-(1,6)-fucosyltransferase (Alpha1-6FucT) (EC 2.4.1.68) (Fucosyltransferase 8)FUT8575
(GDP-L-Fuc:N-acetyl-beta-D-glucosaminide alpha1,6-fucosyltransferase) (GDP-fucose--
glycoprotein fucosyltransferase) (Glycoprotein 6-alpha-L-fucosyltransferase)
P19526FUT1_HUMANGalactoside 2-alpha-L-fucosyltransferase 1 (EC 2.4.1.69) (Alpha(1,2)FT 1) (Blood groupFUT1 H HSC365
H alpha 2-fucosyltransferase) (Fucosyltransferase 1) (GDP-L-fucose:beta-D-galactoside
2-alpha-L-fucosyltransferase 1)
P51993FUT6_HUMANAlpha-(1,3)-fucosyltransferase 6 (EC 2.4.1.65) (Fucosyltransferase 6)FUT6 FCT3A359
(Fucosyltransferase VI) (Fuc-TVI) (FucT-VI) (Galactoside 3-L-fucosyltransferase)
Q9H3Q3G3ST2_HUMANGalactose-3-O-sulfotransferase 2 (Gal3ST-2) (EC 2.8.2.-) (Beta-galactose-3-O-GAL3ST2 GP3ST398
sulfotransferase 2) (Gal-beta-1,3-GalNAc 3′-sulfotransferase 2) (Glycoprotein beta-Gal
3′-sulfotransferase 2)
Q10981FUT2_HUMANGalactoside 2-alpha-L-fucosyltransferase 2 (EC 2.4.1.69) (Alpha(1,2)FT 2)FUT2 SEC2343
(Fucosyltransferase 2) (GDP-L-fucose:beta-D-galactoside 2-alpha-L-fucosyltransferase 2)
(SE2) (Secretor blood group alpha-2-fucosyltransferase) (Secretor factor) (Se)
P22083FUT4_HUMANAlpha-(1,3)-fucosyltransferase 4 (EC 2.4.1.-) (ELAM-1 ligand fucosyltransferase)FUT4 ELFT FCT3A530
(Fucosyltransferase 4) (Fucosyltransferase IV) (Fuc-TIV) (FucT-IV) (Galactoside 3-L-
fucosyltransferase)
Q96A11G3ST3_HUMANGalactose-3-O-sulfotransferase 3 (Gal3ST-3) (EC 2.8.2.-) (Beta-galactose-3-O-GAL3ST3431
sulfotransferase 3) (Gal3ST3) (Gal-beta-1,3-GalNAc 3′-sulfotransferase 3)
Q10472GALT1_HUMANPolypeptide N-acetylgalactosaminyltransferase 1 (EC 2.4.1.41) (Polypeptide GalNAcGALNT1559
transferase 1) (GalNAc-T1) (pp-GaNTase 1) (Protein-UDP
acetylgalactosaminyltransferase 1) (UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase 1) [Cleaved into: Polypeptide N-
acetylgalactosaminyltransferase 1 soluble form]
Q10471GALT2_HUMANPolypeptide N-acetylgalactosaminyltransferase 2 (EC 2.4.1.41) (Polypeptide GalNAcGALNT2571
transferase 2) (GalNAc-T2) (pp-GaNTase 2) (Protein-UDP
acetylgalactosaminyltransferase 2) (UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase 2) [Cleaved into: Polypeptide N-
acetylgalactosaminyltransferase 2 soluble form]
Q14435GALT3_HUMANPolypeptide N-acetylgalactosaminyltransferase 3 (EC 2.4.1.41) (Polypeptide GalNAcGALNT3633
transferase 3) (GalNAc-T3) (pp-GaNTase 3) (Protein-UDP
acetylgalactosaminyltransferase 3) (UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase 3)
Q8NCL4GALT6_HUMANPolypeptide N-acetylgalactosaminyltransferase 6 (EC 2.4.1.41) (Polypeptide GalNAcGALNT6622
transferase 6) (GalNAc-T6) (pp-GaNTase 6) (Protein-UDP
acetylgalactosaminyltransferase 6) (UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase 6)
Q6P4F1FUT10_HUMANAlpha-(1,3)-fucosyltransferase 10 (EC 2.4.1.-) (Fucosyltransferase X) (Fuc-TX) (FucT-X)FUT10479
(Galactoside 3-L-fucosyltransferase 10) (Fucosyltransferase 10)
Q99999G3ST1_HUMANGalactosylceramide sulfotransferase (GalCer sulfotransferase) (EC 2.8.2.11) (3′-GAL3ST1 CST423
phosphoadenosine-5′-phosphosulfate:GalCer sulfotransferase) (3′-
phosphoadenylylsulfate:galactosylceramide 3′-sulfotransferase) (Cerebroside
sulfotransferase)
Q96RP7G3ST4_HUMANGalactose-3-O-sulfotransferase 4 (Gal3ST-4) (EC 2.8.2.-) (Beta-galactose-3-O-GAL3ST4 PP6968486
sulfotransferase 4) (Gal-beta-1,3-GalNAc 3′-sulfotransferase)
Q9NY28GALT8_HUMANProbable polypeptide N-acetylgalactosaminyltransferase 8 (EC 2.4.1.41) (PolypeptideGALNT8637
GalNAc transferase 8) (GalNAc-T8) (pp-GaNTase 8) (Protein-UDP
acetylgalactosaminyltransferase 8) (UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase 8)
Q9HCQ5GALT9_HUMANPolypeptide N-acetylgalactosaminyltransferase 9 (EC 2.4.1.41) (Polypeptide GalNAcGALNT9603
transferase 9) (GalNAc-T9) (pp-GaNTase 9) (Protein-UDP
acetylgalactosaminyltransferase 9) (UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase 9)
Q495W5FUT11_HUMANAlpha-(1,3)-fucosyltransferase 11 (EC 2.4.1.-) (Fucosyltransferase XI) (Fuc-TXI) (FucT-FUT11492
XI) (Galactoside 3-L-fucosyltransferase 11) (Fucosyltransferase 11)
P21217FUT3_HUMANGalactoside 3(4)-L-fucosyltransferase (EC 2.4.1.65) (Blood group Lewis alpha-4-FUT3 FT3B LE361
fucosyltransferase) (Lewis FT) (Fucosyltransferase 3) (Fucosyltransferase III) (FucT-III)
Q9Y231FUT9_HUMANAlpha-(1,3)-fucosyltransferase 9 (EC 2.4.1.-) (Fucosyltransferase 9) (FucosyltransferaseFUT9359
IX) (Fuc-TIX) (FucT-IX) (Galactoside 3-L-fucosyltransferase)
Q7Z7M9GALT5_HUMANPolypeptide N-acetylgalactosaminyltransferase 5 (EC 2.4.1.41) (Polypeptide GalNAcGALNT5940
transferase 5) (GalNAc-T5) (pp-GaNTase 5) (Protein-UDP
acetylgalactosaminyltransferase 5) (UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase 5)
Q9P109GCNT4_HUMANBeta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 4GCNT4453
(EC 2.4.1.102) (Core 2-branching enzyme 3) (Core2-GlcNAc-transferase 3) (C2GnT3)
Q6ZNI0GCNT7_HUMANBeta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 7GCNT7 C20orf105430
(EC 2.4.1.-)
Q11128FUT5_HUMANAlpha-(1,3)-fucosyltransferase 5 (EC 2.4.1.65) (Fucosyltransferase 5)FUT5374
(Fucosyltransferase V) (Fuc-TV) (FucT-V) (Galactoside 3-L-fucosyltransferase)
Q11130FUT7_HUMANAlpha-(1,3)-fucosyltransferase 7 (EC 2.4.1.-) (Fucosyltransferase 7) (FucosyltransferaseFUT7342
VII) (Fuc-TVII) (FucT-VII) (Galactoside 3-L-fucosyltransferase) (Selectin ligand synthase)
Q02742GCNT1_HUMANBeta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferaseGCNT1 NACGT2428
(EC 2.4.1.102) (Core 2-branching enzyme) (Core2-GlcNAc-transferase) (C2GNT) (Core 2 GNT)
Q8N5D6GBGT1_HUMANGloboside alpha-1,3-N-acetylgalactosaminyltransferase 1 (EC 2.4.1.-) (ForssmanGBGT1 UNQ2513/PRO6002347
glycolipid synthase-like protein)
Q5T4J0GCNT6_HUMANBeta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 6GCNT6391
(EC 2.4.1.-)
Q4G0N0GGTA1_HUMANInactive N-acetyllactosaminide alpha-1,3-galactosyltransferase (Glycoprotein alpha-GGTA1P GGTA1100
galactosyltransferase 1 pseudogene)
Q68CQ7GL8D1_HUMANGlycosyltransferase 8 domain-containing protein 1 (EC 2.4.1.-)GLT8D1 GALA4A AD-017 MSTP137371
UNQ572/PRO1134
Q8N4A0GALT4_HUMANPolypeptide N-acetylgalactosaminyltransferase 4 (EC 2.4.1.41) (Polypeptide GalNAcGALNT4578
transferase 4) (GalNAc-T4) (pp-GaNTase 4) (Protein-UDP
acetylgalactosaminyltransferase 4) (UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase 4)
Q86SF2GALT7_HUMANN-acetylgalactosaminyltransferase 7 (EC 2.4.1.-) (Polypeptide GalNAc transferase 7)GALNT7657
(GalNAc-T7) (pp-GaNTase 7) (Protein-UDP acetylgalactosaminyltransferase 7) (UDP-
GalNAc:polypeptide N-acetylgalactosaminyltransferase 7)
O95395GCNT3_HUMANBeta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase 3GCNT3438
(EC 2.4.1.102) (EC 2.4.1.150) (C2GnT-mucin type) (C2GnT-M) (hC2GnT-M) (Core 2/core
4 beta-1,6-N-acetylglucosaminyltransferase) (C2/4GnT)
P19440GGT1_HUMANGamma-glutamyltranspeptidase 1 (GGT 1) (EC 2.3.2.2) (Gamma-glutamyltransferase 1)GGT1 GGT569
(Glutathione hydrolase 1) (EC 3.4.19.13) (Leukotriene-C4 hydrolase) (EC 3.4.19.14) (CD
antigen CD224) [Cleaved into: Gamma-glutamyltranspeptidase 1 heavy chain; Gamma-
glutamyltranspeptidase 1 light chain]
Q7Z4J2GL6D1_HUMANGlycosyltransferase 6 domain-containing protein 1 (EC 2.4.1.-) (GalactosyltransferaseGLT6D1 GLTDC1 GT6M7308
family 6 domain-containing 1)
O94923GLCE_HUMAND-glucuronyl C5-epimerase (EC 5.1.3.17) (Heparan sulfate C5-epimerase) (Hsepi)GLCE KIAA0836617
(Heparin/heparan sulfate:glucuronic acid C5-epimerase) (Heparosan-N-sulfate-
glucuronate 5-epimerase)
Q86SR1GLT10_HUMANPolypeptide N-acetylgalactosaminyltransferase 10 (EC 2.4.1.41) (Polypeptide GalNAcGALNT10603
transferase 10) (GalNAc-T10) (pp-GaNTase 10) (Protein-UDP
acetylgalactosaminyltransferase 10) (UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase 10)
Q8IXK2GLT12_HUMANPolypeptide N-acetylgalactosaminyltransferase 12 (EC 2.4.1.41) (Polypeptide GalNAcGALNT12581
transferase 12) (GalNAc-T12) (pp-GaNTase 12) (Protein-UDP
acetylgalactosaminyltransferase 12) (UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase 12)
Q96FL9GLT14_HUMANPolypeptide N-acetylgalactosaminyltransferase 14 (EC 2.4.1.41) (Polypeptide GalNAcGALNT14 UNQ2434/PRO4994552
transferase 14) (GalNAc-T14) (pp-GaNTase 14) (Protein-UDP
acetylgalactosaminyltransferase 14) (UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase 14)
Q8N428GLT16_HUMANPolypeptide N-acetylgalactosaminyltransferase 16 (EC 2.4.1.41) (Polypeptide GalNAcGALNT16 GALNTL1 KIAA1130558
transferase 16) (GalNAc-T16) (Polypeptide GalNAc transferase-like protein 1) (GalNAc-T-
like protein 1) (pp-GaNTase-like protein 1) (Polypeptide N-
acetylgalactosaminyltransferase-like protein 1) (Protein-UDP
acetylgalactosaminyltransferase-like protein 1) (UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase-like protein 1)
P36269GGT5_HUMANGamma-glutamyltransferase 5 (GGT 5) (EC 2.3.2.2) (Gamma-glutamyl transpeptidase-GGT5 GGTLA1586
related enzyme) (GGT-rel) (Gamma-glutamyltransferase-like activity 1) (Gamma-
glutamyltranspeptidase 5) (Glutathione hydrolase 5) (EC 3.4.19.13) (Leukotriene-C4
hydrolase) (EC 3.4.19.14) [Cleaved into: Gamma-glutamyltransferase 5 heavy chain;
Gamma-glutamyltransferase 5 light chain]
Q6P531GGT6_HUMANGamma-glutamyltransferase 6 (GGT 6) (EC 2.3.2.2) (Gamma-glutamyltranspeptidase 6)GGT6493
(Glutathione hydrolase 6) (EC 3.4.19.13) [Cleaved into: Gamma-glutamyltransferase 6
heavy chain; Gamma-glutamyltransferase 6 light chain]
Q9UJ14GGT7_HUMANGamma-glutamyltransferase 7 (GGT 7) (EC 2.3.2.2) (Gamma-glutamyltransferase-like 3)GGT7 GGTL3 GGTL5662
(Gamma-glutamyltransferase-like 5) (Gamma-glutamyltranspeptidase 7) (Glutathione
hydrolase 7) (EC 3.4.19.13) [Cleaved into: Gamma-glutamyltransferase 7 heavy chain;
Gamma-glutamyltransferase 7 light chain]
Q6ZMI3GLDN_HUMANGliomedin [Cleaved into: Gliomedin shedded ectodomain]GLDN COLM UNQ9339/PRO34011551
Q8IUC8GLT13_HUMANPolypeptide N-acetylgalactosaminyltransferase 13 (EC 2.4.1.41) (Polypeptide GalNAcGALNT13 KIAA1918556
transferase 13) (GalNAc-T13) (pp-GaNTase 13) (Protein-UDP
acetylgalactosaminyltransferase 13) (UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase 13)
Q6P9A2GLT18_HUMANPolypeptide N-acetylgalactosaminyltransferase 18 (EC 2.4.1.41) (Polypeptide GalNAcGALNT18 GALNTL4607
transferase 18) (GalNAc-T18) (Polypeptide GalNAc transferase-like protein 4) (GalNAc-T-
like protein 4) (pp-GaNTase-like protein 4) (Polypeptide N-
acetylgalactosaminyltransferase-like protein 4) (Protein-UDP
acetylgalactosaminyltransferase-like protein 4) (UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase-like protein 4)
Q49A17GLTL6_HUMANPolypeptide N-acetylgalactosaminyltransferase-like 6 (EC 2.4.1.41) (Polypeptide GalNAcGALNTL6 GALNT17601
transferase 17) (GalNAc-T17) (pp-GaNTase 17) (Protein-UDP
acetylgalactosaminyltransferase 17) (Putative polypeptide N-
acetylgalactosaminyltransferase 17) (UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase 17)
Q3T906GNPTA_HUMANN-acetylglucosamine-1-phosphotransferase subunits alpha/beta (EC 2.7.8.17) (GlcNAc-GNPTAB GNPTA KIAA12081256
1-phosphotransferase subunits alpha/beta) (Stealth protein GNPTAB) (UDP-N-
acetylglucosamine-1-phosphotransferase subunits alpha/beta) [Cleaved into: N-
acetylglucosamine-1-phosphotransferase subunit alpha; N-acetylglucosamine-1-
phosphotransferase subunit beta]
A6NGU5GGT3_HUMANPutative gamma-glutamyltranspeptidase 3 (GGT 3) (EC 2.3.2.2) (Gamma-GGT3P GGT3568
glutamyltransferase 3) (Glutathione hydrolase 3) (EC 3.4.19.13) [Cleaved into: Putative
gamma-glutamyltranspeptidase 3 heavy chain; Putative gamma-glutamyltranspeptidase 3
light chain]
Q9H1C3GL8D2_HUMANGlycosyltransferase 8 domain-containing protein 2 (EC 2.4.1.-)GLT8D2 GALA4A UNQ1901/PRO4347349
Q8N3T1GLT15_HUMANPolypeptide N-acetylgalactosaminyltransferase 15 (EC 2.4.1.41) (Polypeptide GalNAcGALNT15 GALNTL2 UNQ770/PRO1564639
transferase-like protein 2) (GalNAc-T-like protein 2) (pp-GaNTase-like protein 2)
(Polypeptide N-acetylgalactosaminyltransferase-like protein 2) (Protein-UDP
acetylgalactosaminyltransferase-like protein 2) (UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase-like protein 2)
Q6IS24GLTL3_HUMANPutative polypeptide N-acetylgalactosaminyltransferase-like protein 3 (EC 2.4.1.41)WBSCR17 GALNTL3598
(Polypeptide GalNAc transferase-like protein 3) (GalNAc-T-like protein 3) (pp-GaNTase-
like protein 3) (Protein-UDP acetylgalactosaminyltransferase-like protein 3) (UDP-
GalNAc:polypeptide N-acetylgalactosaminyltransferase-like protein 3) (Williams-Beuren
syndrome chromosomal region 17 protein)
Q8NCW6GLT11_HUMANPolypeptide N-acetylgalactosaminyltransferase 11 (EC 2.4.1.41) (Polypeptide GalNAcGALNT11608
transferase 11) (GalNAc-T11) (pp-GaNTase 11) (Protein-UDP
acetylgalactosaminyltransferase 11) (UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase 11)
Q7Z4T8GLTL5_HUMANInactive polypeptide N-acetylgalactosaminyltransferase-like protein 5 (PolypeptideGALNTL5 GALNT15443
GalNAc transferase 15) (GalNAc-T15) (pp-GaNTase 15) (Protein-UDP
acetylgalactosaminyltransferase 15) (UDP-GalNAc:polypeptide N-
acetylgalactosaminyltransferase 15)
Q8N0V5GNT2A_HUMANN-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase (N-GCNT2 GCNT5 II NACGT1402
acetylglucosaminyltransferase) (EC 2.4.1.150) (I-branching enzyme) (IGNT)
O00461GOLI4_HUMANGolgi integral membrane protein 4 (Golgi integral membrane protein, cis) (GIMPc) (GolgiGOLIM4 GIMPC GOLPH4 GPP130696
phosphoprotein 4) (Golgi-localized phosphoprotein of 130 kDa) (Golgi phosphoprotein of 130 kDa)
Q8NBJ4GOLM1_HUMANGolgi membrane protein 1 (Golgi membrane protein GP73) (Golgi phosphoprotein 2)GOLM1 C9orf155 GOLPH2 PSEC0242401
UNQ686/PRO1326
A0PJZ3GXLT2_HUMANGlucoside xylosyltransferase 2 (EC 2.4.2.n2) (Glycosyltransferase 8 domain-containingGXYLT2 GLT8D4443
protein 4)
Q4G148GXLT1_HUMANGlucoside xylosyltransferase 1 (EC 2.4.2.n2) (Glycosyltransferase 8 domain-containingGXYLT1 GLT8D3440
protein 3)
Q96MM7H6ST2_HUMANHeparan-sulfate 6-O-sulfotransferase 2 (HS6ST-2) (EC 2.8.2.-)HS6ST2 PSEC0092605
O60243H6ST1_HUMANHeparan-sulfate 6-O-sulfotransferase 1 (HS6ST-1) (EC 2.8.2.-)HS6ST1 HS6ST411
Q8IZP7H6ST3_HUMANHeparan-sulfate 6-O-sulfotransferase 3 (HS6ST-3) (EC 2.8.2.-)HS6ST3471
P04233HG2A_HUMANHLA class II histocompatibility antigen gamma chain (HLA-DR antigens-associatedCD74 DHLAG296
invariant chain) (Ia antigen-associated invariant chain) (Ii) (p33) (CD antigen CD74)
Q7LGA3HS2ST_HUMANHeparan sulfate 2-O-sulfotransferase 1 (2-O-sulfotransferase) (2OST) (EC 2.8.2.-)HS2ST1 HS2ST KIAA0448356
Q8IZT8HS3S5_HUMANHeparan sulfate glucosamine 3-O-sulfotransferase 5 (EC 2.8.2.23) (Heparan sulfate D-HS3ST5 3OST5 HS3OST5346
glucosaminyl 3-O-sulfotransferase 5) (3-OST-5) (Heparan sulfate 3-O-sulfotransferase 5)
(h3-OST-5)
P05981HEPS_HUMANSerine protease hepsin (EC 3.4.21.106) (Transmembrane protease serine 1) [CleavedHPN TMPRSS1417
into: Serine protease hepsin non-catalytic chain; Serine protease hepsin catalytic chain]
Q9Y663HS3SA_HUMANHeparan sulfate glucosamine 3-O-sulfotransferase 3A1 (EC 2.8.2.30) (Heparan sulfate D-HS3ST3A1 3OST3A1 HS3ST3A406
glucosaminyl 3-O-sulfotransferase 3A1) (3-OST-3A) (Heparan sulfate 3-O-UNQ2551/PRO6180
sulfotransferase 3A1) (h3-OST-3A)
Q9Y278HS3S2_HUMANHeparan sulfate glucosamine 3-O-sulfotransferase 2 (EC 2.8.2.29) (Heparan sulfate D-HS3ST2 3OST2 UNQ2442/PRO5004367
glucosaminyl 3-O-sulfotransferase 2) (3-OST-2) (Heparan sulfate 3-O-sulfotransferase 2)
(h3-OST-2)
Q9Y661HS3S4_HUMANHeparan sulfate glucosamine 3-O-sulfotransferase 4 (EC 2.8.2.23) (Heparan sulfate D-HS3ST4 3OST4456
glucosaminyl 3-O-sulfotransferase 4) (3-OST-4) (Heparan sulfate 3-O-sulfotransferase 4)
(h3-OST-4)
Q96QI5HS3S6_HUMANHeparan sulfate glucosamine 3-O-sulfotransferase 6 (EC 2.8.2.23) (Heparan sulfate D-HS3ST6 HS3ST5342
glucosaminyl 3-O-sulfotransferase 6) (3-OST-6) (Heparan sulfate 3-O-sulfotransferase 6)
(h3-OST-6)
Q9Y662HS3SB_HUMANHeparan sulfate glucosamine 3-O-sulfotransferase 3B1 (EC 2.8.2.30) (Heparan sulfate D-HS3ST3B1 3OST3B1 HS3ST3B390
glucosaminyl 3-O-sulfotransferase 3B1) (3-OST-3B) (Heparan sulfate 3-O-
sulfotransferase 3B1) (h3-OST-3B)
P07099HYEP_HUMANEpoxide hydrolase 1 (EC 3.3.2.9) (Epoxide hydratase) (Microsomal epoxide hydrolase)EPHX1 EPHX EPOX455
P46695IEX1_HUMANRadiation-inducible immediate-early gene IEX-1 (Differentiation-dependent gene 2IER3 DIF2 IEX1 PRG1156
protein) (Protein DIF-2) (Immediate early protein GLY96) (Immediate early response 3
protein) (PACAP-responsive gene 1 protein) (Protein PRG1)
P55073IOD3_HUMANThyroxine 5-deiodinase (EC 1.21.99.3) (5DIII) (DIOIII) (Type 3 DI) (Type III iodothyronineDIO3 ITDI3 TXDI3304
deiodinase)
Q9NX62IMPA3_HUMANInositol monophosphatase 3 (IMP 3) (IMPase 3) (EC 3.1.3.25) (EC 3.1.3.7) (Golgi 3-IMPAD1 IMPA3359
prime phosphoadenosine 5-prime phosphate 3-prime phosphatase) (Golgi-resident PAP
phosphatase) (gPAPP) (Inositol monophosphatase domain-containing protein 1) (Inositol-
1(or 4)-monophosphatase 3) (Myo-inositol monophosphatase A3)
Q01628IFM3_HUMANInterferon-induced transmembrane protein 3 (Dispanin subfamily A member 2b)IFITM3133
(DSPA2b) (Interferon-inducible protein 1-8U)
Q9NQX7ITM2C_HUMANIntegral membrane protein 2C (Cerebral protein 14) (Transmembrane protein BRI3)ITM2C BRI3 hucep-14 NPD018267
[Cleaved into: CT-BRI3]PSEC0047
O43736ITM2A_HUMANIntegral membrane protein 2A (Protein E25)ITM2A UNQ603/PRO1189263
Q6NSJ0K1161_HUMANUncharacterized family 31 glucosidase KIAA1161 (EC 3.2.1.-)KIAA1161714
Q9Y287ITM2B_HUMANIntegral membrane protein 2B (Immature BRI2) (imBRI2) (Protein E25B)ITM2B BRI BRI2266
(Transmembrane protein BRI) (Bri) [Cleaved into: BRI2, membrane form (Mature BRI2)
(mBRI2); BRI2 intracellular domain (BRI2 ICD); BRI2C, soluble form; Bri23 peptide (Bri2-
23) (ABri23) (C-terminal peptide) (P23 peptide)]
Q9NZS2KLRF1_HUMANKiller cell lectin-like receptor subfamily F member 1 (Lectin-like receptor F1) (ActivatingKLRF1 CLEC5C ML232
coreceptor NKp80) (C-type lectin domain family 5 member C)
P23276KELL_HUMANKell blood group glycoprotein (EC 3.4.24.-) (CD antigen CD238)KEL732
Q5H943KKLC1_HUMANKita-kyushu lung cancer antigen 1 (KK-LC-1) (Cancer/testis antigen 83)CT83 CXorf61 KKLC1113
Q13241KLRD1_HUMANNatural killer cells antigen CD94 (KP43) (Killer cell lectin-like receptor subfamily DKLRD1 CD94179
member 1) (NK cell receptor) (CD antigen CD94)
Q8N3Y3LARG2_HUMANGlycosyltransferase-like protein LARGE2 (EC 2.4.-.-) (Glycosyltransferase-like 1B)GYLTL1B LARGE2 PP5656721
[Includes: Xylosyltransferase LARGE2 (EC 2.4.2.-); Beta-1,3-glucuronyltransferase
LARGE2 (EC 2.4.1.-)]
Q12918KLRB1_HUMANKiller cell lectin-like receptor subfamily B member 1 (C-type lectin domain family 5KLRB1 CLEC5B NKRP1A225
member B) (HNKR-P1a) (NKR-P1A) (Natural killer cell surface protein P1A) (CD antigen CD161)
Q96E93KLRG1_HUMANKiller cell lectin-like receptor subfamily G member 1 (C-type lectin domain family 15KLRG1 CLEC15A MAFA MAFAL195
member A) (ITIM-containing receptor MAFA-L) (MAFA-like receptor) (Mast cell function-
associated antigen)
Q9UIQ6LCAP_HUMANLeucyl-cystinyl aminopeptidase (Cystinyl aminopeptidase) (EC 3.4.11.3) (Insulin-LNPEP OTASE1025
regulated membrane aminopeptidase) (Insulin-responsive aminopeptidase) (IRAP)
(Oxytocinase) (OTase) (Placental leucine aminopeptidase) (P-LAP) [Cleaved into: Leucyl-
cystinyl aminopeptidase, pregnancy serum form]
O95461LARGE_HUMANGlycosyltransferase-like protein LARGE1 (EC 2.4.-.-) (Acetylglucosaminyltransferase-likeLARGE KIAA0609 LARGE1756
1A) [Includes: Xylosyltransferase LARGE (EC 2.4.2.-); Beta-1,3-glucuronyltransferase
LARGE (EC 2.4.1.-)]
D3W0D1KLRF2_HUMANKiller cell lectin-like receptor subfamily F member 2 (Lectin-like receptor F2) (ActivatingKLRF2207
coreceptor NKp65)
Q86UP2KTN1_HUMANKinectin (CG-1 antigen) (Kinesin receptor)KTN1 CG1 KIAA00041357
P42167LAP2B_HUMANLamina-associated polypeptide 2, isoforms beta/gamma (Thymopoietin, isoformsTMPO LAP2454
beta/gamma) (TP beta/gamma) (Thymopoietin-related peptide isoforms beta/gamma)
(TPRP isoforms beta/gamma) [Cleaved into: Thymopoietin (TP) (Splenin); Thymopentin
(TP5)]
Q8NES3LFNG_HUMANBeta-1,3-N-acetylglucosaminyltransferase lunatic fringe (EC 2.4.1.222) (O-fucosylpeptideLFNG379
3-beta-N-acetylglucosaminyltransferase)
Q96AG4LRC59_HUMANLeucine-rich repeat-containing protein 59 (Ribosome-binding protein p34) (p34)LRRC59 PRO1855307
Q5SRI9MANEA_HUMANGlycoprotein endo-alpha-1,2-mannosidase (Endo-alpha mannosidase)MANEA462
(Endomannosidase) (hEndo) (EC 3.2.1.130) (Mandaselin)
Q5VSG8MANEL_HUMANGlycoprotein endo-alpha-1,2-mannosidase-like protein (EC 3.2.1.-)MANEAL457
Q5VT66MARC1_HUMANMitochondrial amidoxime-reducing component 1 (mARC1) (EC 1.-.-.-) (MolybdenumMARC1 MOSC1337
cofactor sulfurase C-terminal domain-containing protein 1) (MOSC domain-containing
protein 1) (Moco sulfurase C-terminal domain-containing protein 1)
Q9UKM7MA1B1_HUMANEndoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase (EC 3.2.1.113)MAN1B1 UNQ747/PRO1477699
(ER alpha-1,2-mannosidase) (ER mannosidase 1) (ERMan1) (Man9GlcNAc2-specific-
processing alpha-mannosidase) (Mannosidase alpha class 1B member 1)
Q16706MA2A1_HUMANAlpha-mannosidase 2 (EC 3.2.1.114) (Golgi alpha-mannosidase II) (AMan II) (Man II)MAN2A1 MANA21144
(Mannosidase alpha class 2A member 1) (Mannosyl-oligosaccharide 1,3-1,6-alpha-
mannosidase)
P49641MA2A2_HUMANAlpha-mannosidase 2x (EC 3.2.1.114) (Alpha-mannosidase IIx) (Man IIx) (MannosidaseMAN2A2 MANA2X1150
alpha class 2A member 2) (Mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase)
P33908MA1A1_HUMANMannosyl-oligosaccharide 1,2-alpha-mannosidase IA (EC 3.2.1.113) (Man(9)-alpha-MAN1A1653
mannosidase) (Man9-mannosidase) (Mannosidase alpha class 1A member 1)
(Processing alpha-1,2-mannosidase IA) (Alpha-1,2-mannosidase IA)
O60476MA1A2_HUMANMannosyl-oligosaccharide 1,2-alpha-mannosidase IB (EC 3.2.1.113) (Mannosidase alphaMAN1A2 MAN1B641
class 1A member 2) (Processing alpha-1,2-mannosidase IB) (Alpha-1,2-mannosidase IB)
Q9NR34MA1C1_HUMANMannosyl-oligosaccharide 1,2-alpha-mannosidase IC (EC 3.2.1.113) (HMIC)MAN1C1 MAN1A3 MAN1C630
(Mannosidase alpha class 1C member 1) (Processing alpha-1,2-mannosidase IC) (Alpha-
1,2-mannosidase IC)
Q9UEW3MARCO_HUMANMacrophage receptor MARCO (Macrophage receptor with collagenous structure)MARCO SCARA2520
(Scavenger receptor class A member 2)
O00587MFNG_HUMANBeta-1,3-N-acetylglucosaminyltransferase manic fringe (EC 2.4.1.222) (O-fucosylpeptideMFNG321
3-beta-N-acetylglucosaminyltransferase)
Q09327MGAT3_HUMANBeta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase (EC 2.4.1.144)MGAT3 GGNT3533
(N-glycosyl-oligosaccharide-glycoprotein N-acetylglucosaminyltransferase III) (GNT-III)
(GlcNAc-T III) (N-acetylglucosaminyltransferase III)
Q3V5L5MGT5B_HUMANAlpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase B (EC 2.4.1.-)MGAT5B KIAA2008792
(EC 2.4.1.155) (Alpha-mannoside beta-1,6-N-acetylglucosaminyltransferase B) (GlcNAc-
T Vb) (GNT-Vb) (hGnTVb) (Mannoside acetylglucosaminyltransferase 5B) (N-
acetylglucosaminyl-transferase Vb) (N-acetylglucosaminyltransferase IX) (GNT-IX)
Q8IX19MCEM1_HUMANMast cell-expressed membrane protein 1MCEMP1 C19orf59187
O43451MGA_HUMANMaltase-glucoamylase, intestinal [Includes: Maltase (EC 3.2.1.20) (Alpha-glucosidase);MGAM MGA MGAML1857
Glucoamylase (EC 3.2.1.3) (Glucan 1,4-alpha-glucosidase)]
Q9UBM8MGT4C_HUMANAlpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase C (ECMGAT4C478
2.4.1.145) (N-acetylglucosaminyltransferase IV homolog) (hGnT-IV-H) (N-glycosyl-
oligosaccharide-glycoprotein N-acetylglucosaminyltransferase IVc) (GlcNAc-T IVc) (GnT-
IVc) (N-acetylglucosaminyltransferase IVc) (UDP-N-acetylglucosamine:alpha-1,3-D-
mannoside beta-1,4-N-acetylglucosaminyltransferase IVc)
Q10469MGAT2_HUMANAlpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (EC 2.4.1.143)MGAT2447
(Beta-1,2-N-acetylglucosaminyltransferase II) (GlcNAc-T II) (GNT-II) (Mannoside
acetylglucosaminyltransferase 2) (N-glycosyl-oligosaccharide-glycoprotein N-
acetylglucosaminyltransferase II)
P26572MGAT1_HUMANAlpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (EC 2.4.1.101)MGAT1 GGNT1 GLCT1 GLYT1 MGAT445
(N-glycosyl-oligosaccharide-glycoprotein N-acetylglucosaminyltransferase I) (GNT-I)
(GlcNAc-T I)
Q9UM21MGT4A_HUMANAlpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase A (ECMGAT4A535
2.4.1.145) (N-glycosyl-oligosaccharide-glycoprotein N-acetylglucosaminyltransferase IVa)
(GlcNAc-T IVa) (GnT-IVa) (N-acetylglucosaminyltransferase IVa) (UDP-N-
acetylglucosamine:alpha-1,3-D-mannoside beta-1,4-N-acetylglucosaminyltransferase
IVa) [Cleaved into: Alpha-1,3-mannosyl-glycoprotein 4-beta-N-
acetylglucosaminyltransferase A soluble form]
Q9UQ53MGT4B_HUMANAlpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B (ECMGAT4B UNQ906/PRO1927548
2.4.1.145) (N-glycosyl-oligosaccharide-glycoprotein N-acetylglucosaminyltransferase IVb)
(GlcNAc-T IVb) (GnT-IVb) (N-acetylglucosaminyltransferase IVb) (UDP-N-
acetylglucosamine:alpha-1,3-D-mannoside beta-1,4-N-acetylglucosaminyltransferase
IVb)
Q9BY79MFRP_HUMANMembrane frizzled-related protein (Membrane-type frizzled-related protein)MFRP579
Q495T6MMEL1_HUMANMembrane metallo-endopeptidase-like 1 (EC 3.4.24.11) (Membrane metallo-MMEL1 MELL1 MMEL2 NEP2779
endopeptidase-like 2) (NEP2(m)) (Neprilysin II) (NEPII) (Neprilysin-2) (NEP2) (NL2)
[Cleaved into: Membrane metallo-endopeptidase-like 1, soluble form (Neprilysin-2
secreted) (NEP2(s))]
O75900MMP23_HUMANMatrix metalloproteinase-23 (MMP-23) (EC 3.4.24.-) (Femalysin) (MIFR-1) (MatrixMMP23A MMP21; MMP23B MMP21 MMP22390
metalloproteinase-21) (MMP-21) (Matrix metalloproteinase-22) (MMP-22) [Cleaved into:
Matrix metalloproteinase-23, soluble form]
Q09328MGT5A_HUMANAlpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A (ECMGAT5 GGNT5741
2.4.1.155) (Alpha-mannoside beta-1,6-N-acetylglucosaminyltransferase) (GlcNAc-T V)
(GNT-V) (Mannoside acetylglucosaminyltransferase 5) (N-acetylglucosaminyl-transferase V)
Q13724MOGS_HUMANMannosyl-oligosaccharide glucosidase (EC 3.2.1.106) (Processing A-glucosidase I)MOGS GCS1837
P21757MSRE_HUMANMacrophage scavenger receptor types I and II (Macrophage acetylated LDL receptor IMSR1 SCARA1451
and II) (Scavenger receptor class A member 1) (CD antigen CD204)
Q9NZM1MYOF_HUMANMyoferlin (Fer-1-like protein 3)MYOF FER1L3 KIAA12072061
Q58DX5NADL2_HUMANInactive N-acetylated-alpha-linked acidic dipeptidase-like protein 2 (NAALADase L2)NAALADL2795
Q9Y3Q0NALD2_HUMANN-acetylated-alpha-linked acidic dipeptidase 2 (EC 3.4.17.21) (GlutamateNAALAD2740
carboxypeptidase III) (GCPIII) (N-acetylated-alpha-linked acidic dipeptidase II)
(NAALADase II)
O95803NDST3_HUMANBifunctional heparan sulfate N-deacetylase/N-sulfotransferase 3 (EC 2.8.2.8)NDST3 HSST3 UNQ2544/PRO4998873
(Glucosaminyl N-deacetylase/N-sulfotransferase 3) (NDST-3) (hNDST-3) (N-heparan
sulfate sulfotransferase 3) (N-HSST 3) [Includes: Heparan sulfate N-deacetylase 3 (EC
3.-.-.-); Heparan sulfate N-sulfotransferase 3 (EC 2.8.2.-)]
Q9UQQ1NALDL_HUMANN-acetylated-alpha-linked acidic dipeptidase-like protein (NAALADase L) (EC 3.4.17.21)NAALADL1 NAALADASEL NAALADL740
(100 kDa ileum brush border membrane protein) (I100) (Ileal dipeptidylpeptidase)
Q9UHE5NAT8_HUMANN-acetyltransferase 8 (EC 2.3.1.-) (Acetyltransferase 2) (ATase2) (Camello-like protein 1)NAT8 CML1 GLA TSC501227
(Cysteinyl-conjugate N-acetyltransferase) (CCNAT) (EC 2.3.1.80)
Q6PIU2NCEH1_HUMANNeutral cholesterol ester hydrolase 1 (NCEH) (EC 3.1.1.-) (Arylacetamide deacetylase-NCEH1 AADACL1 KIAA1363408
like 1)
P52848NDST1_HUMANBifunctional heparan sulfate N-deacetylase/N-sulfotransferase 1 (EC 2.8.2.8)NDST1 HSST HSST1882
(Glucosaminyl N-deacetylase/N-sulfotransferase 1) (NDST-1) (N-heparan sulfate
sulfotransferase 1) (N-HSST 1) ([Heparan sulfate]-glucosamine N-sulfotransferase 1)
(HSNST 1) [Includes: Heparan sulfate N-deacetylase 1 (EC 3.-.-.-); Heparan sulfate N-
sulfotransferase 1 (EC 2.8.2.-)]
P52849NDST2_HUMANBifunctional heparan sulfate N-deacetylase/N-sulfotransferase 2 (EC 2.8.2.8)NDST2 HSST2883
(Glucosaminyl N-deacetylase/N-sulfotransferase 2) (NDST-2) (N-heparan sulfate
sulfotransferase 2) (N-HSST 2) [Includes: Heparan sulfate N-deacetylase 2 (EC 3.-.-.-);
Heparan sulfate N-sulfotransferase 2 (EC 2.8.2.-)]
Q9H3R1NDST4_HUMANBifunctional heparan sulfate N-deacetylase/N-sulfotransferase 4 (EC 2.8.2.8)NDST4 HSST4872
(Glucosaminyl N-deacetylase/N-sulfotransferase 4) (NDST-4) (N-heparan sulfate
sulfotransferase 4) (N-HSST 4) [Includes: Heparan sulfate N-deacetylase 4 (EC 3.-.-.-);
Heparan sulfate N-sulfotransferase 4 (EC 2.8.2.-)]
P26717NKG2C_HUMANNKG2-C type II integral membrane protein (CD159 antigen-like family member C) (NKKLRC2 NKG2C231
cell receptor C) (NKG2-C-activating NK receptor) (CD antigen CD159c)
P26718NKG2D_HUMANNKG2-D type II integral membrane protein (Killer cell lectin-like receptor subfamily KKLRK1 D12S2489E NKG2D216
member 1) (NK cell receptor D) (NKG2-D-activating NK receptor) (CD antigen CD314)
Q9UHF3NAT8B_HUMANPutative N-acetyltransferase 8B (EC 2.3.1.-) (Acetyltransferase 1) (ATase1) (Camello-likeNAT8B CML2227
protein 2)
P08473NEP_HUMANNeprilysin (EC 3.4.24.11) (Atriopeptidase) (Common acute lymphocytic leukemia antigen)MME EPN750
(CALLA) (Enkephalinase) (Neutral endopeptidase 24.11) (NEP) (Neutral endopeptidase)
(Skin fibroblast elastase) (SFE) (CD antigen CD10)
P26715NKG2A_HUMANNKG2-A/NKG2-B type II integral membrane protein (CD159 antigen-like family memberKLRC1 NKG2A233
A) (NK cell receptor A) (NKG2-A/B-activating NK receptor) (CD antigen CD159a)
Q14494NF2L1_HUMANNuclear factor erythroid 2-related factor 1 (NF-E2-related factor 1) (NFE2-related factor 1)NFE2L1 HBZ17 NRF1 TCF11772
(Locus control region-factor 1) (Nuclear factor, erythroid derived 2, like 1) (Transcription
factor 11) (TCF-11) (Transcription factor HBZ17) (Transcription factor LCR-F1)
O43908NKG2F_HUMANNKG2-F type II integral membrane protein (NK cell receptor F) (NKG2-F-activating NKKLRC4 NKG2F158
receptor)
P42857NSG1_HUMANNeuron-specific protein family member 1 (Brain neuron cytoplasmic protein 1)NSG1 D4S234185
Q07444NKG2E_HUMANNKG2-E type II integral membrane protein (NK cell receptor E) (NKG2-E-activating NKKLRC3 NKG2E240
receptor)
Q9Y328NSG2_HUMANNeuron-specific protein family member 2 (Protein p19) (Hmp19)NSG2171
O95502NPTXR_HUMANNeuronal pentraxin receptorNPTXR500
Q6PK18OGFD3_HUMAN2-oxoglutarate and iron-dependent oxygenase domain-containing protein 3 (EC 1.14.11.-)OGFOD3 C17orf101319
Q9NXG6P4HTM_HUMANTransmembrane prolyl 4-hydroxylase (P4H-TM) (EC 1.14.11.-) (Hypoxia-inducible factorP4HTM PH4502
prolyl hydroxylase 4) (HIF-PH4) (HIF-prolyl hydroxylase 4) (HPH-4)
Q9HC10OTOF_HUMANOtoferlin (Fer-1-like protein 2)OTOF FER1L21997
P78380OLR1_HUMANOxidized low-density lipoprotein receptor 1 (Ox-LDL receptor 1) (C-type lectin domainOLR1 CLEC8A LOX1273
family 8 member A) (Lectin-like oxidized LDL receptor 1) (LOX-1) (Lectin-like oxLDL
receptor 1) (hLOX-1) (Lectin-type oxidized LDL receptor 1) [Cleaved into: Oxidized low-
density lipoprotein receptor 1, soluble form]
Q8NF37PCAT1_HUMANLysophosphatidylcholine acyltransferase 1 (LPC acyltransferase 1) (LPCAT-1) (LysoPCLPCAT1 AYTL2 PFAAP3534
acyltransferase 1) (EC 2.3.1.23) (1-acylglycerophosphocholine O-acyltransferase) (1-
alkylglycerophosphocholine O-acetyltransferase) (EC 2.3.1.67) (Acetyl-CoA:lyso-platelet-
activating factor acetyltransferase) (Acetyl-CoA:lyso-PAF acetyltransferase) (Lyso-PAF
acetyltransferase) (LysoPAFAT) (Acyltransferase-like 2) (Phosphonoformate immuno-
associated protein 3)
Q7L5N7PCAT2_HUMANLysophosphatidylcholine acyltransferase 2 (LPC acyltransferase 2) (LPCAT-2) (LysoPCLPCAT2 AGPAT11 AYTL1544
acyltransferase 2) (EC 2.3.1.23) (1-acylglycerol-3-phosphate O-acyltransferase 11) (1-
AGP acyltransferase 11) (1-AGPAT 11) (EC 2.3.1.51) (1-acylglycerophosphocholine O-
acyltransferase) (1-alkylglycerophosphocholine O-acetyltransferase) (EC 2.3.1.67)
(Acetyl-CoA:lyso-platelet-activating factor acetyltransferase) (Acetyl-CoA:lyso-PAF
acetyltransferase) (Lyso-PAF acetyltransferase) (LysoPAFAT) (Acyltransferase-like 1)
(Lysophosphatidic acid acyltransferase alpha) (LPAAT-alpha)
Q7Z412PEX26_HUMANPeroxisome assembly protein 26 (Peroxin-26)PEX26305
Q9NST1PLPL3_HUMANPatatin-like phospholipase domain-containing protein 3 (EC 3.1.1.3) (Acylglycerol O-PNPLA3 ADPN C22orf20481
acyltransferase) (EC 2.3.1.-) (Adiponutrin) (Calcium-independent phospholipase A2-
epsilon) (iPLA2-epsilon)
Q9NRQ2PLS4_HUMANPhospholipid scramblase 4 (PL scramblase 4) (Ca(2+)-dependent phospholipidPLSCR4 GIG43329
scramblase 4) (Cell growth-inhibiting gene 43 protein) (TRA1)
P78562PHEX_HUMANPhosphate-regulating neutral endopeptidase (EC 3.4.24.-) (MetalloendopeptidasePHEX PEX749
homolog PEX) (Vitamin D-resistant hypophosphatemic rickets protein) (X-linked
hypophosphatemia protein) (HYP)
O15162PLS1_HUMANPhospholipid scramblase 1 (PL scramblase 1) (Ca(2+)-dependent phospholipidPLSCR1318
scramblase 1) (Erythrocyte phospholipid scramblase) (MmTRA1b)
Q8NAT1PMGT2_HUMANProtein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2 (POMGnT2) (ECPOMGNT2 AGO61 C3orf39 EOGTL GTDC2580
2.4.1.-) (Extracellular O-linked N-acetylglucosamine transferase-like)
(Glycosyltransferase-like domain-containing protein 2)
Q8IV08PLD3_HUMANPhospholipase D3 (PLD 3) (EC 3.1.4.4) (Choline phosphatase 3) (HindIII K4L homolog)PLD3490
(Hu-K4) (Phosphatidylcholine-hydrolyzing phospholipase D3)
Q9NRY6PLS3_HUMANPhospholipid scramblase 3 (PL scramblase 3) (Ca(2+)-dependent phospholipidPLSCR3295
scramblase 3)
Q9NRY7PLS2_HUMANPhospholipid scramblase 2 (PL scramblase 2) (Ca(2+)-dependent phospholipidPLSCR2297
scramblase 2)
Q96AD5PLPL2_HUMANPatatin-like phospholipase domain-containing protein 2 (EC 3.1.1.3) (Adipose triglyceridePNPLA2 ATGL FP17548504
lipase) (Calcium-independent phospholipase A2) (Desnutrin) (IPLA2-zeta) (Pigment
epithelium-derived factor) (TTS2.2) (Transport-secretion protein 2) (TTS2)
Q9BX97PLVAP_HUMANPlasmalemma vesicle-associated protein (Fenestrated endothelial-linked structurePLVAP FELS PV1442
protein) (Plasmalemma vesicle protein 1) (PV-1)
Q8WZA1PMGT1_HUMANProtein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1 (POMGnTI) (ECPOMGNT1 MGAT1.2 UNQ746/PRO1475660
2.4.1.-) (UDP-GlcNAc:alpha-D-mannoside beta-1,2-N-acetylglucosaminyltransferase I.2)
(GnT I.2)
Q8TE99PXYP1_HUMAN2-phosphoxylose phosphatase 1 (EC 3.1.3.-) (Acid phosphatase-like protein 2) (XylosylPXYLP1 ACPL2 HEL124 XYLP UNQ370/480
phosphatase) (epididymis luminal protein 124)PRO706
Q8TC12RDH11_HUMANRetinol dehydrogenase 11 (EC 1.1.1.300) (Androgen-regulated short-chainRDH11 ARSDR1 PSDR1 SDR7C1 CGI-82318
dehydrogenase/reductase 1) (HCV core-binding protein HCBP12) (Prostate short-chain
dehydrogenase/reductase 1) (Retinal reductase 1) (RalR1) (Short chain
dehydrogenase/reductase family 7C member 1)
Q9Y644RFNG_HUMANBeta-1,3-N-acetylglucosaminyltransferase radical fringe (EC 2.4.1.222) (O-fucosylpeptideRFNG331
3-beta-N-acetylglucosaminyltransferase)
Q6AZY7SCAR3_HUMANScavenger receptor class A member 3 (Cellular stress response gene protein)SCARA3 CSR606
Q6ZMJ2SCAR5_HUMANScavenger receptor class A member 5 (Scavenger receptor hIg)SCARA5 UNQ2938/PRO28700495
P67812SC11A_HUMANSignal peptidase complex catalytic subunit SEC11A (EC 3.4.21.89) (EndopeptidaseSEC11A SEC11L1 SPC18 SPCS4A179
SP18) (Microsomal signal peptidase 18 kDa subunit) (SPase 18 kDa subunit) (SEC11
homolog A) (SEC11-like protein 1) (SPC18)
Q9BY50SC11C_HUMANSignal peptidase complex catalytic subunit SEC11C (EC 3.4.21.89) (Microsomal signalSEC11C SEC11L3 SPC21 SPCS4C192
peptidase 21 kDa subunit) (SPase 21 kDa subunit) (SEC11 homolog C) (SEC11-like
protein 3) (SPC21)
Q8IXA5SACA3_HUMANSperm acrosome membrane-associated protein 3 (Cancer/testis antigen 54) (CT54)SPACA3 LYC3 LYZL3 SLLP1 SPRASA215
(Lysozyme-like acrosomal sperm-specific secretory protein ALLP-17) (Lysozyme-likeUNQ424/PRO862
protein 3) (Sperm lysozyme-like protein 1) (Sperm protein reactive with antisperm
antibodies) (Sperm protein reactive with ASA) [Cleaved into: Sperm acrosome
membrane-associated protein 3, membrane form; Sperm acrosome membrane-
associated protein 3, processed form]
P0C7V7SC11B_HUMANPutative signal peptidase complex catalytic subunit SEC11B (EC 3.4.21.89) (SEC11SEC11B SEC11L2 SPCS4B166
homolog B) (SEC11-like protein 2)
Q9NSC7SIA7A_HUMANAlpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 (EC 2.4.99.3) (GalNAcST6GALNAC1 SIAT7A UNQ543/PRO848600
alpha-2,6-sialyltransferase I) (ST6GalNAc I) (ST6GalNAcI) (Sialyltransferase 7A) (SIAT7-
A)
Q9H4F1SIA7D_HUMANAlpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3-N-acetyl-galactosaminide alpha-2,6-ST6GALNAC4 SIAT3C SIAT7D302
sialyltransferase (EC 2.4.99.7) (NeuAc-alpha-2,3-Gal-beta-1,3-GalNAc-alpha-2,6-
sialyltransferase) (ST6GalNAc IV) (ST6GalNAcIV) (Sialyltransferase 3C) (SIAT3-C)
(Sialyltransferase 7D) (SIAT7-D)
Q92186SIA8B_HUMANAlpha-2,8-sialyltransferase 8B (EC 2.4.99.-) (Sialyltransferase 8B) (SIAT8-B)ST8SIA2 SIAT8B STX375
(Sialyltransferase St8Sia II) (ST8SiaII) (Sialyltransferase X) (STX)
P15907SIAT1_HUMANBeta-galactoside alpha-2,6-sialyltransferase 1 (Alpha 2,6-ST 1) (EC 2.4.99.1) (B-cellST6GAL1 SIAT1406
antigen CD75) (CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,6-
sialyltransferase 1) (ST6Gal I) (ST6GalI) (Sialyltransferase 1)
Q16585SGCB_HUMANBeta-sarcoglycan (Beta-SG) (43 kDa dystrophin-associated glycoprotein) (43DAG) (A3b)SGCB318
Q13326SGCG_HUMANGamma-sarcoglycan (Gamma-SG) (35 kDa dystrophin-associated glycoprotein) (35DAG)SGCG291
Q96LD1SGCZ_HUMANZeta-sarcoglycan (Zeta-SG) (ZSG1)SGCZ299
Q92185SIA8A_HUMANAlpha-N-acetylneuraminide alpha-2,8-sialyltransferase (EC 2.4.99.8) (Alpha-2,8-ST8SIA1 SIAT8 SIAT8A356
sialyltransferase 8A) (Ganglioside GD3 synthase) (Ganglioside GT3 synthase)
(Sialyltransferase 8A) (SIAT8-A) (Sialyltransferase St8Sia I) (ST8SiaI)
Q92187SIA8D_HUMANCMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase (EC 2.4.99.-) (Alpha-2,8-ST8SIA4 PST PST1 SIAT8D359
sialyltransferase 8D) (Polysialyltransferase-1) (Sialyltransferase 8D) (SIAT8-D)
(Sialyltransferase St8Sia IV) (ST8SiaIV)
P61647SIA8F_HUMANAlpha-2,8-sialyltransferase 8F (EC 2.4.99.-) (Sialyltransferase 8F) (SIAT8-F)ST8SIA6 SIAT8F398
(Sialyltransferase St8Sia VI) (ST8SiaVI)
Q96JF0SIAT2_HUMANBeta-galactoside alpha-2,6-sialyltransferase 2 (Alpha 2,6-ST 2) (EC 2.4.99.1) (CMP-N-ST6GAL2 KIAA1877 SIAT2529
acetylneuraminate-beta-galactosamide-alpha-2,6-sialyltransferase 2) (ST6Gal II)
(ST6GalII) (hST6Gal II) (Sialyltransferase 2)
A6NLE4SIM23_HUMANSmall integral membrane protein 23SMIM23 C5orf50156
Q07837SLC31_HUMANNeutral and basic amino acid transport protein rBAT (NBAT) (D2h) (Solute carrier family 3SLC3A1 RBAT685
member 1) (b(0, +)-type amino acid transport protein)
O43173SIA8C_HUMANSia-alpha-2,3-Gal-beta-1,4-GlcNAc-R:alpha 2,8-sialyltransferase (EC 2.4.99.-) (Alpha-ST8SIA3 SIAT8C380
2,8-sialyltransferase 8C) (Alpha-2,8-sialyltransferase III) (ST8 alpha-N-acetyl-
neuraminide alpha-2,8-sialyltransferase 3) (Sialyltransferase 8C) (SIAT8-C)
(Sialyltransferase St8Sia III) (ST8SiaIII)
Q11201SIA4A_HUMANCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 (Alpha 2,3-ST3GAL1 SIAT4 SIAT4A340
ST 1) (Beta-galactoside alpha-2,3-sialyltransferase 1) (EC 2.4.99.4) (Gal-NAc6S) (Gal-
beta-1,3-GalNAc-alpha-2,3-sialyltransferase) (SIATFL) (ST3Gal I) (ST3GalI) (ST3GalA.1)
(ST3O) (Sialyltransferase 4A) (SIAT4-A)
Q969X2SIA7F_HUMANAlpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 6 (EC 2.4.99.-) (GalNAcST6GALNAC6 SIAT7F UNQ708/PRO1359333
alpha-2,6-sialyltransferase VI) (ST6GalNAc VI) (ST6GalNAcVI) (hST6GalNAc VI)
(Sialyltransferase 7F) (SIAT7-F)
Q9UNP4SIAT9_HUMANLactosylceramide alpha-2,3-sialyltransferase (EC 2.4.99.9) (CMP-ST3GAL5 SIAT9 UNQ2510/PRO5998418
NeuAc:lactosylceramide alpha-2,3-sialyltransferase) (Ganglioside GM3 synthase)
(STSGal V) (STSGalV) (Sialyltransferase 9)
Q9H5K3SG196_HUMANProtein O-mannose kinase (POMK) (EC 2.7.1.183) (Protein kinase-like protein SgK196)POMK SGK196350
(Sugen kinase 196)
Q9Y274SIA10_HUMANType 2 lactosamine alpha-2,3-sialyltransferase (EC 2.4.99.-) (CMP-NeuAc:beta-ST3GAL6 SIAT10331
galactoside alpha-2,3-sialyltransferase VI) (ST3Gal VI) (ST3GalVI) (Sialyltransferase 10)
Q16842SIA4B_HUMANCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 2 (Alpha 2,3-ST3GAL2 SIAT4B350
ST 2) (Beta-galactoside alpha-2,3-sialyltransferase 2) (EC 2.4.99.4) (Gal-NAc6S) (Gal-
beta-1,3-GalNAc-alpha-2,3-sialyltransferase) (ST3Gal II) (ST3GalII) (ST3GalA.2)
(Sialyltransferase 4B) (SIAT4-B)
Q11206SIA4C_HUMANCMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 (Alpha 2,3-ST3GAL4 CGS23 NANTA3 SIAT4C STZ333
ST 4) (Beta-galactoside alpha-2,3-sialyltransferase 4) (EC 2.4.99.-) (Alpha 2,3-
sialyltransferase IV) (Gal-NAc6S) (Gal-beta-1,4-GalNAc-alpha-2,3-sialyltransferase)
(SAT-3) (ST-4) (ST3Gal IV) (ST3GalIV) (ST3GalA.2) (STZ) (Sialyltransferase 4C)
(SIAT4-C)
Q9UJ37SIA7B_HUMANAlpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 (EC 2.4.99.-) (GalNAcST6GALNAC2 SIAT7B SIATL1 STHM374
alpha-2,6-sialyltransferase II) (ST6GalNAc II) (ST6GalNAcII) (SThM) (Sialyltransferase
7B) (SIAT7-B)
Q9BVH7SIA7E_HUMANAlpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 (EC 2.4.99.-) (GD1 alphaST6GALNAC5 SIAT7E336
synthase) (GalNAc alpha-2,6-sialyltransferase V) (ST6GalNAc V) (ST6GalNAcV)
(Sialyltransferase 7E) (SIAT7-E)
Q11203SIAT6_HUMANCMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase (EC 2.4.99.6)ST3GAL3 SIAT6375
(Beta-galactoside alpha-2,3-sialyltransferase 3) (Alpha 2,3-ST 3) (Gal beta-1,3(4) GlcNAc
alpha-2,3 Sialyltransferase) (N-acetyllactosaminide alpha-2,3-sialyltransferase) (ST3Gal
III) (STSGalIII) (ST3N) (Sialyltransferase 6)
Q12884SEPR_HUMANProlyl endopeptidase FAP (EC 3.4.21.26) (170 kDa melanoma membrane-boundFAP760
gelatinase) (Dipeptidyl peptidase FAP) (EC 3.4.14.5) (Fibroblast activation protein alpha)
(FAPalpha) (Gelatine degradation protease FAP) (EC 3.4.21.-) (Integral membrane serine
protease) (Post-proline cleaving enzyme) (Serine integral membrane protease) (SIMP)
(Surface-expressed protease) (Seprase) [Cleaved into: Antiplasmin-cleaving enzyme
FAP, soluble form (APCE) (EC 3.4.14.5) (EC 3.4.21.-) (EC 3.4.21.26)]
Q8NDV1SIA7C_HUMANAlpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 3 (EC 2.4.99.-) (GalNAcST6GALNAC3 SIAT7C UNQ2787/PRO7177305
alpha-2,6-sialyltransferase III) (ST6GalNAc III) (ST6GalNAcIII) (STY) (Sialyltransferase
7C) (SIAT7-C)
O15466SIA8E_HUMANAlpha-2,8-sialyltransferase 8E (EC 2.4.99.-) (Sialyltransferase 8E) (SIAT8-E)ST8SIA5 SIAT8E376
(Sialyltransferase St8Sia V) (ST8SiaV)
Q92629SGCD_HUMANDelta-sarcoglycan (Delta-SG) (35 kDa dystrophin-associated glycoprotein) (35DAG)SGCD289
Q86WD7SPA9_HUMANSerpin A9 (Centerin) (Germinal center B-cell-expressed transcript 1 protein)SERPINA9 GCET1 SERPINA11417
UNQ692/PRO1337
P61009SPCS3_HUMANSignal peptidase complex subunit 3 (EC 3.4.-.-) (Microsomal signal peptidase 22/23 kDaSPCS3 SPC22 UNQ1841/PRO3567180
subunit) (SPC22/23) (SPase 22/23 kDa subunit)
Q9UH99SUN2_HUMANSUN domain-containing protein 2 (Protein unc-84 homolog B) (Rab5-interacting protein)SUN2 FRIGG KIAA0668 RAB5IP UNC84B717
(Rab5IP) (Sad1/unc-84 protein-like 2)
Q9Y5Y6ST14_HUMANSuppressor of tumorigenicity 14 protein (EC 3.4.21.109) (Matriptase) (Membrane-typeST14 PRSS14 SNC19 TADG15855
serine protease 1) (MT-SP1) (Prostamin) (Serine protease 14) (Serine protease TADG-
15) (Tumor-associated differentially-expressed gene 15 protein)
P14410SUIS_HUMANSucrase-isomaltase, intestinal [Cleaved into: Sucrase (EC 3.2.1.48); Isomaltase (ECSI1827
3.2.1.10)]
O94901SUN1_HUMANSUN domain-containing protein 1 (Protein unc-84 homolog A) (Sad1/unc-84 protein-like 1)SUN1 KIAA0810 UNC84A812
Q9NUM4T106B_HUMANTransmembrane protein 106BTMEM106B274
Q9H7V2SYNG1_HUMANSynapse differentiation-inducing gene protein 1 (SynDIG1) (Dispanin subfamily CSYNDIG1 C20orf39 TMEM90B258
member 2) (DSPC2) (Transmembrane protein 90B)
P02786TFR1_HUMANTransferrin receptor protein 1 (TR) (TfR) (TfR1) (Trfr) (T9) (p90) (CD antigen CD71)TFRC760
[Cleaved into: Transferrin receptor protein 1, serum form (sTfR)]
Q9UP52TFR2_HUMANTransferrin receptor protein 2 (TfR2)TFR2801
Q9NRS4TMPS4_HUMANTransmembrane protease serine 4 (EC 3.4.21.-) (Channel-activating protease 2)TMPRSS4 TMPRSS3 UNQ776/PRO1570437
(CAPH2) (Membrane-type serine protease 2) (MT-SP2)
P50591TNF10_HUMANTumor necrosis factor ligand superfamily member 10 (Apo-2 ligand) (Apo-2L) (TNF-TNFSF10 APO2L TRAIL281
related apoptosis-inducing ligand) (Protein TRAIL) (CD antigen CD253)
O43508TNF12_HUMANTumor necrosis factor ligand superfamily member 12 (APO3 ligand) (TNF-related weakTNFSF12 APO3L DR3LG UNQ181/PRO207249
inducer of apoptosis) (TWEAK) [Cleaved into: Tumor necrosis factor ligand superfamily
member 12, membrane form; Tumor necrosis factor ligand superfamily member 12,
secreted form]
Q06643TNFC_HUMANLymphotoxin-beta (LT-beta) (Tumor necrosis factor C) (TNF-C) (Tumor necrosis factorLTB TNFC TNFSF3244
ligand superfamily member 3)
P41273TNFL9_HUMANTumor necrosis factor ligand superfamily member 9 (4-1BB ligand) (4-1BBL)TNFSF9254
Q6ZMR5TM11A_HUMANTransmembrane protease serine 11A (EC 3.4.21.-) (Airway trypsin-like protease 1)TMPRSS11A ECRG1 HATL1 HESP421
(Epidermal type-II transmembrane serine protease) (Esophageal cancer-susceptibility
gene 1 protein)
Q6ZWK6TM11F_HUMANTransmembrane protease serine 11F (EC 3.4.21.-) (Airway trypsin-like protease 4)TMPRSS11F HATL4438
P23510TNFL4_HUMANTumor necrosis factor ligand superfamily member 4 (Glycoprotein Gp34) (OX40 ligand)TNFSF4 TXGP1183
(OX40L) (TAX transcriptionally-activated glycoprotein 1) (CD antigen CD252)
P01375TNFA_HUMANTumor necrosis factor (Cachectin) (TNF-alpha) (Tumor necrosis factor ligand superfamilyTNF TNFA TNFSF2233
member 2) (TNF-a) [Cleaved into: Tumor necrosis factor, membrane form (N-terminal
fragment) (NTF); Intracellular domain 1 (ICD1); Intracellular domain 2 (ICD2); C-domain
1; C-domain 2; Tumor necrosis factor, soluble form]
O15393TMPS2_HUMANTransmembrane protease serine 2 (EC 3.4.21.-) (Serine protease 10) [Cleaved into:TMPRSS2 PRSS10492
Transmembrane protease serine 2 non-catalytic chain; Transmembrane protease serine
2 catalytic chain]
Q9H3S3TMPS5_HUMANTransmembrane protease serine 5 (EC 3.4.21.-) (Spinesin)TMPRSS5457
Q7RTY8TMPS7_HUMANTransmembrane protease serine 7 (EC 3.4.21.-) (Matriptase-3)TMPRSS7843
O43557TNF14_HUMANTumor necrosis factor ligand superfamily member 14 (Herpes virus entry mediator ligand)TNFSF14 HVEML LIGHT UNQ391/PRO726240
(HVEM-L) (Herpesvirus entry mediator ligand) (CD antigen CD258) [Cleaved into: Tumor
necrosis factor ligand superfamily member 14, membrane form; Tumor necrosis factor
ligand superfamily member 14, soluble form]
P48023TNFL6_HUMANTumor necrosis factor ligand superfamily member 6 (Apoptosis antigen ligand) (APTL)FASLG APT1LG1 CD95L FASL TNFSF6281
(CD95 ligand) (CD95-L) (Fas antigen ligand) (Fas ligand) (FasL) (CD antigen CD178)
[Cleaved into: Tumor necrosis factor ligand superfamily member 6, membrane form;
Tumor necrosis factor ligand superfamily member 6, soluble form (Receptor-binding FasL
ectodomain) (Soluble Fas ligand) (sFasL); ADAM10-processed FasL form (APL); FasL
intracellular domain (FasL ICD) (SPPL2A-processed FasL form) (SPA)]
Q86T26TM11B_HUMANTransmembrane protease serine 11B (EC 3.4.21.-) (Airway trypsin-like protease 5)TMPRSS11B HATL5416
O95150TNF15_HUMANTumor necrosis factor ligand superfamily member 15 (TNF ligand-related molecule 1)TNFSF15 TL1 VEGI251
(Vascular endothelial cell growth inhibitor) [Cleaved into: Tumor necrosis factor ligand
superfamily member 15, membrane form; Tumor necrosis factor ligand superfamily
member 15, secreted form]
Q9UL52TM11E_HUMANTransmembrane protease serine 11E (EC 3.4.21.-) (Serine protease DESC1)TMPRSS11E DESC1 TMPRSS11E2423
(Transmembrane protease serine 11E2) [Cleaved into: Transmembrane protease serineUNQ742/PRO1461
11E non-catalytic chain; Transmembrane protease serine 11E catalytic chain]
Q8IU80TMPS6_HUMANTransmembrane protease serine 6 (EC 3.4.21.-) (Matriptase-2)TMPRSS6 UNQ354/PRO618811
Q7Z410TMPS9_HUMANTransmembrane protease serine 9 (EC 3.4.21.-) (Polyserase-I) (Polyserine protease 1)TMPRSS91059
(Polyserase-1) [Cleaved into: Serase-1; Serase-2; Serase-3]
Q9BYE2TMPSD_HUMANTransmembrane protease serine 13 (EC 3.4.21.-) (Membrane-type mosaic serineTMPRSS13 MSP TMPRSS11586
protease) (Mosaic serine protease)
O14788TNF11_HUMANTumor necrosis factor ligand superfamily member 11 (Osteoclast differentiation factor)TNFSF11 OPGL RANKL TRANCE317
(ODF) (Osteoprotegerin ligand) (OPGL) (Receptor activator of nuclear factor kappa-B
ligand) (RANKL) (TNF-related activation-induced cytokine) (TRANCE) (CD antigen
CD254) [Cleaved into: Tumor necrosis factor ligand superfamily member 11, membrane
form; Tumor necrosis factor ligand superfamily member 11, soluble form]
O60507TPST1_HUMANProtein-tyrosine sulfotransferase 1 (EC 2.8.2.20) (Tyrosylprotein sulfotransferase 1)TPST1370
(TPST-1)
O60235TM11D_HUMANTransmembrane protease serine 11D (EC 3.4.21.-) (Airway trypsin-like protease)TMPRSS11D HAT418
[Cleaved into: Transmembrane protease serine 11D non-catalytic chain; Transmembrane
protease serine 11D catalytic chain]
Q9Y2B1TMEM5_HUMANTransmembrane protein 5TMEM5443
P57727TMPS3_HUMANTransmembrane protease serine 3 (EC 3.4.21.-) (Serine protease TADG-12) (Tumor-TMPRSS3 ECHOS1 TADG12 UNQ323/454
associated differentially-expressed gene 12 protein)PRO382
Q9Y275TN13B_HUMANTumor necrosis factor ligand superfamily member 13B (B lymphocyte stimulator) (BLyS)TNFSF13B BAFF BLYS TALL1 TNFSF20 ZTNF4285
(B-cell-activating factor) (BAFF) (Dendritic cell-derived TNF-like molecule) (TNF- andUNQ401/PRO738
APOL-related leukocyte expressed ligand 1) (TALL-1) (CD antigen CD257) [Cleaved into:
Tumor necrosis factor ligand superfamily member 13b, membrane form; Tumor necrosis
factor ligand superfamily member 13b, soluble form]
P32971TNFL8_HUMANTumor necrosis factor ligand superfamily member 8 (CD30 ligand) (CD30-L) (CD antigenTNFSF8 CD30L CD30LG234
CD153)
Q13061TRDN_HUMANTriadinTRDN729
Q9UNG2TNF18_HUMANTumor necrosis factor ligand superfamily member 18 (Activation-inducible TNF-relatedTNFSF18 AITRL GITRL TL6 UNQ149/199
ligand) (AITRL) (Glucocorticoid-induced TNF-related ligand) (hGITRL)PRO175
Q9H2S6TNMD_HUMANTenomodulin (TeM) (hTeM) (Chondromodulin-1-like protein) (ChM1L) (hChM1L)TNMD CHM1L UNQ771/PRO1565317
(Chondromodulin-I-like protein) (Myodulin) (Tendin)
O60704TPST2_HUMANProtein-tyrosine sulfotransferase 2 (EC 2.8.2.20) (Tyrosylprotein sulfotransferase 2)TPST2377
(TPST-2)
Q9UKU6TRHDE_HUMANThyrotropin-releasing hormone-degrading ectoenzyme (TRH-DE) (TRH-degradingTRHDE UNQ2507/PRO59951024
ectoenzyme) (EC 3.4.19.6) (Pyroglutamyl-peptidase II) (PAP-II) (TRH-specific
aminopeptidase) (Thyroliberinase)
Q9Y2C2UST_HUMANUronyl 2-sulfotransferase (EC 2.8.2.-)UST DS2ST406
Q8NBZ7UXS1_HUMANUDP-glucuronic acid decarboxylase 1 (EC 4.1.1.35) (UDP-glucuronate decarboxylase 1)UXS1 UNQ2538/PRO6079420
(UGD) (UXS-1)
Q86Y38XYLT1_HUMANXylosyltransferase 1 (EC 2.4.2.26) (Peptide O-xylosyltransferase 1) (Xylosyltransferase I)XYLT1 XT1959
(XT-I) (XylT-I)
P17861XBP1_HUMANX-box-binding protein 1 (XBP-1) (Tax-responsive element-binding protein 5) (TREB-5)XBP1 TREB5 XBP2261
[Cleaved into: X-box-binding protein 1, cytoplasmic form; X-box-binding protein 1, luminal
form]
O75063XYLK_HUMANGlycosaminoglycan xylosylkinase (EC 2.7.1.-) (Xylose kinase)FAM20B KIAA0475409
Q8NBI6XXLT1_HUMANXyloside xylosyltransferase 1 (EC 2.4.2.n3) (UDP-xylose:alpha-xyloside alpha-1,3-XXYLT1 C3orf21 PSEC0251393
xylosyltransferase)
Q9H1B5XYLT2_HUMANXylosyltransferase 2 (EC 2.4.2.26) (Peptide O-xylosyltransferase 1) (XylosyltransferaseXYLT2 XT2 UNQ3058/PRO9878865
II) (XT-II) (XylT-II)
A8MXE2YI036_HUMANPutative UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase LOC100288842369
(EC 2.4.1.-) (Putative UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase
LOC402377) (UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 pseudogene)
Q5STJ7Q5STJ7_HUMANHexosyltransferase (EC 2.4.1.-)B3GALT4 hCG_17511378
A0A090N7X6A0A090N7X6_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDPGALNT11 hCG_1990637 tcag7.1057608
acetylgalactosaminyltransferase)
Q5Q0U2Q5Q0U2_HUMANFucosyltransferase 9 (EC 2.4.1.152) (Fucosyltransferase 9 (Alpha (1,3)FUT9 hCG_16703359
fucosyltransferase), isoform CRA_a) (cDNA, FLJ95882, Homo sapiens fucosyltransferase
9 (alpha (1,3) fucosyltransferase) (FUT9), mRNA)
A8K9Q8A8K9Q8_HUMANHexosyltransferase (EC 2.4.1.-)hCG_2018639384
A8K737A8K737_HUMANFucosyltransferase (Fucosyltransferase 3 (Galactoside 3(4)-L-fucosyltransferase, LewisFUT3 hCG_1645372361
blood group)) (cDNA FLJ78078, highly similar to Human alpha (1,3/1,4)
fucosyltransferase (FUT3))
G3V1S6G3V1S6_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDPGALNT2 hCG_15927533
acetylgalactosaminyltransferase)
Q58A54Q58A54_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDPGalNAc-T18 GALNT18 GALNTL4607
acetylgalactosaminyltransferase)hCG_1991780
A0A087WY64A0A087WY64_HUMANHexosyltransferase (EC 2.4.1.-)B3GALNT292
A3KLL5A3KLL5_HUMANSodium/potassium-transporting ATPase subunit betaATP1B1 hCG_37798303
Q2L4S5Q2L4S5_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDPGALNT19 WBSCR17 hCG_19354598
acetylgalactosaminyltransferase)tcag7.519
B7ZKW0B7ZKW0_HUMANSodium/potassium-transporting ATPase subunit betaATP1B4314
Q9P1W6Q9P1W6_HUMANAlpha-(1,3/1,4)-fucosyltransferase (cDNA, FLJ94139, highly similar to Homo sapiensFUT3361
fucosyltransferase 3 (galactoside 3(4)-L-fucosyltransferase, Lewis blood group included)
(FUT3), mRNA)
A0A024RC48A0A024RC48_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDPGALNT1 hCG_2042960559
acetylgalactosaminyltransferase)
D3DNF9D3DNF9_HUMANSodium/potassium-transporting ATPase subunit betaATP1B3 hCG_19938265
A0A024RBT1A0A024RBT1_HUMANHexosyltransferase (EC 2.4.1.-)hCG_2016450378
D3DQI7D3DQI7_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDPGALNT10 hCG_36809506
acetylgalactosaminyltransferase)
B7Z5G5B7Z5G5_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDP527
acetylgalactosaminyltransferase)
B5B9M4B5B9M4_HUMANFucosyltransferaseFUT3361
Q68VJ8Q68VJ8_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDPGALNT16 GALNTL1 hCG_21969558
acetylgalactosaminyltransferase)
E7EVF0E7EVF0_HUMANHexosyltransferase (EC 2.4.1.-)B3GALNT191
B2R8J0B2R8J0_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDP633
acetylgalactosaminyltransferase)
C9J368C9J368_HUMANHexosyltransferase (EC 2.4.1.-) (Fragment)B3GNT550
B2RC53B2RC53_HUMANcDNA, FLJ95856, highly similar to Homo sapiens fucosyltransferase 11 (alpha (1,3)492
fucosyltransferase) (FUT11), mRNA
A8KAJ7A8KAJ7_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDP559
acetylgalactosaminyltransferase)
Q8NHI0Q8NHI0_HUMANHexosyltransferase (EC 2.4.1.-)67
B4DIE4B4DIE4_HUMANHexosyltransferase (EC 2.4.1.-)91
B3KT16B3KT16_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDP372
acetylgalactosaminyltransferase)
B7ZKV9B7ZKV9_HUMANSodium/potassium-transporting ATPase subunit betaATP1B4322
Q6RC02Q6RC02_HUMANHexosyltransferase (EC 2.4.1.-)102
A0A087WV18A0A087WV18_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDPWBSCR17519
acetylgalactosaminyltransferase)
R4X5Z0R4X5Z0_HUMANHexosyltransferase (EC 2.4.1.-)B3GALNT183
C9JGI4C9JGI4_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDPGALNT15617
acetylgalactosaminyltransferase)
Q24JS2Q24JS2_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDPGALNT6622
acetylgalactosaminyltransferase)
B7ZKV8B7ZKV8_HUMANSodium/potassium-transporting ATPase subunit betaATP1B4357
I3L1V9I3L1V9_HUMANSodium/potassium-transporting ATPase subunit beta (Fragment)ATP1B2167
B4DLS4B4DLS4_HUMANcDNA FLJ55721, highly similar to Homo sapiens fucosyltransferase 10 (alpha (1,3)521
fucosyltransferase) (FUT10), mRNA
Q05BM8Q05BM8_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDPGALNT1499
acetylgalactosaminyltransferase)
A0A087X115A0A087X115_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDPGALNTL6417
acetylgalactosaminyltransferase)
J3KNN1J3KNN1_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDPGALNT9603
acetylgalactosaminyltransferase)
B3KTQ4B3KTQ4_HUMANHexosyltransferase (EC 2.4.1.-)331
B3KY85B3KY85_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDP556
acetylgalactosaminyltransferase)
E7EVS2E7EVS2_HUMANHexosyltransferase (EC 2.4.1.-) (Fragment)B3GALNT1111
B7Z9S8B7Z9S8_HUMANSodium/potassium-transporting ATPase subunit beta247
B3W6H0B3W6H0_HUMANFucosyltransferaseFUT3361
B3GVC1B3GVC1_HUMANFucosyltransferaseFUT3361
Q8TDY1Q8TDY1_HUMANHexosyltransferase (EC 2.4.1.-)OK/KNS-cl.1204
Q6P7E6Q6P7E6_HUMANFucosyltransferase 6 (Alpha (1,3) fucosyltransferase)FUT6359
F8VUJ3F8VUJ3_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDPPOC1B-GALNT4575
acetylgalactosaminyltransferase)
B3KNV8B3KNV8_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDP607
acetylgalactosaminyltransferase)
Q7L9G8Q7L9G8_HUMANHexosyltransferase (EC 2.4.1.-)331
Q6RC00Q6RC00_HUMANHexosyltransferase (EC 2.4.1.-)331
M0QX58M0QX58_HUMANHexosyltransferase (EC 2.4.1.-) (Fragment)B3GNT3127
B4E056B4E056_HUMANcDNA FLJ56031, highly similar to Homo sapiens fucosyltransferase 10 (alpha (1,3)529
fucosyltransferase) (FUT10), mRNA
Q58A70Q58A70_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDPGalNAc-T10581
acetylgalactosaminyltransferase)
B3KQP5B3KQP5_HUMANHexosyltransferase (EC 2.4.1.-)378
B3KRF8B3KRF8_HUMANHexosyltransferase (EC 2.4.1.-)378
Q6RBZ9Q6RBZ9_HUMANHexosyltransferase (EC 2.4.1.-)319
I3L3J8I3L3J8_HUMANSodium/potassium-transporting ATPase subunit beta (Fragment)ATP1B2172
D7UNW5D7UNW5_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDPGALNT6622
acetylgalactosaminyltransferase)
Q49AT3Q49AT3_HUMANHexosyltransferase (EC 2.4.1.-)B3GALNT1331
B4DL56B4DL56_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDP603
acetylgalactosaminyltransferase)
Q6RC01Q6RC01_HUMANHexosyltransferase (EC 2.4.1.-)144
B3KP58B3KP58_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDP460
acetylgalactosaminyltransferase)
E9PJ79E9PJ79_HUMANHexosyltransferase (EC 2.4.1.-) (Fragment)B3GNT6121
B2R7V3B2R7V3_HUMANcDNA, FLJ93618, highly similar to Homo sapiens fucosyltransferase 6 (alpha (1,3)359
fucosyltransferase) (FUT6), mRNA
C9J0F8C9J0F8_HUMANHexosyltransferase (EC 2.4.1.-) (Fragment)B3GALNT165
E5D8G0E5D8G0_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDP601
acetylgalactosaminyltransferase)
B3KQT5B3KQT5_HUMANHexosyltransferase (EC 2.4.1.-)372
C9J5K2C9J5K2_HUMANHexosyltransferase (EC 2.4.1.-) (Fragment)B3GNT581
C9J8U7C9J8U7_HUMANHexosyltransferase (EC 2.4.1.-) (Fragment)B3GALNT154
H0YAH3H0YAH3_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDPGALNT7454
acetylgalactosaminyltransferase) (Fragment)
C9JD16C9JD16_HUMANHexosyltransferase (EC 2.4.1.-) (Fragment)B3GALNT158
B7Z6K2B7Z6K2_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDP533
acetylgalactosaminyltransferase)
B7Z5C5B7Z5C5_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDP517
acetylgalactosaminyltransferase)
Q58A53Q58A53_HUMANPolypeptide N-acetylgalactosaminyltransferase (EC 2.4.1.-) (Protein-UDPGalNAc-T17598
acetylgalactosaminyltransferase)
C9IYY0C9IYY0_HUMANHexosyltransferase (EC 2.4.1.-) (Fragment)B3GNT562
A6NGH2A6NGH2_HUMANSodium/potassium-transporting ATPase subunit beta295
V9GYR2V9GYR2_HUMANSodium/potassium-transporting ATPase subunit beta (Fragment)ATP1B1130
K7ENC0K7ENC0_HUMANAlpha-(1,3)-fucosyltransferase 5FUT5374
R4X604R4X604_HUMANHexosyltransferase (EC 2.4.1.-)B3GALNT1151
Q8NFN0Q8NFN0_HUMANHexosyltransferase (EC 2.4.1.-)181
Q58I18Q58I18_HUMANSodium/potassium-transporting ATPase subunit beta (Fragment)ATP1B3137
R4X601R4X601_HUMANHexosyltransferase (EC 2.4.1.-)B3GALNT1208
Q499Z2Q499Z2_HUMANHexosyltransferase (EC 2.4.1.-) (Fragment)B3GALT6304
Q6LEU2Q6LEU2_HUMANSodium/potassium-transporting ATPase subunit beta (Fragment)ATP1B1303
A0A0A0MS93A0A0A0MS93_HUMANHexosyltransferase (EC 2.4.1.-)B3GALT5314
R4X5Z4R4X5Z4_HUMANHexosyltransferase (EC 2.4.1.-)B3GALNT1331
Q53F50Q53F50_HUMANHexosyltransferase (EC 2.4.1.-) (Fragment)331
M0R199M0R199_HUMANHexosyltransferase (EC 2.4.1.-) (Fragment)B3GNT3250
Table of Sequences in Appended Sequence Listing

SEQ
ID NO:Illustrative Description
1DNA sequence of chimeric protein - comprising the extracellular domain of PD-1, followed by the
hinge-CH2—CH3 domain of human IgG4 and short linker, followed by the extracellular domain of
OX40L.
2Amino acid sequence of chimeric protein - comprising the extracellular domain of PD-1, followed by
the hinge-CH2—CH3 domain of human IgG4 and short linker, followed by the extracellular domain
of OX40L.
3Codon-optimized nucleic acid sequence, which is optimized for expression by Chinese Hamster
(CHO) cells
4DNA sequence encoding the extracellular domain of PD-1 -Fc - the extracellular domain of TL1A
5Amino acid sequence encoded by a codon optimized nucleotide sequence of SEQ ID NO: 4
6Nucleotide sequence of construct (ex: A fusion protein encoding the extracellular domain of BTLA,
linked through an Fc to OX40L)
7Amino acid sequence encoded by nucleotide sequence of SEQ ID NO: 6
8DNA sequence of a fusion protein incorporating the extracellular domain of TIGIT, linked via an Fc
linker to OX40L
9Amino acid sequence encoded by a codon optimized nucleotide sequence of SEQ ID NO: 8
10DNA sequence of a fusion protein incorporating the extracellular domain of TIM3, linked through an
Fc region to human OX40L
11Amino acid sequence encoded by a codon optimized nucleotide sequence of SEQ ID NO: 10
12Nucleotide sequence of the extracellular domain of CD172a adjoined with an Fc linker sequence to
the extracellular domain of human OX40L
13Amino acid sequence encoded by a codon optimized nucleotide sequence of SEQ ID NO: 12
14Nucleotide sequence of the extracellular domain of TMIGD2 adjoined with an Fc linker sequence to
the extracellular domain of human OX40L
15Amino acid sequence encoded by a codon optimized nucleotide sequence of SEQ ID NO: 14
16mRNA sequence of human OX40L
17Amino acid sequence of human OX40L
18Nucleic acid sequence of the hinge-CH2—CH3 Sequence from human IgG1
19cDNA sequence of human PD-1
20Nucleic acid sequence of human PD-1-Fc-OX40L codon optimized for expression by Chinese
Hamster(CHO) cells
21Nucleic acid sequence of human PD-1-Fc-OX40L
22Amino acid sequence of SL-279252
23Amino acid sequence of Linker
24Amino acid sequence of Linker
25Amino acid sequence of Linker
26Amino acid sequence of Linker
27Amino acid sequence of Linker
28Amino acid sequence of Linker
29Amino acid sequence of Linker
30Amino acid sequence of Linker
31Amino acid sequence of Linker
32Amino acid sequence of CD279
33Amino acid sequence of CD172a
34Amino acid sequence of BTLA
35Amino acid sequence of TIGIT
36Amino acid sequence of TIM3
37Amino acid sequence of CD200
38Amino acid sequence of TMIGD2
39Amino acid sequence of VISTA
40Amino acid sequence of VSIG8
41Amino acid sequence of BTNL2
42Amino acid sequence of TNFRSF1b
43Amino acid sequence of CD276
44Amino acid sequence of CD244
45Amino acid sequence of LAG3
46Amino acid sequence of CSF1R
47Amino acid sequence of TGFBR1
48Amino acid sequence of IL-10R
49Amino acid sequence of CD40
50Amino acid sequence of OX40
51Amino acid sequence of 41BB
52Amino acid sequence of CTLA4
53Amino acid sequence of PD-L1
54Amino acid sequence of PD-L2
55Amino acid sequence of B7-H4
56Amino acid sequence of OX40L
57Amino acid sequence of GITRL
58Amino acid sequence of 41BBL
59Amino acid sequence of TL1A
60Amino acid sequence of CD40L
61Amino acid sequence of CD30L
62Amino acid sequence of TRAIL
63Amino acid sequence of CD70
64blank
65blank
66blank
67blank
68blank
69blank
70Amino acid sequence of Linker - IgG4 hinge-CH2—CH3
71Amino acid sequence of Linker - IgG4 hinge-CH2—CH3 S228P
72Amino acid sequence of Linker - IgG4 hinge-CH2—CD3 S228P FcRn
73Amino acid sequence of Joining Linker
74Amino acid sequence of Joining Linker
75Amino acid sequence of Joining Linker
76Amino acid sequence of Joining Linker
77Amino acid sequence of Joining Linker
78Amino acid sequence of Joining Linker

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 32, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 33, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 34, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 35, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 36, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 37, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 38, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 39, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 40, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 41, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 42, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 43, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 44, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 45, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 46, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 47, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 48, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 49, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 50, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 51, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 52, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 53, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 54, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises: (i) the amino acid sequence of SEQ ID NO: 55, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and (ii) one of the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 68, and SEQ ID NO: 69, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, and, optionally (iii) an Ig linker selected from the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto, where, also optionally, one or more of (i) and (ii) are connected to (iii) via (iv) a joining linker of SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, or variants thereof.

In various embodiments, the linkers (iii) or (iv) can be substituted for the amino acid sequence of SEQ ID NOs: 23-31, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises the amino acid sequence of SEQ ID NO: 2, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises the amino acid sequence of SEQ ID NO: 5, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises the amino acid sequence of SEQ ID NO: 7, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises the amino acid sequence of SEQ ID NO: 9, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises the amino acid sequence of SEQ ID NO: 11, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises the amino acid sequence of SEQ ID NO: 13, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises the amino acid sequence of SEQ ID NO: 15, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

In some embodiments, the present chimeric protein comprises the amino acid sequence of SEQ ID NO: 22, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identity thereto.

US11654180B2. Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins (2023-05-23). Heat Biologics, Inc. [US]. Inventors: Taylor Schreiber [US], George Fromm [US], Suresh De Silva [US], Neal Schilling [US].
Patent 2023

Top products related to «Lipid-associated sialic acid»

More about "Lipid-associated sialic acid"

Lipid-associated sialic acid, also known as sialylated lipids or sialo-lipids, refers to the covalent attachment of sialic acid residues to lipid molecules, such as glycolipids and gangliosides.
This modification plays a crucial role in cellular signaling, cell-cell interactions, and immune responses.
Researchers studying this topic may investigate its involvement in various biological processes, including cancer, neurological disorders, and metabolic diseases.
Understanding the complex interplay between lipids and sialic acid can provide valuable insights into health and disease states.
Key subtopics related to lipid-associated sialic acid include glycobiology, glycomic, lipidomics, and biomarker research.
Leveraging AI-driven platforms like PubCompare.ai can help optimize research in this area by locating the best protocols from literature, pre-prints, and patents, and enhancing reproducibility and accuracy.
Elevate your lipid-associated sialic acid research with cutting-edge tools and comprehensive insights.